



(86) Date de dépôt PCT/PCT Filing Date: 2004/09/10
(87) Date publication PCT/PCT Publication Date: 2005/02/14
(45) Date de délivrance/Issue Date: 2008/03/25
(85) Entrée phase nationale/National Entry: 2004/11/18
(86) N° demande PCT/PCT Application No.: CA 2004/001603
(87) N° publication PCT/PCT Publication No.: 2005/024025
(30) Priorités/Priorities: 2003/09/11 (US60/501,821);
2004/05/28 (US60/574,922); 2004/06/23 (US60/581,707)

(51) Cl.Int./Int.Cl. *C12N 1/20* (2006.01),
A61K 31/164 (2006.01), *A61K 31/195* (2006.01),
A61K 31/197 (2006.01), *A61K 31/35* (2006.01),
A61K 31/357 (2006.01), *A61K 31/7028* (2006.01),
A61P 31/04 (2006.01), *C07C 229/30* (2006.01),
C07C 237/16 (2006.01), *C07C 279/12* (2006.01),
C07C 279/14 (2006.01), *C07D 309/10* (2006.01),
C07D 493/04 (2006.01), *C07H 15/10* (2006.01),
C07H 15/18 (2006.01), *C12P 1/06* (2006.01),
C12P 13/00 (2006.01), *C12P 17/10* (2006.01),
C12P 19/44 (2006.01)

(72) Inventeurs/Inventors:
MCALPINE, JAMES B., CA; ...

(54) Titre : POLYCETIDES POLYENIQUES ET METHODES DE PRODUCTION CONNEXES
(54) Title: POLYENE POLYKETIDES AND METHODS OF PRODUCTION

(57) **Abrégé/Abstract:**

Novel polyene polyketides, their pharmaceutically acceptable salts, prodrugs and derivatives have been found to have antibiotic activity. One method for obtaining the compounds is by cultivation of *Amycolatopsis orientalis* ATCC™ 43491 or a mutant or variant such as the strain IDAC-220604-1. Another method for obtaining the compounds is post-biosynthesis chemical modification of the compounds obtained by cultivation. Novel polynucleotide sequences and encoded proteins for the biosynthesis of the polyene polyketides are also presented.

(72) **Inventeurs(suite)/Inventors(continued):** FARNET, CHRIS M., CA; ZAZOPOULOS, EMMANUEL, CA;
SORENSEN, DAN, CA

(73) **Propriétaires(suite)/Owners(continued):**
THALLION PHARMACEUTICALS INC./THALLION PHARMACEUTIQUES INC., CA

(74) **Agent:** ROBIC

3010-5PCT-7CA

ABSTRACT

Novel polyene polyketides, their pharmaceutically acceptable salts, prodrugs and derivatives have been found to have antibiotic activity. One method for obtaining the compounds is by cultivation of *Amycolatopsis orientalis* ATCC™ 43491 or a mutant or variant such as the strain IDAC-220604-1. Another method for obtaining the compounds is post-biosynthesis chemical modification of the compounds obtained by cultivation. Novel polynucleotide sequences and encoded proteins for the biosynthesis of the polyene polyketides are also presented.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

POLYENE POLYKETIDES AND METHODS OF PRODUCTION

FIELD OF THE INVENTION:

This invention relates to novel biologically active polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods of obtaining them. One method for obtaining the compounds is by cultivation of *Amycolatopsis orientalis* ATCC™ 43491, the *Amycolatopsis orientalis* species having accession number IDAC 220604-01, or a mutant or variant of strain ATCC™ 43491 or strain IDAC 220604-1.

10 Another method of producing these polyene polyketides involves expression of the biosynthetic gene cluster of the invention in transformed host cells. Another method of producing these polyene polyketide is by post-biosynthesis chemical modifications. The present invention further relates to *Amycolatopsis orientalis* sp. strains IDAC 220604-01, to the use of the polyene polyketides and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of bacterial cell growth and to pharmaceutical compositions comprising a polyene polyketide of the invention or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of the polyene polyketides

20 of the invention.

BACKGROUND OF THE INVENTION:

Polyketides are a diverse class of naturally occurring molecules typically produced by a variety of organisms, including fungi and mycelial bacteria, in particular actinomycetes. Although polyketides have widely divergent structures, they are classified together because they all share a common general biosynthetic pathway in which the carbon backbone of these molecules are assembled by sequential, step-

3010-5PCT-7CA

- 2 -

wise addition of two carbon or substituted two carbon units referred to as ketides. Polyene polyketides comprise a chain of ketide units that have been strung together by a series of enzymatic reactions by multimodular polyketide synthase proteins. Polyketides are usually found in their natural environment in trace amounts. Moreover, due to their structural complexity, polyketides are notoriously difficult to synthesize chemically. Nevertheless, many polyketides have been developed into effective drugs for the treatment of conditions such as bacterial and fungal infections, cancer and high cholesterol. Adriamycin, erythromycin, zocor and nystatin are but a few examples of polyketide molecules, which have been developed into valuable pharmaceuticals. Linearmycin A, having a 60 carbon chain and a degree of unsaturation of 15, is an example of a linear polyene polyketide reported to possess antifungal and antibacterial activity (Sakuda *et al.*, *Tetrahedron Letters*. Vol. 36, No. 16, 2777-2870 (1995); Sakuda *et al.*, *J. Chem Soc., Perkin Trans.* 1, 2315-2319 (1996)).

Although large numbers of therapeutically important polyketides have been identified, there remains a need to obtain novel polyketides that have enhanced properties or possess completely novel bioactivities. The complex polyketides produced by modular Type I polyketide synthases (PKSs) are particularly valuable, in that they include compounds with known utility as antihelminthics, insecticides, immunosuppressants, cytotoxic, antifungal or antibacterial agents.

Because of their structural complexity, such novel polyketides are not readily obtainable by total chemical synthesis. The present invention addresses this need by providing a new class of polyketide compounds with therapeutic activity, together with means for their production. The compounds of the invention are prepared by fermentation or by fermentation followed by chemical modifications. The compounds of the invention may also be produced by appropriate application of recombinant DNA technology. A wide variety of polyketides can be prepared in a variety of different host cells provided one has access to nucleic acid compounds that encode PKS proteins and polyketide modification enzymes.

PKSs are large proteins that contain multiple enzymatic activities. PKSs catalyse the biosynthesis of polyketides through repeated, decarboxylative Claisen condensations between acylthioester building blocks, such as acetyl, butyryl, isobutyryl, propionyl, malonyl, hydroxymalonyl, methylmalonyl, and ethylmalonyl CoA.

3010-5PCT-7CA

- 3 -

PKS enzymes are generally classified into Type I or “modular” PKSs and Type II or “iterative” PKSs according to the polyketide synthesized and by the mode of synthesis. Type I PKSs are responsible for producing a large number of 12-, 14- and 16- membered macrolide antibiotics.

Type I or modular PKS enzymes are multifunctional proteins containing catalytic sites for acyl transferases (AT), acyl carrier protein (ACP), ketosynthase (KS), dehydratase (DH), and enoyl reductase (ER) activities. Type I enzymes are formed by a set of separate catalytic active sites for each cycle of carbon chain elongation and modification in the polyketide synthesis pathway. Each active site is termed a domain. A set of active sites or domains is termed a module. The typical modular PKS complex is composed of several large PKS polypeptides that act coordinately to achieve polyketide synthesis. Each PKS polypeptide can be segregated from amino to carboxy terminus into a loading module (found only in the first PKS polypeptide of the complex), multiple extender modules, and a releasing or thioesterase (TE) domain (generally found only in the final module of the terminal PKS polypeptide of the complex).

Generally, the loading module is responsible for binding the first building block used to synthesize the polyketide and transferring it to the first extender module. The AT domain of the loading module recognizes a particular acyl-CoA (usually acetyl or propionyl but sometimes butyryl, isobutyryl or other acyl-CoA) and transfers it as a thiol ester to the ACP domain of the loading module. The loading module may not encode a KS domain, or may encode a KS(Q) domain, a KS-like domain that carries an amino acid substitution at the active site cysteine residue (typically a glutamine residue, single letter code Q). KS(Q) domains decarboxylate the acylthioester of the loading domain before proceeding with chain elongation. For example, the loader module of the oleandomycin PKS complex initiates deoxyoleandolide synthesis by loading the ACP with a malonyl unit and performing a decarboxylation to generate acetyl-ACP (Shah, (2000), *J. Antibiotics*, Vol. 53, pp. 502-508).

The AT domain on each of the extender modules recognizes a particular extender-CoA (typically malonyl or alpha-substituted malonyl, i.e. methylmalonyl, ethylmalonyl, and 2-hydroxymalonyl) and transfers it to the ACP domain of that extender module to form a thioester. Each extender module is responsible for accepting a compound from a prior module, binding a building block, attaching the building block to the

3010-5PCT-7CA

- 4 -

compound from the prior module, optionally performing one or more additional functions, and transferring the resulting compound to the next module.

Each extender module of a modular PKS contains a KS, AT, ACP, and zero, one, two or three domains that modify the beta-carbon of the growing polyketide chain. A typical (non-loading) minimal Type I PKS extender module may contain a KS domain, an AT domain, and an ACP domain. Such domains are sufficient to activate a 2-carbon extender unit and attach it to the growing polyketide molecule. The next extender module, in turn, is responsible for attaching the next building block and transferring the growing compound to the next extender module until synthesis of the polyketide is complete.

Once the PKS is primed with acyl- and malonyl-ACPs, the acyl group of the loading module is transferred to form a thiol ester (trans-esterification) at the KS of the first extender module; at this stage, extender module one possesses an acyl-KS and a malonyl (or substituted malonyl)-ACP. The acyl group derived from the loading module is then covalently attached to the alpha-carbon of the malonyl group to form a carbon-carbon bond, driven by concomitant decarboxylation, and generating a new acyl-ACP that carries a backbone two carbons longer than the loading building block (elongation or extension) and side chains if a substituted malonyl unit is used for extension.

The polyketide chain, growing by two or more carbons with each extender module, is sequentially passed as covalently bound thiol esters from extender module to extender module, in an assembly line-like process. The carbon chain produced by this process alone would possess a ketone at every other carbon atom, producing a polyketone, from which the name polyketide arises. Most commonly, however, additional enzymatic activities modify the beta keto group of each two carbon unit just after it has been added to the growing polyketide chain but before it is transferred to the next module.

After traversing the final extender module, the polyketide encounters a releasing domain (TE) that cleaves the polyketide from the PKS and typically cyclizes the polyketide. Further, tailoring enzymes can modify the polyketide; these tailoring enzymes add carbohydrate groups, methyl groups, or make other modifications, i.e. oxidation or reduction, on the polyketide core molecule.

3010-5PCT-7CA

- 5 -

Type I PKSs displays a one-to-one correlation between the number and clustering of active sites in the primary sequence of the PKS and the structure of the polyketide backbone. The activities catalyzed by the domains within a type I PKS are often apparent in the structure of the growing polyketide chain; consequently, nucleotide sequence has become a predictive tool for deducing the biosynthetic route for these compounds (Rangaswamy et al, *Proc. Natl. Acad. Sci. USA*, (1998) Vol. 95, pp. 15469-15474).

10 In Type I PKS polypeptides, the order of catalytic domains is conserved. When all beta-keto processing domains are present in a module, the order of domains in that module from N-to-C-terminus is always KS, AT, DH, ER, KR, and ACP. Some or all of the beta-keto processing domains may be missing in particular modules, but the order of the domains present in a module remains the same. The order of domains within modules is believed to be important for proper folding of the PKS polypeptides into an active complex. Importantly, there is considerable flexibility in PKS enzymes, this flexibility provides a means for genetically engineering novel catalytic complexes. By manipulating the polynucleotide sequences encoding the PKS polypeptide, genetically engineered novel PKSs can be achieved. Genetically engineering PKS enzymes can be achieved by the modification, addition or deletion of domains, or by replacing domains with domains taken from other Type I PKS enzymes. As well, this
20 can also be achieved by deletion, addition or replacement of entire modules with modules taken from other sources. A genetically engineered PKS complex should, of course, have the ability to catalyze the synthesis of the product predicted from the genetic alterations made.

Alignment of the many available amino acid sequences for Type I PKS enzymes has approximately defined the boundaries of the various catalytic domains. Sequence alignments also have revealed linker regions between the catalytic domains and at the N- and C-termini of individual PKS polypeptides. The sequences of these linker regions are less well conserved than are those for the catalytic domains, which is in part how linker regions are identified. Linker regions can be important for proper
30 association between domains and between the individual polypeptides that comprise the PKS complex. One can thus view the linkers and domains together as creating a scaffold on which the domains and modules are positioned in the correct orientation to be active. This organization and positioning, if retained, permits PKS domains of

3010-5PCT-7CA


- 6 -

different or identical substrate specificities to be substituted (usually at the DNA level) between PKS enzymes by various available methodologies. In selecting the boundaries of, for example, an AT domain replacement, one can thus make the replacement so as to retain the linkers of the recipient PKS or to replace them with the linkers of the donor PKS AT domain, or, preferably, make both constructs to ensure that the correct linker regions between the KS and AT domains have been included in at least one of the engineering enzymes. Thus, there is considerable flexibility in the design of new PKS enzymes with the result that known polyketides can be produced more effectively, and novel polyketides can be made.


10

SUMMARY OF THE INVENTION:


In one aspect of this embodiment the invention relates to novel polyene polyketides Compounds 1, 2, 3, 4, 5, 6 and 7:



Compound 1;



Compound 2;




Compound 3;


20

3010-5PCT-7CA


- 7 -




Compound 4;



Compound 5;



Compound 6;




Compound 7;

or a pharmaceutically acceptable salt or prodrug thereof.

10

In another aspect the invention provides polyene polyketides of Formula I, as illustrated below, which compounds may be derived by chemical modification of Compounds 1 to 7.




Formula I

3010-5PCT-7CA

- 8 -

wherein,

A is selected from $-\text{C}(\text{NH})\text{NHR}^1$, CH_3 , H or




R^1 is selected from H, C_{1-6} alkyl, C_{6-10} aryl, $\text{C}(\text{O})\text{C}_{1-6}$ alkyl and $\text{C}(\text{O})\text{C}_{6-10}$ aryl;

R^2 and R^3 are each independently selected from H, C_{1-6} alkyl, C_{2-7} alkene and C_{6-10} aryl;

R^4 is selected from H or CH_3 ;

Z is OH or O when taken with adjacent carbon atom to form a carbonyl; or

10 Z may be a tetrahydropyranoxy of formula:




R^5 is selected from H, COOH , C_{1-6} alkyl or $\text{C}(\text{O})\text{OC}_{1-6}$ alkyl;

R^6 , R^7 and R^8 are each independently selected from H, C_{1-6} alkyl and $\text{C}(\text{O})\text{C}_{1-6}$ alkyl; or

R^6 , R^7 and R^8 may each independently be absent when the adjacent oxygen and carbon atoms are taken together to form a carbonyl; or

R^6 , R^7 and R^8 may each independently be a bond when any of two neighboring R^6 , R^7 and R^8 are taken together with attached oxygen and carbon atoms to form a 1,3-dioxolane ring of formula:




20 R^9 and R^{10} are each independently selected from H, C_{1-6} alkyl, C_{2-7} alkene and C_{6-10} aryl; or

R^9 and R^{10} are taken together with adjacent carbon atom to form a ring having from 5 to 7 carbons;

3010-5PCT-7CA

- 9 -

D is selected from OH, NH₂, NH(C₁₋₃alkyl), N(C₁₋₃alkyl)₂, OC₁₋₃alkyl or



R¹¹ is selected from H or C₁₋₃ alkyl;


or a pharmaceutically acceptable salt or prodrug thereof.

In one embodiment the invention provides compounds of Formula I, wherein A is —C(NH)NH₂; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

10 In a further embodiment of the invention provides compounds of Formula I, wherein A is H; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein A is —C(NH)NHC(O)CH₃; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein A is



and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.


20 In a further embodiment the invention provides compounds of Formula I, wherein R⁴ is CH₃; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein R⁴ is H; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

3010-5PCT-7CA


- 10 -

In a further embodiment the invention provides compounds of Formula I, wherein Z is



and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^6 , R^7 and R^8 are each H, and R^5 is COOH, all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.


In a further embodiment the invention provides compounds of Formula I, wherein Z is



and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^6 , R^7 and R^8 are each H, and R^5 is CO₂CH₃, all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein Z is OH and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein D is




and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^{11} is H and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein D is

3010-5PCT-7CA


- 11 -




and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^{11} is CH_3 and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In another embodiment the invention provides compounds of Formula I, wherein D is OH; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

The following are exemplary compounds of the invention:


10




Compound 1;



Compound 2;




Compound 3;




Compound 4;

3010-5PCT-7CA


- 12 -




Compound 5;




Compound 6;




Compound 7;




Compound 8;



Compound 9;



Compound 10;




Compound 11;


10

3010-5PCT-7CA


- 13 -




Compound 12;




Compound 13;




Compound 14;




Compound 15;



Compound 16;




Compound 17;




Compound 18;

3010-5PCT-7CA


- 14 -




Compound 19;




Compound 20;




Compound 21;



Compound 22;




Compound 23;




Compound 24;

3010-5PCT-7CA


- 15 -




Compound 25;



Compound 26;



Compound 27 and



Compound 28;

10 or a pharmaceutically acceptable salt or prodrug of any one of Compound 1-28.

In a further aspect, the invention relates to a pharmaceutical composition comprising of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, with a pharmaceutically acceptable carrier.

In an additional embodiment the invention relates to pharmaceutical compositions of polyene polyketides of the invention, comprising a therapeutically effective amount of the compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.

The present invention further encompasses methods for producing the compounds of
 20 Formula I and related compounds, the method comprising: (a) cultivating

3010-5PCT-7CA

- 16 -

Amycolatopsis sp. strain under aerobic conditions in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, (b) isolating a compound of Formula I, from the bacteria cultivated in (a). In an aspect of the invention, the *Amycolatopsis orientalis* strain useful in the methods of the invention may be ATCC™ 43491 or a mutant thereof. In another embodiment, the strain is the *Amycolatopsis orientalis* strain deposited on June 22, 2004, at the International Depositary Authority of Canada (IDAC), Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2, and having accession no. 220604-01. In another aspect of the invention, the method of

10 producing the compounds of Formula I comprises: (a) and (b) as described above and (c) chemically modifying the compound isolated in (b). In a further embodiment, the polyene polyketide generates a ¹H NMR spectra essentially as shown in any one of Figures 4 to 10. In a further embodiment, the polyene polyketide is any one of Compounds 1 to 7. In a further embodiment, the nutrient medium is selected from the media of Table 1.

The invention further provides a process for producing a polyene polyketide of the invention comprising cultivation of an *Amycolatopsis* strain in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, and isolation and purification of the polyene polyketide. In another

20 embodiment, the strain is an *Amycolatopsis orientalis*. In a further embodiment, the strain is *Amycolatopsis orientalis* ATCC™ 43491 or a mutant thereof. In a further embodiment, the strain is the *Amycolatopsis orientalis* strain having accession no. 220604-01 deposited at the International Depositary Authority of Canada. In one embodiment, the carbon and nitrogen atoms sources are chosen from the components of Table 1. In a further embodiment, the nutrient medium is selected from the media of Table 1. In a further embodiment, the cultivation is carried out under aerobic conditions. In another embodiment, the cultivation is carried out at a temperature ranging from about 18°C to about 40°C. In another embodiment, the temperature range is 18°C to 29°C. In another embodiment, the cultivation is carried

30 out at a pH ranging from about 6 to about 9.

The invention further provides polyene polyketides of Formula I that are a derivative or structural analog of any one of Compounds 1 to 7. In one embodiment the polyene polyketides of Formula I are produced by post-biosynthesis chemical modification of any one of Compounds 1 to 7. In another embodiment, the polyene

3010-5PCT-7CA

- 17 -

polyketides generate a ^1H NMR spectra essentially as shown in any one of Figures 4 to 10.

The invention further provides an *Amycolatopsis orientalis* strain having accession no. 220604-01 deposited at the International Depositary Authority of Canada.

The invention further provides Compounds 1 to 7, compounds of Formula I, or pharmaceutically acceptable salts or prodrugs thereof, for use as pharmaceuticals for the treatment of a bacterial infection in a subject. In another aspect, the invention provides the use of any one of Compounds 1 to 7, compounds of Formula I, or pharmaceutically acceptable salts or prodrugs thereof, for the manufacture of a medicament for the treatment of a bacterial infection in a subject.

The invention also provides methods of inhibiting bacterial cell growth, which comprise contacting said bacterial cell with a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof. The invention further encompasses methods for treating a bacterial infection in a subject, comprising administering to said subject suffering from said bacterial infection, a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof. Examples of bacteria organisms that may be treated or inhibited according to the methods of the invention include: *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Enterococcus faecium*, *Klebsiella pneumoniae*, *Enterobacter spp.*, *Proteus spp.*, *Pseudomonas aeruginosa*, *E. coli*, *Serratia marcesens*, *Staphylococcus aureus*, Coagulase negative *Staphylococcus*, *Haemophilus influenzae*, *Bacillus anthracis*, *Mycoplasma pneumoniae*, and *Staphylococcus epidermidis*.

The present invention also provides the biosynthetic locus responsible for producing the compounds of Formula I. Thus the invention provides polynucleotides and polypeptides useful in the production and engineering of compounds of Formula I. The present invention provides recombinant DNA vectors that encode all or part of the PKS enzymes useful for the production of polyketide compounds of Formula I. The invention also provides nucleic acid compounds that encode the specific domains of the PKS system useful for the production of polyketides of compound of Formula I. The recombinant DNA vectors, PKS enzymes, PKS systems and nucleic acid compounds encoding the domains of the PKS systems of the invention can be readily used, alone or in combination with nucleic acids encoding other PKS

3010-5PCT-7CA

- 18 -

domains, as intermediates in the construction of recombinant vectors that encode all or part of PKS enzymes that make novel polyketides selected from the compounds of Formula I.

The invention also provides isolated nucleic acids that encode all or part of one or more modules of the PKSs of the invention, each module comprising a ketosynthase activity, an acyl transferase activity, and an acyl carrier protein activity. The invention also provides isolated nucleic acids that encode all or part of a PKS loader module comprising an acyl transferase activity and an acyl carrier protein activity. Thus, in

one aspect, the invention provides an isolated, purified or enriched nucleic acid
10 encoding a domain of a polyketide synthase system for production of a polyene polyketide of claim 1, said nucleic acid comprising a sequence selected from the group consisting of: a nucleic acid encoding the acyl carrier protein of residues 47-109 of SEQ ID NO: 38; a nucleic acid encoding an acyl carrier protein having at least 69% identity to residues 47-109 of SEQ ID NO: 38; a nucleic acid encoding the acyl carrier protein of residues 1691-1753 of SEQ ID NO: 38; a nucleic acid encoding an acyl carrier protein having at least 73% identity to residues 1691-1753 of SEQ ID NO: 38; a nucleic acid encoding the acyl carrier protein of residues 3696-3758 of SEQ ID NO: 38; a nucleic acid encoding an acyl carrier protein having at least 77% identity to residues 3696-3758 of SEQ ID NO: 38; a nucleic acid encoding the acyl carrier
20 protein of residues 1574-1636 of SEQ ID NO: 40; a nucleic acid encoding an acyl carrier protein having at least 78% identity to residues 1574-1636 of SEQ ID NO: 40; a nucleic acid encoding the acyl carrier protein of residues 3545-3607 of SEQ ID NO: 40; a nucleic acid encoding an acyl carrier protein having at least 76% identity to residues 3545-3607 of SEQ ID NO: 40; a nucleic acid encoding the acyl carrier protein of residues 5577-5639 of SEQ ID NO: 40; a nucleic acid encoding an acyl carrier protein having at least 78% identity to residues 5577-5639 of SEQ ID NO: 40; a nucleic acid encoding the acyl carrier protein of residues 1593-1655 of SEQ ID NO: 42; a nucleic acid encoding an acyl carrier protein having at least 76% identity to 1593-1655 of SEQ ID NO: 42; a nucleic acid encoding the acyl carrier protein of
30 residues 1444-1506 of SEQ ID NO: 44; a nucleic acid encoding an acyl carrier protein having at least 82% identity to residues 1444-1506 of SEQ ID NO: 44; a nucleic acid encoding the acyl carrier protein of residues 3122-3184 of SEQ ID NO: 44; a nucleic acid encoding an acyl carrier protein having at least 69% identity to

3010-5PCT-7CA

- 19 -

residues 3122-3184 of SEQ ID NO: 44; a nucleic acid encoding the acyl carrier protein of residues 1597-1659 of SEQ ID NO: 46; a nucleic acid encoding an acyl carrier protein having at least 73% identity to residues 1597-1659 of SEQ ID NO: 46; a nucleic acid encoding the acyl carrier protein of residues 3235-3297 of SEQ ID NO: 46; a nucleic acid encoding an acyl carrier protein having at least 71% identity to residues 3235-3297 of SEQ ID NO: 46; a nucleic acid encoding the acyl carrier protein of residues 4956-5018 of SEQ ID NO: 46; a nucleic acid encoding an acyl carrier protein having at least 72% identity to residues 4956-5018 of SEQ ID NO: 38; a nucleic acid encoding the acyl carrier protein of residues 1582-1644 of SEQ ID NO: 48; a nucleic acid encoding an acyl carrier protein having at least 75% identity to residues 1582-1644 of SEQ ID NO: 48; a nucleic acid encoding the ketosynthase domain of residues 130-554 of SEQ ID NO: 38; a nucleic acid encoding a ketosynthase domain having at least 76% identity to residues 130-554 of SEQ ID NO: 38; a nucleic acid encoding the ketosynthase domain of residues 1771-2195 of SEQ ID NO: 38, a nucleic acid encoding a ketosynthase domain having at least 78% identity to residues 1771-2195 of SEQ ID NO: 38; a nucleic acid encoding the ketosynthase domain of residues 39-463 of SEQ ID NO: 40; a nucleic acid encoding a ketosynthase domain having at least 77% identity to residues 39-463 of SEQ ID NO: 40; a nucleic acid encoding the ketosynthase domain of residues 1657-2082 of SEQ ID NO: 40; a nucleic acid encoding a ketosynthase domain having at least 80% identity to residues 1657-2082 of SEQ ID NO: 40; a nucleic acid encoding the ketosynthase domain of residues 3628-4052 of SEQ ID NO: 40; a nucleic acid encoding a ketosynthase domain having at least 78% identity to residues 3628-4052 of SEQ ID NO: 40; a nucleic acid encoding the ketosynthase domain of residues 34-458 of SEQ ID NO: 42; a nucleic acid encoding a ketosynthase domain having at least 77% identity to residues 34-458 of SEQ ID NO: 42; a nucleic acid encoding the ketosynthase domain of residues 34-461 of SEQ ID NO: 44; a nucleic acid encoding a ketosynthase domain having at least 78% identity to residues 34-461 of SEQ ID NO: 44; a nucleic acid encoding the ketosynthase domain of residues 1528-1952 of SEQ ID NO: 44; a nucleic acid encoding a ketosynthase domain having at least 76% identity to residues 1528-1952 of SEQ ID NO: 44; a nucleic acid encoding the ketosynthase domain of residues 34-460 of SEQ ID NO: 46; a nucleic acid encoding a ketosynthase domain having at least 77% identity to residues 34-460 of SEQ ID

3010-5PCT-7CA

- 20 -

NO: 46; a nucleic acid encoding the ketosynthase domain of residues 1682-2104 of
 SEQ ID NO: 46; a nucleic acid encoding a ketosynthase domain having at least 79%
 identity to residues 1682-2104 of SEQ ID NO: 46; a nucleic acid encoding the
 ketosynthase domain of residues 3317-3741 of SEQ ID NO: 46; a nucleic acid
 encoding a ketosynthase domain having at least 79% identity to residues 3317-3741
 of SEQ ID NO: 46; a nucleic acid encoding the ketosynthase domain of residues 34-
 461 of SEQ ID NO: 48; a nucleic acid encoding a ketosynthase domain having at
 least 78% identity to residues 35-461 of SEQ ID NO: 48; a nucleic acid encoding the acyl
 transferase domain of residues 567-990 of SEQ ID NO: 38; a nucleic acid encoding
 10 an acyl transferase domain having at least 58% identity to residues 567-990 of SEQ
 ID NO: 38; a nucleic acid encoding the acyl transferase domain of residues 2211-
 2638 of SEQ ID NO: 38; a nucleic acid encoding an acyl transferase domain having
 at least 57% identity to residues 2211-2638 of SEQ ID NO: 38; a nucleic acid encoding
 the acyl transferase domain of residues 474-872 of SEQ ID NO: 40; a nucleic acid
 encoding an acyl transferase domain having at least 60% identity to residues 474-872
 of SEQ ID NO: 38; a nucleic acid encoding the acyl transferase domain of residues 2093-
 2495 of SEQ ID NO: 40; a nucleic acid encoding an acyl transferase domain having
 at least 61% identity to residues 2093-2495 of SEQ ID NO: 40; a nucleic acid encoding the
 acyl transferase domain of residues 4068-4489 of SEQ ID NO: 40; a nucleic acid
 20 encoding an acyl transferase domain having at least 59% identity to residues 4068-
 4489 of SEQ ID NO: 40; a nucleic acid encoding the acyl transferase domain of residues
 475-892 of SEQ ID NO: 42; a nucleic acid encoding an acyl transferase domain
 having at least 57% identity to residues 475-892 of SEQ ID NO: 42; a nucleic acid
 encoding the acyl transferase domain of residues 478-905 of SEQ ID NO: 44; a
 nucleic acid encoding an acyl transferase domain having at least 58% identity to
 residues 478-905 of SEQ ID NO: 44; a nucleic acid encoding the acyl transferase domain
 of residues 1963-2383 of SEQ ID NO: 44; a nucleic acid encoding an acyl
 transferase domain having at least 58% identity to residues 1963-2383 of SEQ ID
 NO: 44; a nucleic acid encoding the acyl transferase domain of residues 472-883 of SEQ
 30 ID NO: 46; a nucleic acid encoding an acyl transferase domain having at least 61%
 identity to residues 472-883 of SEQ ID NO: 46; a nucleic acid encoding the acyl
 transferase domain of residues 2115-2523 of SEQ ID NO: 46; a nucleic acid
 encoding an acyl transferase domain having at least 63% identity to residues 2115-

3010-5PCT-7CA

- 21 -

2523 of SEQ ID NO: 46; a nucleic encoding the acyl transferase domain of residues 3752-4181 of SEQ ID NO: 46; a nucleic acid encoding an acyl transferase domain having at least 59% identity to residues 3752-4181 of SEQ ID NO: 46; a nucleic encoding the acyl transferase domain of residues 475-883 of SEQ ID NO: 48; a nucleic acid encoding an acyl transferase domain having at least 57% identity to residues 475-883 of SEQ ID NO: 48; a nucleic acid encoding the dehydratase domain of residues 1001-1101 of SEQ ID NO: 38; a nucleic acid encoding a dehydratase domain of having at least 64% identity to residues 1001-1101 of SEQ ID NO: 38; a nucleic acid encoding the dehydratase domain of residues 2647-2753 of

10 SEQ ID NO: 38; a nucleic acid encoding a dehydratase domain of residues 2647-2753 of SEQ ID NO: 38; a nucleic acid encoding the dehydratase domain of residues 883-990 of SEQ ID NO: 40; a nucleic acid encoding a dehydratase domain of having at least 67% identity to residues 883-990 of SEQ ID NO: 40; a nucleic acid encoding the dehydratase domain of residues 2507-2614 of SEQ ID NO: 40; a nucleic acid encoding a dehydratase domain of having at least 69% identity to residues 2507-2614 of SEQ ID NO: 40; a nucleic acid encoding the dehydratase domain of residues 4497-4604 of SEQ ID NO: 40; a nucleic acid encoding a dehydratase domain of having at least 56% identity to residues 4497-4604 of SEQ ID NO: 40; a nucleic acid encoding the dehydratase domain of residues 901-1006 of SEQ ID NO: 42; a nucleic

20 acid encoding a dehydratase domain of having at least 64% identity to residues 901-1006 of SEQ ID NO: 42; a nucleic acid encoding the dehydratase domain of residues 2395-2502 of SEQ ID NO: 44; a nucleic acid encoding a dehydratase domain of having at least 63% identity to residues 2395-2502 of SEQ ID NO: 44; a nucleic acid encoding the dehydratase domain of residues 895-1002 of SEQ ID NO: 46; a nucleic acid encoding a dehydratase domain of having at least 65% identity to residues 895-1002 of SEQ ID NO: 46; a nucleic acid encoding the dehydratase domain of residues 2534-2641 of SEQ ID NO: 46; a nucleic acid encoding a dehydratase domain of having at least 66% identity to residues 2534-2641 of SEQ ID NO: 46; a nucleic acid encoding the dehydratase domain of residues 4193-4300 of SEQ ID NO: 46; a

30 nucleic acid encoding a dehydratase domain of having at least 65% identity to residues 4193-4300 of SEQ ID NO: 46; a nucleic acid encoding the dehydratase domain of residues 892-999 of SEQ ID NO: 48; a nucleic acid encoding a dehydratase domain of having at least 61% identity to residues 892-999 of SEQ ID

3010-5PCT-7CA

- 22 -

NO: 61; a nucleic acid encoding the ketoreductase domain of residues 1421-1628 of
 SEQ ID NO: 38; a nucleic acid encoding a ketoreductase domain having at least 62%
 identity to residues 1421-1628 of SEQ ID NO: 38; a nucleic acid encoding the
 ketoreductase domain of residues 3405-3622 of SEQ ID NO: 38; a nucleic acid
 encoding a ketoreductase domain having at least 69% identity to residues 3405-3622
 of SEQ ID NO: 38; a nucleic acid encoding the ketoreductase domain of residues
 1291-1501 of SEQ ID NO: 40; a nucleic acid encoding a ketoreductase domain
 having at least 64% identity to residues 1291-1501 of SEQ ID NO: 40; a nucleic acid
 encoding the ketoreductase domain of residues 3253-3470 of SEQ ID NO: 40; a
 10 nucleic acid encoding a ketoreductase domain having at least 69% identity to
 residues 3253-3470 of SEQ ID NO: 40; a nucleic acid encoding the ketoreductase
 domain of residues 5285-5502 of SEQ ID NO: 40; a nucleic acid encoding a
 ketoreductase domain having at least 71% identity to residues 5285-5502 of SEQ ID
 NO: 40; a nucleic acid encoding the ketoreductase domain of residues 1309-1517 of
 SEQ ID NO: 42; a nucleic acid encoding a ketoreductase domain having at least 62%
 identity to residues 1309-1517 of SEQ ID NO: 42; a nucleic acid encoding the
 ketoreductase domain of residues 1157-1366 of SEQ ID NO: 44; a nucleic acid
 encoding a ketoreductase domain having at least 69% identity to residues 1157-1366
 of SEQ ID NO: 44; a nucleic acid encoding the ketoreductase domain of residues
 20 2837-3048 of SEQ ID NO: 44; a nucleic acid encoding a ketoreductase domain
 having at least 67% identity to residues 2837-3048 of SEQ ID NO: 44; a nucleic acid
 encoding the ketoreductase domain of residues 1323-1523 of SEQ ID NO: 46; a
 nucleic acid encoding a ketoreductase domain having at least 63% identity to
 residues 1323-1523 of SEQ ID NO: 46; a nucleic acid encoding the ketoreductase
 domain of residues 2957-3166 of SEQ ID NO: 46; a nucleic acid encoding a
 ketoreductase domain having at least 65% identity to residues 2957-3166 of SEQ ID
 NO: 46; a nucleic acid encoding the ketoreductase domain of residues 4669-4879 of
 SEQ ID NO: 46; a nucleic acid encoding a ketoreductase domain having at least 66%
 identity to residues 4669-4879 of SEQ ID NO: 66; a nucleic acid encoding the
 30 ketoreductase domain of residues 1305-1512 of SEQ ID NO: 48; a nucleic acid
 encoding a ketoreductase domain having at least 61% identity to residues 1305-1512
 of SEQ ID NO: 48; a nucleic acid encoding the enoyl reductase domain of residues
 3060-3401 of SEQ ID NO: 38; a nucleic acid encoding an enoyl reductase domain

3010-5PCT-7CA

- 23 -

having at least 62% identity to residues 3060-3401 of SEQ ID NO: 38; a nucleic acid encoding the enoyl reductase domain of residues 2908-3249 of SEQ ID NO: 40; a nucleic acid encoding an enoyl reductase domain having at least 65% identity to residues 2908-3249 of SEQ ID NO: 40; a nucleic acid encoding the enoyl reductase domain of residues 4933-5281 of SEQ ID NO: 40; a nucleic acid encoding an enoyl reductase domain having at least 64% identity to residues 4933-5281 of SEQ ID NO: 40; a nucleic acid encoding the thioesterase domain of residues 1709-1921 of SEQ ID NO: 48; a nucleic acid encoding a thioesterase domain having at least 47% identity to residues 1709-1921 of SEQ ID NO: 48.

10

The invention provides an isolated nucleic acid that encodes one or more open reading frames of PKS genes of the invention. Thus, in one aspect, the invention provides an isolated, purified or enriched nucleic acid encoding a polyketide synthase, useful in the production of polyene polyketide, said nucleic comprising a sequence selected from the group consisting of SEQ ID NOS: 38, 40, 42, 44, 46, 48 and a nucleic acid encoding a polyketide synthase selected from SEQ ID NOS: 37, 39, 41, 43, 45, 47 and a nucleic acid having at least 80% identity to a nucleic acid of a) or b). The invention also provides recombinant expression vectors containing these nucleic acids.

20 The invention provides a method of preparing polyketide compounds of Formula I, said method comprising transforming a host cell with a recombinant DNA vector that encodes at least one module of a PKS, said method comprising transforming a host cell with a recombinant DNA vector that encodes at least one module of a PKS, said module comprising at least one PKS domain of the invention, and culturing said host cell under conditions such that said PKS is produced and catalyzes synthesis of said polyketide. The invention also provides a method of preparing polyketide compounds of Formula I, said method comprising transforming a host cell with a recombinant DNA vector that encodes at least one gene of the invention, and culturing said host cell under conditions such that said polyketide is produced. In one
30 aspect, the method is practiced with a *Streptomyces* host cell. In another aspect, the polyketide produced is a compound of Formula I. In another aspect, the polyketide produced is a polyketide related in structure to a compound described in any one of Examples 17 to 20.

3010-5PCT-7CA

- 24 -

The invention provides a set of genes in recombinant form sufficient for the synthesis of a compound of Formula I in a heterologous host cell. These genes and the methods of the invention enable one to create recombinant host cells with the ability to produce polyketides.

The invention provides recombinant PKS genes that produce a variety of polyketides that cannot be readily synthesized by chemical methodology alone. Moreover the present invention provides polyketides, some of which are produced only by fermentation and others of which are produced by fermentation and chemical modification. The invention allows direct manipulation of the genes and proteins for
10 production of the compounds of Formula I via genetic engineering of the enzymes involved in the biosynthesis of a polyketide according to the invention.

The present invention provides recombinant DNA vectors that encode all or part of the PKS enzymes useful for the production of a polyketide of Formula I. The invention also provides nucleic acid compounds that encode the various domains of PKS systems useful for the production of a polyketide of Formula I. The recombinant DNA vectors, PKS enzymes, PKS systems and nucleic acid compounds encoding the domains of the PKS systems of the invention can be readily used, alone or in combination with nucleic acids encoding other PKS domains, as intermediates in the construction of recombinant vectors that encode all or part of PKS enzymes that
20 make novel polyketides selected from the compounds of Formula I.

The invention also provides isolated nucleic acids that encode all or part of one or more modules of the PKSs of the invention, each module comprising a ketosynthase activity, an acyl transferase activity, and an acyl carrier protein activity. The invention also provides isolated nucleic acids that encode all or part of a PKS loader module comprising an acyl transferase activity and an acyl carrier protein activity. The invention provides an isolated nucleic acid that encodes one or more open reading frames of PKS genes of the invention. The invention also provides recombinant expression vectors containing these nucleic acids.

The invention provides a method of preparing a polyketide of Formula I, said method
30 comprising transforming a host cell with a recombinant DNA vector that encodes at least one module of a PKS, said method comprising transforming a host cell with a recombinant DNA vector that encodes at least one module of a PKS, said module comprising at least one PKS domain from the PKS system of the invention, and

3010-5PCT-7CA

- 25 -

culturing said host cell under conditions such that said PKS is produced and catalyzes synthesis of said polyketide. In one aspect, the method is practiced using an *Amycolatopsis orientalis* organism for homologous expression of the modified endogenous gene cluster. In another aspect, the method is practiced with a *Streptomyces* host cell. The invention further provides a set of genes in recombinant form sufficient for the synthesis of a compound of Formula I. In one aspect the genes reside in an *Amycolatopsis orientalis* organism for homologous expression of the endogenous gene cluster. In another aspect, a *Streptomyces* host cell is transformed with a recombinant DNA vector containing the set of genes.

- 10 Thus, the invention provides recombinant PKS genes that produce a variety of polyketides that cannot be readily synthesized by chemical methodology alone. Moreover the present invention provides polyketides, some of which are produced only by fermentation and others of which are produced by fermentation and chemical modification.

BRIEF DESCRIPTION OF THE DRAWINGS:

Figure 1: Electrospray mass spectrum (Positive Ion Mode) of Compound 1.

- 20 Figure 2: Electrospray mass (ms/ms of m/z:837.50) spectrum (Positive Ion Mode) of Compound 1.

Figure 3: Electrospray mass spectrum (Negative Ion Mode) of Compound 1.

Figure 4: 500 MHz proton nuclear magnetic resonance (^1H -NMR) spectrum of Compound 1 in d_4 -MeOH.

Figure 5: 500 MHz proton nuclear magnetic resonance (^1H -NMR) spectrum of Compound 2 in d_4 -MeOH.

Figure 6: 500 MHz proton nuclear magnetic resonance (^1H NMR) spectrum of Compound 3 in d_4 -MeOH.

Figure 7: 500 MHz proton nuclear magnetic resonance (^1H NMR) spectrum of Compound 4 in d_4 -MeOH.

- 30 Figure 8: 500 MHz proton nuclear magnetic resonance (^1H NMR) spectrum of Compound 5 in d_4 -MeOH.

Figure 9: 500 MHz proton nuclear magnetic resonance (^1H NMR) spectrum of Compound 6 in d_4 -MeOH.

3010-5PCT-7CA

- 26 -

Figure 10: 500 MHz proton nuclear magnetic resonance (^1H NMR) spectrum of Compound 7 in $\text{d}_4\text{-MeOH}$.

Figure 11: biosynthetic locus producing compounds of Formula I in *Amycolatopsis orientalis*, showing a scale in base pairs units; the position of the three sequence of contiguous nucleic acids of SEQ ID NOS: 1, 24 and 49; the position and orientation of the 27 open reading frames of the biosynthetic locus identified by ORF number with the six polyketide synthase ORFs identified with PKSE designation; and the coverage of the biosynthetic locus by cosmids having deposit accession nos: IDAC 050903-01, IDAC 050903-02, IDAC 050903-03 and IDAC 050903-04.

10 Figures 12 to 18: multiple amino acid alignments comparing the domains of the polyketide synthase system of the biosynthetic locus for the production of the compounds of Formula I, wherein the asterisks (*) indicate positions which have a single, fully conserved residue, colons (:) indicate that one of the following strong groups is fully conserved: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, and FYW, and periods (.) indicate that one of the following weaker groups is fully conserved: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, and HFY.

Figures 12a and 12b: amino acid alignment comparing the twelve ketosynthase (KS) domains present in the polyketide synthase (PKS) system of ORFs 18 to 23 (SEQ ID
20 NOS: 37, 39, 41, 43, 45 and 47). The boundaries and key residues of the KS domains were chosen as described by Kakavas *et al.*, *J. Bacteriol.*, 179, 7515-7522 (1997) and indicated in black.

Figures 13a, 13b and 13c: amino acid alignment comparing the twelve acyl transferase (AT) domains present in the polyketide synthase system of ORFs 18 to 23 (SEQ ID NOS: 37, 39 41, 43, 45 and 47). The boundaries and key residues of the AT domains were chosen as described by Kakavas *et al.*, *supra* and indicated in black.

Figure 14: amino acid alignment comparing the eleven dehydratase (DH) domains present in the polyketide synthase system of ORFs 18 to 23 (SEQ ID NOS: 37, 39,
30 41, 43, 45 and 47). The boundaries and key residues of the DH domains were chosen as described by Kakavas *et al. supra* and indicated in black.

Figure 15: amino acid alignment comparing the three enoyl reductase (ER) domains present in ORFs 18 and 19 (SEQ ID NOS: 37 and 39) with the ER domains from

3010-5PCT-7CA

- 27 -

modules 5 and 15 of the nystatin biosynthetic locus as described by Brautaset *et al.*, *Chem. Biol.*, 7, 395-403 (2000). The boundaries and key residues of the ER domain were chosen as described by Kakavas *et al. supra* and indicated in black.

Figure 16: amino acid alignment comparing the twelve ketoreductase (KR) domains present in ORFs 18 to 23 (SEQ ID NOS: 37, 39, 41, 43, 45 and 47). The boundaries and key residues of the KR domains were chosen as described by Kakavas *et al. supra*, and Fisher *et al. Structure Fold Des.*, 8, 339-347 (2000) and indicated in black.

Figure 17: amino acid alignment comparing the thirteen acyl carrier proteins (ACP) domains present in ORFs 18 to 23 (SEQ ID NOS: 37, 39, 41, 43, 45 and 47). The
10 boundaries and key serine residues of the ACP domains were chosen as described by Kakavas *et al. supra* and indicated in black.

Figure 18: amino acid alignment comparing the TE domain present in ORF 23 (SEQ ID NO: 47) with the TE domain from module 7 in the nystatin biosynthetic locus as described by Brautaset *et al. supra*. The boundaries and key residues of the TE domain were chosen as described by Kakavas *et al. supra* and indicated in black.

Figure 19: phylogenetic analysis of the twelve acyl transferase (AT) domains present in ORFs 18 to 23 (SEQ ID NOS: 37, 39, 41, 43, 45 and 47) along with a malonyl-specific and a methylmalonyl-specific AT domain present in modules 3 and 11 respectively of the nystatin PKS system as described by Brautaset *et al. supra*.

20 Figure 20a: biosynthesis of the 4-guanidino butyryl-CoA component of compounds of Formula I from arginine and involving ORF 7 (SEQ ID NO: 14) and ORF 25 (SEQ ID NO: 52). Figure 20b: biosynthesis of the polyketide core structure of compounds of Formula I involving the polyketide synthase system of ORFs 18 to 23 (SEQ ID NOS: 37, 39, 41, 43, 45 and 47) and incorporation of the 4-guanidino butyryl-CoA component of Figure 20a using ORF 24 (SEQ ID NO: 50).

Figure 21a: biosynthesis of the aminohydroxy-cyclopentenone moiety of compounds of Formula I using ORF 16 (SEQ ID NO: 33) and ORF 17 (SEQ ID NO: 35). Figure 21b: biosynthesis of the glucuronic acid component of compounds of Formula I using ORF 13 (SEQ ID NO: 27). Figure 21c: methylation, glycosylation and amide
30 condensation of the polyketide core structure of compounds of Formula I using ORF 5 (SEQ ID NO: 10), ORF 14 (SEQ ID NO: 29) and ORF 15 (SEQ ID NO: 31) respectively.

3010-5PCT-7CA

- 28 -

Figure 22: inactivation of glycosyltransferase ORF 14 (SEQ ID NO: 29) and sugar oxidoreductase ORF 13 (SEQ ID NO: 27). Figure 22a: inactivation of the glycosyltransferase gene (SEQ ID NO: 30) disrupting the transfer of the sugar moiety onto the backbone of the polyketide core and producing the non-glycosylated Compound 8. Figure 22b: inactivation of sugar oxidoreductase gene product of ORF 13 (SEQ ID NO: 28) followed by transfer of the glucose onto the polyketide backbone chain by the glycosyltransferase gene product of ORF 14 (SEQ ID NO: 29) producing Compound 11.

Figure 23: inactivation of acyltransferase ORF 16 (SEQ ID NO: 33), acyl CoA ligase ORF 17 (SEQ ID NO: 35), or adenylating/condensing synthetase ORF 15 (SEQ ID NO: 31) so as to produce Compound 7.

Figure 24: incorporation of an amidino hydrolase to catalyze the conversion of 4-guanidinobutanamide to γ -amino butanamide resulting in production of Compound 9.

DETAILED DESCRIPTION OF THE INVENTION:

The present invention relates to novel polyene polyketides, exemplified herein as Compound 1, Compound 2 and Compound 7, which are isolated from strains of actinomycetes, *Amycolatopsis* sp. such as *Amycolatopsis orientalis* ATCC™ 43491, or a mutant or a variant thereof.

The invention further relates to pharmaceutically acceptable salts and derivatives of Compound 1, Compound 2 and Compound 7, and to methods for obtaining such compounds. One method of obtaining the compounds is by cultivating *Amycolatopsis orientalis* ATCC™ 43491, or a mutant or a variant thereof, under suitable *Amycolatopsis* sp. culture conditions preferably using the fermentation protocol described herein below.

The invention also relates to polyene polyketides of Formula I, exemplified herein as Compounds 3, 4, 5 and 6, produced from Compound 1, Compound 2 or Compound 7 by selective chemical modification of Compound 1, Compound 2 or Compound 7 using techniques described herein and well known to those skilled in the synthesis of natural products.

The present invention also relates to pharmaceutical compositions comprising a polyene polyketide selected from any one of Compounds 1 to 7, pharmaceutically acceptable salts or prodrugs of any one of Compounds 1 to 7, and derivatives of any

3010-5PCT-7CA

- 29 -

one of Compounds 1 to 7 as defined by Formula I. In another aspect of the invention, Compounds 1 to 7 are each useful as antibacterial agents, and for use as inhibitors of bacterial cell growth. Accordingly, in an aspect the present invention relates to pharmaceutical compositions comprising any one of Compounds 1 to 7 of the invention together with a pharmaceutically acceptable carrier and methods of using the compositions as antibacterial agents to inhibit bacterial cell growth.

The following detailed description discloses how to make and use any of Compounds 1 to 7, compounds of Formula I and compositions containing these compounds to inhibit microbial growth.

10 Accordingly, certain aspects of the present invention relate to pharmaceutical compositions comprising the polyene polyketide compounds of the present invention together with a pharmaceutically acceptable carrier, methods of using the compositions to inhibit bacterial growth, and methods of using the pharmaceutical compositions to treat diseases, including cancer, and chronic and acute inflammation.

The present invention also provides the biosynthetic locus from *Amycolatopsis orientalis* strain ATCC™ 43491 which biosynthetic locus is responsible for producing the compounds of Formula I. Thus the invention provides polynucleotides and polypeptides useful in the production and engineering of compounds of Formula I.

20

Definitions

Molecular terms, when used in this application, have their common meaning unless otherwise specified.

Abbreviations, as used herein, have the following meaning: Me refers to methyl (CH₃), Et refers to ethyl (CH₂CH₃), Pr refers to *n*-propyl (CH₂CH₂CH₃) and Ac refers to acetyl (C(O)CH₃).

The term alkyl refers to a linear or branched hydrocarbon groups. Examples of alkyl groups include, without limitation, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, pentyl, hexyl, heptyl, cyclopentyl, cyclohexyl, cyclohexymethyl, and the like. Alkyl may
30 optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl.

3010-5PCT-7CA

- 30 -

The term alkenyl refers to linear, branched or cyclic hydrocarbon groups containing at least one carbon-carbon double bond. Examples of alkenyl groups include, without limitation, vinyl, 1-propene-2-yl, 1-butene-4-yl, 2-butene-4-yl, 1-pentene-5-yl and the like. Alkenyl may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, alkoxy, aryloxy, sulfinyl, sulfonyl, formyl, oxo and guanidino. The double bond portion(s) of the unsaturated hydrocarbon chain may be either in the cis or trans configuration.

10 The term cycloalkyl or cycloalkyl ring refers to a saturated or partially unsaturated carbocyclic ring in a single or fused carbocyclic ring system having from three to fifteen ring members. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclohexyl, and cycloheptyl. Cycloalkyl may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.

20 The term heterocyclyl, heterocyclic or heterocyclyl ring refers to a saturated or partially unsaturated ring containing one to four hetero atoms or hetero groups selected from O, N, NH, NR^x, PO₂, S, SO or SO₂ in a single or fused heterocyclic ring system having from three to fifteen ring members. Examples of a heterocyclyl, heterocyclic or heterocyclyl ring include, without limitation, morpholinyl, piperidinyl, and pyrrolidinyl. Heterocyclyl, heterocyclic or heterocyclyl ring may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, oxo, thiocarbonyl, imino, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.

The term amino acid refers to any natural amino acid, all natural amino acids are well known to a person skilled in the art.

The term halo is defined as a bromine, chlorine, fluorine or iodine.

30 The term aryl or aryl ring refers to common aromatic groups having "4n+2" electrons, wherein n is an integer from 1 to 3, in a monocyclic or conjugated polycyclic system and having from five to fifteen ring atoms. Aryl ring may include from 1 to 3 heteroatoms such as nitrogen, oxygen and sulphur atoms. Examples of aryl include,

3010-5PCT-7CA

- 31 -

without limitation, phenyl, naphthyl, biphenyl, terphenyl, furyl, pyrrolyl, thienyl, pyridyl, oxazolyl, imidazolyl, pyrazolyl and indolyl groups. Aryl may optionally be substituted with one or more substituent group selected from acyl, amino, acylamino, acyloxy, azido, alkythio, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.

The compounds of the present invention can possess one or more asymmetric carbon atoms and can exist as optical isomers forming mixtures of racemic or non-racemic compounds. The compounds of the present invention are useful as a single isomer
10 or as a mixture of stereochemical isomeric forms. Diastereoisomers, i.e., nonsuperimposable stereochemical isomers, can be separated by conventional means such as chromatography, distillation, crystallization or sublimation. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes.

The invention embraces isolated compounds. An isolated compound refers to a compound which represents at least 10%, 20%, 50% and 80% of the compound of the present invention present in a mixture, provided that the mixture comprising the compound of the invention has demonstrable (i.e. statistically significant) biological activity including antimicrobial activity when tested in conventional biological assays
20 known to a person skilled in the art.

As used herein, the term "treatment" refers to the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disorder, e.g., a disease or condition, a symptom of disease, or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease, the symptoms of disease, or the predisposition toward disease.

As used herein, a "pharmaceutical composition" comprises a pharmacologically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. As used herein, "pharmacologically effective amount," "therapeutically
30 effective amount" or simply "effective amount" refers to that amount of polyene polyketide effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 25% reduction in a measurable parameter associated with a

3010-5PCT-7CA

- 32 -

disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 25% reduction in that parameter.

The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, 10 lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. The term "pharmaceutically acceptable salts" include acid addition salts and base addition salts. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Without being limited, examples of acid addition salts 20 include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulphuric, phosphoric, formic, acetic, citric, tartaric, succinic, oxalic, malic, glutamic, propionic, glycolic, gluconic, maleic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, β -hydroxybutyric, malonic, galactantic, galacturonic acid and the like. Suitable pharmaceutically-acceptable base addition salts of compounds of the invention include, but are not limited to, metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, lysine, procaine and 30 the like. Additional examples of pharmaceutically acceptable salts are listed in Berge SM et al., *Journal of Pharmaceutical Sciences*, (1977) Vol. 66 no 1, pp. 1-19. All of these salts may be prepared by conventional means from the corresponding compounds of Formula I by treating with the appropriate acid or base.

3010-5PCT-7CA

- 33 -

The term "isolated" polynucleotide or polypeptide means that the material is removed from its original environment, e.g. the natural environment if it is naturally-occurring. For example, a naturally-occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

10 The term "purified" polynucleotide or polypeptide does not require absolute purity; rather, it is intended as a relative definition. Individual nucleic acids obtained from a library have been conventionally purified to electrophoretic homogeneity. The purified nucleic acids of the present invention have been purified from the remainder of the genomic DNA in the organism by at least 10^4 to 10^6 fold. However, the term "purified" also includes nucleic acids which have been purified from the remainder of the genomic DNA or from other sequences in a library or other environment by at least one order of magnitude, preferably two or three orders of magnitude, and more preferably four or five orders of magnitude.

20 "Recombinant" nucleic acid means that the nucleic acid is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment. "Enriched" nucleic acids represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. "Backbone" molecules include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid of interest. Preferably, the enriched nucleic acids represent 15% or more, more preferably 50% or more, and most preferably 90% or more, of the number of nucleic acid inserts in the population of recombinant backbone molecules.

30 "Recombinant" polypeptides or proteins refer to polypeptides or proteins produced by the reassortment of sections of DNA or RNA sequences between at least two DNA or RNA molecules that are created by recombinant DNA techniques that are well known in the art. An extensive guide to such techniques is described in Sambrook *et al.*, (1989), Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press. "Synthetic" polypeptides or proteins are those prepared by chemical synthesis.

3010-5PCT-7CA

- 34 -

A "coding sequence" or "sequence encoding" a particular polypeptide or protein, is a DNA sequence which is transcribed and translated into a polypeptide or protein when placed under the control of appropriate regulatory sequences.

Thus, as used herein, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide that includes only coding sequence for the polypeptide as well as a polynucleotide that includes additional coding and/or non-coding sequence.

The term "complement" and "complementary", refers to the ability of two single stranded nucleic acid fragments to sufficiently base pair with each other or to
10 "hybridize" under certain stringent conditions. By way of example, and not limitation, a procedure of using high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hrs. to overnight at 65⁰ C in buffer composed of 6X SSC, 5X Denhardt's solution and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65⁰ C in prehybridization buffer mixture containing a labeled probe (e.g. 5-20 X 10⁶ ³²P labeled probe). Washing of the hybridized filters is conducted at 37⁰ C for 1 hr. in a solution of containing 2 X SSC, 0.1 % SDS. This is followed by a wash in 0.1 X SSC, 0.1 % SDS at 50⁰ C for 45 min. followed by autoradiography. Other conditions for stringency are described in Sambrook *et al.*, *supra*.

20 Expression "control sequences" refers collectively to promoter sequences, ribosomal binding sites, polyadenylation signals, transcription termination sequences, regulatory regions, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell. Not all these control sequences need always be present in a recombinant vector so long as the desired gene is capable of being transcribed or translated.

"Oligonucleotide" refers to a nucleic acid, generally of at least 10 to about 100 nucleotides, that are hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene or other nucleic acid of interest.

A promoter sequence is "operably linked to" a coding sequence recognized by RNA
30 polymerase which initiates transcription at the promoter and transcribes the coding sequence into mRNA.

"Plasmids" are designated herein by a lower case p preceded or followed by capital letters and/or numbers. The starting plasmids herein are commercially available,

3010-5PCT-7CA

- 35 -

publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described herein are known in the art and will be apparent to the skilled artisan.

“Digestion” of DNA refers to enzymatic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinary skilled artisan. For analytical purposes, typically 1 µg of plasmid or DNA fragment is used with about 2
10 units of enzyme in about 20 µl of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the gel electrophoresis may be performed to isolate the desired fragment.


Unless otherwise indicated, all numbers expressing quantities of ingredients and properties such as molecular weight, reaction conditions, MIC and so forth used in the specification and claims are to be understood as being modified in all instances
20 by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present specification and attached claims are approximations. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of significant figures and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the examples, tables and figures are reported as precisely as possible. Any numerical values may inherently contain certain errors resulting from variations in experiments, testing measurements, statistical analysis
30 and such.

3010-5PCT-7CA


- 36 -

Compounds of the invention


In one aspect of this embodiment the invention relates to novel polyene polyketides, referred to herein as Compounds 1 to Compound 7:



Compound 1;




Compound 2;




10

Compound 3;




Compound 4;




Compound 5;

3010-5PCT-7CA

- 37 -



Compound 6;




Compound 7;

or, to a pharmaceutically acceptable salt or prodrug of any of Compounds 1 to 7.
Compounds 1 to 7 may be characterized by any one or more of their
physicochemical and spectral properties given below, such as mass, UV, and NMR
spectroscopic data.

10

In another aspect the invention relates to derivatives of Compound 1 to 7, as
represented by the polyene polyketides of Formula I:




Formula I

wherein,

A is selected from $-\text{C}(\text{NH})\text{NHR}^1$, CH_3 , H or

20



;

R^1 is selected from H, C_{1-6} alkyl, C_{6-10} aryl, $\text{C}(\text{O})\text{C}_{1-6}$ alkyl and $\text{C}(\text{O})\text{C}_{6-10}$ aryl;

R^2 and R^3 are each independently selected from H, C_{1-6} alkyl, C_{2-7} alkene and C_{6-10}
aryl;


3010-5PCT-7CA

- 38 -

R^4 is selected from H or CH_3 ;

Z is OH or O when taken with adjacent carbon atom to form a carbonyl; or

Z may be a tetrahydropyranoxy of formula:




R^5 is selected from H, $COOH$, C_{1-6} alkyl or $C(O)OC_{1-6}$ alkyl;

R^6 , R^7 and R^8 are each independently selected from H, C_{1-6} alkyl and $C(O)C_{1-6}$ alkyl;

or

R^6 , R^7 and R^8 may each independently be absent when the adjacent oxygen and carbon atoms are taken together to form a carbonyl; or


- 10 R^6 , R^7 and R^8 may each independently be a bond when any of two neighboring R^6 , R^7 and R^8 are taken together with attached oxygen and carbon atoms to form a 1,3-dioxolane ring of formula:



R^9 and R^{10} are each independently selected from H, C_{1-6} alkyl, C_{2-7} alkene and C_{6-10} aryl; or

R^9 and R^{10} are taken together with adjacent carbon atom to form a ring having from 5 to 7 carbons;

D is selected from OH, NH_2 , $NH(C_{1-3}alkyl)$, $N(C_{1-3}alkyl)_2$, $OC_{1-3}alkyl$ or



- 20 R^{11} is selected from H or C_{1-3} alkyl;

or a pharmaceutically acceptable salt or prodrug thereof.

3010-5PCT-7CA


- 39 -

In an embodiment the invention provides compounds of Formula I, wherein A is —C(NH)NH_2 ; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment of the invention provides compounds of Formula I, wherein A is H; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein A is —C(NH)NHC(O)CH_3 ; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

- 10 In a further embodiment the invention provides compounds of Formula I, wherein A is




and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein R^4 is CH_3 ; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein R^4 is H; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

- 20 In a further embodiment the invention provides compounds of Formula I, wherein Z is




and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^6 , R^7 and R^8 are each H, and R^5 is COOH , all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein Z is

3010-5PCT-7CA


- 40 -



and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^6 , R^7 and R^8 are each H, and R^5 is CO_2CH_3 , all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein Z is OH and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.


In a further embodiment the invention provides compounds of Formula I, wherein D is



10

and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^{11} is H and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

In a further embodiment the invention provides compounds of Formula I, wherein D is



and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof. In a subclass of this embodiment R^{11} is CH_3 and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.


In another embodiment the invention provides compounds of Formula I, wherein D is OH; and all other groups are as previously defined; or a pharmaceutically acceptable salt or prodrug thereof.

20


The following are exemplary compounds of the invention:

3010-5PCT-7CA


- 41 -




Compound 1;




Compound 2;




Compound 3;



Compound 4;




Compound 5;




Compound 6;

3010-5PCT-7CA


- 42 -




Compound 7;




Compound 8;




Compound 9;




Compound 10;



Compound 11;




Compound 12;




Compound 13;

3010-5PCT-7CA


- 43 -




Compound 14;




Compound 15;




Compound 16;




Compound 17;



Compound 18;




Compound 19;




Compound 20;

3010-5PCT-7CA


- 44 -




Compound 21;




Compound 22;




Compound 23;



Compound 24;




Compound 25;




3010-5PCT-7CA

- 45 -

Compound 26;



Compound 27 and



Compound 28;

or a pharmaceutically acceptable salt or prodrug of any one of Compound 1-28.
 Certain embodiments may exclude one or more of the compounds of Formula I.

10 III. Methods for producing the compounds of the invention by fermentation

The compounds of Formula I may be biosynthesized by various microorganisms. Microorganisms that may synthesize the compounds of the present invention include but are not limited to bacteria of the order Actinomycetales, also referred to as actinomycetes. Non-limiting examples of members belonging to the genera of Actinomycetes include *Nocardia*, *Geodermatophilus*, *Actinoplanes*, *Micromonospora*, *Nocardioidea*, *Saccharothrix*, *Amycolatopsis*, *Kutzneria*, *Saccharomonospora*, *Saccharopolyspora*, *Kitasatospora*, *Streptomyces*, *Microbispora*, *Streptosporangium*, *Actinomadura*. The taxonomy of actinomycetes is complex and reference is made to Goodfellow (1989) Suprageneric classification of actinomycetes, *Bergey's Manual of Systematic Bacteriology*, Vol. 4, Williams and Wilkins, Baltimore, pp 2322-2339, and to Embley and Stackebrandt, (1994), and *The molecular phylogeny and systematics of the actinomycetes*, *Annu. Rev. Microbiol.* 48, 257-289 (1994), for genera that may synthesize the compounds of the invention.

Microorganisms biosynthetically producing compounds of Formula I are cultivated in culture media containing known nutritional sources for actinomycetes having assimilable sources of carbon, nitrogen plus optional inorganic salts and other known

3010-5PCT-7CA

- 46 -

growth factors at a pH of about 6 to about 9, non-limiting examples of growth media are provided in Table 1. Microorganisms are cultivated at incubation temperatures of about 20⁰ C to about 40⁰ C for about 3 to about 40 days.

The culture media inoculated with the microorganisms, which biosynthetically produce compounds of Formula I, may be aerated by incubating the inoculated culture media with agitation, for example shaking on a rotary shaker, or a shaking water bath. Aeration may also be achieved by the injection of air, oxygen or an appropriate gaseous mixture to the inoculated culture media during incubation.

After cultivation and production of compounds of Formula I, the compounds can be
 10 extracted and isolated from the cultivated culture media by techniques known to a skilled person in the art and/or disclosed herein, including for example centrifugation, chromatography, adsorption. For example, the cultivated culture media can be mixed with a suitable organic solvent such as n-butanol, n-butyl acetate and 4-methyl-2-pentanone, the organic layer can be separated for example, by centrifugation followed by the removal of the solvent, by evaporation to dryness or by evaporation to dryness under vacuum. The resulting residue can optionally be reconstituted with for example water, ethyl ether, ethanol acetate, methanol or a mixture thereof, and re-extracted in a two-phase system with a suitable organic solvent such as hexane, carbon tetrachloride, methylene chloride or a mixture
 20 thereof. After removal of the solvent, the compound of Formula I can be further purified by the use of standard techniques such as chromatography.

TABLE 1: Fermentation media

Component	CA	CB	GA ^a	JA	NA	OA	RM
pH ^b	7	7		7.3	7	7	6.9
Glucose	10		10			10	10
Sucrose		20	103				100
Cane molasses	15	5			10		
Corn starch				30			
Potato dextrin	40						
Corn steep liquor				15		3	
Yeast extract			5			3	5
Malt extract				35		3	
Pharmamedia TM				15			
Glycerol					20	5	
N-Z Amine A	10						
Beef extract						3	

3010-5PCT-7CA

- 47 -

Component	CA	CB	GA ^a	JA	NA	OA	RM
Bacto-peptone		2			1		
Casamino acid			0.1		5		0.1
Thiamine						0.1	
MgSO ₄ ·7H ₂ O	1	0.2					
MgCl ₂ ·6H ₂ O			10.12				10.13
CaCO ₃	2	5		2	4	2	
K ₂ SO ₄			0.25				0.25
FeSO ₄ ·7H ₂ O		0.1					
KI		0.5					
MOPS							21
Trace Elements Solution ^c ml/L			2				2

Unless otherwise indicated, all the components are in gm/L

To a liter of media GA add: 10 ml KH₂PO₄ (0.5% solution); 80 ml CaCl₂·2H₂O (3.68% solution); 15 ml L-proline (20% solution); 100 ml TES buffer (5.73% solution, pH 7.2); 5 ml NaOH (1N solution).

The pH is adjusted as marked prior to the addition of CaCO₃.

Solution of trace elements contains: ZnCl₂ 40 mg; FeCl₃·6H₂O (200 mg); CuCl₂·2H₂O (10 mg); (NH₄)₆Mo₇O₂₄·4H₂O (10 mg) per litre.


3010-5PCT-7CA

- 48 -

IV. Chemical modifications of Compounds 1 to 7

The compounds of Formula I that are biosynthesized by microorganisms may optionally be subjected to chemical modifications to form compounds that are derivatives or structural analogs of compounds of Formula I. Derivatives or structural analogs of compounds of Formula I having similar functional activities are within the scope of the present invention. Compounds of Formula I may optionally be modified using methods known in the art and described herein.

General principles of organic chemistry including functional moieties, reactivity and common protocols are described, for example, in Advanced Organic Chemistry 3rd Edition by Jerry March (1985). In addition, it will be appreciated by one of ordinary skill in the art that the synthetic methods described herein may use a variety of protecting groups, whether or not they are explicitly described. A "protecting group" as used herein means a moiety used to block one or more functional moieties such as reactive groups including oxygen, sulfur or nitrogen, so that a reaction can be carried out selectively at another reactive site in a polyfunctional compound. General principles for the use of protective groups, their applicability to specific functional groups and their uses are described for example in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York (1999),

Scheme 1: Modifications of acidic functions:

Scheme 1


wherein R is alkyl or aryl and X is a suitable leaving group

3010-5PCT-7CA

- 49 -

In Scheme 1, acidic functional groups are alkylated either individually or together. Simple ester is prepared from treatment of the carboxylic acid by an RX reagent such as diazoalkanes in the appropriate solvent. In Scheme 1, hydroxycyclopentenone is converted to alkoxycyclopentenone by similar treatment with the suitable RX reagent. In Scheme 1, carboxylic acids are also converted to alcohol by a reducing agent [H] such as lithiumaluminum hydride. Scheme 1 is used to obtain Compounds 3, 4, 5, 11 and 24 from Compound 1, Compounds 17, 18, 20, 26 and 28 respectively from Compounds 2, 7, 11, 25 and 27.

Scheme 2: Modifications to alcohol functions:



Scheme 2

wherein R and X are as in Scheme 1 and R' is alkyl, aryl or H


In Scheme 2, an alkylating agent such as methyl iodide, converts alcohol to ether in the presence of a base such as potassium *tert*-butoxide. In Scheme 2, ester is obtained from the reaction of the alcohol with an activated carboxylic acid such as acid halides or anhydrides and N-hydroxysuccinimide esters in the presence of a base like diisopropylethylamine. In Scheme 2, a ketone is obtained from the oxidation of the alcohol by an oxidizing agent [O] such as Dess-Martin (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)one) or Swern (oxalyl chloride and methylsulfoxide) reagents. In

3010-5PCT-7CA

- 50 -

scheme 2, a vicinal diol is converted to a 1,3-dioxolane ring by reaction with a ketone or an aldehyde (when R' is H) using an acid catalyst such as p-toluenesulfonic acid with removal of the water formed (like: Dean-Stark or molecular sieves). Scheme 2 is used to obtain Compound 10 from Compound 8, Compound 28 from Compound 3, Compounds 21 and 22 from Compound 5 and Compounds 25 and 27 from Compound 1.

Scheme 3: Modifications of guanidine group:



Scheme 3

wherein R and X are as in Scheme 1

In Scheme 3, a pyrimidine ring is obtained from the condensation of the guanidine group with a diketone, such as 2,4-pentadione in a solvent like ethanol under reflux. In Scheme 3, the guanidine functional group is enzymatically [E] hydrolyzed to amine in the appropriate conditions. In Scheme 3, the guanidine group or the amine group are alkylated by a suitable RX or acylated by a suitable RC(O)X in the presence of a base. Scheme 3 is used to produce Compounds 9, 13, 19 and 22 respectively from Compounds 2, 12, 17 and 5 and Compounds 6, 23 and 25 from Compound 1.

3010-5PCT-7CA

- 51 -

The following examples illustrate the invention but are not to be construed as limiting. Unless otherwise noted, all reagents were purchased from Sigma Chemical Co. (St. Louis, MO), (Aldrich).

Genes and proteins for producing the compounds of the invention

The invention also provides the genes and proteins forming the biosynthetic locus for the production of the compounds of Formula I.

Nucleic acid sequences encoding proteins involved in the biosynthesis of compounds of Formula I are provided in the accompanying sequence listing as SEQ ID NOS: 3, 5, 7, 9, 10 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57.

Polypeptides involved in the biosynthesis of compounds of Formula I are provided in the accompanying sequence listing as SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56.

One aspect of the present invention is an isolated, purified, or enriched nucleic acid comprising one of the sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57, the sequences complementary thereto, and isolated, purified or enriched nucleic acids having at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% identity to the above sequences as determined by analysis with BLASTN™ version 2.0 with the default parameters.

20 The isolated, purified or enriched nucleic acids may comprise DNA, including cDNA, genomic DNA, and synthetic DNA. The DNA may be double stranded or single stranded, and if single stranded may be the coding (sense) or non-coding (anti-sense) strand. Alternatively, the isolated, purified or enriched nucleic acids may comprise RNA. As discussed in more detail below, the isolated, purified or enriched nucleic acids of one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57 may be used to prepare one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 respectively or an isolated or purified polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% homology to the polypeptide of SEQ ID NOS: 2, 4, 30 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 as determined by analysis with BLASTP™ version 2.2.2 with the default parameters.

3010-5PCT-7CA

- 52 -

Accordingly, another aspect of the present invention is an isolated, purified or enriched nucleic acid which encodes one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 or an isolated or purified polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% homology to the polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 as determined by analysis with BLASTP™ version 2.2.2 with the default parameters. The coding sequences of these nucleic acids may be identical to one of the coding sequences of one of the nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57 or may be different coding sequences which encode one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 or fragments comprising at least 50, 75, 100, 150, 200, 300 consecutive amino acids of one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 as a result of the redundancy or degeneracy of the genetic code. The genetic code is well known to those of skill in the art and can be obtained, for example, from Stryer, *Biochemistry*, 3rd edition, W. H. Freeman & Co., New York (1998).

The isolated, purified or enriched nucleic acid which encodes one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, may include, but is not limited to: (1) only the coding sequences of one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57; (2) the coding sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57 and additional coding sequences, such as leader sequences or proprotein; and (3) the coding sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57 and non-coding sequences, such as introns or non-coding sequences 5' and/or 3' of the coding sequence.

The invention relates to polynucleotides based on SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57 but having polynucleotide changes that are "silent", for example changes which do not alter the amino acid sequence encoded by the polynucleotides of SEQ ID NOS: 3, 5, 7, 9, 11, 13,

3010-5PCT-7CA

- 53 -

15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57. The invention also relates to polynucleotides which have nucleotide changes which result in amino acid substitutions, additions, deletions, fusions and truncations of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56. Such nucleotide changes may be introduced using techniques such as site directed mutagenesis, random chemical mutagenesis, exonuclease III deletion, and other recombinant DNA techniques.

The isolated, purified or enriched nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57, the sequences
10 complementary thereto may be used as probes to identify and isolate DNAs encoding the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 respectively. In such procedures, a genomic DNA library is constructed from a sample microorganism or a sample containing a microorganism capable of producing a polyketide. The genomic DNA library is then contacted with a probe comprising a coding sequence or a fragment of the coding sequence, encoding one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or a fragment thereof under conditions which permit the probe to specifically hybridize to sequences complementary thereto. In a preferred embodiment, the probe is an oligonucleotide of
20 about 10 to about 30 nucleotides in length designed based on a nucleic acid of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57. Genomic DNA clones which hybridize to the probe are then detected and isolated. Procedures for preparing and identifying DNA clones of interest are disclosed in Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. (1997); and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbor Laboratory Press, (1989). In another embodiment, the probe is a restriction fragment or a PCR amplified nucleic acid derived from SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57.

30 The isolated, purified or enriched nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57, the sequences

3010-5PCT-7CA

- 54 -

complementary thereto may be used as probes to identify and isolate related nucleic acids. In some embodiments, the related nucleic acids may be genomic DNAs (or cDNAs) from potential polyketide producers. In such procedures, a nucleic acid sample containing nucleic acids from a potential microbial producer of a compound of Formula I is contacted with the probe under conditions that permit the probe to specifically hybridize to related sequences. The nucleic acid sample may be a genomic DNA (or cDNA) library from the potential polyketide-producer. Hybridization of the probe to nucleic acids is then detected using any of the methods described above.

Hybridization may be carried out under conditions of low stringency, moderate
10 stringency or high stringency. As an example of nucleic acid hybridization, a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45 °C in a solution consisting of 0.9 M NaCl, 50 mM NaH₂PO₄, pH 7.0, 5.0 mM Na₂EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/ml polyriboadenylic acid. Approximately 2×10^7 cpm (specific activity $4-9 \times 10^8$ cpm/ug) of ³²P end-labeled oligonucleotide probe are then added to the solution. After 12-16 hours of incubation, the membrane is washed for 30 minutes at room temperature in 1X SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na₂EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh 1X SET at T_m-10°C for the oligonucleotide probe where T_m is the melting temperature. The membrane is then exposed to autoradiographic film for
20 detection of hybridization signals.

By varying the stringency of the hybridization conditions used to identify nucleic acids, such as genomic DNAs or cDNAs, which hybridize to the detectable probe, nucleic acids having different levels of homology to the probe can be identified and isolated.

Stringency may be varied by conducting the hybridization at varying temperatures below the melting temperatures of the probes. The melting temperature of the probe may be calculated using the following formulas:

For oligonucleotide probes between 14 and 70 nucleotides in length the melting temperature (T_m) in degrees Celcius may be calculated using the formula:

T_m=81.5+16.6(log [Na⁺]) + 0.41(fraction G+C)-(600/N) where N is the length of the
30 oligonucleotide.

3010-5PCT-7CA

- 55 -

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation $T_m = 81.5 + 16.6(\log [Na^+]) + 0.41(\text{fraction G + C}) - (0.63\% \text{ formamide}) - (600/N)$ where N is the length of the probe. Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 0.1 mg/ml denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 0.1 mg/ml denatured fragmented salmon sperm DNA, 50% formamide. The composition of the SSC and Denhardt's solutions are listed in Sambrook et al., *supra*. Hybridization is conducted by adding the detectable probe to the hybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured by

10 incubating at elevated temperatures and quickly cooling before addition to the hybridization solution. It may also be desirable to similarly denature single stranded probes to eliminate or diminish formation of secondary structures or oligomerization. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25 °C below the T_m . For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 5-10 °C below the T_m . Preferably, the hybridization is conducted in 6X SSC, for shorter probes. Preferably, the hybridization is conducted in 50% formamide containing solutions, for

20 longer probes.

All the foregoing hybridizations would be considered to be examples of hybridization performed under conditions of high stringency.

Following hybridization, the filter is washed for at least 15 minutes in 2X SSC, 0.1% SDS at room temperature or higher, depending on the desired stringency. The filter is then washed with 0.1X SSC, 0.5% SDS at room temperature (again) for 30 minutes to 1 hour. Nucleic acids which have hybridized to the probe are identified by conventional autoradiography and non-radioactive detection methods.

The above procedure may be modified to identify nucleic acids having decreasing levels of homology to the probe sequence. For example, to obtain nucleic acids of decreasing

30 homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5 °C from 68 °C to 42

3010-5PCT-7CA

- 56 -

°C in a hybridization buffer having a Na⁺ concentration of approximately 1M. Following hybridization, the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate stringency" conditions above 50°C and "low stringency" conditions below 50°C. A specific example of "moderate stringency" hybridization conditions is when the above hybridization is conducted at 55°C. A specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 45°C.

Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42 °C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50 °C. These conditions are considered to be "moderate stringency" conditions above 25% formamide and "low stringency" conditions below 25% formamide. A specific example of "moderate stringency" hybridization conditions is when the above hybridization is conducted at 30% formamide. A specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 10% formamide.

Nucleic acids which have hybridized to the probe are identified by conventional autoradiography and non-radioactive detection methods.

For example, the preceding methods may be used to isolate nucleic acids having a sequence with at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% homology to a nucleic acid sequence selected from the group consisting of the sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57, fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases thereof, and the sequences complementary thereto. Homology may be measured using BLASTN™ version 2.0 with the default parameters. For example, the homologous polynucleotides may have a coding sequence that is a naturally occurring allelic variant of one of the coding sequences described herein. Such allelic variant may have a substitution, deletion or addition of one or more nucleotides when compared to the nucleic acids of

3010-5PCT-7CA

- 57 -

SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 51, 53, 55, 57, or the sequences complementary thereto.

Additionally, the above procedures may be used to isolate nucleic acids which encode polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, or at least 70% homology to a polypeptide having the sequence of one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or fragments comprising at least 50, 75, 100, 150, 200, 300 consecutive amino acids thereof as determined using the BLASTP™ version 2.2.2 algorithm with default parameters.

- 10 Another aspect of the present invention is an isolated or purified polypeptide comprising the sequence of one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof. As discussed herein, such polypeptides may be obtained by inserting a nucleic acid encoding the polypeptide into a vector such that the coding sequence is operably linked to a sequence capable of driving the expression of the encoded polypeptide in a suitable host cell. For example, the expression vector may comprise a promoter, a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for modulating expression levels, an origin of replication and a selectable
- 20 marker.

Promoters suitable for expressing the polypeptide or fragment thereof in bacteria include the *E.coli lac* or *trp* promoters, the *lacI* promoter, the *lacZ* promoter, the T3 promoter, the T7 promoter, the *gpt* promoter, the lambda P_R promoter, the lambda P_L promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter. Fungal promoters include the α factor promoter. Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter, LTRs from retroviruses, and the mouse metallothionein-I promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their

30 viruses may also be used.

3010-5PCT-7CA

- 58 -

Mammalian expression vectors may also comprise an origin of replication, any necessary ribosome binding sites, a polyadenylation site, splice donors and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. In some embodiments, DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Vectors for expressing the polypeptide or fragment thereof in eukaryotic cells may also contain enhancers to increase expression levels. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300 bp in length that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancers. In addition, the expression vectors preferably contain one or more selectable marker genes to permit selection of host cells containing the vector. Examples of selectable markers that may be used include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in *E. coli*, and the *S. cerevisiae* TRP1 gene.

In some embodiments, the nucleic acid encoding one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptides or fragments thereof. Optionally, the nucleic acid can encode a fusion polypeptide in which one of the polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is fused to heterologous peptides or polypeptides, such as N-terminal identification peptides which impart desired characteristics such as increased stability or simplified purification or detection.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction

3010-5PCT-7CA

- 59 -

endonucleases. Alternatively, appropriate restriction enzyme sites can be engineered into a DNA sequence by PCR. A variety of cloning techniques are disclosed in Ausbel et al. Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. (1997) and Sambrook et al., Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbour Laboratory Press, (1989). Such procedures and others are deemed to be within the scope of those skilled in the art.

The vector may be, for example, in the form of a plasmid, a viral particle, or a phage. Other vectors include derivatives of chromosomal, nonchromosomal and synthetic DNA sequences, viruses, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. A variety of cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989).

Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC™ 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), pGEM1 (Promega Biotec, Madison, WI, USA) pQE70, pQE60, pQE-9 (Qiagen), pD10, phiX174, pBluescript™ II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7. Particular eukaryotic vectors include pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other vector may be used as long as it is replicable and stable in the host cell.

The host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells or eukaryotic cells. As representative examples of appropriate hosts, there may be mentioned: bacteria cells, such as *E. coli*, *Streptomyces*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, fungal cells, such as yeast, insect cells such as *Drosophila S2* and *Spodoptera Sf9*, animal cells such as CHO, COS or Bowes melanoma, and adenoviruses. The selection of an appropriate host is within the abilities of those skilled in the art.

3010-5PCT-7CA

- 60 -

The vector may be introduced into the host cells using any of a variety of techniques, including electroporation transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Where appropriate, the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.

- 10 Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification. Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art. The expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can
- 20 be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps. Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts (described by Gluzman, Cell, 23:175(1981)), and other cell lines capable of expressing proteins from a compatible vector, such as the C127, 3T3, CHO, HeLa and BHK cell lines.

- 30 The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Depending upon the host employed in a recombinant production procedure, the polypeptide produced by host cells containing the vector may be glycosylated or may be non-glycosylated. Polypeptides of the invention may or may not also include an initial methionine amino acid residue.

3010-5PCT-7CA

- 61 -

Alternatively, the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof can be synthetically produced by conventional peptide synthesizers. In other embodiments, fragments or portions of the polynucleotides may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides.

Cell-free translation systems can also be employed to produce one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof using mRNAs transcribed from a DNA construct comprising a promoter operably linked to a nucleic acid encoding the polypeptide or fragment thereof. In some embodiments, the DNA construct may be linearized prior to conducting an *in vitro* transcription reaction. The transcribed mRNA is then incubated with an appropriate cell-free translation extract, such as a rabbit reticulocyte extract, to produce the desired polypeptide or fragment thereof.

The present invention also relates to variants of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof. The term "variant" includes derivatives or analogs of these polypeptides. In particular, the variants may differ in amino acid sequence from the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination.

The variants may be naturally occurring or created *in vitro*. In particular, such variants may be created using genetic engineering techniques such as site directed mutagenesis, random chemical mutagenesis, Exonuclease III deletion procedures, and standard cloning techniques. Alternatively, such variants, fragments, analogs, or derivatives may be created using chemical synthesis or modification procedures. Other methods of making variants are also familiar to those skilled in the art. These include procedures in which nucleic acid sequences obtained from natural isolates are

3010-5PCT-7CA

- 62 -

modified to generate nucleic acids that encode polypeptides having characteristics which enhance their value in industrial or laboratory applications. In such procedures, a large number of variant sequences having one or more nucleotide differences with respect to the sequence obtained from the natural isolate are generated and characterized. Preferably, these nucleotide differences result in amino acid changes with respect to the polypeptides encoded by the nucleic acids from the natural isolates. For example, variants may be created using error prone PCR. In error prone PCR, DNA amplification is performed under conditions where the fidelity of the DNA polymerase is low, such that a high rate of point mutation is obtained along the entire length of the PCR product. Error prone PCR is described in Leung, D.W., *et al.*, *Technique*, 1:11-15 (1989) and Caldwell, R. C. & Joyce G.F., *PCR Methods Applic.*, 2:28-33 (1992). Variants may also be created using site directed mutagenesis to generate site-specific mutations in any cloned DNA segment of interest. Oligonucleotide mutagenesis is described in Reidhaar-Olson, J.F. & Sauer, R.T., *et al.*, *Science*, 241:53-57 (1988). Variants may also be created using directed evolution strategies such as those described in US patent nos. 6,361,974 and 6,372,497. The variants of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, may be (i) variants in which one or more of the amino acid residues of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code.

Conservative substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, Val, Leu and Ile with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa; replacement of an acidic residue such as Asp or Glu with another acidic residue; replacement of a residue bearing an amide group, such as Asn or Gln, with another residue bearing an amide group; exchange of a basic residue such

3010-5PCT-7CA

- 63 -

as Lys or Arg with another basic residue; and replacement of an aromatic residue such as Phe or Tyr with another aromatic residue.

Other variants are those in which one or more of the amino acid residues of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56 includes a substituent group.

Still other variants are those in which the polypeptide is associated with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

Additional variants are those in which additional amino acids are fused to the
10 polypeptide, such as leader sequence, a secretory sequence, a proprotein sequence or a sequence which facilitates purification, enrichment, or stabilization of the polypeptide. In some embodiments, the fragments, derivatives and analogs retain the same biological function or activity as the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56. In other embodiments, the fragment, derivative or analogue includes a fused heterologous sequence which facilitates purification, enrichment, detection, stabilization or secretion of the polypeptide that can be enzymatically cleaved, in whole or in part, away from the fragment, derivative or analogue.

Another aspect of the present invention are polypeptides or fragments thereof which
20 have at least 70%, at least 80%, at least 85%, at least 90%, or more than 95% homology to one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or a fragment comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof. Homology may be determined using a program, such as BLASTP version 2.2.2 with the default parameters, which aligns the polypeptides or fragments being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid "homology" includes conservative substitutions such as those described above.

The polypeptides or fragments having homology to one of the polypeptides of SEQ ID
30 NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50,

3010-5PCT-7CA

- 64 -

52, 54, 56, or a fragment thereof may be obtained by isolating the nucleic acids encoding them using the techniques described above.

Alternatively, the homologous polypeptides or fragments may be obtained through biochemical enrichment or purification procedures. The sequence of potentially homologous polypeptides or fragments may be determined by proteolytic digestion, gel electrophoresis and/or microsequencing. The sequence of the prospective homologous polypeptide or fragment can be compared to one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 47, 50, 52, 54, 56, or a fragment thereof using a program such as BLASTP version 2.2.2 with the default parameters.

The PKS system of SEQ ID NOS: 37, 39, 41, 43, 45 and 47 may be modified to produce compounds of Formula I. Genetic modifications of PKS biosynthetic loci are well known in the art. The WO 01/34816 patent publication teaches the construction of a library of structural variants of the macrolide polyketide rapamycin derived from the genetic modification of genes in the locus that directs rapamycin synthesis. The genetic modifications taught include gene inactivations, gene insertions and gene replacements. These modifications, both individually and in combination at different positions within the rapamycin locus, resulted in alteration of polyketide starter units, chain length and hydroxyl stereospecificities in rapamycin. Similarly, McDaniel, *et.al.* [Proc Natl Acad Sci USA, 1999, 96:18646-51] generated a library of over 50 derivatives of the macrolide antibiotic erythromycin using a combination of genetic modifications including gene inactivations, macrolide chain length and hydroxyl stereospecificity modifications of the erythromycin biosynthesis genes. The PKS system of the invention may be genetically modified to produce compounds of Formula I. The biosynthetic locus of Example 1 is modified by deletion, mutagenesis, inactivation or replacement of one or more nucleic acid sequence that encode enzymatic activities. The modified gene locus of Example 1 produces compounds of Formula I that differ in size, degree of saturation and degree of oxidation. Compounds produced by these genetic modifications include, without limitations, Compounds 12, 14 and 16.

3010-5PCT-7CA

- 65 -

Pharmaceutical composition comprising the compounds of the invention

The compounds of the present invention, or pharmaceutically acceptable salts or prodrugs thereof, can be formulated for oral, intravenous, intramuscular, subcutaneous, topical or parenteral administration for the therapeutic or prophylactic treatment of diseases, particularly bacterial infections. For oral or parental administration, compounds of the present invention can be mixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers and the like. The compositions comprising a compound of this present invention will contain from about 0.1% to about 99.9%, about 5% to about 95%, about 10% to about 80% or about 15% to about 60% by weight of the active compound.

The pharmaceutical preparations disclosed herein are prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent, or eliminate bacterial infection (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA and Goodman and Gilman's the Pharmaceutical Basis of Therapeutics, Pergamon Press, New York, NY, for a general description of the methods for administering various antimicrobial agents for human therapy). The compositions of the present invention can be delivered using controlled (e.g., capsules) or sustained release delivery systems (e.g., bioerodable matrices). Exemplary delayed release delivery systems for drug delivery that are suitable for administration of the compositions of the invention (preferably of Formula I) are described in U.S. Patent Nos 4,452,775 (issued to Kent), 5,039,660 (issued to Leonard), 3,854,480 (issued to Zaffaroni).

The pharmaceutically-acceptable compositions of the present invention comprise one or more compounds of the present invention in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants and/or excipients, collectively referred to herein as "carrier" materials, and if desired other active ingredients. The compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid. The compositions may contain crosarmellose sodium, microcrystalline cellulose, sodium starch glycolate and alginic acid.

3010-5PCT-7CA

- 66 -

Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Providone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicon fluid, talc, waxes, oils and colloidal silica. Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring or the like can also be used. It may also be desirable to add a coloring agent to make the dosage form more esthetic in appearance or to help identify the product comprising a compound of the present invention.

- 10 For oral use, solid formulations such as tablets and capsules are particularly useful. Sustained released or enterally coated preparations may also be devised. For pediatric and geriatric applications, suspension, syrups and chewable tablets are especially suitable. For oral administration, the pharmaceutical compositions are in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a therapeutically-effective amount of the active ingredient. Examples of such dosage units are tablets and capsules. For therapeutic purposes, the tablets and capsules which can contain, in addition to the active ingredient, conventional carriers such as binding agents, for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth; fillers, for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose; lubricants, for example, magnesium stearate, polyethylene glycol, silica or talc; disintegrants, for example, potato starch, flavoring or coloring agents, or acceptable wetting agents. Oral liquid preparations generally are in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents and flavoring agents. Examples of additives for liquid preparations include acacia, almond oil, ethyl alcohol, fractionated coconut oil, gelatin, glucose syrup, glycerin, hydrogenated edible fats, lecithin, methyl cellulose, methyl or propyl *para*-hydroxybenzoate, propylene glycol, sorbitol, or sorbic acid.
- 20
- 30 For intravenous (IV) use, compounds of the present invention can be dissolved or suspended in any of the commonly used intravenous fluids and administered by

3010-5PCT-7CA

- 67 -

infusion. Intravenous fluids include, without limitation, physiological saline or Ringer's solution.

Formulations for parental administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions or suspensions can be prepared from sterile powders or granules having one or more of the carriers mentioned for use in the formulations for oral administration. The compounds can be dissolved in polyethylene glycol, propylene glycol, ethanol, corn oil, benzyl alcohol, sodium chloride, and/or various buffers.

10 For intramuscular preparations, a sterile formulation of compounds of the present invention or suitable soluble salts forming the compound, can be dissolved and administered in a pharmaceutical diluent such as Water-for-Injection (WFI), physiological saline or 5% glucose. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.

For topical use the compounds of present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of creams, ointments, liquid sprays or inhalants, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient.

20 For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Alternatively, the compound of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery. In another embodiment, the unit dosage form of the compound can be a solution of the compound or a salt thereof in a suitable diluent in sterile, hermetically sealed ampoules.

30

3010-5PCT-7CA

- 68 -

The amount of the compound of the present invention in a unit dosage comprises a therapeutically-effective amount of at least one active compound of the present invention which may vary depending on the recipient subject, route and frequency of administration. A recipient subject refers to a plant, a cell culture or an animal such as an ovine or a mammal including a human.

According to this aspect of the present invention, the novel compositions disclosed herein are placed in a pharmaceutically acceptable carrier and are delivered to a recipient subject (including a human subject) in accordance with known methods of drug delivery. In general, the methods of the invention for delivering the compositions of the
10 invention in vivo utilize art-recognized protocols for delivering the agent with the only substantial procedural modification being the substitution of the compounds of the present invention for the drugs in the art-recognized protocols.

Likewise, the methods for using the claimed composition for treating cells in culture, for example, to eliminate or reduce the level of bacterial contamination of a cell culture, utilize art-recognized protocols for treating cell cultures with antibacterial agents with the only substantial procedural modification being the substitution of the compounds of the present invention for the agents used in the art-recognized protocols.

The compounds of the present invention provide a method for treating microbial infections. As used herein the term unit dosage refers to a quantity of a therapeutically-
20 effective amount of a compound of the present invention that elicits a desired therapeutic response. As used herein the phrase therapeutically-effective amount means an amount of a compound of the present invention that prevents the onset, alleviates the symptoms, or stops the progression of a bacterial infection. The term treating is defined as administering, to a subject, a therapeutically-effective amount of at least one compound of the present invention, both to prevent the occurrence of a bacterial infection, or to control or eliminate a bacterial infection. The term desired therapeutic response refers to treating a recipient subject with a compound of the present invention such that a bacterial infection is reversed, arrested or prevented in a recipient subject.

30 The compounds of the present invention can be administered as a single daily dose or in multiple doses per day. The treatment regime may require administration over extended

3010-5PCT-7CA

- 69 -

periods of time, e.g., for several days or for from two to four weeks. The amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the age and general health of the recipient subject, the tolerance of the recipient subject to the compound and the type of the bacterial infection.

A compound according to this invention may also be administered in the diet or feed of a patient or animal. The diet for animals can be normal foodstuffs to which the compound can be added or it can be added to a premix.

10 The compounds of the present invention may be taken in combination, together or separately with any known clinically approved antibiotic to treat a recipient subject in need of such treatment.

Method of Inhibiting Bacterial Growth

In one embodiment, the present invention relates to a method for treating bacterial infection in a mammalian subject in need thereof, comprising the step of administering to the mammal a therapeutically effective amount of a polyene polyketide of Formula I, a compound as described herein, or a pharmaceutically acceptable derivative or prodrug thereof.

20 In another embodiment, the present invention relates to the use of a polyene polyketide of Formula I, a compound as described herein, or a pharmaceutically acceptable salt, derivative or prodrug thereof, as a pharmaceutical for treating bacterial infection in a mammalian subject in need thereof.

According to another embodiment, the invention provides a method of decreasing bacterial quantity in a biological sample. This method comprises the step of contacting the biological sample with a polyene polyketide of Formula I, a compound as described herein, or a pharmaceutically acceptable derivative or prodrug thereof. This method is effective if the number of bacteria decreases by at least 10%, and preferably more, e.g., 25%, 50%, 75% or even 100% after contacting the biological sample with a polyene polyketide of Formula I, a compound as described herein, or a pharmaceutically
30 acceptable derivative or prodrug thereof.

3010-5PCT-7CA

- 70 -

These pharmaceutical compositions effective to treat or prevent a bacterial infection which comprise any one of Compounds 1 to 7, a compound of Formula I as described herein, or a pharmaceutically acceptable derivative or prodrug thereof in an amount sufficient to measurably decrease bacterial quantity, and a pharmaceutically acceptable carrier, are another embodiment of the present invention. The term "measurably decrease bacterial quantity", as used herein means a measurable change in the number of bacteria between a sample containing the inhibitor and a sample not containing the inhibitor.

Agents which increase the susceptibility of bacterial organisms to antibiotics are known.

10 For example, U.S. Pat. No. 5,523,288, U.S. Pat. No. 5,783,561 and U.S. Pat. No. 6,140,306 describe methods of using bactericidal/permeability-increasing protein (BPI) for increasing antibiotic susceptibility of gram-positive and gram-negative bacteria.

Agents that increase the permeability of the outer membrane of bacterial organisms have been described by Vaara, M. in *Microbiological Reviews* (1992) pp. 395-411, and the sensitization of gram-negative bacteria has been described by Tsubery, H., et al, in *J. Med. Chem.* (2000) pp. 3085-3092.

For the method of the invention related to treatment of subjects with a bacterial infection, a typical effective unit dose of any one of Compounds 1 to 7, a compound of Formula I as described herein or a pharmaceutically acceptable derivative or prodrug thereof given
20 orally or parenterally would be from about 5 to about 100 mg/kg of body weight of the subject with a daily dose ranging from about 15 to about 300 mg/kg of body weight of the subject.

Another preferred embodiment of this invention relates to a method, as described above, of treating a bacterial infection in a mammal in need thereof, but further comprising the step of administering to the mammal an agent which increases the susceptibility of bacterial organisms to antibiotics.

According to another preferred embodiment, the invention provides a method, as described above, of decreasing bacterial quantity in a biological sample, but further comprising the step of contacting the biological sample with an agent which increases
30 the susceptibility of bacterial organisms to antibiotics.

3010-5PCT-7CA

- 71 -

Methods of decreasing bacterial quantity are effective if the number of bacteria decreases at least 10%, and preferably more, e.g., 25%, 50%, 75% or even 100% after contacting the biological sample with any one of Compounds 1 to 7, a compound of Formula I as described herein, or a pharmaceutically acceptable derivative or prodrug thereof.

The pharmaceutical compositions and methods of this invention will be useful generally for controlling bacterial infections *in vivo*. Examples of bacterial organisms that may be controlled by the compositions and methods of this invention include, but are not limited to the following organisms: *Streptococcus pneumoniae*, *Streptococcus pyogenes*,
10 *Enterococcus faecalis*, *Enterococcus faecium*, *Klebsiella pneumoniae*, *Enterobacter* spp., *Proteus* spp., *Pseudomonas aeruginosa*, *Escherichia coli*, *Serratia marcesens*, *Staphylococcus aureus*, *Haemophilus influenzae*, *Bacillus anthracis*, *Mycoplasma pneumoniae*, and Coagulase negative *Staphylococcus* including *Staphylococcus epidermidis*. The compositions and methods will therefore be useful for controlling, treating or reducing the advancement, severity or effects of nosocomial or non-nosocomial infections. Examples of nosocomial uses include, but are not limited to, urinary tract infections, pneumonia, surgical wound infections, bacteremia and therapy for febrile neutropenic patients. Examples of non-nosocomial uses include but are not limited to urinary tract infections, pneumonia, prostatitis, skin and soft tissue infections
20 and intra-abdominal infections.

In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified disorders.

A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are
30 administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent

3010-5PCT-7CA

- 72 -

compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

Example 1: Genes and proteins for producing the compounds of the invention

10 *Amycolatopsis orientalis* ATCC™ 43491 was obtained from the American Type Culture Collection (P.O. Box 1549, Manassas, VA 20108, USA). The biosynthetic locus for the production of the compound of Formula I was identified in the genome of *Amycolatopsis orientalis* ATCC™ 43491 using the genome scanning method described in US patent publication 2003/0138810 A1, CA 2,352,451 and Zazopoulos *et. al.*, *Nature Biotechnol.*, 21, 187-190 (2003).

The biosynthetic locus spans approximately 100,000 base pairs of DNA and encodes 27 proteins. More than 10 kilobases of DNA sequence were analyzed on each side of the locus and these regions were deemed to contain primary genes or genes unrelated to the synthesis of the compound of Formula I. As illustrated in Figure 11, the locus is contained within three sequences of contiguous base pairs, namely Contig 1 having the 12,647 contiguous base pairs of SEQ ID NO: 1 and comprising ORFs 1 to 11 (SEQ ID
20 NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23), Contig 2 having the 73,599 contiguous base pairs of SEQ ID NO: 24 and comprising ORFs 12 to 23 (SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48), and Contig 3 having the 6,995 base pairs of SEQ ID NO: 49 and comprising ORFs 24 to 27 (SEQ ID NOS: 51, 53, 55 and 57). The order, relative position and orientation of the 27 open reading frames representing the proteins of the biosynthetic locus are illustrated schematically in Figure 11. The top line in Figure 11 provides a scale in base pairs. The black bars depict the three DNA contigs (SEQ ID NOS: 1, 24 and 49) that cover the locus. The empty arrows represent the 27 open reading frames of this biosynthetic locus. The black arrows represent the four deposited cosmid clones covering the locus.

30 The biosynthetic locus will further be understood with reference to the sequence listing which provides contiguous nucleotide sequences and deduced amino acid sequences of

3010-5PCT-7CA

- 73 -

the locus from *Amycolatopsis orientalis* ATCC™ 43491. The contiguous nucleotide sequences are arranged such that, as found within the biosynthetic locus, Contig 1 (SEQ ID NO: 1) is adjacent to the 5' end of Contig 2 (SEQ ID NO: 24), which in turn is adjacent to Contig 3 (SEQ ID NO: 49). The ORFs illustrated in Figure 11 and provided in the sequence listing represent open reading frames deduced from the nucleotide sequences of Contigs 1, 2 and 3 (SEQ ID NOS: 1, 24 and 49). Referring to the Sequence Listing, ORF 1 (SEQ ID NO: 3) is the polynucleotide drawn from residues 1 to 438 (sense/antisense strand) of SEQ ID NO: 1, and SEQ ID NO: 2 represents that polypeptide deduced from SEQ ID NO: 3. ORF 2 (SEQ ID NO: 5) is the polynucleotide drawn from residues 435 to 1544 of SEQ ID NO: 1, and SEQ ID NO: 4 represents the polypeptide deduced from SEQ ID NO: 5. ORF 3 (SEQ ID NO: 7) is the polynucleotide drawn from residues 1656 to 2171 of SEQ ID NO: 1, and SEQ ID NO: 6 represents the polypeptide deduced from SEQ ID NO: 7. ORF 4 (SEQ ID NO: 9) is the polynucleotide drawn from residues 2393 to 5203 of SEQ ID NO: 1, and SEQ ID NO: 8 represents the polypeptide deduced from SEQ ID NO: 9. ORF 5 (SEQ ID NO: 11) is the polynucleotide drawn from residues 6231 to 5419 of SEQ ID NO: 1, and SEQ ID NO: 10 represents the polypeptide deduced from SEQ ID NO: 11. ORF 6 (SEQ ID NO: 13) is the polynucleotide drawn from residues 6415 to 7104 of SEQ ID NO: 1, and SEQ ID NO: 12 represents the polypeptide deduced from SEQ ID NO: 13. ORF 7 (SEQ ID NO: 15) is the polynucleotide drawn from residues 7213 to 8874 of SEQ ID NO: 1, and SEQ ID NO: 14 represents the polypeptide deduced from SEQ ID NO: 15. ORF 8 (SEQ ID NO: 17) is the polynucleotide drawn from residues 9477 to 8938 of SEQ ID NO: 1, and SEQ ID NO: 16 represents the polypeptide deduced from SEQ ID NO: 17. ORF 9 (SEQ ID NO: 19) is the polynucleotide drawn from residues 9655 to 10323 of SEQ ID NO: 1, and SEQ ID NO: 18 represents the polypeptide deduced from SEQ ID NO: 19. ORF 10 (SEQ ID NO: 21) is the polynucleotide drawn from residues 11655 to 10516 of SEQ ID NO: 1, and SEQ ID NO: 20 represents the polypeptide deduced from SEQ ID NO: 21. ORF 11 (SEQ ID NO: 23) is the polynucleotide drawn from residues 11855 to 12610 of SEQ ID NO: 1, and SEQ ID NO: 22 represents the polypeptide deduced from SEQ ID NO: 23. ORF 12 (SEQ ID NO: 26) is the polynucleotide drawn from residues 520 to 32 of SEQ ID NO: 24, and SEQ ID NO: 25 represents the polypeptide deduced from SEQ ID NO: 26.

3010-5PCT-7CA

- 74 -

ORF 13 (SEQ ID NO: 28) is the polynucleotide drawn from residues 840 to 2165 of SEQ ID NO: 24, and SEQ ID NO: 27 represents the polypeptide deduced from SEQ ID NO: 28. ORF 14 (SEQ ID NO: 30) is the polynucleotide drawn from residues 2201 to 3424 of SEQ ID NO: 24, and SEQ ID NO: 29 represents the polypeptide deduced from SEQ ID NO: 30. ORF 15 (SEQ ID NO: 32) is the polynucleotide drawn from residues 3429 to 4994 of SEQ ID NO: 24, and SEQ ID NO: 31 represents the polypeptide deduced from SEQ ID NO: 32. ORF 16 (SEQ ID NO: 34) is the polynucleotide drawn from residues 4991 to 6199 of SEQ ID NO: 24, and SEQ ID NO: 33 represents the polypeptide deduced from SEQ ID NO: 34. ORF 17 (SEQ ID NO: 36) is the polynucleotide drawn from residues 6389 to 7924 of SEQ ID NO: 24, and SEQ ID NO: 35 represents the polypeptide deduced from SEQ ID NO: 36. ORF 18 (SEQ ID NO: 38) is the polynucleotide drawn from residues 8404 to 19908 of SEQ ID NO: 24, and SEQ ID NO: 37 represents the polypeptide deduced from SEQ ID NO: 38. ORF 19 (SEQ ID NO: 40) is the polynucleotide drawn from residues 19910 to 37081 of SEQ ID NO: 24, and SEQ ID NO: 39 represents the polypeptide deduced from SEQ ID NO: 40. ORF 20 (SEQ ID NO: 42) is the polynucleotide drawn from residues 37085 to 42292 of SEQ ID NO: 24, and SEQ ID NO: 41 represents the polypeptide deduced from SEQ ID NO: 42. ORF 21 (SEQ ID NO: 44) is the polynucleotide drawn from residues 42617 to 52411 of SEQ ID NO: 24, and SEQ ID NO: 43 represents the polypeptide deduced from SEQ ID NO: 44. ORF 22 (SEQ ID NO: 46) is the polynucleotide drawn from residues 52438 to 67737 of SEQ ID NO: 24, and SEQ ID NO: 45 represents the polypeptide deduced from SEQ ID NO: 46. ORF 23 (SEQ ID NO: 48) is the polynucleotide drawn from residues 67751 to 73516 of SEQ ID NO: 24, and SEQ ID NO: 47 represents the polypeptide deduced from SEQ ID NO: 48. ORF 24 (SEQ ID NO: 51) is the polynucleotide drawn from residues 939 to 16 of SEQ ID NO: 49, and SEQ ID NO: 50 represents the polypeptide deduced from SEQ ID NO: 51. ORF 25 (SEQ ID NO: 53) is the polynucleotide drawn from residues 2374 to 944 of SEQ ID NO: 49, and SEQ ID NO: 52 represents the polypeptide deduced from SEQ ID NO: 53. ORF 26 (SEQ ID NO: 55) is the polynucleotide drawn from residues 2600 to 2391 of SEQ ID NO: 49, and SEQ ID NO: 54 represents the polypeptide deduced from SEQ ID NO: 55. ORF 27 (SEQ ID NO: 57) is the

3010-5PCT-7CA

- 75 -

polynucleotide drawn from residues 3378 to 2614 of SEQ ID NO: 49, and SEQ ID NO: 56 represents the polypeptide deduced from SEQ ID NO: 57.

Some open reading frames provided in the Sequence Listing, namely ORF 2 (SEQ ID NO: 4), ORF 5 (SEQ ID NO: 10), ORF 12 (SEQ ID NO: 25), ORF 13 (SEQ ID NO: 27), ORF 15 (SEQ ID NO: 31), ORF 17 (SEQ ID NO: 35), ORF 19 (SEQ ID NO: 39), ORF 20 (SEQ ID NO: 41), ORF 22 (SEQ ID NO: 45), ORF 24 (SEQ ID NO: 50), ORF 26 (SEQ ID NO: 54) and ORF 27 (SEQ ID NO: 56) initiate with non-standard initiation codons (eg. GTG – Valine, or CTG – Leucine) rather than standard initiation codon ATG methionine. All ORFs are listed with the appropriate M, V or L amino acids at the amino-terminal position to indicate the specificity of the first codon of the ORF. It is expected, however, that in all cases the biosynthesized protein will contain a methionine residue, and more specifically a formylmethionine residue, at the amino terminal position, in keeping with the widely accepted principle that protein synthesis in bacteria initiates with methionine (formylmethionine) even when the encoding gene specifies a non-standard initiation codon (e.g. Stryer BioChemistry 3rd edition, 1998, W.H. Freeman and Co., New York, pp. 752-754).

Four deposits of *E. coli* DH10B vectors, each harbouring a cosmid clone of a partial biosynthetic locus for the compound of Formula I from *Amycolatopsis orientalis* (ATCC™ 43491) and together spanning the full biosynthetic locus for production of the compound of Formula I have been deposited with the International Depositary Authority of Canada, Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2 on September 5, 2003 and were assigned deposit accession numbers IDAC 050903-01, IDAC 050903-02, IDAC 050903-03 and IDAC 050903-04 respectively. The cosmid of deposit IDAC 050903-03 covers residue 1 to residue 8800 of Contig 1 (SEQ ID NO: 1). The cosmid of deposit IDAC 050903-01 covers residue 1600 of Contig 1 (SEQ ID NO: 1) to residue 19840 of Contig 2 (SEQ ID NO: 24). The cosmid of deposit IDAC 050903-02 covers the residue 14700 to residue 52230 of Contig 2 (SEQ ID NO: 24). The cosmid of deposit IDAC 050903-04 covers residue 41090 of Contig 2 (SEQ ID NO: 24) to residue 3378 of Contig 3 (SEQ ID NO: 49). The sequence of the polynucleotides comprised in the deposited strains, as well as the amino acid sequence

3010-5PCT-7CA

- 76 -

of any polypeptide encoded thereby are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strains has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The deposited strains will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strains are provided merely as convenience to those skilled in the art and are not an admission that a deposit is required for enablement. A license may be required to make, use or sell the deposited strains, and compounds derived therefrom, and no such license is

10 hereby granted.

In order to identify the function of the proteins coded by the genes forming the biosynthetic locus for the production of the compounds of Formula I the gene products of ORFs 1 to 27, namely SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 50, 52, 54 and 56, were compared, using the BLASTP version 2.2.6 algorithm with the default parameters, to sequences in the National Center for Biotechnology Information (NCBI) nonredundant protein database and the DECIPHER[®] database of microbial genes, pathways and natural products (Ecopia BioSciences Inc. St.-Laurent, QC, Canada).

20 The accession numbers of the top GenBank[™] hits of this BLAST analysis are presented in Table 2 along with the corresponding E values. The E value relates the expected number of chance alignments with an alignment score at least equal to the observed alignment score. An E value of 0.00 indicates a perfect homolog. The E values are calculated as described in Altschul *et al. J. Mol. Biol.*, 215, 403-410 (1990). The E value assists in the determination of whether two sequences display sufficient similarity to justify an inference of homology.

Table 2

ORF	Family	# aa	Genbank homology	probability	% identity	% similarity	proposed function of GenBank match
1	UNBP	145	CAD60535.1, 194aa	1e-21	52/127(40.94%)	71 / 127 (55.91%)	Cinorf13 protein Streptomyces cinnamoneus
			NP_822919.1, 176aa	1e-06	36 / 113 (31.86%)	57 / 113 (50.44%)	hypothetical protein Streptomyces avermitilis
			NP_301329.1, 79aa	0.014	20 / 56 (35.71%)	29 / 56 (51.79%)	hypothetical protein Mycobacterium leprae
2	MEBA	369	CAB86101, 260aa	6.00E-05	69 /260 (26%)	97 / 260 (36%)	membrane protein
3	REQB	171	NP_301177.1, 132aa	4e-10	41 / 131 (31.3%)	73 / 131 (55.73%)	conserved hypothetical protein Mycobacterium leprae pir
			NP_218366.1, 132aa	4e-10	41 / 131 (31.3%)	73 / 131 (55.73%)	hypothetical protein Rv3849 Mycobacterium tuberculosis
			CAD60534.1, 163aa	2e-09	42 / 120 (35%)	61 / 120 (50.83%)	Cinorf12 protein Streptomyces cinnamoneus
4	REGD	936	AAC68887.1, 928aa	1e-149	345 / 919 (37.54%)	476 / 919 (51.8%)	putative transcriptional activator PikD Streptomyces venezuelae
			AAM88362.1, 945aa	1e-146	337 / 915 (36.83%)	469 / 915 (51.26%)	NbmM Streptomyces narbonensis
			NP_824077.1, 942aa	1e-138	343 / 933 (36.76%)	457 / 933 (48.98%)	LuxR-family transcriptional regulator Streptomyces avermitilis
5	MTNA	271	AAP36564.1, 237aa	6e-20	74 / 214 (34.58%)	99 / 214 (46.26%)	Homo sapiens guanidinoacetate N-methyltransferase
			NP_036925.1, 236aa	2e-20	72 / 214 (33.64%)	100 / 214 (46.73%)	guanidinoacetate methyltransferase Rattus norvegicus
			AAP36564.1, 237aa	6e-20	74 / 214 (34.58%)	99 / 214 (46.26%)	Homo sapiens guanidinoacetate N-methyltransferase
6	MEMO	229	NP_825904.1, 233aa	5e-23	71 / 187 (37.97%)	91 / 187 (48.66%)	putative membrane protein Streptomyces avermitilis
			NP_627542.1, 238aa	5e-19	64 / 191 (33.51%)	93 / 191 (48.69%)	putative membrane protein Streptomyces coelicolor
			AAN07910.1, 277aa	3e-17	58 / 181 (32.04%)	88 / 181 (48.62%)	AlbD Streptomyces noursei
7	TMOA	553	NP_828069.1, 565aa	0.0	328 / 548 (59.85%)	394 / 548 (71.9%)	putative amino oxidase Streptomyces avermitilis
			NP_625735.1, 565aa	0.0	325 / 548 (59.31%)	394 / 548 (71.9%)	putative amino oxidase Streptomyces coelicolor
			ZP_00086824.1, 560aa	1e-172	290 / 552 (52.54%)	371 / 552 (67.21%)	hypothetical protein Pseudomonas fluorescens
8	UNEW	179	ZP_00100936.1, 308aa	0.086	30 / 98 (30.61%)	49 / 98 (50%)	hypothetical protein Desulfitobacterium hafniense

3010-5PCT-7CA

- 78 -

ORF	Family	# aa	Genbank homology	probability	% identity	% similarity	proposed function of GenBank match
			NP_629948.1, 229aa	6e-55	120/225 (53.3%)	143/225 (63.56%)	two-component response regulator Streptomyces
			NP_628533.1, 226aa	1e-43	101/219 (46.12%)	130/219 (59.36%)	two-component response regulator Streptomyces
10	SPKF	379	NP_629947.1, 384aa	2e-34	93 / 216 (43.06%)	119 / 216 (55.09%)	putative two-component sensor Streptomyces coelicolor
			NP_823615.1, 384aa	4e-34	93 / 216 (43.06%)	122 / 216 (56.48%)	putative two-component sensor kinase Streptomyces
			NP_628532.1, 403aa	8e-29	87 / 231 (37.66%)	115 / 231 (49.78%)	putative two component sensor kinase Streptomyces
11	TESA	251	AAO65810.1, 267aa	8e-50	112 / 251 (44.62%)	139 / 251 (55.38%)	thioesterase; MonAX Streptomyces cinnamonensis
			NP_822128.1, 250aa	1e-48	107 / 242 (44.21%)	134 / 242 (55.37%)	thioesterase Streptomyces avermitilis
			NP_851508.1, 265aa	1e-47	103 / 225 (45.78%)	131 / 225 (58.22%)	probable thioesterase Streptomyces rochei
12	UNIQ	162	No hits	No hits	No hits	No hits	No hits
13	SOXA	441	AAF23790.1, 437aa	6e-88	176 / 436 (40.37%)	256 / 436 (58.72%)	UDP-glucose dehydrogenase Zymomonas mobilis
			NP_385188.1, 437aa	1e-87	180 / 438 (41.1%)	253 / 438 (57.76%)	UDP-GLUCOSE 6-DEHYDROGENASE Sinorhizobium
			ZP_00052125.1, 439aa	2e-87	182 / 434 (41.94%)	248 / 434 (57.14%)	hypothetical protein Magnetospirillum magnetotacticum
14	GTFA	407	AAM54103.1, 402aa	4e-67	165 / 409 (40.34%)	207 / 409 (50.61%)	glycosyltransferase Actinosynnema pretiosum subsp. auranticum
			AAM70336.1, 392aa	1e-16	103 / 418 (24.64%)	158 / 418 (37.8%)	CalG1 Micromonospora echinospora
			NP_624398.1, 407aa	1e-13	87 / 270 (32.22%)	122 / 270 (45.19%)	putative glycosyl transferase Streptomyces coelicolor
15	ADSN	521	AAG34183.1, 519aa	1e-111	223 / 515 (43.3%)	297 / 515 (57.67%)	SimL Streptomyces antibioticus
			AAG29784.1, 529aa	2e-76	178 / 510 (34.9%)	246 / 510 (48.24%)	putative ligase Streptomyces rishirensis
			AAN65228.1, 527aa	4e-76	175 / 513 (34.11%)	246 / 513 (47.95%)	amide synthetase Streptomyces roseochromogenes subsp. oscitans
16	AYTP	402	NP_387095.1, 405aa	1e-101	190 / 382 (49%)	237 / 382 (62%)	5-aminolevulinic acid synthase Sinorhizobium meliloti
			BAA35068.1, 403aa	1e-101	191 / 400 (47%)	251 / 400 (62%)	5-aminolevulinate synthase Rhodopseudomonas palustris
			ZP_00011134.1, 443aa	1e-101	193 / 400 (48%)	249 / 400 (62%)	hypothetical protein Rhodopseudomonas palustris

3010-5PCT-7CA

- 79 -

ORF	Family	# aa	Genbank homology	probability	% identity	% similarity	proposed function of GenBank match
17	CALB	511	NP_631034.1, 511aa	1e-125	240 / 493 (48.68%)	298 / 493 (60.45%)	probable long-chain-fatty-acid-CoA ligase Streptomyces coelicolor
			NP_822779.1, 503aa	1e-123	236 / 491 (48.07%)	294 / 491 (59.88%)	putative long-chain fatty acid:CoA ligase Streptomyces avermitilis
			ZP_00059397.1, 557aa	1e-117	224 / 496 (45.16%)	291 / 496 (58.67%)	hypothetical protein Thermobifida fusca
18	PKSH	3834	AAF71776.1, 11096aa	0.0	1806 / 3951 (45.71%)	2169 / 3951 (54.9%)	NysC Streptomyces noursei
			AAF71776.1, 11096aa	0.0	1417 / 3280 (43.2%)	1733 / 3280 (52.84%)	NysC Streptomyces noursei
			AAF71776.1, 11096aa	0.0	1132 / 2687 (42.13%)	1387 / 2687 (51.62%)	NysC Streptomyces noursei
19	PKSH	5723	AAK73514.1, 10917aa	0.0	2653 / 5231 (50.72%)	3158 / 5231 (60.37%)	AmphC Streptomyces nodosus
			AAK73514.1, 10917aa	0.0	1682 / 3155 (53.31%)	2014 / 3155 (63.84%)	AmphC Streptomyces nodosus
			AAK73514.1, 10917aa	0.0	1643 / 3190 (51.5%)	1984 / 3190 (62.19%)	AmphC Streptomyces nodosus
20	PKSH	1735	NP_821593.1, 3564aa	0.0	876 / 1803 (48.59%)	1051 / 1803 (58.29%)	modular polyketide synthase Streptomyces avermitilis
			NP_821593.1, 3564aa	0.0	805 / 1750 (46%)	988 / 1750 (56.46%)	modular polyketide synthase Streptomyces avermitilis
			BAB69304.1, 3524aa	0.0	876 / 1803 (48.59%)	1051 / 1803 (58.29%)	modular polyketide synthase Streptomyces avermitilis
21	PKSH	3264	NP_824071.1, 3613aa	0.0	1600 / 3344 (47.85%)	1951 / 3344 (58.34%)	modular polyketide synthase Streptomyces avermitilis
			T17409, 4613aa	0.0	1562 / 3444 (45.35%)	1898 / 3444 (55.11%)	polyketide synthase type I - Streptomyces venezuelae
			T17409, 4613aa	0.0	492 / 994 (49.5%)	616 / 994 (61.97%)	polyketide synthase type I - Streptomyces venezuelae
22	PKSH	5099	CAB41041.1, 6797aa	0.0	2006 / 4012 (50%)	2442 / 4012 (60.87%)	polyketide synthase Streptomyces natalensis
			CAB41041.1, 6797aa	0.0	1105 / 2269 (48.7%)	1342 / 2269 (59.14%)	polyketide synthase Streptomyces natalensis
			CAB41041.1, 6797aa	0.0	541 / 881 (61.41%)	637 / 881 (72.3%)	polyketide synthase Streptomyces natalensis
23	PKSH	1921	NP_821593.1, 3564aa	0.0	888 / 1748 (50.8%)	1083 / 1748 (61.96%)	modular polyketide synthase Streptomyces avermitilis
			NP_821593.1, 3564aa	0.0	848 / 1757 (48.26%)	1030 / 1757 (58.62%)	modular polyketide synthase Streptomyces avermitilis
			BAB69304.1, 3524aa	0.0	888 / 1748 (50.8%)	1083 / 1748 (61.96%)	modular polyketide synthase Streptomyces avermitilis

ORF	Family	# aa	Genbank homology	probability	% identity	% similarity	proposed function of GenBank match
24	AYTF	307	AAK60008.1, 316aa	7e-12	83 / 312 (26.6%)	126 / 312 (40.38%)	malonyl-CoA:acyl carrier protein transacylase-like protein Streptomyces aureofaciens
			NP_657821.1, 314aa	2e-07	64 / 305 (20.98%)	118 / 305 (38.69%)	Acyl_transf, Acyl transferase domain Bacillus anthracis
			NP_228607.1, 293aa	4e-07	64 / 294 (21.77%)	118 / 294 (40.14%)	malonyl CoA-acyl carrier protein transacylase Thermotoga maritima
25	CALB	476	AAL35216.1, 540aa	3e-34	142 / 485 (29.28%)	224 / 485 (46.19%)	4-coumarate:CoA ligase Amorpha fruticosa
			AAC97600.1, 547aa	2e-33	132 / 487 (27.1%)	223 / 487 (45.79%)	4-coumarate:CoA ligase isoenzyme 2 Glycine max
			NP_821780.1, 518aa	3e-33	132 / 470 (28.09%)	201 / 470 (42.77%)	putative acyl-CoA synthetase, long-chain fatty acid:CoA ligase Streptomyces avermitilis
26	UNAC	69	AAC01708.1, 88aa	7e-06	32 / 70 (45.71%)	38 / 70 (54.29%)	unknown Amycolatopsis mediterranei
27	TESA	254	NP_824079.1, 252aa	4e-80	149 / 238 (62.61%)	172 / 238 (72.27%)	putative thioesterase Streptomyces avermitilis
			NP_822128.1, 250aa	7e-80	145 / 237 (61.18%)	170 / 237 (71.73%)	thioesterase Streptomyces avermitilis
			NP_821582.1, 255aa	2e-75	136 / 243 (55.97%)	169 / 243 (69.55%)	putative thioesterase Streptomyces avermitilis

3010-5PCT-7CA

- 81 -

The ORFs encoding proteins involved in the biosynthesis of compounds of Formula I are assigned a putative function and grouped together in families based on sequence similarity to known proteins. To correlate structure and function, the protein families are given a four-letter designation used throughout the description and figures as indicated in Table 3. The meaning of the four letter designations is as follows: ADSN designates an amide synthetase; AYTF and AYTP designate acyltransferase activities; CALB designates an acylCoA ligase; GTFA designates a glycosyltransferase; MEBA and UNEW designate membrane proteins; MTNA designates a methyltransferase; PKSH designates a type I polyketide synthase system; REGD, REQB and RREB designate transcriptional regulators; SPKF designates a sensory protein kinase; TESA designates a thioesterase activity; TMOA designates an amino acid oxidase; UNIQ, UNBP and UNAC designate proteins of unknown function.

Table 3

Family	Function
ADSN	adenylating /condensing synthetase, amide synthetase, enzymes able to activate substrates as acyl adenylates and subsequently transfer the acyl group to an amino group of the acceptor molecule
AYTP	acyltransferase; pyridoxal phosphate dependent
AYTF	acyltransferase; acyl CoA-acyl carrier protein transacylase); includes malonyl CoA-ACP transacylases
CALB	acyl CoA ligase; shows similarity to plant coumarate CoA ligases, other aryl CoA ligases, yeast CoA synthetase and aminocoumarin ligases
GTFA	Glycosyltransferases
MEBA	membrane protein; putative transporter, permease;
MTNA	N-methyltransferase
PKSH	Polyketide synthase, type I
REGD	transcriptional regulator
REQB	Regulator
RREB	Response regulator
SOXA	sugar oxidoreductase
SPKF	sensory protein kinase
TESA	Thioesterase
TMOA	amino acid monooxygenase
UNIQ	Unknown;
UNBP	Unknown
UNAC	Unknown
UNEW	Similarity to membrane proteins

3010-5PCT-7CA

- 82 -

Biosynthesis of the compounds of Formula I involves the action of a multimodular type I polyketide synthase system (PKS) corresponding to ORFs 18 to 23 (SEQ ID NOS: 37, 39, 41, 43, 45 and 47). Type I PKSs are large modular proteins that condense acyl thioester units in a sequential manner. PKS systems consist of one or more polyfunctional polypeptides each of which is made up of modules. Each type I PKS module contains three domains: a β -ketoacyl protein synthase (KS), an acyltransferase (AT) and an acyl carrier protein (ACP). Domains conferring additional enzymatic activities such as ketoreductase (KR), dehydratase (DH) and enoylreductase (ER) can also be found in the PKS modules. These additional domains result in various degrees of reduction of the β -keto groups of the growing polyketide chain. Each module is responsible for one round of condensation and reduction of the β -ketoacyl units. As a result, there is a direct correlation between the number of modules and the length of the polyketide chain as well as between the domain composition of the modules and the degree of reduction of the polyketide product. The final polyketide product is released from the PKS protein through the action of a thioesterase (TE) domain found in the ultimate module of the PKS system. The genetic organization of most type I PKS enzymes is colinear with the order of biochemical reactions giving rise to the polyketide chain. This feature allows prediction of polyketide core structure based on the architecture of the PKS modules found in a given biosynthetic pathway (Hopwood, *Chem. Rev.*, 97, 2465-2497 (1997)).

The PKS system in the biosynthetic locus for the production of the compounds of Formula I is composed of ORFs 18 to 23 (SEQ ID NOS: 37, 39, 41, 43, 45 and 47) and comprises a total of 12 modules as described below in Table 4. The first module contains only an ACP domain and corresponds to the loading module (module 0) whereas each of the remaining 12 modules contain domains KS, AT and ACP in various combinations with KR, DH and ER domains. The thioesterase domain present in ORF 23/module 12 indicates that this module is the ultimate one in the biosynthesis of the polyketide chain.

3010-5PCT-7CA

- 83 -

Table 4: Domain coordinates for PKS system

ORF Nos.	Amino acid coordinates	Domain	Module No.
18	47-109	ACP	0
	130-554	KS	1
	567-990	AT	
	1001-1101	DH	
	1421-1628	KR	
	1691-1753	ACP	
	1771-2195	KS	2
	2211-2638	AT	
	2647-2753	DH	
	3060-3401	ER	
	3405-3622	KR	
	3696-3758	ACP	
19	39-463	KS	3
	474-872	AT	
	883-990	DH	
	1291-1501	KR	
	1574-1636	ACP	
	1657-2082	KS	4
	2093-2495	AT	
	2507-2614	DH	
	2908-3249	ER	
	3253-3470	KR	
	3545-3607	ACP	
	3628-4052	KS	5
	4068-4489	AT	
	4497-4604	DH	
	4933-5281	ER	
	5285-5502	KR	
	5577-5639	ACP	
20	34-458	KS	6
	475-892	AT	
	901-1006	DH	
	1309-1517	KR	
	1593-1655	ACP	

3010-5PCT-7CA

- 84 -

ORF Nos.	Amino acid coordinates	Domain	Module No.
21	34-461	KS	7
	478-905	AT	
	1157-1366	KR	
	1444-1506	ACP	
	1528-1952	KS	8
	1963-2383	AT	
	2395-2502	DH	
	2837-3048	KR	
	3122-3184	ACP	
22	34-460	KS	9
	472-883	AT	
	895-1002	DH	
	1323-1523	KR	
	1597-1659	ACP	
	1682-2104	KS	10
	2115-2523	AT	
	2534-2641	DH	
	2957-3166	KR	
	3235-3297	ACP	
	3317-3741	KS	11
	3752-4181	AT	
	4193-4300	DH	
	4669-4879	KR	
	4956-5018	ACP	
23	35-461	KS	12
	475-883	AT	
	892-999	DH	
	1305-1512	KR	
	1582-1644	ACP	
	1709-1921	TE	

3010-5PCT-7CA

- 85 -

Multiple amino acid alignment of KS domains present in the PKS system, described in Figures 12a and 12b, shows an overall similarity of domains and conservation of amino acid residues and domain regions important for activity indicating that all KS domains are functional. Similarly, multiple amino acid alignment of AT domains (described in Figures 13a, 13b and 13c), DH domains (described in Figure 14), ER domains (described in Figure 15), KR domains (described in Figure 16), ACP domains (described in Figure 17) and TE domains (described in Figure 18) show an overall similarity of related domains and a high conservation of protein regions and of amino acid residues important for catalytic activity. The domains that occur only once in the PKS system, namely the thioesterase (TE) domain in ORF 23 (SEQ ID NO: 47) is compared to prototypical domains from the nystatin type I polyketide system (Brautaset, *supra*). Phylogenetic analysis of the AT domains in the PKS system was conducted to assess the nature of the β -keto acyl units that are incorporated in the growing polyketide chain. The AT domains of the PKS system were compared to two domains, AAF71779mod03 and AAF71766mod11 (National Center for Biotechnology Information (NCBI) nonredundant protein database), derived from the nystatin PKS system (Brautaset, *supra*) and responsible for the incorporation of malonyl-CoA and methylmalonyl-CoA respectively. Figure 19 shows the phylogenetic relatedness of the various AT domains indicating that, in the PKS system for production of compounds of Formula I, module 2 of ORF 18 (SEQ ID NO: 37), module 5 of ORF 19 (SEQ ID NO: 39), module 6 of ORF 20 (SEQ ID NO: 41), module 7 of ORF 21 (SEQ ID NO: 43) and module 12 of ORF 23 (SEQ ID NO: 47) incorporate methylmalonate in the polyketide backbone of compounds of Formula I, whereas all remaining AT domains, namely module 1 of ORF 18 (SEQ ID NO: 37), modules 3 and 4 of ORF 19 (SEQ ID NO: 39), module 8 of ORF 21 (SEQ ID NO: 43) and modules 9, 10 and 11 of ORF 22 (SEQ ID NO: 45) incorporate malonate extender β -keto acyl units in the polyketide backbone of compounds of Formula I. Type I PKS domains and the reactions they carry out are well known to those skilled in the art and well documented in the literature (see, for example, Hopwood, *supra*). Those skilled in the art will readily appreciate that it is possible to determine the polyketide core structure produced by PKS system through domain analysis. The genes and proteins of the invention provide for biosynthesis of compounds of Formula I.

3010-5PCT-7CA

- 86 -

While not intending to be limited to any particular mode of action or biosynthetic scheme, Figures 20 and 21 describe production of Compound 1 using the genes and proteins of the invention. Figure 20b schematically describes a series of reactions catalyzed by the PKS system based on the correlation between the deduced domain architecture and the polyketide core of compounds of Formula I. Figure 20a describes a biosynthetic pathway for the production of the γ -aminobutyryl-CoA starter unit. Referring to Figure 20a, the amino acid monooxygenase of ORF 7 (SEQ ID NO: 14) catalyzes the decarboxylative oxidation of arginine forming 4-guanidinobutanamide that is further activated by the acyl CoA ligase of ORF 25 (SEQ ID NO: 52) to give 4-guanidinobutyryl-CoA. Referring to Figure 20b, the acyltransferase of ORF 24 (SEQ ID NO: 50) loads the 4-guanidinobutyryl-CoA extender unit onto the ACP domain of the loading module (module 0) of the type I polyketide synthase of ORF 18 (SEQ ID NO: 37). The polyketide chain continues to grow by the sequential condensation of malonyl-CoA and methylmalonyl-CoA extender units that are further reduced by specific domains to various degrees. The mature polyketide chain is then released through the action of the thioesterase domain found in module 12 of the type I polyketide synthase of ORF 23 (SEQ ID NO: 47). The polyketide core structure described in Figure 20b based on the architecture of the PKS system of the biosynthetic locus for the production of Compound 1 is entirely consistent with the polyketide portion of the chemical structure of Compound 1 as determined by MS spectra data (Figures 1, 2 and 3), ^1H NMR (Figure 4) and ^{13}C NMR spectra data, demonstrating that the biosynthetic locus of the invention is responsible for the biosynthesis of Compound 1.

The biosynthetic locus contains genes involved in the synthesis of two other components found in the chemical structure of compounds of Formula I. Figure 21a describes a biosynthetic pathway for the production of the aminohydroxycyclopentenone moiety found in compounds of Formula I. Referring to Figure 21a, the pyridoxal phosphate dependent acyltransferase of ORF 16 (SEQ ID NO: 33) condenses glycine with succinyl-CoA forming 5-aminolevulinate. The 5-aminolevulinate intermediate is further activated through the action of the acyl CoA ligase of ORF 17 (SEQ ID NO: 35) forming 5-aminolevulinate-CoA, which in turn, cyclizes to produce aminohydroxycyclopentenone. Referring to Figure 21c, the

3010-5PCT-7CA

- 87 -

aminohydroxycyclopentenone moiety is activated and condensed to the carboxy terminus of the polyketide chain through the action of the adenylating/condensing synthetase of ORF 15 (SEQ ID NO: 31). Figure 21b describes the biosynthesis of the sugar component of compounds of Formula I. The sugar oxidoreductase of ORF 13 (SEQ ID NO: 27) oxidizes D-glucose to form D-glucuronic acid that is subsequently transferred onto a hydroxyl group of the polyketide core structure through the action of the glycosyltransferase of ORF 14 (SEQ ID NO: 29) as shown in Figure 21c. D-glucose derives from the primary metabolism of the microorganism and is expected to be activated by the primary metabolism enzyme nucleotidyl transferase that catalyzes the formation of NDP-D-Glucose. It is expected that the sugar oxidoreductase of ORF 13 (SEQ ID NO: 27) acts on NDP-D-Glucose to generate NDP-D-Glucuronic acid that is subsequently transferred onto the polyketide core structure through the action of the glycosyltransferase of ORF 14 (SEQ ID NO: 29).

The final modification of the polyketide core structure is the methylation reaction catalyzed by the N-methyltransferase of ORF 5 (SEQ ID NO: 10). Referring to Figure 21c, the N-methyltransferase of ORF 5 (SEQ ID NO: 10) catalyzes the transfer of a methyl group derived from S-adenosylmethionine onto the guanidine moiety or the polyketide structure. While Figure 21c describes the reactions catalyzed by the N-methyltransferase of ORF 5 (SEQ ID NO: 10), the adenylating/condensing synthetase of ORF 15 (SEQ ID NO: 31) and the glycosyltransferase of ORF 14 (SEQ ID NO: 29), the invention does not reside in the actual timing and order of the reactions, which may be different than as described in Figure 21c.

In regards to other ORFs forming the biosynthetic locus for production of the compounds of Formula I, the thioesterases of ORFs 11 and 27 (SEQ ID NOS: 22 and 56) are expected to have polyketide-priming editing functions; the regulator of ORF 3 (SEQ ID NO: 6), the transcriptional regulator of ORF 4 (SEQ ID NO: 8), the response regulator of ORF 9 (SEQ ID NO: 18) and the sensory protein kinase of ORF 10 (SEQ ID NO: 20) are expected to regulate synthesis of the compound of Formula I; and the membrane transporters of ORF 2 (SEQ ID NO: 4) and of ORF 8 (SEQ ID NO: 16) are expected to be involved in transmembrane transport.

3010-5PCT-7CA

- 88 -

The genes and proteins of the invention may be used to produce compounds of Formula I as described below in Examples 17 to 20.

Example 2: Production of Compounds 1, 2, 7, 8 and 15 by fermentation

Amycolatopsis orientalis ATCC™ 43491 was cultivated under aerobic conditions in an aqueous nutrient medium containing assimilable sources of carbon, assimilable sources of nitrogen, inorganic salts and vitamins. Preferred carbon sources are glucose, glycerol and the like. Preferred nitrogen sources are beef extract, malt extract, yeast extract, and the like. Representative media are provided in Table 1.

- 10 Compounds 1, 2, 7, 8 and 15 were produced by the following procedure: *Amycolatopsis orientalis* ATCC™ 43491 was maintained and sporulated on agar plates of ISP2 medium (Difco). The inoculum for the production phase was prepared by adding two loopfull of the spores obtained from the surface of the ISP2 agar plate to a 125-ml flask containing 25 ml of ITSB medium (Zahn et al. (2001). *Applied and Environmental Microbiology* 76, 377-386) composed of 30 g trypticase soy broth (Bacto), 3 g yeast extract, 2 g MgSO₄, 5 g glucose, 4 g maltose made up to one liter with distilled water. The flasks are shaken (250 rpm) for about 60 hours at 28 °C and then 10 ml of the culture is used to inoculate each 2-L flasks containing ten glass beads and 500 ml of sterile production medium OA consisting of glucose 10 g, glycerol 5 g, corn steep liquor 3 g, beef extract 3 g, malt
- 20 extract 3 g, yeast extract 3 g, calcium carbonate 2 g, thiamine 0.1 g made up to one liter with distilled water (Kanzaki et al. (1998). *Biosci Biotechnol Biochem* 62; 438-442). The medium was adjusted at pH 7.0, and then 1 ml of silicon defoamer-oil (Chem Service) was added to each flask before sterilization. The fermentation batches are incubated aerobically under stirring (200 rpm) at 28°C for a period of 4 days. A fermentation period of 7 days without defoamer-oil was also used to produce Compound 1.

Compounds 1, 2, 7, 8 and 15 could also be produced in other media including JA, GA, RM, NA, CA, and CB (Table 1). Compounds 1 and 2 were further produced as described above using a preferred strain, namely *Amycolatopsis orientalis* IDAC 220604-01.

3010-5PCT-7CA

- 89 -

Example 3: Purification of Compound 1, 2 and 7*Procedure 1: (for 12 x500mL of fermentation)*

a) The whole fermentation broth at harvest was centrifuged at 3500 rpm for 20 minutes and the supernatant liquid was decanted and discarded. The residual mycelial pellet was treated with methanol (200 mL/L of original fermentation broth volume), stirred and centrifuged. The methanolic supernatant liquid was removed and the mycelial solid was extracted with acetone, the same manner as the methanol extraction. The combined methanol and acetone extracts are evaporated to dryness to a crude residue.

10 b) The crude residue of a) was partitioned between 100mL(per litre of fermentation) of chloroform (CHCl_3) and 100mL(per litre of fermentation) of methanol (MeOH) in water (3:2) buffered to pH 10 with ammonium hydroxide (NH_4OH) and at 10mM ammonium bicarbonate (NH_4HCO_3) salt concentration. The two layers were separated and the methanol: water layer evaporated to dryness. The residue from the upper phase was partitioned between n-butanol (100 ml/L of fermentation) and water (100 ml/L of fermentation), buffered as above. The butanol layer was concentrated to a orange-brown residue.

The residue was further purified by HPLC (Waters Autopurification System with ACD), using a Waters Xterra MS C18 column (5μ , 19 x 150 mm), and a gradient of 10mM aqueous NH_4HCO_3 , pH 10/ acetonitrile 85:15 to 25:75 over 30 min at 19 mL/min, UV
20 detector set at 261 nm. The sample was loaded as a suspension in DMSO/MeOH (3:1).

The pooling of eluate gave samples of Compound 7 (< 1 mg, RT: 16-17 min) and a mixture of Compounds 1 and 2 (1.04 g, non-freezedried, RT: 11.8-12.1 min).

Alternatively, the first purification (step 2) was also accomplished using a Phenomenex Max-RP C12 column (4μ , 21.2 x 250 mm) using the gradient buffer (as above) and acetonitrile 89.5:10.5 to 20:80 over 25 minutes, with the same flow and UV detection.

Fractions were collected at a retention time of 16.5-17 minutes (mixture of Compounds 1 and 2) and at RT: 21-22 minutes (Compound 7).

The mixture of Compounds 1 and 2 is further purified by HPLC (Waters Autopurification System with ACD), using a RCM Column (Novapak C-18, 6μ , 40 x 200 mm), and a
30 gradient of 10mM aqueous ammonium acetate (NH_4OAc) to pH 5 with glacial acetic

3010-5PCT-7CA

- 90 -

acid / acetonitrile 80:20 to 20:80 over 25 min at 35 mL/min. Fractions were collected and freeze-dried to give pure Compound 1 (RT: 18.5-18.8 minutes, 224.5 mg) and pure Compound 2 (RT: 17.3-17.6 minutes, 34.6 mg).

Procedure 2:

The crude residue of 1 a) (see Procedure 1) was partitioned between 100mL(per litre of fermentation) of hexanes and 100mL(per litre of fermentation) of methanol (MeOH) in water (3:2) buffered to pH 10 with ammonium hydroxide (NH₄OH) and at 10mM ammonium bicarbonate (NH₄HCO₃) salt concentration. The two layers were separated and the methanol: water layer evaporated to dryness. The procedure was repeated and concentrated to dryness.

The crude residue was purified by solid phase extraction. Methanol washed Diaion® HP-20 resin (30mL) was added to the crude residue. The mixture was added to a column made of 75 mL of methanol washed HP-20 resin and eluted with a mixture of ethanol and pH 10 buffered aqueous ammonium carbonate following the following gradient:

Fraction	Ethanol	Aqueous	Volume
1	10	90	500
2	20	80	200
3	30	70	200
20 4	40	60	200
5	50	50	200
6	60	40	200
7	80	20	200
8	100	0	200

Fractions 4, 5 and 6 were combined and concentrated to give a mixture of Compounds 1 and 2 and Compound 7 was found in the concentrated fraction 7.

The mixture of Compounds 1 and 2 was further purified by HPLC (Waters Autopurification System with ACD), using a Symmetry C18 column (5μ, 30 x 100 mm), and a gradient of 10mM aqueous NH₄OAc, made to pH 5 with glacial acetic acid /


3010-5PCT-7CA

- 91 -

acetonitrile 74:26 to 50:50 over 20 min at 39 mL/min. The collection was triggered by UV 261 nm (PDA). The sample was loaded as a suspension in DMSO: MeOH (3:1). The pooling of eluates gave pure Compound 1 (RT: 14.9-15.2 min) and pure Compound 2 (RT: 14.1-14.2 min), generally with a ratio of 5:1. Compound 7 had a retention time of 13-14 minutes using the same conditions.

Example 4: Structure identification of Compounds 1, 2 and 7

Compounds 1, 2 and 7 were produced by fermentation as described in Example 2 and isolated as described in Example 3.



Compound 1 is named 3,4,5-trihydroxy-6-[1-[11-(2-hydroxy-5-oxocyclopent-1-enylcarbamoyl)-1-methyldodeca-2,4,6,8,10-pentaenyl]-2,4,10-trimethyl-16-(*N*-methylguanidino)-hexadeca-2,8,12-trienyloxy]-tetrahydropyran-2-carboxylic acid.

Compound 1 structure determination was based on mass, UV and NMR data. The NMR data detailed in Table 5 was collected at 500 MHz in d_4 -MeOH including ^1H -NMR spectrum of Figure 4, and the multidimensional pulse sequences gCOSY, gDQCOSY, gHSQC, and gHMBC. The molecular formula of $\text{C}_{46}\text{H}_{68}\text{N}_4\text{O}_{10}$ and the chemical structure were established based the ^1H -NMR data, the COSY, HSQC and HMBC measured on about 500 μg of very pure material of structure illustrated above. The carbon assignments shown in Table 5 were made by virtue of the HSQC and HMBC. The straight chain nature of Compound 1 was supported by the fact that the two protons on each of the seven methylene groups were of almost indistinguishable chemical shift.

20

3010-5PCT-7CA

- 92 -

Table 5

¹ H and ¹³ C NMR (δ, ppm) Data for Compounds 1 in MeOH-D ₄			
Assignment	δ _H (ppm)	δ _C (ppm)	Group
1	–	170.1	C
2	–	138.8	C
3	7.09	135.2	CH
4	6.60	127.9	CH
5	6.38	132.5	CH
6	6.38	135.8	CH
7	6.56	127.9	CH
8	6.23	132.5	CH
9	6.23	131.3	CH
10	6.08	130.0	CH
11	5.51	137.9	CH
12	2.52	40.3	CH
13	3.58	93.8	CH
14	–	134.3	C
15	5.03	136.4	CH
16	2.32	32.2	CH
17	1.13	37.4	CH ₂
18	1.29	37.3	CH ₂
19	1.87	32.9	CH ₂
20	5.24	135.9	CH
21	5.27	129.3	CH
22	2.11	37.3	CH
23	1.97	40.6	CH ₂
24	5.41	130.0	CH
25	5.41	130.0	CH
26	2.01	29.6	CH ₂
27	1.64	27.2	CH ₂
28	3.34	48.2	CH ₂
29	2.06	12.4	CH ₃
30	1.21	17.4	CH ₃
31	1.60	11.4	CH ₃
32	0.92	20.7	CH ₃
33	0.97	20.3	CH ₃
1'	–	111.4	C
2'	–	199.3	C
3'	2.35	31.0	CH ₂
4'	2.35	31.0	CH ₂
5'	–	199.3	C
1''	4.20	102.9	CH
2''	3.27	74.6	CH

3010-5PCT-7CA

- 93 -

¹ H and ¹³ C NMR (δ, ppm) Data for Compounds 1 in MeOH-D ₄			
Assignment	δ _H (ppm)	δ _C (ppm)	Group
3''	3.36	77.6	CH
4''	3.41	72.9	CH
5''	3.40	76.2	CH
6''	–	176.1	C
1'''	–	157.7	C
1''''	3.00	35.8	CH ₃


Mass spectra (Figures 1, 2, and 3) analysis shown in Table 6 gave a mass (m/z) of 836.4, which confirmed a molecular formula of C₄₆H₆₈N₄O₁₀, and fragments that also confirmed structure assignment of Compound 1 including a sugar moiety.

Table 6

Mass Spectrometry data for Compound 1			
Figure	Ionization	Mass (m/z)	Fragment
1	+ mode (+ Q1)	837.5	(M+H) ⁺
		823.7	(M-CH ₃) ⁺
2	+ mode (+ EPI)	837.3	(M+H) ⁺
		662.1	(M-sugar) ⁺
		644.1	(M-O-sugar) ⁺
3	mode (- Q1)	835.3	(M-H) ⁻
		821.5	(M-CH ₃) ⁻

The UV spectrum for Compound 1 exhibited UV λ_{max} at 258.77 and 362.77 nm in methanol in accordance with the methylpentaene amide of the 2-aminocyclopenta-1,3-dione tautomer.

10




3010-5PCT-7CA

- 94 -

Compound 2 is named 6-{16-guanidino-1-[11-(2-hydroxy-5-oxocyclopent-1-enylcarbamoyl)-1-methyldodeca-2,4,6,8,10-pentaenyl]-2,4,10-trimethylhexadeca-2,8,12-trienyloxy}-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid.

Structure of Compound 2 was confirmed by ^1H (Figure 5) and ^{13}C NMR. The signals of $1''''$ carbon (35.8 ppm) and protons (singlet at 3.00 ppm) of Compound 1 (see Table 5) were absent from the spectra, which confirmed the absence of this CH_3 residue. Only small shifts in the guanidine area were observed in the ^{13}C NMR of Compound 2. No further changes from the structure of Compound 1 previously described were present.



10

Compound 7

Compound 7 is named 6-[1-(11-carboxy-1-methyldodeca-2,4,5,8,10-pentaenyl)-2,4,10-trimethyl-16-(*N*-methylguanidino)-hexadeca-2,8,12-trienyloxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.

Structure analysis of Compound 7 was accomplished by spectral data analysis including ^1H NMR (Figure 10) and Mass spectra. The later gave a mass of 739.37 at negative ionization (ES-) and 741.53 at positive ionization (ES+), which is consistent with a molecular formula of $\text{C}_{41}\text{H}_{63}\text{N}_3\text{O}_9$ and a calculated mass of 741.95.

Analysis of the ^1H NMR (Figure 10) showed the absence of the signal at δ 2.35 ppm (Table 5) from the NMR spectrum of Compound 1. This signal was previously assigned to the two methylene groups of the cyclopentenone of Compound 1. An effect was also observed at position 3, which doublet (found at about 7.1 ppm in the case of Compound 1) has moved 0.1 ppm (to 7.0 ppm), the rest of the spectra remaining mostly the same.

20

Example 5: Preparation and identification of Compounds 3, 4 and 5


Compounds 3, 4 and 5 were prepared according to the following procedure. A 0.1M solution of sodium hydroxide in methanol (334 μL , Fisher Chemicals) was added to

3010-5PCT-7CA

- 95 -

Compound 1 (20 mg) in methanol (2 mL). Dimethyl sulfate (5.68 μ L, Sigma) was added and the reaction stirred at room temperature for 24 hours. Additional sodium hydroxide in methanol (334 μ L) and dimethyl sulfate (10 μ L) were added and the reaction stirred for an additional 24 hours. A third portion of sodium hydroxide in methanol (400 μ L) and dimethyl sulfate (15 μ L) were added and the reaction mixture stirred for an additional 24 hours. The reaction was monitored by TLC (Merck Silica gel 60 F₂₅₄, eluting with 7 % methanol in chloroform) visualized under UV. The reaction was concentrated *in vacuo*. The crude residue was purified by multiple injection on an HPLC Waters Auto-Purification System using a Symmetry (C-18, 5 μ , 30x100 mm) column and the following eluent: A (10mM ammonium acetate in water (10mM NH₄OAc)) and B acetonitrile (MeCN), 74:26 to 50:50 A:B gradient in 20 minutes, 40mL/min. The fractions having retention times 9.4, 11.5 and 15.5 minutes were collected to give respectively Compound 4 (0.53 mg), Compound 3 (5.36 mg) and Compound 5 (4.04 mg).

Structures of Compounds 3, 4 and 5:



Compound 3


Compound 3 is named 3,4,5-trihydroxy-6-[1-[11-(2-hydroxy-5-oxocyclopent-1-enylcarbamoyl)-1-methyldodeca-2,4,6,8,10-pentaenyl]-2,4,10-trimethyl-16-(*N*-methylguanidino)-hexadeca-2,8,12-trienyloxy]-tetrahydropyran-2-carboxylic acid methyl ester.

Structure determination of Compound 3 was accomplished by spectral data analysis including ¹H NMR (Figure 6) and ¹³C NMR and mass spectrometry. The molecular ion was found at mass 852.03 (M+H)⁺ and 849.97 (M-H)⁻, respectively for positive and negative ionization, which confirms a calculated molecular weight of 851.08, for C₄₇H₇₀N₄O₁₀ as molecular formula. The methyl group (in the squares) was easily assigned to the carboxylic ester from NMR chemical shifts, of the new methyl group (singlet at δ 3.73 ppm integrating for 3 protons) and of the surrounding proton and carbon atoms. The protons most affected were 4'' and 5'' (δ 3.40-3.48 ppm (Table 5)

3010-5PCT-7CA

- 96 -

moved to δ 3.50-3.56 ppm), 1" (doublet δ 4.20 ppm (Table 5) moved to δ 4.26 ppm), 13 (doublet δ 4.58 ppm (Table 5) moved to δ 4.68 ppm) and 31 (δ 1.60 ppm (Table 5) moved to δ 1.52 ppm). Smaller effects were also observed at proton positions 4 to 10 and 32. These last effects might be due to a minor change in conformation and polarity difference between the carboxylic acid of Compound 1 and the ester of Compound 3.


**Compound 4**

Compound 4 is named 3,4,5-trihydroxy-6-[1-[11-(2-methoxy-5-oxo-cyclopent-1-enylcarbamoyl)-1-methyldodeca-2,4,6,8,10-pentaenyl]-2,4,10-trimethyl-16-(N-methyl-guanidino)-hexadeca-2,8,12-trienyloxy]-tetrahydropyran-2-carboxylic acid.


Structure determination of Compound 4 was accomplished by spectral data analysis including ^1H NMR (Figure 7) and ^{13}C NMR and mass spectrometry. The molecular ion was found at mass 852.03 ($\text{M}+\text{H}$) $^+$ and 849.98 ($\text{M}-\text{H}$) $^-$, respectively for positive and negative ionization, which confirms a calculated molecular weight of 851.08, for $\text{C}_{47}\text{H}_{70}\text{N}_4\text{O}_{10}$ as molecular formula. The ^1H NMR spectral analysis confirmed the presence of the methyl group (in the square) as a singlet integrating for three protons at 4.07 ppm. This methyl was also confirmed to be on the cyclopentenone as the two methylene groups were non-equivalent. In fact, in Compound 1, the two methylene groups from the cyclopentenone (positions 3' and 4') are equivalent (a 4 proton singlet at 2.35 ppm) due to the symmetry of the tautomeric forms. In Compound 4, the protons of these two positions appear as two separate triplets at 2.84 ppm and 2.52 ppm, integrating for two protons each.

3010-5PCT-7CA

- 97 -

**Compound 5**

Compound 5 is named 3,4,5-trihydroxy-6-[1-[11-(2-methoxy-5-oxo-cyclopent-1-enylcarbamoyl)-1-methyldodeca-2,4,6,8,10-pentaenyl]-2,4,10-trimethyl-16-(*N*-methylguanidino)-hexadeca-2,8,12-trienyloxy]-tetrahydropyran-2-carboxylic acid methyl ester. Structure determination of Compound 5 was accomplished by spectral data analysis including ^1H NMR (Figure 8) and ^{13}C NMR and mass spectrometry. The molecular ion was found at mass 866.06 ($\text{M}+\text{H}^+$) and 863.89 ($\text{M}-\text{H}^-$), respectively for positive and negative ionization, which confirms a calculated molecular weight of 865.11, for $\text{C}_{48}\text{H}_{72}\text{N}_4\text{O}_{10}$ as molecular formula. The ^1H NMR spectral analysis confirmed the presence of two methyl groups (in the square) as singlets integrating for three protons at 3.73 ppm and 4.07 ppm. One of the methyl (4.07 ppm) was confirmed to be on the cyclopentenone as the two methylene groups, as in Compound 4, were non-equivalent and appearing as two separate triplets at 2.84 ppm and 2.52 ppm, integrating for two protons each. The other methyl group (3.73 ppm) was confirmed as the methyl ester of the glucuronic acid (see Compound 3 determination above).

Example 6: Preparation of Compound 3 by esterification of Compound 1**Compound 3**


Diazomethane was generated by standard methods in an Aldrich diazomethane-generator [Z41, 173-6]. Approx. 2mL 5N sodium hydroxide was added dropwise to 450mg 1-methyl-3-nitro-1-nitrosoguanidine and the generated gaseous diazomethane

3010-5PCT-7CA

- 98 -

was condensed in 4 mL of diethyl ether at 0°C. The diazomethane solution was added dropwise to a solution of Compound 1 (10 mg) in 6 mL of methanol. The reaction was carried out at room temperature with magnetic stirring maintained for 15 minutes until completion. The reaction product was evaporated at 30°C under a gentle stream of N₂. The crude material was purified by multiple injections on HPLC using a YMC ODS-A 10×250mm column and a gradient of 5mM NH₄OAc / acetonitrile at 5mL/min (90:10 for 1min, 90:10 - 30:70 o. 20min). The combined yield of pure Compound 3 derived from two separate 10 mg batches was 0.99 mg.

10 **Example 7: Preparation and identification of Compound 6**



Compound 6

Compound 6 is named 6-{16-(N'-acetyl-N-methylguanidino)-1-[11-(2-hydroxy-5-oxocyclopent-1-enylcarbamoyl)-1-methyldodeca-2,4,6,8,10-pentaenyl]-2,4,10-trimethylhexadeca-2,8,12-trienyloxy}-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid. Compound 6 was prepared by acetylation of Compound 1 using the following procedure. Acetic anhydride (3.38 µL, Sigma) was added to a solution of Compound 1 (20 mg) in methanol (2 mL) and the reaction stirred at room temperature for 72 hours. Additional portions of acetic anhydride (20 µL) were added after 24 and 48 hours. The reaction was monitored by TLC (Merck Silica gel 60 F₂₅₄, eluting with 7 % methanol in chloroform) visualized under UV. The reaction was concentrated *in vacuo*.

The crude residue was purified by multiple injection on an HPLC Waters Auto-Purification System using a Symmetry (C-18, 5µ, 30x100 mm) column and the following eluent: A (10mM ammonium acetate in water (10mM NH₄OAc)) adjusted to pH 5 with glacial acetic acid and B acetonitrile (MeCN), 74:26 to 50:50 A:B gradient in 20 minutes, 40mL/min. The fractions having retention times 9.4, 11.5 and 15.5 minutes were collected to give Compound 6 (6.43 mg).

3010-5PCT-7CA

- 99 -

Structure determination of Compound 6 was accomplished by spectral data analysis including ^1H NMR (Figure 9) and ^{13}C NMR and mass spectrometry. The molecular ion was found at mass 880.03 ($\text{M}+\text{H}^+$) and 877.98 ($\text{M}-\text{H}^-$), respectively for positive and negative ionization, which confirms a calculated molecular weight of 879.09, for $\text{C}_{48}\text{H}_{70}\text{N}_4\text{O}_{11}$ as molecular formula. Analysis of the ^1H NMR spectrum also confirmed the presence of an acetyl group as a singlet at 1.95 ppm integrating for 3 protons. No important changes were observed at other positions, which indicate this acetyl group is on the guanidine.

10 **Example 8: Anti-microbial activity of Compounds 1 to 7**

Antibacterial activity of Compounds 1 and 2 (Table 7) was measured by determining the minimal inhibitory concentration (MIC) necessary to obtain a complete inhibition of bacteria growth in eight indicator strains, namely *Staphylococcus aureus* (ATCC™ 6538P), , *Staphylococcus aureus* MRS3 (ATCC™ 700699), *Staphylococcus epidermidis* (ATCC™ 12228), *Bacillus subtilis* (ATCC™ 23857), *Bacillus megaterium* (ATCC™ 14581), *Enterococcus faecalis* VRE-1 (ATCC™ 29212), *Enterococcus faecalis* VRE-2 (ATCC™ 51299) and *Micrococcus luteus* (ATCC™ 9341) . Indicator strains preparation and MIC determination were performed according to the National Committee for Clinical Laboratory Standards (NCCLS) guideline M7-A5 *Methods for Dilution Antimicrobial*
20 *Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Fifth Edition*. (NCCLS document M7-A5, ISBN 1-56238-394-9; NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA).

Compounds 1 and 2 were prepared as 100x stock solution in DMSO, with concentrations ranging from 3.2 mg/ml to 0.003 mg/ml (a two-fold dilution series over 11 points). An aliquot of each 100x stock solution was diluted 50-fold in test medium described below to give a set of eleven (11) 2x solutions. 50 μl of each of the eleven 2x solutions was aliquoted into the corresponding well of a 12-well row, with the final well reserved for medium alone control.

Vancomycin (Sigma™) used as positive control compounds, was prepared as 2x stock
30 solutions in Mueller-Hinton test medium ranging from 64 $\mu\text{g}/\text{ml}$ to 0.06 $\mu\text{g}/\text{ml}$ (a two-fold

3010-5PCT-7CA

- 100 -

dilution series over 11 points). An aliquot of 50 µl corresponding to each concentration (at 2x) was then transferred to 96-well microplates to obtain a series of eleven two-fold dilutions.

An isolated colony of each of the eight indicator strains was used to inoculate tubes containing 2 ml of test medium. Mueller-Hinton test medium was used for

Staphylococcus aureus (ATCC™ 6538P), *Staphylococcus aureus* MRS3 (ATCC™ 700699), *Staphylococcus epidermidis* (ATCC™ 12228), *Bacillus subtilis* (ATCC™ 23857), *Bacillus megaterium* (ATCC™ 14581) and *Micrococcus luteus* (ATCC™ 9341) indicator strains, and BHI test medium was used for *Enterococcus faecalis* VRE-1

10 (ATCC™ 29212) and *Enterococcus faecalis* VRE-2 (ATCC™ 51299) indicator strains.

Cells were grown overnight at 28°C with shaking. Inoculum density for each indicator strain was adjusted to OD₆₀₀ = 0.1 in 5ml 0.85% saline, then further diluted 1/100 in appropriate medium. 50 µl of the final dilution (in test medium) of each indicator strain was added to each well of a 12-well row. This brings the final dilution of the test article or control compound in solution to 1x. The final inoculum is approximately 5 x 10⁵ CFU/ml. The indicator strains were incubated with 11 concentrations of each of Compounds 1 and 2, Vancomycin (Sigma™) control compound and one media alone control. For MIC determination, assay plates were incubated at 35°C for 16 to 20 hours. The MIC for each indicator was assessed as the lowest concentration of compound resulting in total
20 absence of growth and is shown below.

Table 7

Antibacterial activity of Compounds 1 and 2, MIC (µg/ml)			
Strain	Compound 1	Compound 2	Vancomycin
<i>S. aureus</i> ATCC™ 6538P	2	1	2
<i>S. aureus</i> ATCC™ 700699	4	2	4
<i>S. epidermidis</i> ATCC™ 12228	4	2	2
<i>B. subtilis</i> ATCC™ 23857	1	2	0.25
<i>B. megaterium</i> ATCC™ 14581	1	1	0.125
<i>E. faecalis</i> ATCC™ 29212	8-16	16	4
<i>E. faecalis</i> ATCC™ 51299	16	16	8-16
<i>M. luteus</i> ATCC™ 9341	4	1-2	1

3010-5PCT-7CA

- 101 -

Antibacterial activity of Compounds 3, 4, 5, 6 and 7 are accomplished using the same method in a panel of bacterial strains and Vancomycin as positive control.


Antibacterial efficacy of Compounds 1, 2, 3, 4, 5 and 6 on bacterial strain *Staphylococcus aureus* NRRL B-313 (ATCC™ 6538P) was determined at different pH concentrations. These results are shown in Table 8 together with the antibacterial activity of Compound 7 on the same strain.

Table 8

Compounds 1 to 7 Antibacterial activity on <i>S. Aureus</i> (ATCC™ 6538P), and effect of pH (MIC (µg/ml))								
	1	2	3	4	5	6	7	Vancomycin
pH 5.0	0.125	0.0625	2	2	2	0.25	ND*	1
pH 6.0	0.25	0.125	4-8	2	4	0.5	ND*	1
pH 7.0	1	1	16	2	4	2	32-64	1

10 *ND: not determined


Example 9: Preparation of Compound 10 by oxidation of Compound 8

**Compound 10**


20 To a methylene chloride solution of Dess-Martin periodinane (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)one, Sigma-Aldrich Co.) is added a solution of Compound 8 in methylene chloride and the reaction stirred at room temperature for 1 hour. The mixture is diluted with diethyl ether and a saturated aqueous sodium bicarbonate solution containing sodium thiosulfate. Organic layer is separated and washed with saturated aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude residue is purified by HPLC according to the procedure described in Example 5. Pure Compound 10 is obtained by pooling and concentrating the appropriate eluate fractions.

3010-5PCT-7CA

- 102 -

Example 10: Preparation of Compound 11 by reduction of Compound 1**Compound 11**


LAH (lithium aluminum hydride) is added to a 0°C solution of Compound 1 in THF (tetrahydrofuran). After hydrogen gas has stopped evolving, the reaction is allowed to warm to room temperature and stirred overnight. Water is slowly added and 1M hydrochloric solution is used to acidify the solution carefully. The mixture is extracted three times with ethyl acetate. Organic layers are combined and washed with saturated aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. Pure Compound 11 is obtained by pooling and concentrating the appropriate fractions of HPLC purification according to Example 5.

Example 11: Preparation of Compound 23 from Compound 1**Compound 23**


Compound 23 is prepared by modification of the guanidino group of Compound 1 according to the procedure described in Argoudelis *et al.*, J. Antibiotics, Vol. XL, No. 6, June 1987, pp 750-760. A mixture of 200 mg of Compound 1 in 1.2 ml water, 1.0 ml of absolute ethanol, 1.0 ml of 2,4-pentadione and 120 mg of sodium bicarbonate is stirred at 90 °C for 3 hours. The mixture is allowed to cool to room temperature, concentrated to dryness, dissolved in 5 ml of 2N acetic acid, and purified by HPLC as described in Example 5. Pure Compound 23 is obtained by pooling and concentrating the appropriate eluate fractions.

3010-5PCT-7CA

- 103 -

Example 12: Preparation of Compound 24 by alkylation of Compound 1**Compound 24**


Compound 24 is prepared as follows. See Bartzatt et al., *Biotechnol. Appl. Biochem.* (2002) 36, 89-93. A Wheaton-type double-chamber device (Wheaton Co., Millville, NJ, U.S.A.) is utilized to generate diazopropane ($\text{CH}_3\text{CH}_2\text{CHN}_2$). Approx. 5.0 mg of Compound 1 is placed into an organic solvent (ethyl acetate/diethyl ether, 1:1, v/v) and the diazopropane gas formed is allowed to dissolve in the mixture. Diazopropane is
 10 generated by mixing 0.15 ml of 5 M NaOH with 0.15 g of 3-nitro-1-nitroso-1-propylguanidine. Excess diazoalkane and the solvent are removed by nitrogen gas flow or under vacuum. The remaining residue is dissolved in methanol, and the methanol solution is purified by HPLC as described in Example 5. Pure Compound 24 is obtained by pooling and concentrating the appropriate eluate fractions.

Example 13: Preparation of Compound 25 by acylation of Compound 1**Compound 25**


Compound 25 is prepared by acylation of Compound 1 as follows. Acetic anhydride
 20 (4.5 equivalents) is added dropwise to a solution of 50 mg/ml of Compound 1 and in acetonitrile and pyridine (9:1). The mixture is stirred under reflux and monitored by TLC (see example 5). The solvent is removed under vacuum and the residue is dissolved in methanol. The methanol solution is purified by HPLC as described in Example 5. Pure Compound 25 is obtained by pooling and concentratin the appropriate eluate fractions.

3010-5PCT-7CA

- 104 -

Example 14: Preparation of Compound 26 by esterification of Compound 25**Compound 26**


To a solution of Compound 25 in diethyl ether/ethyl acetate (1/1) is added 1 equivalent of diazomethane in diethyl ether. The reaction mixture is allowed to stand at room temperature overnight. Excess diazomethane and the solvent are removed by nitrogen gas flow or under vacuum. The remaining residue is dissolved in methanol, and the methanol solution is purified by HPLC as described in Example 5. Pure Compound 26 is obtained by pooling and concentrating the appropriate eluate fractions.

Example 15: Preparation of Compound 27 by acylation of Compound 1**Compound 27**

Compound 27 is prepared by acylation of Compound 1 as follows. Acetic anhydride (3.2 equivalents) is added dropwise to a solution of 50 mg/ml of Compound 1 in acetonitrile. The mixture is stirred under reflux and monitored by TLC (see Example 5). The solvent is removed under vacuum and the residue is dissolved in methanol. The methanol solution is purified by HPLC as described in Example 5. Pure Compound 27 is obtained by pooling and concentrating the appropriate eluate fractions.


3010-5PCT-7CA

- 105 -

Example 16: Preparation of Compound 28 by esterification of Compound 27**Compound 28**

To a solution of Compound 27 in diethyl ether is added 1 equivalent of diazomethane in diethyl ether. The reaction mixture is allowed to stand at room temperature overnight. Excess diazomethane and the solvent is removed by nitrogen gas flow or under vacuum. The remaining residue is dissolved in methanol, and the methanol solution is purified by HPLC as described in Example 5. Pure Compound 28 is obtained by pooling and concentrating the appropriate eluate fractions.

10

Example 17: Biosynthesis and Isolation of Compound 8**Compound 8**

Compound 8 is produced by inactivation of glycosyltransferase ORF 14 (SEQ ID NO: 29) followed by fermentation as described in Example 2 and isolation of the compound as described in Example 3. Targeted inactivation of the gene product of ORF 14 (SEQ ID NO: 29) is achieved by insertional gene disruption using replicative plasmid-mediated homologous recombination. Inactivation of glycosyltransferase ORF 14 (SEQ ID NO: 29) is described in Figure 22a. Referring to Figure 22a, inactivation of the glycosyltransferase gene (SEQ ID NO: 30) disrupts the transfer of the sugar moiety onto the backbone of the polyketide core. The absence of the sugar moiety results in a non-glycosylated Compound 8. Insertional inactivation of glycosyltransferase genes involved in polyketide biosynthesis in streptomyces is known in the art. Blanco *et al.* (*Mol. Gen. Genet.* 262, 991-1000 (2000)), identified two genes of the mithramycin biosynthetic gene cluster as glycosyltransferases by the production of a non-glycosylated mithramycin upon inactivation of these genes. Similarly, Chen *et al.* (*Gene*

20

3010-5PCT-7CA


- 106 -

263, 255-64 (2001)) investigated genes responsible for glycosylation in the biosynthetic pathways encoding pikromycin, narbomycin, methymycin and neomethymycin by producing non-glycosylated analogs.

A plasmid for homologous recombination is constructed by cloning a kanamycin resistance marker between the left and right flanking regions of SEQ ID NO: 30. The construct is cloned into a delivery plasmid that is marked with thiostrepton resistance producing a disruption plasmid. The plasmid is introduced into *Amycolatopsis orientalis* by either PEG-mediated protoplast transformation or RK2-mediated conjugation.

10 Spores from individual transformants or transconjugants are cultured on non-selective plates to induce recombination. This cycle is repeated three times to enhance the opportunity for recombination. Crossovers yielding targeted gene recombinants are then selected and screened using kanamycin and thiostrepton for single crossovers and kanamycin for double crossovers. Replica plating and southern hybridization are used to confirm the double crossover inactivation in *Amycolatopsis orientalis* transformants. The *Amycolatopsis orientalis* transformant is cultured as described in Example 2 and Compound 8 is isolated using the protocol of Example 3.

Example 18: Biosynthesis and Isolation of Compound 11



20

Compound 11

Compound 11 is produced by inactivation of sugar oxidoreductase gene product of ORF 13 (SEQ ID NO: 27) followed by transfer of the glucose onto the polyketide backbone chain by the glycosyltransferase gene product of ORF 14 (SEQ ID NO: 29) as illustrated in Figure 22b. Referring to Figure 22b, glucuronic acid is synthesised by oxidation of glucose catalyzed by the sugar oxidoreductase gene product of ORF 13 (SEQ ID NO: 27). Inactivation of the ORF 13 (SEQ ID NO: 27) disrupts the conversion of glucose to glucuronic acid producing Compound 11 when the glucose

3010-5PCT-7CA


- 107 -

substrate is transferred onto the polyketide backbone chain by the glycosyltransferase gene product of ORF 14 (SEQ ID NO: 29). Targeted inactivation of the sugar oxidoreductase ORF 13 (SEQ ID NO: 27) is achieved by insertional gene disruption using replicative plasmid-mediated homologous recombination.

A plasmid for homologous recombination is constructed by cloning a kanamycin resistance marker between the left and right flanking regions of SEQ ID NO: 28. The construct is cloned into a delivery plasmid that is marked with thiostrepton resistance producing a disruption plasmid. The plasmid is introduced into *Amycolatopsis orientalis* by either PEG-mediated protoplast transformation or RK2-mediated conjugation.

- 10 Spores from individual transformants or transconjugants are cultured on non-selective plates to induce recombination. This cycle is repeated three times to enhance the opportunity for recombination. Crossovers yielding targeted gene recombinants are then selected and screened using kanamycin and thiostrepton for single crossovers and kanamycin for double crossovers. Replica plating and southern hybridization are used to confirm the double crossover inactivation in *Amycolatopsis orientalis* transformants. The *Amycolatopsis orientalis* transformant is cultured as described in Example 2 and Compound 11 is isolated using the protocol of Example 3.

Example 19: Biosynthesis and Isolation of Compound 7



Compound 7

Compound 7 is also produced by inactivation of any one of acyltransferase ORF 16 (SEQ ID NO: 33), acyl CoA ligase ORF 17 (SEQ ID NO: 35), or adenylating/condensing synthetase ORF 15 (SEQ ID NO: 31) followed by fermentation as described in Example 2 and isolation of the compound as described in Example 3. Referring to Figure 23, gene disruption of ORF 16 (SEQ ID NO: 34) results in the inactivation of the acyltransferase gene product of ORF 16 (SEQ ID NO: 33) preventing condensation of

3010-5PCT-7CA

- 108 -

succinyl-CoA and glycine to form 5-aminolevulinate. Gene disruption of ORF 17 (SEQ ID NO: 36) results in the inactivation of the acyl CoA ligase gene product of ORF 17 (SEQ ID NO: 35) preventing the conversion of 5-aminolevulinate to 5-aminolevulinate-CoA which cyclizes to form aminohydroxycyclopentenone. Gene disruption of ORF 15 (SEQ ID NO: 32) results in the inactivation of the adenylating/condensing synthetase gene product of ORF 15 (SEQ ID NO: 31) preventing transfer of the aminohydroxycyclopentenone unit to the polyketide chain. Compound 7 is provided by targeted inactivation of acyltransferase ORF 16 (SEQ ID NO: 33), acyl CoA ligase ORF 17 (SEQ ID NO: 35), or adenylating/condensing synthetase ORF 15 (SEQ ID NO: 31).


- 10 Targeted inactivation of ORF 16, ORF 17 or ORF 14 (SEQ ID NO: 29) is achieved by insertional gene disruption using replicative plasmid-mediated homologous recombination.

A plasmid for homologous recombination is constructed by cloning a kanamycin resistance marker between the left and right flanking regions of SEQ ID NOS: 34, 36 or 32. The construct is cloned into a delivery plasmid that is marked with thiostrepton resistance producing a disruption plasmid. The plasmid is introduced into *Amycolatopsis orientalis* by either PEG-mediated protoplast transformation or RK2-mediated conjugation. Spores from individual transformants or transconjugants are cultured on non-selective plates to induce recombination. This cycle is repeated three

20 times to enhance the opportunity for recombination. Crossovers yielding targeted gene recombinants are then selected and screened using kanamycin and thiostrepton for single crossovers and kanamycin for double crossovers. Replica plating and southern hybridization are used to confirm the double crossover inactivation in *Amycolatopsis orientalis* transformants. The *Amycolatopsis orientalis* transformant is cultured as described in Example 2 and Compound 7 is isolated using the protocol of Example 3.

3010-5PCT-7CA

- 109 -

Example 20: Biosynthesis and Isolation of Compound 9**Compound 9**

Compound 9 is produced by incorporation of the amidino hydrolase of SEQ ID NO: 67 of co-pending application CA 2,453,071 (see below). The amidino hydrolase catalyzes the conversion of 4-guanidinobutanamide to γ -amino butanamide. The supplementation of SEQ ID NO: 67 of co-pending application CA 2,453,071 effects synthesis of γ -amino butanamide from 4-guanidino butanamide, as described in Figure 24. To promote catalytic activity of the amidinohydrolase enzyme, the N-methyltransferase of ORF 5 (SEQ ID NO: 10) is inactivated by insertional mutagenesis to prevent methylation of the guanidino group and thus avoid interference with the enzymatic activity of the amidino hydrolase SEQ ID NO: 67 of co-pending application CA 2,453,071. Referring to Figure 24, the γ -amino butanamide is converted by acyl CoA ligase ORF 25 (SEQ ID NO: 52) to form γ -aminobutyryl-CoA which is then tethered onto the ACP domain of module 0 of ORF 18 (SEQ ID NOS: 37) of the polyketide synthase enzyme through the action of acyltransferase ORF 24 (SEQ ID NO: 50).

To supplement amidinohydrolase activity, SEQ IS NO: 67 of co-pending application CA 2,453,071, i.e ORF 33 of a biosynthetic locus for the production of a polyketide in *Streptomyces aizunensis*, is cloned into vector pBW160 as described in Hussain and Ward (*Appl. Environ. Microbiol.* 69, 373-382 (2003)) and the vector transferred into *Amycolatopsis orientalis*. The vector contains inducible promoter elements placed upstream of the cloned amidinohydrolase gene. Transfer of the expression vector to *Amycolatopsis* host strain is achieved by direct transformation of mycelia and electroporation. Development of cloning vectors and transformation methods for amycolatopsis are described in Dhingra *et al.* (*J. Ind. Microbiol. Biotechnol.* 30, 195-204

3010-5PCT-7CA

- 110 -

(2003)). The *Amycolatopsis orientalis* transformant is cultured as described in Example 2 and Compound 9 is isolated using the protocol of Example 3.

The amidino hydrolase of SEQ ID NO: 67 of Canadian patent application 2,453,071 is defined in one letter code as follows:

MTAHPNGVTPPLPPTETDRTLHFAGPATFGRIPRIDQVEKTDIAVVGVPFDSGVTY
 RPGARFGGNAIREASRTLRPYNPAQNVYPFHFSQVADAGDISANPFDLNDVETIE
 AAADDLISSGARLMTLGGDHTIALPMLRAVAKKHGPLAVLHFD AHLDTWDDYFGQ
 QYTHGMPFRRAVEEGILDTSALSHVGTRGPIYGKKDLDDDEKLGFGIVTSADV MR
 10 RGVDEVAQQLRERVGDRPLYISIDIDVLDP AHAPGTGTPEAGGLTSRELLEILRGLA
 DCHLVSADIVEVAPAYDHADITSVAASHAAYELISIMSKQIAPVRWGATQ;

and is prepared synthetically or by using cosmid IDAC 250203-05, deposited on February 25, 2003, at the International Depositary Authority of Canada (IDAC), Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2, comprising the encoding nucleic acid.

While this invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the
 20 scope of the invention encompassed by the appended claims.

SEQUENCE LISTING

<110> ECOPIA BIOSCIENCES INC.

McAlpine, James B.

Farnet, Chris M.

Zazopoulos, Emmanuel

Sorensen, Dan

<120> POLYENE POLYKETIDES AND METHODS OF PRODUCTION

<130> 3010-5PCT-7CA

<160> 57

<170> PatentIn version 3.0

<210> 1

<211> 12647

<212> DNA

<213> Amycolatopsis orientalis

<400> 1

```

atggccgaac tctgccgccg catcggggaa agccgaggtc ggccgatcaa actcgtcgcg      60
ttcccgatgg aggttcccgg cccgtgtgga gcgtggctga gcgcgtcttc cggcgactac      120
atcgtcttcc agtcggagac caccgggata caccaagagc acatcatcgc gcatgagctg      180
gggcatatcc tctccggaca tcgggcgga cggacgaag aggaaatatg gtcccgggttc      240
atgcccgaac tcgatccggg ggtaattcgg aggctgttga aaagaacgca gtacgactcg      300
gtccggggagc gggaggccga gacgatcgcc accctcctgc tcgaacgttc cctggtcgtc      360
cggctgctcg acgagccggg ttcgtcgcgg accaggcgga tgcggcacgt cctcggcgag      420
gcgcgggggt ggctgtgagc ctggccaagg aattcgtgat cgcggcgctg gtgtggttct      480
cctaccgggt ggcgcgatcg ccgcgcgacc cggcgatctg ggcgctggtc ggctgcctgg      540
tgctgcgggt gctgaccgcg ccttcgagca tggtagcgct gcacgagttc accggaggga      600
cgctcgacgt cgacaccttc cgctgggtcc agacggtcgt gctcgacgcc agcctgttct      660
tcctgctggg cttcttctctg ctctccgcgg gcggctcgcg gcggcggggtg gccctcgacg      720
cctgggttgc gctactggtc tgcgcggccc tggcggtggc catgttcgtg gtcccggccg      780
cgccccgcga gcaggccttc ggtgtcggcg cggcgctgcc ggcggtcgtg acggagccgg      840
gggtggcgct cttcttctctg gtcgacgcgg cgtacggcac ctacacgacc gtgcaggctg      900
cgagctgggc gctgcgtgac gccgtggaaa ccccgctccg ggtccgctgg gggctgcgga      960
tcgccgcctg cggcctgate acgctcgcgg tgacctcggt cgcgcggttc ggcacgatcc     1020
tggtgcgctg gtccggcggc gacgtgccgt cgtccctgcc ggtcgcgacg gccgtgctgg     1080
tccacgtggg aatcatacctg ttcattggcc ggatcaccct ggtcgggctg ctgcgccgtgc     1140

```

tcgccgccgt caggctgtgg ctgcggcacc ggcggcggta cgaggatctg cgaccgctgt	1200
gggggcacct gcacgacgtg ttccccgggtg acgcgctgta cgccggggcag cgcggcggat	1260
ggctggagga actcgcgttc tggcggatgc atcgccggta ctggcgaagg gtcgtcgaga	1320
tccgtgacgg actggtccgg ctgagcccat acctggccga ctgcggtttc gtcgaaggca	1380
gggagcgggt ttcgcccagag gtcttccgcg aggcactggc caggttgcgg tcgggggagc	1440
ggccgacctc gcgtaccgcg gtggcgggtgg cgcgccccga ggggcaggac gtcgaggccg	1500
acgtcgggga gctcgtcacg ctgtcgaaga cgctgcgcgc ctgatcgtec gttttttcct	1560
cagttgtacg gaaccgggag ggatccattc acgtcagttg atgaaaggga ggtgggcacc	1620
tatactccgg tactcggggg gacctgcacc gccatatggc agcgcggcac gggttcgtga	1680
ggaactcggc agtgttcttg ggaggcagca tgtcccggca ggacggacca ggccggagcc	1740
tggccgaaaa actcgaccat ctgttcgcgc acgtcacccg gcgcaacggc accgagttca	1800
cgtacgaaga ggtcgcgtcc gcgatcaccg ccgaggggtgt gacgatctcc cagagctacg	1860
tctggcagct gcgcaaggga aagaaggaca acccgacgct caagcacctg caagggctgg	1920
cggatttctt cgggtgtccc gtcacgtact tcttcaacga ggacgtgagc gaccgggtgg	1980
accggcagct ggagtacctg cgcgcggaac aggcgcgggt gcgtgagctg gccgaaaccg	2040
acgaggtccg cctgatggcc atgcgcgcgg gcgagttgac gaccgatcgc cgcgaactgg	2100
tgaagaacct cctcgacgtg gtctggcggg atcagcaggc catgcgagag cgtgggtcca	2160
aacaggactg acgcctccgg cgacgccgggt tgtgcttgtc gtgcctgggt ttctgcttcg	2220
tccacagtgg tcatccactg aggaaaacgg actaacctct catatgttct cttgggtcga	2280
cacgataggg tgacgtcctc taggctcctc ggcaagagat cctgcgtgga acggacgacg	2340
tcgggtccgc gccggactcc acattgcggg tttgccatgg gggcgacgaa gaatgcacgt	2400
gaaatcagtg atcagagtgg acggcgacgt ccgcgcgagg gcgtatcccc gcgcggagct	2460
gctggtcctg cgagacttct tgacggaatc cgaacaggga aacgccgtcg cggcggtggt	2520
caccggaacc gccgcgagcg ggaaaagtga acttctgcac gcattcgcgc aacaatgcgc	2580
tgaagcggaa gcaacgggtg tgagcgcgct ttgcgtggaa gcggagaagg atctcccgtt	2640
caccgcgctg ttccagcttt tccgtggccc ggcactgtcc ggagatctgc gcgcgaaggc	2700
cgcggaacct ctgacgcggg ccgaacggac cgggctgacc gggcgggcca gcacacatct	2760
catgctcgac ctgctggagc tcgtgcgcga gctcgcgcgc caccgtccgg tcgtggtcct	2820
ggtcgacgac ttccaccatg tggacacccc gtcgttgac tggtgatgt tcctcatgcg	2880
ccgcatgcgc acgatgaacg tgctcgtcgt gctgacggag tcgttggtccg ccaagcagac	2940

gttgcccttg	ctgggcgccg	agtacctccg	gctcccgcac	tgccgcccga	tccggctgaa	3000
gccgctgggc	cgcgacgagg	tggcccgggt	cgtcccgcgc	ggccaggacg	acaccctggt	3060
gaagggcctg	cacgagctca	gcggcgggaa	tccgttgctg	gctcaggcac	tcctcgaaga	3120
tctccgtgcc	tcgggcgtag	ccctcgcgcc	cgagaccocg	ccgatccccg	gcgatcacta	3180
ctgccaggcg	gtggcgggct	gtctccagcg	cggcgaccag	gacaccocga	ccctcgccgg	3240
tgctctcgcg	gtgctgggta	aaggggaaac	ggtctgcctc	gccgtccggg	tgaccgggat	3300
ggaccagcgc	accgccggcc	gtgcgatcgc	cctcctgcac	caggtcggcc	tgctcgacgc	3360
gggcccggttc	cggcatccga	tgacggtgac	cgcggtgctg	gccgacgtcc	cggtcgcgga	3420
acgcgcgcga	ctgcacgagc	gcgccgcggg	gctcctgcat	cacgacggcg	ccggcgcgct	3480
cgacgtggcc	cgccacctcg	tcgccgccga	ccgggcccgc	cggccgtggg	cggtgcccgt	3540
gctgcgcacc	gcggccgaac	tggccaaagt	ggacaaccgg	acctcgttcg	cgggtccaatg	3600
cctgaaactg	gcctgccggg	cgtgcggcga	cgaagcgctc	gaggtcgaga	tggtgaccca	3660
gctcgccggc	ctggaatggc	ggaacaaccc	ggccatcggc	gccgtgcaca	cggaccacct	3720
ctacgagatc	ttcctcgccg	ggcagctccc	ggtgcggggc	gccgccatcc	tggtgcgggt	3780
cctgctgtgg	cacggccgca	ccgcggaagc	gggtgagggt	ctcgacaagc	tcgccgtcat	3840
ggagccttcg	gccgacgatc	gcaccgaggc	ggaactgcgc	atcaccocgg	tggttcattct	3900
ctgttcctat	cccgtttctg	gcgacaagct	gcctgccccg	gccgcgaagg	accgcgttcc	3960
cgcgcaatcc	ttcgacccca	acgtgcaggc	ggcgatggcg	ctgagccgga	tcgtcacgaa	4020
cggccccgac	gacgacgcga	tcgcttcggc	tgagaacgtg	ctgaagagca	tccagctcgg	4080
cgacacgatg	gtcgaatccg	tgcgacgcgc	gctgttcgcg	ctcatctacg	ccgaccggct	4140
ggacaaggcg	gtgccgtggg	gcgagctgct	gcagcaggag	gccgccgact	gcgacgcgcc	4200
cagctggcag	gccgtgttcg	ccgcggccag	ggcggaatat	gcgctgcgcc	agggagatct	4260
ggtgacggcg	gagaagcagg	ccaaggcggc	cttgacgttc	atcacgccgc	agagctgggg	4320
cgtggccgctc	ggagtcccgc	tggcgacgct	gtgcctcgcc	gccgtcggga	tgggcaagtt	4380
cgaggaggcg	gcgtcgcata	tcaaccagcc	ggtgccggcc	tcgatgctgc	aaaccocggt	4440
cggcctgcac	tacctgcgcg	cccgcggcag	gctctacctg	gagaccgacc	gggtgcacgc	4500
cgcgctcggc	gacttcgtcc	tgtgcggggg	actcagcaag	agctgggatt	tcgacctgcc	4560
ggtgctgggt	ccctggcgcg	gcgacacggc	cgaggcgtag	ctccggctcg	gcatgccgga	4620
gaaggcgaag	tccttgctgg	acgagcagct	cgcgaagctc	gccggctcga	cgtctcatgt	4680
gcggggaatc	tcgttgccgg	tcaaggccaa	gatcgccgaa	ccgcagaagc	gcccgggaatt	4740
gctgcgtgaa	gcgggtgaaga	tcttccaggc	gggcgggtatc	cgcctcgaac	tcgcccgcgc	4800

gctcggcgat ctcagccgcg cgcactacac gctggccgag tcgggtcgcg cgcgcacggt 4860
 ggcccggcag gcgtggcata tcgcgaaggg ttgccacgcc gacgtgatct gccgggatct 4920
 gcgtctcgac gggacaggcg acgagggaaa gccggcgctc accgcggcgg agatcgccgc 4980
 gtcgggcgtc gaacgcgagc tcatcgagtc gctgagcgag gccgagcgac gggtcgccgg 5040
 gctggcctcc ctcgggcaca cgaaccgggc gatcgcgagc aagctctaca tcacggtgag 5100
 cacggtcgaa cagcatctca cccgcgtcta tcgcaaactg gacgtcaacc ggcgccggga 5160
 tctcccgtcg tggctccagg ttctgggtcgt caacagcgcc tgaccgaaag aaccggcg 5220
 gtcgcgtcgt agctctcaag tcacgcatgt cgggtggcgt gagtggcgat tcgggttaga 5280
 accacccaaa tcaactcacga ccctcgcgcg aagcggccaa tcgggcattt ggcgaggatc 5340
 gtggtcgata tccggctcgc gaaacgacga aggtctcctt acccggctcg ggtaaggaga 5400
 ccttcgtcgt cccgtctact tgacggcggt cacggcggcc atcgtgcccg cccaccagta 5460
 ggtgcagtcg gccggcggct tcagggtccc gacgacctc acccggaacg agctgaagtg 5520
 ttcgagcagg gcgcgctggg gtgcccggct cagtgagtcg atttcgttgg tgtagtagga 5580
 gaagacgcca ccgggacgaa ggtgggcggc ggcgtgctcg aagaattcgg ccgccagcac 5640
 gatggccttc gggcccaggg tcctggcgaa ttcccgtcgc tcggtcggat aggtgtcgta 5700
 caggatcgcg tcgtactggc cgaggccgcc gagcacgtcc tgccaggcgc cgagttccag 5760
 ccggatatcg cgggtccggcc actgggcacg ccatttctcg aactccgcct tcacctcgga 5820
 gttgatttcg atcaggggtg gcgaccggac gccgcgctcc tggacgtagg tggccgaaat 5880
 acccatcccg aaaccgactt cgagcagatc ccgcgcgttc gccgcggcgt tttccgccag 5940
 caccttcacg agcggccggt cccagttctg catcacctgc tggccctgga tgagcagctg 6000
 cgtcggatcg ctgtagtccg cagtgtgtc ctgccagttc cggcggatca gcggccggtg 6060
 cgagccgtcg acgaattcct gctggatggg gtccagatgt tccagatcgc tggcgaactc 6120
 gaacaccgcg cggccgagaa ggagggtgcg ctggccgggc cccttcgccc ggaggaagtc 6180
 gtccctgacc ggggtccaccg ttatcttgaa ttccctgaag ttccgttgca ttctggtata 6240
 tctcctacgg tcacgcgagt cctttcaagc ccacggtatc ggtgatcttg gtccggtagc 6300
 cgaaatgcag ggggtgactt gaccactgaa cggcactgac gccgggaata ggggttcgga 6360
 gaataggggg tgaagttctc cgcacggggg gtttccccgt gataggaact tcacatgccg 6420
 ggggaaacca agaaccagga caccgacggc cgcggcgcgc gcaggcgctc cgtcgtatcg 6480
 ttgatcgccg acgtcacctg gccggtcgtc gtctactacg cgctgctcgc cttcgggtgg 6540
 agcagcggct ccgccttggg ggccggccacg gtcgccatcg gggtcctcgt gtcgccgtc 6600

gcggtcaagg aacgcagggt cgacggcttc ggggtgttcg tgctcggagt ctgcgcggtg 6660
 accctgctgg tctccttggt gagcggggac gaacgcctgc tgttggccaa ggatcccttc 6720
 accagcggcc tggccgggat cgccttcctc ggcagcctcg tcttcgggaa accggtgacc 6780
 ttcttcatct cccgccggat ccgggcgctc accccggctc ggcgcctggg ctgggaccgg 6840
 ctgtacgcgc cggaaccgca gttccgcaaa ctgcatcgcg tctccaccgc gggctggggc 6900
 gtggtcctgg tcaccgagtc cgccgcccgg ctcgctctga tctacctgct gcccgcgctc 6960
 gtgatggtcg gcctgtccac cgcgatcgaa ctgaccgcga tcaccggcgt ggtcgccctg 7020
 accatctggt accggcgctc ctcgcgggc cacggctctg aaaagtcgct tcgcacggcg 7080
 gatgcggcgc ccgctgctgt ctaaattgga ctaggggcga gtaggggaaa gtgaggggtt 7140
 ggtccgcgc gccacccgct gtacgttttc gtcgagacag tgtggccccg atgaccaggg 7200
 agatccgcca cgatgaccgc agccgatttc gcgccccgc tgaccactct ctgccccgat 7260
 ttcccgttcg cctacgacga ttggctcgcg catccggccg ggctcgggtga gctgccgccg 7320
 gaccgcctcg gccaggaggt cgccgtcgtc ggtggcggga tagcgggtgt ggtcgcggct 7380
 tacgaactgc tgcgcctcgg cctgaaaccg gtggtctacg aagcgggcca gatcggcggg 7440
 cggatgcgct ccatccccctt ggcgggcgag gacggcgcgg tcgcggagat gggcgcgatg 7500
 cggttcccgc cctcggccac caccctgtac cggtacatcg acgaagtcgg cctggagacc 7560
 aagccgttcg cgaaccggtt gtcccgcagc acttccacca cggatgatcaa cctcgacggg 7620
 gtgacctacc gcgcgcggac cccggcggac ctcccgtcgg tgttccacga ggtcgacgac 7680
 gcctggcaca aggccctgca ggaactggcc gatctgtcca ccatgcgcga cgccatccgg 7740
 atgcgcgaca ccgccatggt gaaggcgatc tggaaccggc tgctgcccga actcgacgac 7800
 cagtccttct atggtttcct ggcacggtcg accgcttttc cctccttcgg ccatcgtgag 7860
 atcttcggcc aggtcggctt cggcaccggc ggctgggaca ccgatttccc caactccgtg 7920
 ctggaaatcc tccgcgtcat ctacaccggt gtcgaggagg ggccgcggca gatcatcgg 7980
 ggctgccagc aacttccgcg gcggttgtgg aaccacgcac ccgcgtctgc gcgcttctgg 8040
 cctgccggga catcggtcgc gtcgctgcac gacggatcgc cgcgccccgc cgtcctcggg 8100
 ttgcgcccgg ccgcggacgg gttcgccgtc gaggacgcga acggtgacgt gcggacctat 8160
 ccggccgtgg tcttcaccgc gcagcaccgg gtctgtctca ccaagatcgc cggagtgcgc 8220
 ccgctgctgc ccgcgaacgt gtggaccgcg ctggaacgca cgcactacat gggtgcttcg 8280
 aagttgttcg tcccggtcga ccggccgttc tggcacgacg tcgatccccg caccggtgag 8340
 gaactgatgg ggatgacct caccgaccgg accccgcgca gcgtctacct gttcgacgac 8400
 gggccggatt cgccggccgc gctgtgcctt tcctatacct ggaacgacga ttcgctcaag 8460

ttcgcgacgc tcggccccggc ggaccggctc gaactcgcgc tcgacgcgct cgccgacatc	8520
tacccgggtg tcgacatccg ctcccacatc accggcgatc cggtcaccgt cacctgggag	8580
aacgagccga acttccaagg cgcgttcaag gcgaacctgc cagggcagta ccgctatcag	8640
cgccgcctgt tcacccattt ccggcaagac gaccttcccc cgctcagcg cggcctgttc	8700
ctcgccggtg acgacatctc gtggatgggc ggcttcgccg aaggggcggt caccagcgcg	8760
ctcaacgcgg tgtggggggac gctgcgccat ctcggcgggg ccaccgaccc gcgtaatccc	8820
ggccccggcg acgtcttcga ccacatcgcg ccgatcgaac tgccccgagtc ctgaacgggc	8880
cgaggccccg tccgtcgact ggggggtagt cggcggaccg ggcaggcgag acagtgtctca	8940
gctcgcgtag ctgggggttc gctgagcctg cctgagtacc ttggccccgt agaccagac	9000
cccggcggtg cggaagatga ccatcgtcag cgccatggtg acgaagaagg cggagacgcc	9060
gccggcgtcg atcccgggtg ccatcaggaa cttgccgaag tcggccgcga acgagtggct	9120
gtgttcgagg gtgtagacga agatgagccg tccgaccagg acgaacagcc acagtcccaa	9180
gtagaccag cccgccctgg ttagacggc ggatttctcc tgggtcccact cgaccttcgt	9240
gcccttcagc aatccccagc cgatcaggac gcccgccgcg atgccgacca gcccggccag	9300
tgtgttcggc gtggtcagct tgaggtcgta gaggaccgcc cagcccacca gcgcgcacgt	9360
gaagaacggc aggatcagga tgaccaggtg ggccttatgg cgaccgatgt gcgtgaacag	9420
caccagcgcc agcagtacgc cgctcaggat gagggcgttt cgcattggctt cactcatcaa	9480
aactccttcg aaagactccc catccggcag ttcgatgccg gttgtcccga aatctaaggc	9540
gagcggccgg gccgatcatc ggcgtgcggg tgggaatccg gttggagatc ggcgtccacc	9600
tcgaggtgga gtgccgtgtg gcgcggacag gtgagggcag gagatgatgc aggcattggtc	9660
gaagaagtgc ccccggtccg gatcgtgatc gccgaagacc aggcggcggt acgcgaagga	9720
ctggccctcc tgggtggggac ggtcgcgggg atcacctggg tcggccaggc acccgacggc	9780
gaggtcgccg tgcggctggc cggggaactg cgcccggacg tcgtcctgat ggatctctcc	9840
atgccccggt gcgacggcgt cgaggcgacc cggcggatca aggaacggca tccggagatc	9900
gagatcgtcg tgctcaccac ctacgccgac gacgactggg tgctgcgcgc gttggaggcc	9960
ggggcgttgg gatacctgac gaaatcggcc aacaaacacg aaatcggggc cgcggtacac	10020
gccgccgcgg cgggccaggc cctgctcgat ccgcagggtc agcgacgggt gctcggcgcc	10080
gccctgacgt ccgcgccccg ttcggcgcca ccgccggagg acgacgcgaa cctcaccaag	10140
cgggaagccc atgtgctgac gctgatcgcg gcggggcaca gcaacaagga gatcgccgcg	10200
gaactgttcg tcagcgagac gacggtcaag agccatatca accggatctt cgccaagacg	10260

gggagccggg atcgcgcgca ggccgtccgt tatgcctacc aagcgggcta tgtgcgggac 10320
 tgacgcggcg ctccgccgac gtcgttactg tccttcctgg gtgggctgaa ggctcccttc 10380
 accacgtctg atgcggtgaa gggagccttc agccccggcg gatacgggct ctcgggcctt 10440
 ggagctgata aaccaggcat gccgcgccga cgttgcgaaa gccactttcg caacaacgcc 10500
 aacgcgcttt ggggcctacc cggggaccgg ggcggtgacg tcccagaacc ggccgtcggg 10560
 cccggtgacc agcgtgccgt cgacgagttc gatccgttcg cgcattcccg tcaggccgta 10620
 gcccggcgtg tgcccggggg cgggcgcggc ggcgagggga ttgcggacgt gcagccggac 10680
 ctggtccggc ggggtactcca gttcgacgct caccgcctcg cccgcggcgt gtttgggcgc 10740
 gttcgtcagc gcttcccggc agatccgcag cagcgcgatc gtctgtgccg acgggagatc 10800
 gcggtgctcg cccagcatgg tgaaatccgc cggagtgtcg tgttcccggc cgaagggtccg 10860
 caccagttcg gtcagcgcg cgggcagggc gcggacgtcc tcgcgacg cgcaccagc 10920
 gtcccggacg tctactgagc cttgggtcggc gagacttcgc gacagcgca gcgaacgcag 10980
 ggcgccttcg gtgtcgttct cctccaccag cagggtgtgc atcacctcca gctggaccgg 11040
 cagcgcgccg agggaaatgg cgacgacgtc gtggatctcg cgggcgatgc ggggtgcgtc 11100
 gtccagcgtc gccgcgcgca cggcgcggt gtgcgccagc cgttcctggt gcagcaaccg 11160
 ttccgcctgc gcgaccctgg tcagatgacc gcggcggggtg aatccgacga ggaccacgat 11220
 gacgaccg cccagtgcgc ccagccaggc ctccgaagga cgggtggccga gcaggctgga 11280
 aaccacgatg gcggcgggcgt cgaagaccat cagcgcgatg atcgcgacgg tgcccggctc 11340
 cagccgtgaa gcgaacgcgg cgaggggtgat gcaggctcatg atcacggcgg tgccgtcggg 11400
 ggcggcgccg gtaccgaagg cggggaccgc gctcgccg cgcagcgga gcagggcggc 11460
 acgggggaag cgctcgctga tgccgatcca cagcagccag ctcgccgacg acaccgcgta 11520
 gagcaccac agccagccgg cggcgccgg tacggtcg cgtcatctggg tgacggccag 11580
 cagcgccgtc cggcgggcg gcgcggccca tcgccagcga cgttcctcga cctcgtcgga 11640
 cactgcgtcg gtcatacgac gatcgtaggg ccacgacggt tttccgctcg cgggtgatca 11700
 ttccgagggg ggaaataacc tcaccgttgg taggaggtcg ctctcgcgcg gttgtttccg 11760
 caggaagcgt ccggctagtg ttcgccgagg cgaaagaaag cggctctccc cccctccgcc 11820
 gaacaattcc catccctttc ggaggaatcc tgcatgacc gctccaagcg gcgatgccgg 11880
 ggactgggtc cgtgttttcc ggcccggagg accgtcggta ccgcgtctga tctgcctgcc 11940
 cgacgcccgt gcggccgcga atgcgttctt cccgctttcc gccgcgctcg cgcgggggat 12000
 cgagggtcac gcggtgcaat atccgggacg ccaggatcgg gtcgcggaac cgtgcgccga 12060
 agacatcggg gaattggccg accgggtcac cggggcgctc gcgctctggg aaggcgcgcc 12120

gttcgcggtg tacggccacg gaatgggagc ggtcgtcgtt ttcgaggtgg ccagacggct 12180
 ggagcagggc ctgaccggga gcccggtcgc gctgatcgtg tccggctgtc ccgccccgtc 12240
 ccggtccggc accgcccggc tccacctgct gccggatcag gacctcgtgg ccgagctgta 12300
 ctccgcagcg gccgcccggc cgcggggcgc gcgggacgcg gagctgctca aggccacctt 12360
 cccggccatc cgggcccact tccggggcgt gcccgcttac cggccccgagc ccgcgcccgc 12420
 gctgcgctgc ccggtcacgg tgctcgtcgg cgacagcgat ccgacgggtg ccctcgacga 12480
 ggcgcgcgac tggcacgagt acaccaccgg cccgttcgac ctccaggtct tccctgggtg 12540
 gcacggtttt ccggaggcgc gtcccagga gttcggcag gtggtgaccg ccgcgggtccg 12600
 gcggcggtga accggcgctt gcgcctcaca aaagcgggtc gtgagtg 12647

<210> 2
 <211> 145
 <212> PRT
 <213> Amycolatopsis orientalis

<400> 2

Met Ala Glu Leu Cys Arg Arg Ile Gly Glu Ser Arg Gly Arg Pro Ile
 1 5 10 15
 Lys Leu Val Ala Phe Pro Met Glu Val Pro Gly Pro Cys Gly Ala Trp
 20 25 30
 Leu Ser Ala Ser Ser Gly Asp Tyr Ile Val Phe Gln Ser Glu Thr Thr
 35 40 45
 Arg Ile His Gln Glu His Ile Ile Ala His Glu Leu Gly His Ile Leu
 50 55 60
 Ser Gly His Arg Ala Glu Pro Asp Glu Glu Glu Ile Trp Ser Arg Phe
 65 70 75 80
 Met Pro Asp Leu Asp Pro Gly Val Ile Arg Arg Leu Leu Lys Arg Thr
 85 90 95
 Gln Tyr Asp Ser Val Arg Glu Arg Glu Ala Glu Thr Ile Ala Thr Leu
 100 105 110
 Leu Leu Glu Arg Ser Leu Val Val Arg Leu Leu Asp Glu Pro Gly Ser
 115 120 125
 Ser Arg Thr Arg Arg Met Arg His Val Leu Gly Glu Ala Arg Gly Trp
 130 135 140
 Leu
 145

<210> 3
 <211> 438
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 3
 atggccgaac tctgccgccg catcggggaa agccgaggtc ggccgatcaa actcgtcgcg 60
 ttcccgatgg aggttccccg cccgtgtgga gcgtggctga gcgcgtcttc cggcgactac 120
 atcgtcttcc agtcggagac caccggata caccaagagc acatcatcgc gcatgagctg 180
 gggcatatcc tctccggaca tcgggcggaa ccggacgaag aggaaatatg gtcccgggttc 240
 atgcccgacc tcgatccggg ggtaattcgg aggctgttga aaagaacgca gtacgactcg 300
 gtccgggagc gggaggccga gacgatcgcc accctcctgc tcgaacgttc cctggtcgtc 360
 cggctgctcg acgagccggg ttcgtcgcgg accaggcgga tgcggcacgt cctcggcgag 420
 gcgcggggct ggetgtga 438

<210> 4
 <211> 369
 <212> PRT
 <213> Amycolatopsis orientalis

<400> 4

Val	Ser	Leu	Ala	Lys	Glu	Phe	Val	Ile	Ala	Ala	Leu	Val	Trp	Phe	Ser	1	5	10	15
Tyr	Arg	Leu	Ala	Arg	Ser	Pro	Arg	Asp	Pro	Ala	Ile	Trp	Ala	Leu	Val	20	25	30	
Gly	Cys	Leu	Val	Leu	Arg	Leu	Leu	Thr	Ala	Pro	Ser	Ser	Met	Val	Ala	35	40	45	
Leu	His	Glu	Phe	Thr	Gly	Gly	Thr	Leu	Asp	Val	Asp	Thr	Phe	Arg	Leu	50	55	60	
Val	Gln	Thr	Val	Val	Leu	Asp	Ala	Ser	Leu	Phe	Phe	Leu	Leu	Val	Phe	65	70	75	80
Phe	Leu	Leu	Ser	Ala	Gly	Gly	Ser	Arg	Arg	Arg	Val	Ala	Leu	Asp	Ala	85	90	95	
Trp	Leu	Leu	Leu	Leu	Val	Cys	Ala	Ala	Leu	Ala	Val	Ala	Met	Phe	Val	100	105	110	
Val	Pro	Ala	Ala	Ser	Arg	Glu	Gln	Ala	Phe	Gly	Val	Gly	Ala	Ala	Leu	115	120	125	
Pro	Ala	Val	Val	Thr	Glu	Pro	Gly	Val	Ala	Leu	Phe	Phe	Leu	Val	Asp	130	135	140	
Ala	Ala	Tyr	Gly	Thr	Tyr	Thr	Thr	Val	Gln	Ala	Ala	Ser	Trp	Ala	Leu	145	150	155	160
Arg	Asp	Ala	Val	Glu	Thr	Pro	Leu	Arg	Val	Arg	Trp	Gly	Leu	Arg	Ile	165	170	175	
Ala	Ala	Cys	Gly	Leu	Ile	Thr	Leu	Ala	Val	Thr	Ser	Val	Ala	Arg	Phe	180	185	190	

Gly Thr Ile Leu Val Arg Trp Ser Gly Gly Asp Val Pro Ser Ser Leu
 195 200 205
 Pro Val Ala Thr Ala Val Leu Val His Val Gly Ile Ile Leu Phe Met
 210 215 220
 Ala Gly Ile Thr Leu Val Gly Leu Leu Ala Val Leu Ala Ala Val Arg
 225 230 235 240
 Leu Trp Leu Arg His Arg Arg Arg Tyr Glu Asp Leu Arg Pro Leu Trp
 245 250 255
 Gly His Leu His Asp Val Phe Pro Gly Asp Ala Leu Tyr Ala Gly Gln
 260 265 270
 Arg Gly Gly Trp Leu Glu Glu Leu Ala Phe Trp Arg Met His Arg Arg
 275 280 285
 Tyr Trp Arg Arg Val Val Glu Ile Arg Asp Gly Leu Val Arg Leu Ser
 290 295 300
 Pro Tyr Leu Ala Asp Cys Gly Phe Val Glu Gly Arg Glu Arg Val Ser
 305 310 315 320
 Pro Glu Val Phe Arg Glu Ala Leu Ala Arg Leu Arg Ser Gly Glu Arg
 325 330 335
 Pro Thr Ser Arg Thr Ala Val Ala Val Ala Arg Pro Glu Gly Gln Asp
 340 345 350
 Val Glu Ala Asp Val Gly Glu Leu Val Thr Leu Ser Lys Thr Leu Arg
 355 360 365

Ala

<210> 5
 <211> 1110
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 5
 gtgagcctgg ccaaggaatt cgtgatcgcg gcgctggtgt gggtctccta ccggctggcg 60
 cgatcgccgc gcgaccgggc gatctgggcg ctggtcggct gcctgggtgct gcggttgctg 120
 accgcgcctt cgagcatggt ggcgctgcac gagttcaccg gagggacgct cgacgtcgac 180
 accttcgcc tgggtccagac ggctcgtgctc gacgccagcc tggtcttcct gctggtcttc 240
 ttctgctct ccgcgggcg ctcgcggcg cggtggccc tcgacgctg gttgctgcta 300
 ctggtctgcg cggccctggc ggtggccatg ttctggtcc cggccgcgtc ccgcgagcag 360
 gccttcgggtg tcggcgcggc gctgccggcg gtcgtgacgg agccgggggt ggcgctcttc 420
 ttctgggtcg acgcggcgta cggcacctac acgaccgtgc aggctgcgag ctgggcgctg 480
 cgtgacgccg tggaaacccc gctccgggtc cgctgggggc tgcggatcgc cgctgcggc 540

```

ctgatcacgc tcgcggtgac ctcggtcgcg cggttcggca cgatcctggt gcgctgggtcc 600
ggcggcgacg tgccgtcgtc cctgccggtc gcgacggccg tgctgggtcca cgtgggaatc 660
atcctgtttca tggccgggat caccctggtc gggctgctcg ccgtgctcgc cgccgtcagg 720
ctgtgggtgc ggcaccggcg gcggtacgag gatctgcgac cgctgtgggg gcacctgcac 780
gacgtgtttcc ccggtgacgc gctgtacgcc gggcagcgcg gcggatggct ggaggaactc 840
gcgttctggc ggatgcatcg ccggtactgg cgaagggtcg tcgagatccg tgacggactg 900
gtccgggtga gcccatacct ggccgactgc ggtttcgtcg aaggcagggg gcgggtttcg 960
cccgaggtct tccgcgaggc actggccagg ttgcggtcgg gggagcggcc gacctcgcgt 1020
accgcggtgg cgggtggcgcg ccccgagggg caggacgtcg aggccgacgt cggggagctc 1080
gtcacgctgt cgaagacgct gcgcgcctga 1110

```

```

<210> 6
<211> 171
<212> PRT
<213> Amycolatopsis orientalis

```

```

<400> 6

```

```

Met Ala Ala Arg His Gly Phe Val Arg Asn Ser Ala Val Phe Leu Gly
1          5          10          15
Gly Ser Met Ser Arg Gln Asp Gly Pro Gly Arg Ser Leu Ala Glu Lys
20          25          30
Leu Asp His Leu Phe Ala His Val Thr Arg Arg Asn Gly Thr Glu Phe
35          40          45
Thr Tyr Glu Glu Val Ala Ser Ala Ile Thr Ala Glu Gly Val Thr Ile
50          55          60
Ser Gln Ser Tyr Val Trp Gln Leu Arg Lys Gly Lys Lys Asp Asn Pro
65          70          75          80
Thr Leu Lys His Leu Gln Gly Leu Ala Asp Phe Phe Gly Val Pro Val
85          90          95
Thr Tyr Phe Phe Asn Glu Asp Val Ser Asp Arg Val Asp Arg Gln Leu
100         105         110
Glu Tyr Leu Arg Ala Glu Gln Ala Arg Leu Arg Glu Leu Ala Glu Thr
115         120         125
Asp Glu Val Arg Leu Met Ala Met Arg Ala Gly Glu Leu Thr Thr Asp
130         135         140
Arg Arg Glu Leu Val Lys Asn Leu Leu Asp Val Val Trp Arg Asp Gln
145         150         155         160
Gln Ala Met Arg Glu Arg Gly Ser Lys Gln Asp
165         170

```

<210> 7
 <211> 516
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 7
 atggcagcgc ggcacgggtt cgtgaggaac tcggcagtgt tcttgggagg cagcatgtcc 60
 cggcaggacg gaccaggccg gagcctggcc gaaaaactcg accatctgtt cgcgcacgtc 120
 acccggcgca acggcaccga gttcacgtac gaagaggtcg cgtccgcgat caccgccgag 180
 ggtgtgacga tctcccagag ctacgtctgg cagctgcgca agggaaagaa ggacaacccg 240
 acgctcaagc acctgcaagg gctggcggat ttcttcggtg tcccgggtcac gtacttcttc 300
 aacgaggacg tgagcgaccg ggtggaccgg cagctggagt acctgcgcgc ggaacaggcg 360
 cggttgcgtg agctggccga aaccgacgag gtccgcctga tggccatgcg cgcgggcgag 420
 ttgacgaccg atcgccgcga actggtgaag aacctcctcg acgtggtctg gcgggatcag 480
 caggccatgc gagagcgtgg gtccaaacag gactga 516

<210> 8
 <211> 936
 <212> PRT
 <213> Amycolatopsis orientalis

<400> 8

Met	His	Val	Lys	Ser	Val	Ile	Arg	Val	Asp	Gly	Asp	Val	Arg	Ala	Arg	1	5	10	15
Ala	Tyr	Pro	Arg	Ala	Glu	Leu	Leu	Val	Leu	Arg	Asp	Phe	Leu	Thr	Glu	20	25	30	
Ser	Glu	Gln	Gly	Asn	Ala	Val	Ala	Ala	Val	Val	Thr	Gly	Thr	Ala	Ala	35	40	45	
Ser	Gly	Lys	Ser	Glu	Leu	Leu	His	Ala	Phe	Ala	Gln	Gln	Cys	Ala	Glu	50	55	60	
Ala	Glu	Ala	Thr	Val	Met	Ser	Ala	Leu	Cys	Val	Glu	Ala	Glu	Lys	Asp	65	70	75	80
Leu	Pro	Phe	Thr	Ala	Leu	Phe	Gln	Leu	Phe	Arg	Gly	Pro	Ala	Leu	Ser	85	90	95	
Gly	Asp	Leu	Arg	Ala	Lys	Ala	Ala	Asp	Leu	Leu	Thr	Arg	Ala	Glu	Arg	100	105	110	
Thr	Gly	Leu	Thr	Gly	Arg	Pro	Ser	Thr	His	Leu	Met	Leu	Asp	Leu	Leu	115	120	125	
Glu	Leu	Val	Arg	Glu	Leu	Ala	Ala	His	Arg	Pro	Val	Val	Val	Leu	Val	130	135	140	
Asp	Asp	Phe	His	His	Val	Asp	Thr	Pro	Ser	Leu	His	Trp	Leu	Met	Phe	145	150	155	160

Leu Met Arg Arg Met Arg Thr Met Asn Val Leu Val Val Leu Thr Glu
 165 170 175
 Ser Leu Ser Ala Lys Gln Thr Leu Pro Leu Leu Gly Ala Glu Tyr Leu
 180 185 190
 Arg Leu Pro His Cys Arg Arg Ile Arg Leu Lys Pro Leu Gly Arg Asp
 195 200 205
 Glu Val Ala Arg Phe Val Pro Pro Gly Gln Asp Asp Thr Leu Val Lys
 210 215 220
 Gly Leu His Glu Leu Ser Gly Gly Asn Pro Leu Leu Ala Gln Ala Leu
 225 230 235 240
 Leu Glu Asp Leu Arg Ala Ser Gly Val Pro Leu Ala Pro Glu Thr Arg
 245 250 255
 Pro Ile Pro Gly Asp His Tyr Cys Gln Ala Val Ala Ala Cys Leu Gln
 260 265 270
 Arg Gly Asp Gln Asp Thr Arg Thr Leu Ala Gly Val Leu Ala Val Leu
 275 280 285
 Gly Lys Gly Glu Thr Val Cys Leu Ala Val Arg Val Thr Gly Met Asp
 290 295 300
 Gln Arg Thr Ala Gly Arg Ala Ile Ala Leu Leu His Gln Val Gly Leu
 305 310 315 320
 Leu Asp Ala Gly Arg Phe Arg His Pro Met Thr Val Thr Ala Val Leu
 325 330 335
 Ala Asp Val Pro Val Ala Glu Arg Ala Arg Leu His Glu Arg Ala Ala
 340 345 350
 Val Leu Leu His His Asp Gly Ala Gly Ala Leu Asp Val Ala Arg His
 355 360 365
 Leu Val Ala Ala Asp Arg Ala Asp Arg Pro Trp Ala Val Pro Val Leu
 370 375 380
 Arg Thr Ala Ala Glu Leu Ala Lys Val Asp Asn Arg Thr Ser Phe Ala
 385 390 395 400
 Val Gln Cys Leu Lys Leu Ala Cys Arg Ser Cys Gly Asp Glu Ala Leu
 405 410 415
 Glu Val Glu Met Val Thr Gln Leu Ala Gly Leu Glu Trp Arg Asn Asn
 420 425 430
 Pro Ala Ile Gly Ala Val His Thr Asp His Leu Tyr Glu Ile Phe Leu
 435 440 445
 Ala Gly Gln Leu Pro Val Arg Ala Ala Ala Ile Leu Val Arg Phe Leu
 450 455 460
 Leu Trp His Gly Arg Thr Ala Glu Ala Gly Glu Val Leu Asp Lys Leu
 465 470 475 480

Ala	Val	Met	Glu	Pro	Ser	Ala	Asp	Asp	Arg	Thr	Glu	Ala	Glu	Leu	Arg	485	490	495	
Ile	Thr	Arg	Leu	Phe	Ile	Leu	Cys	Ser	Tyr	Pro	Val	Leu	Arg	Asp	Lys	500	505	510	
Leu	Pro	Ala	Pro	Ala	Ala	Lys	Asp	Arg	Val	Pro	Ala	Gln	Ser	Phe	Asp	515	520	525	
Pro	Asn	Val	Gln	Ala	Ala	Met	Ala	Leu	Ser	Arg	Ile	Val	Thr	Asn	Gly	530	535	540	
Pro	Asp	Asp	Asp	Ala	Ile	Ala	Ser	Ala	Glu	Asn	Val	Leu	Lys	Ser	Ile	545	550	555	560
Gln	Leu	Gly	Asp	Thr	Met	Val	Glu	Ser	Val	Arg	Ser	Ala	Leu	Phe	Ala	565	570	575	
Leu	Ile	Tyr	Ala	Asp	Arg	Leu	Asp	Lys	Ala	Val	Pro	Trp	Cys	Glu	Leu	580	585	590	
Leu	Gln	Gln	Glu	Ala	Ala	Asp	Cys	Asp	Ala	Pro	Ser	Trp	Gln	Ala	Val	595	600	605	
Phe	Ala	Ala	Ala	Arg	Ala	Glu	Met	Ala	Leu	Arg	Gln	Gly	Asp	Leu	Val	610	615	620	
Thr	Ala	Glu	Lys	Gln	Ala	Lys	Ala	Ala	Leu	Thr	Phe	Ile	Thr	Pro	Gln	625	630	635	640
Ser	Trp	Gly	Val	Ala	Val	Gly	Val	Pro	Leu	Ala	Thr	Leu	Cys	Leu	Ala	645	650	655	
Ala	Val	Gly	Met	Gly	Lys	Phe	Glu	Glu	Ala	Ala	Ser	His	Ile	Asn	Gln	660	665	670	
Pro	Val	Pro	Ala	Ser	Met	Leu	Gln	Thr	Arg	Phe	Gly	Leu	His	Tyr	Leu	675	680	685	
Arg	Ala	Arg	Gly	Arg	Leu	Tyr	Leu	Glu	Thr	Asp	Arg	Val	His	Ala	Ala	690	695	700	
Leu	Gly	Asp	Phe	Val	Leu	Cys	Gly	Glu	Leu	Ser	Lys	Ser	Trp	Asp	Phe	705	710	715	720
Asp	Leu	Pro	Val	Leu	Val	Pro	Trp	Arg	Gly	Asp	Thr	Ala	Glu	Ala	Tyr	725	730	735	
Leu	Arg	Leu	Gly	Met	Pro	Glu	Lys	Ala	Lys	Ser	Leu	Leu	Asp	Glu	Gln	740	745	750	
Leu	Ala	Lys	Leu	Ala	Gly	Ser	Thr	Ser	His	Val	Arg	Gly	Ile	Ser	Leu	755	760	765	
Arg	Leu	Lys	Ala	Lys	Ile	Ala	Glu	Pro	Gln	Lys	Arg	Pro	Glu	Leu	Leu	770	775	780	
Arg	Glu	Ala	Val	Lys	Ile	Phe	Gln	Ala	Gly	Gly	Ile	Arg	Leu	Glu	Leu	785	790	795	800
Ala	Arg	Ala	Leu	Gly	Asp	Leu	Ser	Arg	Ala	His	Tyr	Thr	Leu	Ala	Glu				

805	810	815
Ser Gly Arg Ala Arg Thr Val Ala Arg Gln Ala Trp His Ile Ala Lys		
820	825	830
Gly Cys His Ala Asp Val Ile Cys Arg Asp Leu Arg Leu Asp Gly Thr		
835	840	845
Gly Asp Glu Gly Lys Pro Ala Ser Thr Ala Ala Glu Ile Ala Ala Ser		
850	855	860
Gly Val Glu Arg Glu Leu Ile Glu Ser Leu Ser Glu Ala Glu Arg Arg		
865	870	880
Val Ala Gly Leu Ala Ser Leu Gly His Thr Asn Arg Ala Ile Ala Ser		
885	890	895
Lys Leu Tyr Ile Thr Val Ser Thr Val Glu Gln His Leu Thr Arg Val		
900	905	910
Tyr Arg Lys Leu Asp Val Asn Arg Arg Arg Asp Leu Pro Ser Trp Leu		
915	920	925
Gln Val Ser Val Val Asn Ser Ala		
930	935	

<210> 9
 <211> 2811
 <212> DNA
 <213> *Amycolatopsis orientalis*

<400> 9
 atgcacgtga aatcagtgat cagagtggac ggcgacgtcc gcgcgagggc gtatccccgc 60
 gcggagctgc tggtcctgcg agacttcttg acggaatccg aacagggaaa cgccgtcgcg 120
 gcggtggtca ccggaaccgc cgcgagcggg aaaagtgaac ttctgcacgc attcgcgcaa 180
 caatgcgctg aagcggaagc aacggtgatg agcgcgcttt gcgtggaagc ggagaaggat 240
 ctcccgttca ccgcgctggt ccagcttttc cgtggcccgg cactgtccgg agatctgcgc 300
 gcgaaggccg cggacctgct gacgcggggc gaacggaccg ggctgaccgg gcggcccagc 360
 acacatctca tgctcgacct gctggagctc gtgcgcgagc tcgccgcgca ccgtccggtc 420
 gtggtcctgg tcgacgactt ccaccatgtg gacaccccgt cgttgcaactg gctgatgttc 480
 ctcatgcgcc gcatgcgcac gatgaacgtg ctcgctcgtg tgacggagtc gttgtccgcc 540
 aagcagacgt tgcccttgct gggcgccgag tacctccggc tcccgcactg ccgccggatc 600
 cggctgaagc cgctgggccc cgacgaggtg gcccggttcg tcccgcccgg ccaggacgac 660
 accctggtga agggcctgca cgagctcagc ggcggggaatc cgttgctggc tcaggcactc 720
 ctcgaagatc tccgtgcctc gggcgtacct ctgcgcgccg agaccggcc gatccccggc 780
 gatcactact gccaggcggt ggcggcgtgt ctccagcgcg gcgaccagga caccggacc 840
 ctgcgccgtg tcctcgcggt gctgggtaaa ggggaaacgg tctgcctcgc cgtccgggtg 900

accgggatgg accagcgcac cgccggccgt gcgatcgccc tcctgcacca ggtcggcctg	960
ctcgacgcgg gccggttccg gcatccgatg acggtgaccg cggtgctggc cgacgtcccg	1020
gtcgcggaac gcgcgcgact gcacgagcgc gccgcggtgc tcctgcatca cgacggcgcc	1080
ggcgcgctcg acgtggcccc ccacctcgtc gccgcgcacc gggccgaccg gccgtgggcg	1140
gtgcccgtgc tgcgcaccgc ggccgaactg gccaaagtgg acaaccggac ctcgttcgcg	1200
gtccaatgcc tgaaactggc ctgcccgtcg tgcggcgacg aagcgctcga ggtcgagatg	1260
gtgacccagc tcgccggcct ggaatggcgg aacaaccgga ccatcggcgc cgtgcacacg	1320
gaccacctct acgagatctt cctcgccggg cagctcccgg tgcggggcgc cgccatcctg	1380
gtgcggttcc tgctgtggca cggccgcacc gcggaagcgg gtgaggtgct cgacaagctc	1440
gccgtcatgg agccttcggc cgacgatcgc accgaggcgg aactgcgcac caccggctg	1500
ttcattctct gtccctatcc cgttctgcgc gacaagctgc ctgccccggc cgccaaggac	1560
cgcgttcccg cgcaatcctt cgaccccaac gtgcaggcgg cgatggcgct gagccggatc	1620
gtcacgaacg gccccgacga cgacgcgatc gcttcggctg agaacgtgct gaagagcatc	1680
cagctcggcg acacgatggc cgaatccgtg cgcagcgcgc tgttcgcgct catctacgcc	1740
gaccggctgg acaaggcggc gccgtggtgc gagctgctgc agcaggaggc cgccgactgc	1800
gacgcgcca gctggcaggc cgtgttcgcc gcggccaggg cggaaatggc gctgcgccag	1860
ggagatctgg tgacggcgga gaagcaggcc aaggcggcct tgacgttcat cacgccgacg	1920
agctggggcg tggccgtcgg agtcccgtg gcgacgctgt gcctcgccgc cgtcgggatg	1980
ggcaagtctg aggaggcggc gtgcgatatc aaccagccgg tgccggcctc gatgctgcaa	2040
acccggttctg gcctgcacta cctgcgcgcc cgcggcaggc tctacctgga gaccgaccgg	2100
gtgcacgccg cgctcggcga cttcgtcctg tgcggggaac tcagcaagag ctgggatttc	2160
gacctgccgg tgctggtgcc ctggcgcggc gacacggccg aggcgtacct ccggctcggc	2220
atgccggaga aggcgaagtc cctgctggac gagcagctcg cgaagctcgc cggctcgacg	2280
tctcatgtgc ggggaatctc gttgcggctc aaggccaaga tcgccgaacc gcagaagcgc	2340
ccggaattgc tgcgtgaagc ggtgaagatc ttccaggcgg gcggtatccg cctcgaactc	2400
gcccgcgcgc tcggcgatct cagccgcgcg cactacacgc tggccgagtc gggtcgcgcg	2460
cgcacggtgg cccggcaggc gtggcatatc gcgaagggtt gccacgccga cgtgatctgc	2520
cgggatctgc gtctcgacgg gacaggcgac gagggaaagc cggcgtccac cgcggcggag	2580
atcgccgcgt cgggcgtcga acgcgagctc atcgagtcgc tgagcgaggc cgagcgacgg	2640
gtcgccgggc tggcctccct cgggcacacg aaccgggcga tcgcgagcaa gctctacatc	2700

acggtgagca cggtcgaaca gcattctcacc cgcgtctatc gcaaactgga cgtcaaccgg 2760
cgccgggata tcccgtcgtg gctccaggtt tcggtcgtca acagcgctg a 2811

<210> 10
<211> 271
<212> PRT
<213> Amycolatopsis orientalis

<400> 10

Met	Gln	Arg	Asn	Phe	Lys	Glu	Phe	Lys	Ile	Thr	Val	Asp	Pro	Val	Arg	1	5	10	15
Asp	Asp	Phe	Leu	Arg	Ala	Lys	Gly	Pro	Gly	Gln	Arg	Asn	Leu	Leu	Leu	20	25	30	
Gly	Arg	Ala	Val	Phe	Glu	Phe	Ala	Ser	Asp	Leu	Glu	His	Leu	Asp	Thr	35	40	45	
Ile	Gln	Gln	Glu	Phe	Val	Asp	Gly	Ser	His	Arg	Pro	Leu	Ile	Arg	Arg	50	55	60	
Asn	Trp	Gln	Asp	Ser	Thr	Ala	Asp	Tyr	Ser	Asp	Pro	Thr	Gln	Leu	Leu	65	70	75	80
Ile	Gln	Gly	Gln	Gln	Val	Met	Gln	Asn	Trp	Glu	Arg	Pro	Leu	Met	Lys	85	90	95	
Val	Leu	Ala	Glu	Asn	Ala	Ala	Ala	Asn	Gly	Gly	Asp	Leu	Leu	Glu	Val	100	105	110	
Gly	Phe	Gly	Met	Gly	Ile	Ser	Ala	Thr	Tyr	Val	Gln	Asp	Ala	Gly	Val	115	120	125	
Arg	Ser	His	Thr	Leu	Ile	Glu	Ile	Asn	Ser	Glu	Val	Lys	Ala	Glu	Phe	130	135	140	
Glu	Lys	Trp	Arg	Ala	Gln	Trp	Pro	Asp	Arg	Asp	Ile	Arg	Leu	Glu	Leu	145	150	155	160
Gly	Ala	Trp	Gln	Asp	Val	Leu	Gly	Gly	Leu	Gly	Gln	Tyr	Asp	Ala	Ile	165	170	175	
Leu	Tyr	Asp	Thr	Tyr	Pro	Thr	Asp	Glu	Arg	Glu	Phe	Ala	Arg	Thr	Leu	180	185	190	
Gly	Pro	Lys	Ala	Ile	Val	Leu	Ala	Ala	Glu	Phe	Phe	Glu	His	Ala	Ala	195	200	205	
Ala	His	Leu	Arg	Pro	Gly	Gly	Val	Phe	Ser	Tyr	Tyr	Thr	Asn	Glu	Ile	210	215	220	
Asp	Ser	Leu	Ser	Arg	Ala	His	Gln	Arg	Ala	Leu	Leu	Glu	His	Phe	Ser	225	230	235	240
Ser	Phe	Arg	Val	Glu	Val	Val	Arg	Asp	Leu	Lys	Pro	Pro	Ala	Asp	Cys	245	250	255	
Thr	Tyr	Trp	Trp	Ala	Gly	Thr	Met	Ala	Ala	Val	Thr	Ala	Val	Lys					

260 265 270

<210> 11
 <211> 813
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 11
 cttgacggcg gtcacggcgg ccatcgtgcc cgcccaccag taggtgcagt cggccggcgg 60
 cttcaggtcc cggacgacct ccacccggaa cgagctgaag tgttcgagca gggcgcgctg 120
 gtgtgcccgg ctcagtgagt cgatttcgtt ggtgtagtag gagaagacgc caccgggacg 180
 aaggtggggc gcggcgtgct cgaagaattc ggccgccagc acgatggcct tcggggcccag 240
 ggtcctggcg aattcccgtc cgtcggtcgg ataggtgtcg tacaggatcg cgtcgtactg 300
 gccgaggccg ccgagcacgt cctgccaggc gccgagttcc agccggatat cgcggtccgg 360
 ccactgggca cgccatttct cgaactccgc cttcacctcg gagttgattt cgatcagggt 420
 gtgcgaccgg acgcccgcgt cctggacgta ggtggccgaa atacccatcc cgaaaccgac 480
 ttcgagcaga tccccgccgt tcgccgcggc gttttccgcc agcaccttca tcagcggccg 540
 ttcccagttc tgcatacact gctggccctg gatgagcagc tgcgtcggat cgctgtagtc 600
 cgcagtgctg tcctgccagt tccggcggat cagcggccgg tgcgagccgt cgacgaattc 660
 ctgctggatg gtgtccagat gttccagatc gctggcgaac tcgaacaccg cgcggccgag 720
 aaggaggttg cgctggccgg gcccttcgc ccggaggaag tcgtccctga ccgggtccac 780
 cgttatcttg aattccttga agttccgttg cat 813

<210> 12
 <211> 229
 <212> PRT
 <213> Amycolatopsis orientalis

<400> 12

Met	Pro	Gly	Glu	Thr	Lys	Asn	Gln	Asp	Thr	Asp	Gly	Arg	Gly	Ala	Arg
1				5					10					15	
Arg	Arg	Ser	Val	Val	Ser	Leu	Ile	Ala	Asp	Val	Thr	Val	Pro	Val	Val
			20					25					30		
Val	Tyr	Tyr	Ala	Leu	Leu	Ala	Phe	Gly	Trp	Ser	Ser	Gly	Ser	Ala	Leu
			35				40					45			
Val	Ala	Ala	Thr	Val	Ala	Ile	Gly	Val	Leu	Val	Leu	Ala	Val	Ala	Val
			50			55					60				
Lys	Glu	Arg	Arg	Val	Asp	Gly	Phe	Gly	Val	Phe	Val	Leu	Gly	Val	Cys
65					70				75					80	
Ala	Val	Thr	Leu	Leu	Val	Ser	Leu	Val	Ser	Gly	Asp	Glu	Arg	Leu	Leu
			85					90						95	

Leu Ala Lys Asp Pro Phe Thr Ser Gly Leu Ala Gly Ile Ala Phe Leu
 100 105 110
 Gly Ser Leu Val Phe Gly Lys Pro Val Thr Phe Phe Ile Ser Arg Arg
 115 120 125
 Ile Arg Ala Leu Thr Pro Ala Arg Arg Leu Gly Trp Asp Arg Leu Tyr
 130 135 140
 Ala Ala Glu Pro Glu Phe Arg Lys Leu His Arg Val Ser Thr Ala Gly
 145 150 155 160
 Trp Gly Val Val Leu Val Thr Glu Ser Ala Ala Arg Leu Val Leu Ile
 165 170 175
 Tyr Leu Leu Pro Ala Ser Val Met Val Gly Leu Ser Thr Ala Ile Glu
 180 185 190
 Leu Thr Ala Ile Thr Gly Val Val Ala Trp Thr Ile Trp Tyr Arg Arg
 195 200 205
 Arg Ser Ala Gly His Gly Leu Glu Lys Ser Leu Arg Thr Ala Asp Ala
 210 215 220
 Ala Pro Ala Ala Val
 225

<210> 13
 <211> 687
 <212> DNA
 <213> *Amycolatopsis orientalis*

<400> 13
 atgccggggg aaaccaagaa ccaggacacc gacggccgcg gcgcgcgcag gcgctccgtc 60
 gtatcgttga tcgccgacgt caccgtgccg gtcgtcgtct actacgcgct gctcgccttc 120
 ggggtggagca gcggctccgc cttggtggcg gccacggtcg ccatcggggg cctcgtgctc 180
 gccgtcgcgg tcaaggaacg cagggtcgac ggcttcgggg tggtcgtgct cggagtctgc 240
 gcggtgaccc tgctggtctc cttggtgagc ggggacgaac gcctgctggt ggccaaggat 300
 cccttcacca gcggcctggc cgggatcgcc ttctcggca gcctcgtctt cgggaaaccg 360
 gtgaccttct tcattctccg ccggatccgg gcgctcacc cggctcggcg cctgggctgg 420
 gaccggctgt acgccgcgga acccgagttc cgcaaaactgc atcgcgtctc caccgcgggc 480
 tggggcggtgg tcctggtcac cgagtccgcc gcccggtcgc tcctgatcta cctgctgccc 540
 gcgtcgggtga tggtcggcct gtccaccgcg atcgaactga ccgcgatcac cggcgtggtc 600
 gcctggacca tctggtaccg gcgtcgtctc gccggccacg gtctggaaaa gtcgcttcgc 660
 acggcggatg cggcgcccgc tgctgtc 687

<210> 14
 <211> 553

<212> PRT

<213> Amycolatopsis orientalis

<400> 14

```

Met Thr Ala Ala Asp Phe Ala Pro Pro Leu Thr Thr Leu Cys Pro Asp
1          5          10          15

Phe Pro Phe Ala Tyr Asp Asp Trp Leu Ala His Pro Ala Gly Leu Gly
20          25          30

Glu Leu Pro Pro Asp Arg Leu Gly Gln Glu Val Ala Val Val Gly Gly
35          40          45

Gly Ile Ala Gly Val Val Ala Ala Tyr Glu Leu Leu Arg Leu Gly Leu
50          55          60

Lys Pro Val Val Tyr Glu Ala Gly Gln Ile Gly Gly Arg Met Arg Ser
65          70          75          80

Ile Pro Leu Ala Gly Glu Asp Gly Ala Val Ala Glu Met Gly Ala Met
85          90          95

Arg Phe Pro Pro Ser Ala Thr Thr Leu Tyr Arg Tyr Ile Asp Glu Val
100         105         110

Gly Leu Glu Thr Lys Pro Phe Ala Asn Pro Leu Ser Arg Ser Thr Ser
115         120         125

Thr Thr Val Ile Asn Leu Asp Gly Val Thr Tyr Arg Ala Arg Thr Pro
130         135         140

Ala Asp Leu Pro Ser Val Phe His Glu Val Asp Asp Ala Trp His Lys
145         150         155         160

Ala Leu Gln Glu Leu Ala Asp Leu Ser Thr Met Arg Asp Ala Ile Arg
165         170         175

Met Arg Asp Thr Ala Met Val Lys Ala Ile Trp Asn Arg Leu Leu Pro
180         185         190

Glu Leu Asp Asp Gln Ser Phe Tyr Gly Phe Leu Ala Arg Ser Thr Ala
195         200         205

Phe Ala Ser Phe Arg His Arg Glu Ile Phe Gly Gln Val Gly Phe Gly
210         215         220

Thr Gly Gly Trp Asp Thr Asp Phe Pro Asn Ser Val Leu Glu Ile Leu
225         230         235         240

Arg Val Ile Tyr Thr Gly Val Glu Glu Gly Pro Arg Gln Ile Ile Gly
245         250         255

Gly Cys Gln Gln Leu Pro Arg Arg Leu Trp Asn His Ala Pro Ala Ser
260         265         270

Ala Arg Phe Trp Pro Ala Gly Thr Ser Val Ala Ser Leu His Asp Gly
275         280         285

Ser Pro Arg Pro Ala Val Leu Gly Leu Arg Pro Ala Ala Asp Gly Phe
290         295         300

```

Ala Val Glu Asp Ala Asn Gly Asp Val Arg Thr Tyr Pro Ala Val Val
305 310 315 320

Phe Thr Ala Gln His Arg Val Leu Leu Thr Lys Ile Ala Gly Val Arg
325 330 335

Pro Leu Leu Pro Ala Asn Val Trp Thr Ala Leu Glu Arg Thr His Tyr
340 345 350

Met Gly Ala Ser Lys Leu Phe Val Pro Val Asp Arg Pro Phe Trp His
355 360 365

Asp Val Asp Pro Arg Thr Gly Glu Glu Leu Met Gly Met Thr Leu Thr
370 375 380

Asp Arg Thr Pro Arg Ser Val Tyr Leu Phe Asp Asp Gly Pro Asp Ser
385 390 395 400

Pro Ala Ala Leu Cys Leu Ser Tyr Thr Trp Asn Asp Asp Ser Leu Lys
405 410 415

Phe Ala Thr Leu Gly Pro Ala Asp Arg Leu Glu Leu Ala Leu Asp Ala
420 425 430

Leu Ala Asp Ile Tyr Pro Gly Val Asp Ile Arg Ser His Ile Thr Gly
435 440 445

Asp Pro Val Thr Val Thr Trp Glu Asn Glu Pro Asn Phe Gln Gly Ala
450 455 460

Phe Lys Ala Asn Leu Pro Gly Gln Tyr Arg Tyr Gln Arg Arg Leu Phe
465 470 475 480

Thr His Phe Arg Gln Asp Asp Leu Pro Ala Ala Gln Arg Gly Leu Phe
485 490 495

Leu Ala Gly Asp Asp Ile Ser Trp Met Gly Gly Phe Ala Glu Gly Ala
500 505 510

Val Thr Ser Ala Leu Asn Ala Val Trp Gly Thr Leu Arg His Leu Gly
515 520 525

Gly Ala Thr Asp Pro Arg Asn Pro Gly Pro Gly Asp Val Phe Asp His
530 535 540

Ile Ala Pro Ile Glu Leu Pro Glu Ser
545 550

<210> 15

<211> 1659

<212> DNA

<213> Amycolatopsis orientalis

<400> 15

atgaccgcag ccgatttcgc gccccgcgtg accactctct gccccgattt cccgttcgcc 60

tacgacgatt ggctcgcgca tccggccggg ctcggtgagc tgccgccgga ccgcctcggc 120

caggaggtcg ccgtcgtcgg tggcgggata gcgggtgtgg tcgcggctta cgaactgctg 180

cgccctcggcc tgaaaccggt ggtctacgaa gcgggcccaga tcggcgggcg gatgcgctcc 240
 atcccccttgg cgggcgagga cggcgcggtc gcggagatgg gcgcgatgcg gttccccgcc 300
 tcggccacca ccctgtaccg gtacatcgac gaagtcggcc tggagaccaa gccgttcgcg 360
 aacccgttgt cccgcagcac ttccaccacg gtgatcaacc tcgacgggggt gacctaccgc 420
 gcgcggaccc cggcggacct cccgtcgggtg ttccacgagg tcgacgacgc ctggcacaag 480
 gccctgcagg aactggccga tctgtccacc atgcgcgacg ccatccggat gcgcgacacc 540
 gccatggtga aggcgatctg gaaccggctg ctgcccgaac tcgacgacca gtccttctat 600
 ggtttccttg cacggtcgac cgcttttcgcc tccttccgcc atcgtgagat cttcggccag 660
 gtcggcttcg gcaccggcgg ctgggacacc gatttcccca actccgtgct ggaaatcctc 720
 cgcgtcatct acaccggtgt cgaggagggg ccgcggcaga tcatcgggtg ctgccagcaa 780
 cttccgcggc gggtgtggaa ccacgcaccc gcgtctgcgc gcttctggcc tgccgggaca 840
 tcggtcgcgt cgctgcacga cggatcgccg cggcccgccg tcctcgggtt gcgcccggcc 900
 gcggacgggt tcgccgtcga ggacgcgaac ggtgacgtgc ggacctatcc ggccgtggtc 960
 ttcaccgcgc agcaccgggt cctgctcacc aagatcgccg gagtgcgccc gctgctgccc 1020
 gcgaacgtgt ggaccgcgct ggaacgcacg cactacatgg gtgcttcgaa gttgttcgtc 1080
 ccggtcgacc ggccgttctg gcacgacgtc gatccccgca ccggtgagga actgatgggg 1140
 atgaccctca ccgaccggac cccgcgcagc gtctacctgt tcgacgacgg gccggattcg 1200
 ccggccgcgc tgtgcctttc ctatacctgg aacgacgatt cgctcaagtt cgcgacgctc 1260
 ggcccggcgg accggctcga actcgcgctc gacgcgctcg ccgacatcta cccgggtgtc 1320
 gacatccgct cccacatcac cggcgatccg gtcaccgtca cctgggagaa cgagccgaac 1380
 ttccaaggcg cgttcaaggc gaacctgcc a gggcagtacc gctatcagcg ccgcctgttc 1440
 acccatttcc ggcaagacga ccttccccgc gctcagcgcg gcctgttcct cgccgggtgac 1500
 gacatctcgt ggatgggagg cttcgccgaa ggggcgggtca ccagcgcgct caacgcggtg 1560
 tgggggacgc tgcgccatct cggcgggggc accgaccgc gtaatcccg ccccggcgac 1620
 gtcttcgacc acatcgcgcc gatcgaactg cccgagtcc 1659

<210> 16
 <211> 179
 <212> PRT
 <213> Amycolatopsis orientalis

<400> 16

Met Ser Glu Ala Met Arg Asn Ala Leu Ile Leu Ser Gly Val Leu Leu
 1 5 10 15

Ala Leu Val Leu Phe Thr His Ile Gly Arg His Lys Ala His Leu Val
 20 25 30

Ile Leu Ile Leu Pro Phe Phe Thr Cys Ala Leu Val Gly Trp Ala Val
 35 40 45

Leu Tyr Asp Leu Lys Leu Thr Thr Pro Asn Thr Leu Ala Gly Leu Val
 50 55 60

Gly Ile Ala Ala Gly Val Leu Ile Gly Trp Gly Leu Leu Lys Gly Thr
 65 70 75 80

Lys Val Glu Trp Asp Gln Glu Lys Ser Ala Val Tyr Thr Arg Ala Gly
 85 90 95

Trp Val Tyr Leu Gly Leu Trp Leu Phe Val Leu Val Gly Arg Leu Ile
 100 105 110

Phe Val Tyr Thr Leu Glu His Ser His Ser Phe Ala Ala Asp Phe Gly
 115 120 125

Lys Phe Leu Met Asp Thr Gly Ile Asp Ala Gly Gly Val Ser Ala Phe
 130 135 140

Phe Val Thr Met Ala Leu Thr Met Val Ile Phe Arg Thr Ala Gly Val
 145 150 155 160

Trp Val Tyr Arg Ala Lys Val Leu Arg Gln Ala Gln Arg Thr Pro Ser
 165 170 175

Tyr Ala Ser

<210> 17
 <211> 540
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 17
 atgagtgaag ccatgcgaaa cgccctcatc ctgagcggcg tactgctggc gctgggtgctg 60
 ttcacgcaca tcggtcgcca taaggccac ctggtcatcc tgatcctgcc gttcttcacg 120
 tgcgcgctgg tgggctgggc ggtcctctac gacctcaagc tgaccacgcc gaacacactg 180
 gccgggctgg tcggcatcgc ggcgggcgtc ctgatcggct ggggattgct gaagggcacg 240
 aaggtcgagt gggaccagga gaaatccgcc gtctacacca gggcgggctg ggtctacttg 300
 ggactgtggc tgttcgtcct ggtcggacgg ctcatcttcg tctacaccct cgaacacagc 360
 cactcgttcg cggccgactt cggcaagttc ctgatggaca ccgggatcga cgccggcggc 420
 gtctccgcct tcttcgtcac catggcgctg acgatggta tcttcgcac cgccgggggtc 480
 tgggtctacc gggccaaggt actcaggcag gctcagcgaa ccccagcta cgcgagctga 540

<210> 18
 <211> 222
 <212> PRT

<213> Amycolatopsis orientalis

<400> 18

Met Val Glu Glu Val Pro Pro Val Arg Ile Val Ile Ala Glu Asp Gln
1 5 10 15

Ala Ala Val Arg Glu Gly Leu Ala Leu Leu Val Gly Thr Val Ala Gly
20 25 30

Ile Thr Val Val Gly Gln Ala Pro Asp Gly Glu Val Ala Val Arg Leu
35 40 45

Ala Gly Glu Leu Arg Pro Asp Val Val Leu Met Asp Leu Ser Met Pro
50 55 60

Arg Cys Asp Gly Val Glu Ala Thr Arg Arg Ile Lys Glu Arg His Pro
65 70 75 80

Glu Ile Glu Ile Val Val Leu Thr Thr Tyr Ala Asp Asp Asp Trp Val
85 90 95

Leu Arg Ala Leu Glu Ala Gly Ala Leu Gly Tyr Leu Thr Lys Ser Ala
100 105 110

Asn Lys His Glu Ile Gly Arg Ala Val His Ala Ala Ala Gly Gln
115 120 125

Ala Leu Leu Asp Pro Gln Val Gln Arg Arg Val Leu Gly Ala Ala Leu
130 135 140

Thr Ser Ala Pro Ala Ser Ala Pro Pro Pro Glu Asp Asp Ala Asn Leu
145 150 155 160

Thr Lys Arg Glu Ala His Val Leu Thr Leu Ile Ala Ala Gly His Ser
165 170 175

Asn Lys Glu Ile Ala Ala Glu Leu Phe Val Ser Glu Thr Thr Val Lys
180 185 190

Ser His Ile Asn Arg Ile Phe Ala Lys Thr Gly Ser Arg Asp Arg Ala
195 200 205

Gln Ala Val Arg Tyr Ala Tyr Gln Ala Gly Tyr Val Arg Asp
210 215 220

<210> 19

<211> 666

<212> DNA

<213> Amycolatopsis orientalis

<400> 19

atggtcgaag aagtgcctccc ggtccggatc gtgatcgccg aagaccaggc ggcggtacgc 60
gaaggactgg ccctcctggt ggggacgggc gcggggatca ccgtggtcgg ccaggcaccc 120
gacggcgagg tcgccgtgcg gctggccggg gaactgcgcc cggacgtcgt cctgatggat 180
ctctccatgc cccggtgcga cggcgtcgag gcgaccgggc ggatcaagga acggcatccg 240
gagatcgaga tcgtcgtgct caccacctac gccgacgacg actgggtgct gcgcgcgttg 300

gaggccgggg cggtgggata cctgacgaaa tcggccaaca aacacgaaat cgggcgcgcg 360
 gtacacgccg ccgcggcggg ccaggccctg ctcgatccgc aggtgcagcg acgggtgctc 420
 ggcgccgccc tgacgtccgc gcccgccttcg gcgccaccgc cggaggacga cgcgaaacctc 480
 accaagcggg aagcccatgt gctgacgctg atcgcgggcg ggcacagcaa caaggagatc 540
 gccgcggaac tgttcgtcag cgagacgacg gtcaagagcc atatcaaccg gatcttcgcc 600
 aagacgggga gccgggatcg cgcgcaggcc gtccgttatg cctaccaagc gggctatgtg 660
 cgggac 666

<210> 20
 <211> 379
 <212> PRT
 <213> *Amycolatopsis orientalis*

<400> 20

Met	Thr	Asp	Ala	Val	Ser	Asp	Glu	Val	Glu	Glu	Arg	Arg	Trp	Arg	Trp	1	5	10	15
Ala	Ala	Pro	Ala	Ala	Gly	Thr	Ala	Leu	Leu	Ala	Val	Thr	Gln	Met	Thr	20	25	30	
Ala	Thr	Val	Pro	Ala	Gly	Ala	Gly	Trp	Leu	Trp	Val	Leu	Tyr	Ala	Val	35	40	45	
Ser	Ser	Ala	Ser	Trp	Leu	Leu	Trp	Ile	Gly	Ile	Ser	Glu	Arg	Phe	Pro	50	55	60	
Arg	Ala	Ala	Leu	Leu	Pro	Leu	Ala	Ala	Ala	Ser	Ala	Val	Pro	Ala	Phe	65	70	75	80
Gly	Thr	Gly	Ala	Ala	Thr	Asp	Gly	Thr	Ala	Val	Ile	Met	Thr	Cys	Ile	85	90	95	
Thr	Leu	Ala	Ala	Phe	Ala	Ser	Arg	Leu	Glu	Pro	Gly	Thr	Val	Ala	Ile	100	105	110	
Ile	Ala	Leu	Met	Val	Phe	Asp	Ala	Ala	Ala	Ile	Val	Val	Ser	Ser	Leu	115	120	125	
Leu	Gly	His	Arg	Pro	Ser	Glu	Ala	Trp	Leu	Gly	Ala	Leu	Gly	Ala	Val	130	135	140	
Val	Ile	Val	Val	Leu	Val	Gly	Phe	Thr	Arg	Arg	Gly	His	Leu	Thr	Arg	145	150	155	160
Val	Ala	Gln	Ala	Glu	Arg	Leu	Leu	His	Gln	Glu	Arg	Leu	Ala	His	Thr	165	170	175	
Arg	Gly	Val	Arg	Ala	Ala	Thr	Leu	Asp	Glu	Arg	Thr	Arg	Ile	Ala	Arg	180	185	190	
Glu	Ile	His	Asp	Val	Val	Ala	His	Ser	Leu	Gly	Ala	Leu	Arg	Val	Gln	195	200	205	

Leu Glu Val Met His Thr Leu Leu Val Glu Glu Asn Asp Thr Glu Gly
 210 215 220
 Ala Leu Arg Ser Leu Ala Leu Ser Arg Ser Leu Ala Asp Gln Gly Leu
 225 230 235 240
 Ser Asp Val Arg Asp Ala Val Ala Ala Leu Arg Glu Asp Val Arg Ala
 245 250 255
 Leu Pro Asp Ala Leu Thr Glu Leu Val Arg Thr Phe Gly Arg Glu His
 260 265 270
 Asp Thr Pro Ala Asp Phe Thr Met Leu Gly Glu His Arg Asp Leu Pro
 275 280 285
 Ser Ala Gln Thr Ile Ala Leu Leu Arg Ile Cys Arg Glu Ala Leu Thr
 290 295 300
 Asn Ala Ala Lys His Ala Ala Gly Glu Ala Val Ser Val Glu Leu Glu
 305 310 315 320
 Tyr Pro Pro Asp Glu Val Arg Leu His Val Arg Asn Pro Leu Ala Ala
 325 330 335
 Ala Pro Asp Pro Gly His Thr Pro Gly Tyr Gly Leu Thr Gly Met Arg
 340 345 350
 Glu Arg Ile Glu Leu Val Asp Gly Thr Leu Val Thr Gly Pro Asp Gly
 355 360 365
 Arg Phe Trp Asp Val Thr Ala Arg Val Pro Gly
 370 375

<210> 21
 <211> 1140
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 21
 atgaccgacg cagtgtccga cgaggctcag gaacgtcgtt ggcgatgggc cgcgcccgcc 60
 gccgggacgg cgctgctggc cgtcacccag atgaccgcga ccgtaccggc cggcgccggc 120
 tggctgtggg tgctctacgc ggtgtcgtcg gcgagctggc tgctgtggat cggcatcagc 180
 gagcgcttcc cccgtgccgc cctgctcccg ctgcgccggg cgagcgcggt cccgccttc 240
 ggtaccggcg ccgccaccga cggcaccgcc gtgatcatga cctgcatcac cctcgccgcg 300
 ttcgcttcac ggctggagcc gggcaccgtc gcatcatcg cgctgatggt cttcgacgcc 360
 gccgccatcg tggtttccag cctgctcggc caccgtcctt cggaggcctg gctgggcgca 420
 ctgggcgcgg tcgtcatcgt ggtcctcgtc ggattcaccc gccgcggtca tctgaccagg 480
 gtcgcgcagg cggaacgggt gctgcaccag gaacggctgg cgcacaccgc cggcgtgcgc 540
 gcggcgacgc tggacgagcg caccgcgcat gccgcgaga tccacgacgt cgtcgcccat 600
 tccctcggcg cgctgcgggt ccagctggag gtgatgcaca cctgctggt ggaggagaac 660

gacaccgaag gcgccctgcg ttcgctcgcg ctgtcgcgaa gtctcgccga ccaagggctc 720
 agtgacgtcc gggacgccgt ggcggcgctg cgcgaggacg tccgcgccct gccggacgcg 780
 ctgaccgaac tgggtgcggac cttcggccgg gaacacgaca ctccggcgga tttcaccatg 840
 ctgggcgagc accgcgatct cccgtcggca cagacgatcg cgctgctgcg gatctgccgg 900
 gaagcgctga cgaacgcggc caaacacgcc gcgggcgagg cggtgagcgt cgaactggag 960
 taccgcggcg acgaggtccg gctgcacgtc cgcaatcccc tcgccgccgc gccggacccc 1020
 gggcacacgc cgggctacgg cctgaccggg atgcgcgaac ggatcgaact cgtcgacggc 1080
 acgctgggtca ccggggccga cggccgggtc tgggacgtca ccgcccggtt cccggggtag 1140

<210> 22
 <211> 251
 <212> PRT
 <213> *Amycolatopsis orientalis*

<400> 22

Met	Thr	Ala	Pro	Ser	Gly	Asp	Ala	Gly	Asp	Trp	Val	Arg	Val	Phe	Arg	1	5	10	15
Pro	Gly	Gly	Pro	Ser	Val	Pro	Arg	Leu	Ile	Cys	Leu	Pro	Asp	Ala	Gly	20	25	30	
Ala	Ala	Ala	Asn	Ala	Phe	Phe	Pro	Leu	Ser	Ala	Ala	Leu	Ala	Pro	Gly	35	40	45	
Ile	Glu	Val	His	Ala	Val	Gln	Tyr	Pro	Gly	Arg	Gln	Asp	Arg	Val	Ala	50	55	60	
Glu	Pro	Cys	Ala	Glu	Asp	Ile	Gly	Glu	Leu	Ala	Asp	Arg	Val	Thr	Gly	65	70	75	80
Ala	Leu	Ala	Leu	Trp	Glu	Gly	Ala	Pro	Phe	Ala	Val	Tyr	Gly	His	Gly	85	90	95	
Met	Gly	Ala	Val	Val	Gly	Phe	Glu	Val	Ala	Arg	Arg	Leu	Glu	Gln	Ala	100	105	110	
Leu	Thr	Gly	Ser	Pro	Val	Ala	Leu	Ile	Val	Ser	Gly	Cys	Pro	Ala	Pro	115	120	125	
Ser	Arg	Ser	Gly	Thr	Ala	Gly	Leu	His	Leu	Leu	Pro	Asp	Gln	Asp	Leu	130	135	140	
Val	Ala	Glu	Leu	Tyr	Ser	Gln	Arg	Ala	Ala	Gly	Ser	Pro	Gly	Ala	Arg	145	150	155	160
Asp	Ala	Glu	Leu	Leu	Lys	Ala	Thr	Phe	Pro	Ala	Ile	Arg	Ala	Asp	Phe	165	170	175	
Arg	Ala	Leu	Ala	Ala	Tyr	Arg	Pro	Glu	Pro	Ala	Pro	Pro	Leu	Arg	Cys	180	185	190	

Pro Val Thr Val Leu Val Gly Asp Ser Asp Pro Thr Val Ser Leu Asp
 195 200 205

Glu Ala Arg Asp Trp His Glu Tyr Thr Thr Gly Pro Phe Asp Leu Gln
 210 215 220

Val Phe Pro Gly Gly His Gly Phe Pro Glu Ala Arg Pro Glu Glu Phe
 225 230 235 240

Ala Glu Val Val Thr Ala Ala Val Arg Arg Arg
 245 250

<210> 23
 <211> 753
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 23
 atgaccgctc caagcggcga tgccggggac tgggtccgtg ttttccggcc cggaggaccg 60
 tcggtaccgc gtctgatctg cctgcccagac gccggtgcgg ccgcgaatgc gttcttcccg 120
 ctttccggccg cgctcgcgcc ggggatcgag gtgcacgcgg tgcaatatcc gggacgccag 180
 gatcgggtcg cggaaccgtg cgccgaagac atcggggaat tggccgaccg ggtcaccggg 240
 gcgctcgcgc tctgggaagg cgcccggttc gcggtgtacg gccacggaat gggcgcggtc 300
 gtcggtttcg aggtggccag acggctggag caggcgctga ccgggagccc ggtcgcgctg 360
 atcgtgtccg gctgtcccgc cccgtcccgg tccggcaccg ccgggctcca cctgctgccg 420
 gatcaggacc tcgtggccga gctgtactcg cagcgcgccg ccggctcgcc gggcgcgcgg 480
 gacgcggagc tgctcaaggc caccttcccg gccatccggg ccgacttccg ggcgctggcc 540
 gcttaccggc ccgagcccgc gccgccgctg cgctgcccgg tcacggtgct cgtcggcgac 600
 agcgatccga cgggtgtccct cgacgaggcg cgcgactggc acgagtacac caccggcccc 660
 ttcgacctcc aggtcttccc tgggtgggcac ggttttccgg aggcgcgtcc cgaggagttc 720
 gccgaggtgg tgaccgccgc ggtccggcgg cgg 753

<210> 24
 <211> 73599
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 24
 tcacgaccg ctgtatcgac gcccgaaatgt gtcagcgtg cgggctgccg ccggggacct 60
 tggcgccgcc gaggcgggcg gacagcacga gcgtcatcg catcaggttc gcgcccagcg 120
 agagcaggat ggtgccgccg ccggagggtca gcgtcgcgcc ggcgaagtgc ccgatcacgc 180
 cgagcacgcc gcggacgagc agcaggccca cccagacggc gaggccgacc acgccgatcc 240
 gctggtagac cttgtcgccg cgccgctgca gctgcgtcat cgcgcccatc gcggcgccgc 300

cgaggagcga gaccagcagg cccaccccga ggaagacgat gtcggtcacg ctgatggtgg	360
tgtccagatg ccgcatctgg atgaccccga tggcgaccag ggtgagcggc ccgccccaga	420
tctccacgtt ctccagcggc ttccagctca tgcgctggta gatcacgtag acgacgacgg	480
cgatggcgac cgcgatgttg atcagcgtgc tgggtgtccac tgcgcactct cctcggctgt	540
gggcgacctg ttcgttcggt atcgatcacg agcgtaggag ccggggcccc ccgcggcgac	600
caaccacggg ttgaggtccg ggtggaattc cccggtccac ccgaaccggg gatccggcga	660
ttaggggtgg gcaccggtcg ctagggggtt ttggtgcttc gaggccgatc ctactgtcgg	720
gttcatcggc cggaccgccg attcccggcc cgatcggctc tcgcttccga atcccccttc	780
ccggaattcg gagccggatt tcgccgactg aaaggtgtct cacgttgcat tectaccaag	840
tggccgtcgt cggcgccgga tacgtcgggc tgaccaccgc ggcgtgtctc gcctcgctcg	900
ggcaccgggt ccgatgcacc gattccgatc gcggcaaatt ggcccggctc aaacgaggcg	960
aggtcgacat cctggaaaag ggctgcccg gtctggtcgc cgagggaatc gccgccggac	1020
ggctcggttt cgtcgagtcg gccgcggagg ccgtcgagac cgcggaggcc gtgttccttt	1080
gtgtaccac cccgatgggc gagggcggga tggccgatct gtcggccgct atcgacgtcg	1140
cgaccaaggt ccgtgacgtg ctttcgccgg gttgtgtact ggtgaacaag tcgaccgtgc	1200
cggtcgggac cgcggccagg gtcgccgcgc tgctcggccg ggacgacgtc gcggtggtga	1260
gcaatccgga gttcctcgc gagggcaccg ccgtccacga cttcctcaac ccggaccgga	1320
tcgtcgtcgg ttccgacacg cgcggccccg cggaacgggt cgcggcgctc tacgcccggc	1380
tcggcgcccc gacggtgctg accgacgcgg cgagcgcgga gatggtcaag tacgccgcca	1440
actgtttcct cgcgacgaaa ctgtcctatg tgaacgccat ccccgaactg tgcgagcggc	1500
tcggcgccga catcggcgac gtcaccgaag gcatgggcta cgaccgccgg atcggccccga	1560
cgttcctctc gccggggccg ggctggggcg gttcctgcct gcccaggac accatggcgc	1620
tcaaacaggt cgcgaggtc gcgggtttcg agttcggcct gtcgacgag gtcattctcg	1680
gcaacgcgaa acaggcgtcc cgagtggtcg aacggatcgc cgtcgctgt ggactcgacg	1740
cggacgcgga cctcaccggc ctgcggatcg gcctgctcgg gctgaccttc aaggcgggca	1800
ccaacgacct ccgggattcc ccggcgctca gcgtcgccc gctgctggcc gagcgcggcg	1860
cggagctgac cggatacgac cccggtctca ccggcgccga acctccgatc cccggcgtcc	1920
gggtcgtcga cgaccctac tacatcgca aggacgcgca cgcgctcgtc ctgctgaccg	1980
attggccgca gttccgtgcc ctcgactggc cgcggatcgc cggctctgctc gaaggaccgg	2040
tcgtcatcga caccgcaac cacctcgacc ccgacgcgct cagccgggccc ggcatcgctt	2100
ggcgcggtt cggcaggccc ccggtcgacc cggtgcgcac gccgtccctc gaccccgctc	2160

cctgatcgtc	ctcaaaggac	agaaaagaaa	ggtggacccc	atgcggggttt	tgtgcaccgt	2220
gaccggctcg	cagggccacg	cacgggcggt	gctgcccttg	gccagggcgg	cggcgaaggc	2280
gggccacgaa	gtgctcgtcg	tgaccccgcc	ggaactggcc	gacgtcttcg	aacccgggct	2340
gatgcggatc	gaaccggtgc	tcccggggat	ggtcgaggcg	atcgggcgga	tggtccagga	2400
acgccaggag	gccgaagcgg	ccgggacccc	gcgcggggtg	ctggacacgc	gcgaacagct	2460
gatcgccacc	gcgagcggcc	cgcacgtcac	caccgcctac	cagaagctct	acccactggc	2520
caaggagttt	cagcccgaca	tcgtgctgcg	cgacggcgcg	gagctgtccg	gcgcgctggt	2580
cgccgagcag	ctcggcgtgc	cctacatcag	cgcgccgtcg	ggtgcgggca	acctgatcga	2640
cccggcgggc	ctggtggagc	cgtgaacga	gcgcgccag	gagctggggc	tcgccgccga	2700
acccgacgcc	gggatgggtgc	accgctacgg	ccgtttcgac	tgctgccccg	ccgacacctc	2760
gttcgccgcc	ttcgatctgc	cgacgccgtt	cacctaccgc	cagccgtcgg	aggtggccac	2820
cggtgaggtc	ctgccgccgg	agatcgccgc	attgcccgcg	gaccggccgc	tggtgctcgc	2880
ctcggtcggc	accgcgctgc	ccatgctcgg	cgcgttcaag	gccttcggca	tcgacccgcc	2940
ggaggagatg	gaagatcccc	acgtcacggt	gcgcgccctg	atcgaaggac	tgtccagtgt	3000
ggactgttcg	gcggtgggtgg	cgacggccgg	gttcccgatc	ggcgacgtcg	aggtcggcga	3060
caacgtgctc	gtcgtcgaac	ggatgccgca	gccgctgctg	ctcgaatgcg	cgcagctggt	3120
cctgaccac	gccgggtaca	acagcatccg	cgaggcgctg	cgtgccggag	tcccgatggc	3180
cacgctgccg	cagttcggcg	accagccgca	caacgcgcgc	cgcacgagg	agctcggggt	3240
cggcaagcag	atccccgcca	ccacgccgga	agcggtcgcc	gagacctgcc	gcgcgggtgct	3300
ggccgacgcc	acgatcgcg	ccaccgtcgc	acgggcccac	cggcggagcc	tgaccatgcc	3360
gggcgtggaa	tccgccgtgg	cccatctcga	agagctcgcc	ggccggggccg	cgggaacgga	3420
gtagcgcggt	gcagatcgac	cactacgtca	gccagctgct	ggacgtgctt	tccacccgcc	3480
cggacgagat	cgcgttgcg	tacggcgacg	aagcgtgac	gtcggcgga	ttcgcccgcg	3540
cgatcaccgg	tgccgcgcgc	gcgctgcgcg	accgcgggac	cggcgaaggc	ggggtgggtgg	3600
ccctgctgac	cgtggggaac	agcccggcga	cgtgatcgg	ccggtacgcc	gccaacctga	3660
tcggcgccac	cgtggtgcac	ctgcgcggga	tcaacgccgc	cgatccgctg	gacgaactcc	3720
cggtcgccac	gcaggtcgag	atcgtcgacg	acaccggcac	caccgtcctg	ctcaccgacg	3780
cggcgaacct	cgaccgggcc	aggaagatcc	gcgacgccat	ggcgggaaccg	gcggcactgg	3840
cggctttcgg	ggacttcggt	gacgacgtcg	ccgacctcac	cgggaccgcg	agcgaggtcg	3900
agccgcgagc	cgagggcacc	gccgtgctga	cctacaccag	tgggaccacc	ggcaggccca	3960

agggcatcgg	ccgcgggttc	ggcgggctgg	gcgcggtggt	caccaaggcc	cggcacatga	4020
ccgagcgctg	cacgatgctg	gtcaccacgc	cgctcagcca	ttccgtctcg	tccacagtgg	4080
acgacgcggt	cgcctccggc	gggatgatcg	tcctgcacga	ggggttcgac	gccggcgccg	4140
tgctcgaagc	cgtggaacgc	caccgggtca	accgggtcta	cctggccacc	ccgcagctct	4200
acgacctgct	cgaccatccg	gcactgggca	ccaccgacca	ttccagcctg	cgcgagctgt	4260
actacggcgg	gagcccggcc	tccccggtgc	ggctctcccg	ggccgcggag	gtgttcggcg	4320
cgaagctgat	ccagatctac	ggcaccaccg	aaagctgggt	gatcgccgcg	ctttcgccgg	4380
aagagcacct	gaaaccggaa	ctgctcacca	cggtcggcaa	ggcgggtccc	ttcgtccagg	4440
tcggcatccg	cgacccgcat	gtgcggcacg	agctgcccgc	cgggaagacc	ggggagatct	4500
gcgtccggtc	gccgatgatg	atggacgggt	actggaagcg	gcccgaacctg	acctcgaagg	4560
tcctcatcga	cggctggctg	cacaccggcg	acgtcggcta	cctcgacgag	aacggctacc	4620
tgtacctggt	cgaccggctc	gccgacatga	tcaagaccaa	cggcatcaag	gtgtatccgg	4680
ccgaggtcga	gaacgcgctg	ctggcccata	cggacgtcgc	gcaggccgcg	gtgttcgggg	4740
tcgccgacga	ggacaacgtc	gagtacatgc	acgcgatcgc	ggtgccacgc	cgccggcaggg	4800
acgtggatcc	cgccgaacct	gccgcgcatg	tcgcgcgggt	gctgtccccg	agccacgtgc	4860
cggcggagat	ccggctccgc	gccgagcttc	cgctgaccga	cgccggggaag	ccggacaagc	4920
tccgcctccg	cgaagaggcg	aaacccgcca	ccaagtccag	ccacgccgag	ccagagagcg	4980
agttgacgtc	atgaccacct	acctggagtc	cttccagcgc	acctgcaag	gcgaagtgct	5040
gcagaaacgc	gacttcctgg	agatcgggcg	gcaggcgggc	cggttccccg	cggccagccg	5100
gtacgaggag	gccgaagcgg	tcgccgagat	caacgtctgg	tgcagcaacg	actacctcgg	5160
catgggccag	cacccggacg	tgctctccgc	gatgaaggag	gccgtcgagc	ggttcggcgc	5220
cggggcgggc	ggttcacgca	acatcgcggg	caccaaccac	taccacgtgg	cgctcgaacg	5280
cgaactggcc	gaactgcacg	gcaaagagga	cgcgctgctc	ttcacctccg	gctacaccgc	5340
caacgacggt	tcgctgaccg	tgctggcggg	ccgccccgag	gactgcatcg	tgttctccga	5400
cgagaagaac	cacgcctcca	tcatcgacgg	gttgcggcac	agtgggtgtg	agaagaagat	5460
cttccgccac	aacgacgtcg	cccatctggc	cgagctgctc	gccgccgccc	cggcggaccg	5520
gccgaagatg	atcgtgttcg	agtcgggtcta	ctcgatgaac	ggcgacatcg	cgccgctggc	5580
cgaattcgcc	gcgttggcga	agcagtacga	cgccatgacc	tatgtggacg	aagtgcacgc	5640
cgtcggaatg	tacgggccc	aaggtgccgg	gatcgccgcg	cgcgagggga	tcgccgacga	5700
gttcaccgtc	gtgatgggca	cgctggccaa	gggtttcggc	accaccggcg	gatacatcgc	5760
cgggcccgc	gcgctgatcg	acgccgtgcg	cacgcattcg	cgatcgttca	tcttcaccac	5820

cgcgctgccg cccgccgtgg ccgccggagc gctcgccgcc gtccggcacc tgcgttcgtc	5880
ggagcgggag cgcgagatcc tcgccgacaa cgcgcagctg ctgcacaaac tgctcgccga	5940
acgcggcatc cccttcctct cggacgagtc gcatatcgtg tcgatacctgg tcggcgacga	6000
cgcgctctgc aagaaggtgc acgaactcct gttgcagcgg cacgggatct acatccagtc	6060
gatcaacgcg ccgagtgtcc cgttcggaca ggagatcctg cgcacggccc cgtcggcggt	6120
gcacaccggc agcgacgtgc agaagatggc cgaggcgctg gaccagatct ggctggatct	6180
cggctctgcc cgcggctgag tgcgtgttg tgaaccctg tccgcgatcg acgtcggcag	6240
gacgccgctg gtcattcaca tcgcgatggc ggacaaggcg tcctgccacc gcgatagcgg	6300
ggccttcggc caggggtgggt tcacgcgttc ggggtgcttg cgaggtaaa cttcagcttc	6360
cgccaacagg ctctgagagg ggagaccggt gtccttgtcc ctagcggccg tcctcgccga	6420
ctcggcgggc aggcggccgg accaccccg cctcgtgttc gacggggaac cgttctccta	6480
ccgggaactc tgggccgggg cgaagaggta cgcctccgcg ctccgggacc agggggtcgc	6540
cgccggcgac cgggtcgtgc tgctcctgcc gaacacgccg gagttcccga tggctactt	6600
cggcgcgctg gcgctcggcg cggtcgtcgt gccggtgcac acgttgctcg tcgcggagga	6660
gatccactac atcctcaccg actgtgacgc ccgggtgctg atctgcggag ccgccctgct	6720
ggagcagggc ggcgaggccg ccgacgcggc cgggtgtcga gtcctgacga tgctggagga	6780
ctccgacacc ggccgcgtcc gcctcgacgt cctcgccggg gacgcggccg agatcgagcg	6840
gtacgaaccg cgtgaaccct cggacctcgc gctgatactc tacacctcg ggaccaccg	6900
caaacccaag ggcgcgatgc tgaccacact gagcatcgtg ctgaacgttt ccaccacgat	6960
gctgtcgccg ttcgacttcc acgccgacga cgtgctgctc ggctgcctgc cgctgttcca	7020
caccttcggc cagatctgcg ggatggcgac ctgtttccgc gccggcgca cgatgggtgct	7080
gatgtcgcgg ttcgacgcgc gagccgcgct ggaactgatg gtggagcaga actgctcgt	7140
gttcatgggc gtgccgacga tgtacgtcgc gttgctggag gccgccgagg acgagccgcg	7200
gcggcccaaa ctcgaccggg ccttctccgg tggttcgtcg ctgcccgtag cgctgctgga	7260
gcggttcgag gccgtgttcg actgcccgat ctacgaggga tacggcctca ccgagacctc	7320
gcccggtggtg gcctacaacc agcgcgcgct gccgaccgc gcgggcaccg tcggcaaacc	7380
gatctggggc gtggacgtcg ccatcgcgcg ccgcgagacc gaagaccgga tcgaaccctg	7440
gccgccgggt gaggtcggcg agatcgtcgt ccggggccac aacgtgatgg cgggctacct	7500
gaaccgtccc gaggccacgg cggccgcgat cgtggacggc tggttccgca gcggcgacct	7560
aggcttctc gacgacgacg gctatctgtc cattgtggac cgtaagaagg acatgatcct	7620

tcgcggcggc tacaacgtgt atccgcgcga gatcgaggaa gtgctggcca ggcatcccgc	7680
gatcgcccag gtcgcggtcg tcggcgtgcc ggacgaacgg tacggcgagg agatctgcgc	7740
cgtcgtggtg gccgcttccg atcgggaacc cgggccggaa ctggcgggcg aactcgtggc	7800
gtggagcaag aagcgcgtgg cggcctacaa gtatccgcgc cgcgtggagt tcctggacgc	7860
gatgccgctc gggcccagcg ggaagatcct caagcgggag ctggcggagc tcctcgggca	7920
ctgactcctg tgcttcggcc caggcggaat cgcggcacgg tcgagtgtgg aggatttggg	7980
acgttgagtg tcccaaatacc tccacactcg aatcacctgg ccagctcaag cgttggcgtg	8040
tctggtgttg acgatgtagg aatcgggacg ttgagtgtcc cgattcctac atcgtcgggg	8100
gaccgggtct cggatcttga tcaacggagg attggggaca ctcagcgtcc ccaatcctcc	8160
gtcgatcaag gtcgcagccg agtggggaag atttcggaca ctggacgtcc tcaatcttcc	8220
ccgctcgccg acgttgcgaa agccactttc ccaaccttca actttgcgaa agtggctttc	8280
gcagcacacc gccgctcgcc aaccctgcc cccaccccgcc gcccgaccgt gaacaggggg	8340
acgtaggggt gcgaaagggg tccgttcccg cactagcttc ggaatcccat cctcgaaccc	8400
gaaatgcgga ccatgcgaga cgaactgatt ctgcgaactc gacgtgttcg gccggactgg	8460
gccacgggtg tggccgcttt cgacgaaacc ccggacgggg agcggcgggc ggcgctcgcc	8520
gcgctggtcg tcgccgagac cgaagcggtg ctggaggcga agccgggtgc ggggaccgcc	8580
gcgcccggca cgcccttcgc cgaactcggg ttcgattccc tcgcggcggt ggaactgcac	8640
cggcggatct ccgcggccac cgcgctggag ctgccggtga cgctcgtctt cgaccacccg	8700
acaccgtcgg cgctcgccgg tcactctgcgc gatctgctcg ccggtgaggc cgtggccgag	8760
atcgaggact accaggcgat cgccgacgac gagccgatcg cgatcgtcgg catggcctgc	8820
cgttaccctg gtgggatcgg ttccgccggag gacctctggc ggctggtcac cgagggtggg	8880
gacgcgacgt cggacttccc ggccgaccgc ggctgggacg tggaatcgct gtacgacccc	8940
gaccccgggg tgcccggcaa gacctacacc cggcgaggcg ggcttcctcga cggcgccggg	9000
gatttcgacg cgggattctt cgggatctcg ccgcgtgagg cgctggcgat ggatccgcaa	9060
cagcggctcc tgctggagac gtcgtgggag gccttcgagc gggcggggat cgaccccgcg	9120
accttgcggg gaagcgcgac cggcgtgttc gtcggcgcgg agaccagga gtacggaccg	9180
cgtctcggtg gcgcggaaga aggtctcgaa ggttatctgc tgaccggtaa cgcggcgagt	9240
gtcgcgtcgg gccgcgtctc gtacgccttc gggttcgagg gcccgacggt caccgtggac	9300
accgcatgct cgtcgtcgtt ggtggccctg cacctggcag ggcaggcgct gcggctgggg	9360
gagtgcccgga tcgcggtggc cggcggcgct gcggtgatgt cgagccccgg cggtttcctc	9420
gccttcagcc gtcagcgcgg gctcgcgccg gacgggcgct gcaagccgtt ctccgcccg	9480

gcggacggca ccggctggtc cgaaggtgtc gggatgctgg tgctggaaag gctttccgac	9540
gcccggcgca acgggcaccg ggtgctcgcc gtcgtccgcg gcaccgcgat caactccgac	9600
ggcgccagca acggtctcac cgcgcccac ggcgccgctc agcagagggg gatccggcgc	9660
gcgctggcga acgccgggct cgcaccgtcc gaagtggacg ccgtcgaagc acacggcacc	9720
ggtaccgtcc tcggcgaccc gatcgaggcg caggcactgc tggccaccta cggccgcgac	9780
cgtgagcgcc cggttctcct cggctcggtc aagtcgaaca tcgggcacac ccagtcggcc	9840
gccgggggtg ccgggggtgat caagatggtg caggcgatgc ggcacggtgt gctgcccagg	9900
accctgcacg ccgacgagcc caccgccgaag gtcgcctggc cctccgggtc cgtcgaactg	9960
ctcaacgaga ccgttgcttg gccggagaat ggcgcgcctc gccgcgcggc ggtgtcgtcg	10020
ttcgggatga gcgggaccaa cgcgcacgcc gtcctcgaac aggccccgc cgaggacgag	10080
cccagaccgt cgccggaagc gtggcccacc tggctgttcc ccgtcagcgg ccgcgacgag	10140
aaggccctgc gccgtcaggc cgcccggtg cgtgaagccc tgccggacag tgacctcccc	10200
gccatcgccg ccgcgctcgc caccaccgg tccgccctgg agtggcgggc cgtggtgacg	10260
gtcgccgatc gcgcgggatt gttggccggg ttggacgcgt tggccaccgg tgaagctctg	10320
ccgagcctgg tccacgggac ggcgcggatc gggatcgtct tcagcggcca gggcagccag	10380
cgcgcgggga tgggcccgcga actgcaccgc cggttcccgg tgttcgccgc cgccttcgac	10440
gacgcctgcg ggcatctcga cctgcaactg gaccggccgc tggccgagat cgtgttcgcc	10500
gacgagggca ccgaggaagc cggcctgttg caccgcaccg aatacgcgca gtgcgcgttg	10560
ttcgccgtcg aggtcgcgct gttccggctg tacgagcatt ggggcctgcg ccccgattac	10620
gtcgccgggc actcgatcgg cgagctggcc gccgcgcacg ttccgggcat gctttcgctc	10680
tccgacgccg ccgcgctcgt cgccgcgcgg ggacgcctga tgcaggacac gcgcgagggc	10740
ggcgcgatgc tcgcggtgca ggcgacggag gacgaggtcc tgccgctgct tgacgaacgc	10800
ctcgcgatcg cggccgtcaa cggcccgcgg tcggtggctg tctccggcga cgaggccgcg	10860
gtcgaggagg tcgccgccgc gttcgccagg cgcaagacca aacggctcaa ggtgagtcac	10920
gccttccact cgcatacat ggacgggatg ctcgacgagt tccgccggtt cgccgagatc	10980
ctcaccttcc ggaagccggt gatcccgtg gtgtccactg tgtccggtga gctgctcacc	11040
gaggcgacgg cgccggaata ctgggtggag cacgtgcgcc gcccggtgcg gttcgccgac	11100
ggcgtgcggc ggctggacga gctcggcgct gacgtgctcc tggaactcgg cccggacgcg	11160
gtgctgacgc cgatggccgc cgaagtcctc gacggcgagg gagcggcgct ggtgccgagc	11220
ctgcgcgggt cgcggccgga ggcggaggcg ctcgccgcgt cgctggccga actgtgggtc	11280

cgcgggcgccg aactcggctg gcctcaggtg ttcggtgcac acccgagggc cgatttgccg 11340
 acttatgcct tcgaacggca gcggtactgg ctgatcgacc aggacaccgc cggggatccc 11400
 ggcgccctacg gtctggggcga caccgggcat ccgctcctgc gggcgctcggc caccacggcc 11460
 gaagacgggtg cgctgctgct ctccggcagg ttgtccccgc tcacccagcc ctggctcgcc 11520
 gaccacgtcg tcggtggcga cgtggtgctg ccgggtaccg cgctgctcga actggcgctg 11580
 cgggcccgcgg aactcgcggg ggccggggggc gtcgaggaac tgaccctcga agtgccgatg 11640
 gtgctttccg aagcggggcgt tcagggttcag gtgtcgggtcc gggacagcgg gctcctgatc 11700
 ttcttccgtg acaccgagga cgacgagtgg acgcgctgcg cttcggggcac gctcggcgcc 11760
 gcggcgccccg ctcccggctt cggggcgctgg ccgcccgcgc gtgagcccct cgacctttcc 11820
 gatctctacg accggttggc cgactccggc ctcgactacg ggccggcggtt ccgctgcctg 11880
 cgtgccgcat ggcgctccgg tgacgacctc tacgccgagg tcgccgccgt gccggagacc 11940
 cagggcggggt tcggcggtgca tccggcgctg ctggacgcgg cgctgcacgt gctcgaactc 12000
 ggctccggggg gcggtggagg ccccgcgggc ctgccgttcg cgtggtccgg cgtgacgttg 12060
 cacgcgcgcg gcgccgacgt tctgcgcgtc aagctcgaga accacgtcgc gggtgccgaa 12120
 gccgggacgt actcgggtgtc cctgaagggtg gccgacggcg cgggcgaacc cgtcgcgtcg 12180
 gtcgaatcct tagccctgcg acctctttcc acagctcctc gcgcgcagga cggcgcgctt 12240
 tacggcgctg actggatttc gcttcccggg acgccggggc tcgccgagta ccggctctat 12300
 ccggacctca ccgccgtcga cgacgtgcca ccggtcgtcg ccgtccgttg caccactctc 12360
 gaaagcgtgc tggatctcgt ccagacgtgg ctgcgccgac accggttcgc cccggccagg 12420
 ctggcgctgc tcaccgacgg cgccgtcgcc accgaaaacc ccgatcccgc cgcggccgcc 12480
 atgtggggggc ttgtgcgttc cgcgcaggcc gagcaccgg accggtcggc attggccgac 12540
 gtcacgggag aagacggcct cgccgccgga ctggcttccg gcgaaccgga gttcgccgcc 12600
 cgcgacggcg cggtgctggc cccagggctg acgcgtgtgc cgagcccggc cccggcgctg 12660
 ttcaccaccg gcggcacggc gctgatcacc ggcgggaccg gcggtctcgc cgggctgctg 12720
 gcccggcacg tggtcgagcg gcacgaggta cgcagcctgc ttctcgtgag ccgtcgcggc 12780
 gccgcggggc cgctcgtcga cgacctcacc gcgctgggtg ccgacgtcac cgtcgccgcc 12840
 tgcgacatcg ccgaccgca gtccgtcgcg gcaactgctc ccgagcatcc ggtgtcggcg 12900
 gtcgtccacg ccgccgggtg gctcgacgac gcgaccatca ccacgctcga ccacgagcgg 12960
 ctgcgggccg tcctgcggcc gaaggctcacc ggcgcgctcg tcctggacga actcaccggc 13020
 gacctcgacc tgtcggcggt cgtgctgttc tcttcgtccg cggccacctt cgacggcgcg 13080
 ggtcaggcca actacgctgc ggccaatgcc ttctcgaag cgctcgccct ccgccgccgt 13140

gcggaaggcc gccccggcgt cgcactgggc tggggcctct gggccaccgg gatgggagca 13200
 cggctcgacg aggcggggct gcgcgggatc gagcgctccg gccagcgtgc actatccgaa 13260
 gtagacgggc tcgcgctgtt cgacgcggca ctggcggcgg accggccggt actgctgccg 13320
 atgcggatgc accgtgccgc gttgcgtgcc cgcgcctccg ccgaaggact tccggcagtc 13380
 ctgggcggac tcgtccgggt caccgcgccg gcgccgtcgg ccgcaccgcg cggactggac 13440
 gaggcggccc tgctcgacct cgtccggacg acggtcgccg ccgtcctggg ccaccgcggac 13500
 gcgcacgcga tcgaccggga tcgcgcgttc accgaggtgg gtttcgactc gctcgccgcc 13560
 gtggaactgc gcaaccggct gatcgccggc accggactga agatcgcgcc gacgctgggtg 13620
 ttcgatcacc cgaaccgcg tgccggtcgcc gcgttcctcg ccgcgggctc cgctccggtc 13680
 cgggacgagc ccgcgcctcc ggccgaagcc gacgagccga tcgcgatcat cggcatggcc 13740
 tgccgctatc cgggcgggggt gagcacaccg gacgacttgt ggcgtctggg cggcgacggg 13800
 aacgacggca tcaccgggtt ccccgagaac cgcggctggg acaccgacgg cgtctaccac 13860
 cccgacgccg accaccgcgg cacgacctac gtgcgcgagg gcggtttcct gcacgacgcc 13920
 ggacagtctg atcccggctt cttcgggatc tcgccccggg aagcgctggc gatggacccg 13980
 cagcagcggc tgctgctgga gatctccac gaagccgtcg aacgggcccgg gatcgacccg 14040
 aagtccttgc gcggcagtgg aaccggcgtg ttcgccgggg tgatgtacca cgactacgcg 14100
 accgggctga accgcgtccc cgacgacgtc gagggttacc tcggcaacgg gacctcggcc 14160
 agcattcact ccggccgggt cgcctacacc ttcgggctgg aaggcccggc cgtcacgata 14220
 gacacggcct gttcgtcgtc gctgggtggc ctgcacctgg ccgcgcaggc gctgcggcgc 14280
 ggtgagtgtc cgatggcgct ggcgggcccgg gtgaccgtga tggccacgcc cgaggctctc 14340
 gtggacttca gccgtcagcg cggcctcgct cccgatggcc gctgcaagtc cttttcggac 14400
 gaagcagacg gcacgggtgtg gagcgaaggc gtcgggatgc tcctggtgga acgcctttcc 14460
 gacgcccgcc gcaacggcca tcgcgtcctc gcgacgtgc gggggagcgc ggtcaaccag 14520
 gacggcgcgt ccaacggcct caccgccccg agcggctcgt cgcagcaacg ggtgatccgc 14580
 cgggccttgg cggacgccgg tctcaaaccg tccgaagtgg acgctgtgga ggcccacggc 14640
 accgggacgc cgttgggtga tccgatcgag gcgcaggcga tgctcgccac ctacggccag 14700
 gaccgggacc ggccgctgtg gctcgggtcg ctgaagtcga acctcggcca caccaggcc 14760
 gccgcccggc tcggcgggat catcaagatg gtgcaggcga tgcaccacgg tgtgctgccc 14820
 cgcacgtca acctcggcac gccgacgacc aaggctgact ggacatccgg gaacgtgtcc 14880
 ttgctcagcg agcccgtggc ctggccggaa accggcgggc cccggcgtgc ggctgtctcg 14940

tcgttcggga tcagcgggac caacgcgcac gtcgtcctgg agcaggcgga accggtcgaa 15000
 aagtccactt cggacacatc gccgctcggg ggtgacgtgc tgccgttcgt cctgtccgga 15060
 aagacgtccg ccgccctggc cgcgcaggcc gaccggctcg ccgggcacct ggccggcgac 15120
 gtctccctgc ccgccgtggc ccgcgcgctc gcggtgacca ggtccgcgct ggaccaccgt 15180
 gccgtgggtg tgccggggcga ccgcgccggg ttgaccgccg ggctgcgcgc gctggccgac 15240
 gccgtccccg cgcggcacgt ggtcgatggg gtcgccgaga acggcaaggc cgtcttcgtc 15300
 tttccaggcc agggatcgca gtggaccggg atggcggtgg atctgctggg atcgtcggcg 15360
 gtcttcgccg aagcgatggc cgactgcgag gccgcacttc tgtcccatct ggactggaag 15420
 ctgacgcacg tcctgtccga cgcggcgggc ctggaacggg tggacgtcgt ccagccggtg 15480
 ctgttcgcgg tgatggtgtc gctggccccg ctctggcggg cgtgcggcat cgaaccgcc 15540
 gccgtgggtc ggcattcgca gggtagatc gcggccgcgt gtgtcgcggg cgcgctgtcg 15600
 ctggaagacg ccgcacgcgt ggtctgcctg cgcagcaagg cgatcctggc gctgtccgga 15660
 ttgggcgggg tgggtgtcgg cgcggcctct gaggatcgcg tccgggaact gctgcccgat 15720
 ggcgtttccg tggccgtggg gaacggcccc gcttccgtcg tcgtgtccgg tgacgtcgcc 15780
 gggctggagg cgctgctcaa gcgatgcgaa ctgctcgacg tgcgggcgaa gcgggtccc 15840
 gtggactacg cgtcgcactc ggctcacgtc gacgcgatcg aacagcaggc cgtgacggcg 15900
 ctgagcggaa tcatgccgcg cgaagccgaa ctgccgatgt actcgaccgt caccggtgag 15960
 ccgatcgaca cgaccaccct cgacgcggcc tattgggtcc gcaatctccg ggccaccgtc 16020
 cggttcgacc aggcggtgcg gcggtgatc gcggacgggt tccggttctt cgtcgagacg 16080
 agcccgcata cgggtgctgg cgcggggctg accgaactcg tcgaagaggc cgcctgccc 16140
 gccgtcgcgc tcgcgagcct tcgccgtgac gagggtggac cgaccgggtt cgtcacctcc 16200
 ctggccgagg cgcacgtcca cggctctcag cccgattggg ccgcgctgct gcccgaggcg 16260
 ggggtgggtg atctgccgcc ctatgccttc cagcatcagg agttctggct caccgacgcc 16320
 ggggaaccgg gtgacgcgc cggattcggg ctccggcgcca ccgggcatcc gctgctcacc 16380
 gccgcgaccg cgctgccggg ctccggcggc ctgctgctca ccggccggat ctcgacggcc 16440
 gccagccgt ggctggccga ccacgcgggtg cagggcgtgg tgctgctgcc gggtagggcg 16500
 ttcgtggagc tggcgctgca ggccggaacc cacgcgggct gcgggcggat cgacgagctg 16560
 actctcgaag ccccgctgcc gcttcccag cagggcggcg tccgcgtcca ggtcgtcctg 16620
 gggtcggaag tgaacggacg ccgcgaggtc accgtgcact ccaggccga atccggtgac 16680
 gacacctggg tgccggcacgc atccggcttc ctgacttcgg cggaaccccc gggagaggga 16740
 ctgaccgaat ggccgccccg cggcgcgacg agcggcgacc tcgacggctt ttacgccgac 16800

gccgaggcgc agggctacgg ctacgggtccg gcgttccaag ggctgcgagc ggcctggacc 16860
 ctgggttccg acgtcttcgc cgaggtcgtc ctgcccgatg ccgagggcgc ggaccggttc 16920
 ggtctgcata cggcgttgct cgacgccgcc ctccacgcc tcggtaccgt ccggtccggc 16980
 gacggcgcgg aactgccgtt cgcgtggacc ggggtcaccg tgcacgccgt cggcgccacc 17040
 gcgctgcggg tccggctcac cgtggggacg gacaccgtcg cggtgacggc ggccgatccg 17100
 gcgggcgcgc cggtcgcgac cgtcgaaggc ctcgtcacgc ggcccgcgc cctgcccgga 17160
 tcccggcggc cggactcgt gttccgcgtc gactggactc cggttctccac gccggaagcc 17220
 gtcgagacgc cgaccgtcac cgtcctgtcc gacggcgacc tgaccgcgtc cgccgagatc 17280
 cccgacgtgg tgctgggtgcc ggtgggagcc gaggccgggg acctcaccga gagcgtccat 17340
 cgcacgaccg cccgggtgct cgatctgctc cggacctggc tcgacgacga gcggttcgcc 17400
 gacgcgcggc tgggtgctga caccgcggc gcggtcgcg acgtccgcga cctgccggcc 17460
 gcggcggcct ggggcctggg ccggtccgcg caggccgaga accccgaccg gatcgtcctg 17520
 ctcgacagcg acaccgacct tccgccggcg ttgctcgccg aagtgtggc caccggtgag 17580
 gcgcagctcg cgtggcgcg aagggaactg ctcgtgccga ggctcgcaa ggtctccacc 17640
 gacggcacgc tgaccccgcc ggaaggcccc tgggtgctgg acgcgccccg ccgcggcacg 17700
 ctggaagagc tcgcgtcgt cccggcgccc acggccgccc ggccgctcgc cgacggcgag 17760
 gtccggatcc aggtccgggc cgccgggatc aacttccgcg acgtgctcat cacgctcgac 17820
 atgtatcccg aggacaaggc ggtgatgggc agcgagggcg cgggtatcgt caccgaaatc 17880
 ggttccggcg tcaccggcct gaagcccggc gaccgggtct tcggcctggt cgacggcgcg 17940
 ttccggaccg tcgcgatcgc cgaccggcg acggtcacgg aaatgcccgt ggactggacg 18000
 ttccgccaag cggccgctct gccggtcgtc ttctcaccg cctactacgg gctggtcgac 18060
 ctgggcgggc tccggccggg ggagaagggt ctgatccacg gagcgaccgg cgggtgtcggc 18120
 atggccgcgg tccagctggc ccgccacctc ggcccgagg tggtcgccac ggcgagcccc 18180
 ggcaagtggg aagtgtgctg gggcctcggg ttcgacgacg agcacatcg ctcctcccgc 18240
 acgtgggact tcgaggaccg gttcggccgg atggacgtcg tcctggactc gtcgccaag 18300
 gagttcgctc acgcgtcgt gcggctgctg ggcgagggcg gccggttcgt ggagatgggc 18360
 aagaccgaca tccgtgacgc ggacgaggtc gcggccgcgc atcccggcgt cacctaccgc 18420
 gcgttcgacc tgctcgacgc cggacggccg aggatcggcg agatcctggc cgaactgctg 18480
 gacctgttcg gcgcggggtc gtcaccgtg ccccgccga cgggtgtggga cgcgcgccgc 18540
 gcacccgagg tcttccgggt catgagccag gccaaagcaca tcggcaagaa cgtgctcacc 18600

atcccgtcca caatggacgg gaacgggacg gtgctgatca ccggcgccac cgggacactc 18660
 ggcgcgctgg tcgcccggca tctggtcacc gtgcgcggtg tccggcacct gctgctcgtc 18720
 ggccgcccggg gtcgtgcggc ggccgggatg gccgaactcg aagcggaact gaccgcccgc 18780
 ggggctccg tcaccatcg cgcctgcgac gcggccgacc gggcggcgct ggccgccctg 18840
 ctcgccaccg tcccggccga gcatccgctg gccgggggtg tgcacgccgc cgggtgtcctg 18900
 gacgacggcc tcgtcgccac gctgaccccc gagcggtggt cgaagggtgct gcgcccgaag 18960
 gtcgacgccg cgggtcaacct gcacgaactg acccgcgacg cgcattctgc cgagttcgtc 19020
 ctgtttctct cggccgcccg cgcgttcggc gacgccggac agggcaacta cggccgccgcg 19080
 aacagtttcc tcgactcgct cggccggcac cgtcgggcgc aggggttgcc cgcggtctcg 19140
 ctcgcggtggg gtttctgggc cgagctgagc gggatgaccg gccacctcgg tgaagcggat 19200
 ctggcccggc tcaagcggtc cgggatgagc cctctgtcca ctgaggacgg actactgttg 19260
 atggacgccg ccggtgccgg gtacgaaccg gcgcgcgtcc cgatgcacat cgacctcgcc 19320
 gccctgcggg gcgaggaagt gcacccgttg ctgcgggggc tgggtgaaggc accggtgcgc 19380
 cgggcccgcg cggccaccgg cacacagtcc gagggactag ccgaccggct ggccgggctc 19440
 gcccggccg cccgcggccg ggccctgctg gacctgatcc gcgcgaacgt cggcgcggtg 19500
 ctcggtttcg gctcaccgga gcaggtcggg gtccggcagg ccttccggga gctcgggttc 19560
 gactcgctca gcgcggtcga actccgcaac cggctcaacg cggcgaccgg tctgcggctg 19620
 cccgccacgg tcgtgttcga ccattccgacg cccaccgcgc tcgccgaaac cctcggcgac 19680
 cggctggcac ccgccgaaga agccgttgac gacgaggtcg ccggtatcgg cgcggtcctc 19740
 gcttcggtgc ccgccgaccg gctccgcgaa gccggcgtgc tggacctgct gacccggtg 19800
 gccgaccccg gctaccgccc caccgagtcg cccgacggcg cggacatcga cgagatggac 19860
 gccgaccgcc tgatcgcaact cgctttcgac gcttccgacc ccgcctgacg tgaaacaccc 19920
 tggagctgcg atgtccacat ccgagaacaa ggtcgtcgag gccctgcggg cggcgctgaa 19980
 ggaagccgac cgctgcgcg gggagaaccg gcgcctgacc ggcgagccca tcgcgatcat 20040
 cggcatggcc tgccgttacc cgggcggggg ccgctcgccg gaagagctgt gggatctggt 20100
 cgccggagaa cgcaccggcc tcaccggatt cccggtcgac cgcggtggg acctcgacgg 20160
 gctctacgac cccgagcagg ggaaaccggg caagagctat gtccgggaag gcggtttcct 20220
 gcacgacgcc gcccggttcg acccggcgtt ctccgggatc tcgccgcgtg aggcgctggc 20280
 gatggacccg cagcagcgac tgctgctgga gatctcctgg gaggcgatcg aacgcgcggg 20340
 gatcgcgccg gattccctgc ggggcagccg gaccggcgtg ttcgcgggcg tcatccacaa 20400
 cgagtactcg gccatcgcg gcacgccgcc cgcggatctc gagccgtacc tcggcaacgg 20460

gagtttcgcg agcatcgcct ccgggcggggt ttctacacc ttcgggctcg aaggcccggc 20520
 ggtcaccgtc gacacggcgt gtctgctcgtc gctgggtggcg ctgcatctgg cggcacaggc 20580
 gctgcggcag ggcgaatgtt cgctggcgtt ggcggggtggg gtgaccgtga tggccaaccc 20640
 ggcgggcgttc gtggacttca gccgtcagcg cgggctcgcg gcggacgggc ggatcaaggc 20700
 gtctcgccgaa gccgccgacg gcaccgcctg gggcgaaggc gcgggcatgc tgctcgtcga 20760
 gcggctctcc gacgcccggc gcaacgggca ccgcgtcctc gccgtcgtgc gcggatccgc 20820
 ggtgaaccag gacggcgcct cgaacgggct caccgcgcc aacgggtcttt cccagcaacg 20880
 ggtcatccgg caggcactcg cgaacgcgcg gctcgcaccg tccgatgtgg acgcatgga 20940
 ggcgcacggc acgggcaccc ggctcggcga cccgatcgag gcacaggctt tgctggccac 21000
 ctacggccag gaccggacca ccccgctctg gctcggctcg gtgaagtcca acatcgggca 21060
 cagccaggcc gcggccgggg tcgcgtcgat catcaaactc gtcgaggcga tgcggcacgg 21120
 tgtgctgccg aagacgctgc acgtcgacgc gccgacgtcg catgtggact ggtccgaggg 21180
 cgcggtctcg ttgctgaccg aggccgagcc gtggccgaag acggatcgac cccggcgggc 21240
 cgcggtgtcc tcgttcggga tcagcgggac gaacgcgcac gtcgtcctcg aacagcccac 21300
 cgcggaagag gaaccgccgt ccacgtttgc ggggccgggtg ccgttcgtgc tgtccggcaa 21360
 gaccgaagcc gccctgcacg agcaggtggc ccgcgtgcgg gaactcgcgc gggattcgga 21420
 cgtcaccgcg gcggacctgg cgttctcgtt ggccaccacg cggaccgcgc tggatcatcg 21480
 ggccgccctg gtcggcacgc tggacgatct gctgaccgcc actttgggtgg aagggcgggc 21540
 gacggacggc gggacggcgt tcctgttcac gggccagggc agtcagcggc tggggatggg 21600
 ccgcgagctc gccgagcgtt tcccgggtgtt cgctcaagcc ttcgacgacg tctcttcgcg 21660
 gtctgagcga ccgatcgcg agctgtccgc cgaggaaactg aaccagacgg cgaacacgca 21720
 gtgcgcgttg ttcgccttcg aggtggcgct cttccggctg gtcgagaact ggggcctccg 21780
 gccggacttc ctggccgggc attcggtcgg ggagatcgcg gcggctcatg tcgcggacgt 21840
 gctctctctc gacgacgcgg tgacgttggg gtcggctcgt ggccgcctga tgcaggcgtt 21900
 gccgaccggt ggggcgatgg tggcgcttca ggcgaccgag gcggaggtcg ccccgctcct 21960
 gaccgaccgg gtgtcgctgg ccgcgatcaa cggcccggag tcggtggctg tctcgggtga 22020
 cgaagaagcc gtcgccgcgg tgggtgtcca cttcgagggc cggaagagca agcgccttac 22080
 ggtgagtcac gcgttccatt cgccttgat ggagccgatg ctcgacgact tccgcgcggt 22140
 ggtggagggg ctgaccttcg ccgaaccgcg gatcccgatc gtgtccggcg gcctggctga 22200
 agtgtccact tcggactatt gggtcgggca cgtccgtgac gcggtgcggt tccacgattc 22260

ggtcgaattc ctgaaggccg agggcgtcac ccggttcctg gagatcggac ccgacgccgt 22320
 cctgaccgcc atggccaagg aaagcgccga ggacgcggtc gtcctcccgg cttcgcgacg 22380
 ggaccgcccc gaggtgacga cgctgctgac ggcggtcgcc ggactgcacg tccatggggc 22440
 cgaggtcgac tgggcgcccg tgttcgacgg tgcgcggcgc gtcgatctgc cgacgtatcc 22500
 gttccagtac gagcacttct ggctcgaatc cggtgccgct caccgcgacg tgtccgcccg 22560
 cgggctggac gcgtcgcccg acgccttgcg cgcgcgccgc gtccggcccg cgggcgagga 22620
 cgagatcctc ctgacgggca ggatctcgct gagcacactg ccgtggctgg cggaccacgt 22680
 cgtcggcgga aacgtccttc tgcccggtag cgcgttcgcc gaactcgcgc tcgcggcccg 22740
 cgacgaggcc ggttgtgagg ccgtcgagga actgaacctg gaagcgcccg tgggtgctgcc 22800
 cgagaagggc ggggtccagt tgcaggtcgc ggtcggcgcg gctgacgacc agggcaggcg 22860
 ctcggtcacc gtgcacgccc ggccggagga cgacggcttc tgggtgcggc acgcctccgg 22920
 cgtcctcggg accgcagtgt ccacacagga cgagatgac gagtggccgc cctcgggcgc 22980
 ggagcctgtc gacctcgaag gcttctaccc gaacctggcg gccgaagggc tcggctatgg 23040
 ccctgccttt cagggcgctc gtgccgtctg gaccgcgat ggcgacgtgt tcgccgaagt 23100
 ccaggtggac gacactcccg gcaccttcgg gatccacccc gcgttggtcg actccgccct 23160
 gcacgccatc ggcgtcggcg agtcgcgggg gctggagatc cccttcgcct ggtcggatct 23220
 ccgcctgcac gccgacggcg cgacggtgct ccgggttcgc ctacgccccg cgggcgacgg 23280
 tgccgtctcc gttttcgcga ccgaccccgc cggagcgccg gtgttgctcg tcggctcgct 23340
 cagcctgcgg gctccggtcg ccgcgaccgc ctgccttccc cgtgactcgc tgttccgcgt 23400
 cacctggacg ccggtgacgg tgcccgtgg tgctggggaa cccaccgtgg agtcctttgt 23460
 ggacttcgat gacgtccggc aagcgacggc gcacgcccgg cagatcgccg tggagcccgg 23520
 cgaggcccc gtggtgttcc tgaccagcg cgcgttcacc gatcctgcgc aggcgtcggg 23580
 ctggggactc atgcgttcgg cgcgggagga gtaccccggc cggttcgtgc tcgtcgacgc 23640
 cgacgacccc gccacgctca cggccggcct gctggccggc atcgtggcct ccggcgagac 23700
 cgaagccatc gtgcgtgagg gcgaggtccg tgtcccgcgg ctaccccgg tgcgcggggg 23760
 cgaaaccgga ccgggctggg acccggaagg cacggtcctg atcaccggcg gcaccggcgc 23820
 gctcgccacc gaactcgcgc ggcacctcgt cacacgacgc ggtgtgcgga acctgatcct 23880
 cgccggacgc cgcggtcccg ccgcggaagg cgcgagcgag ctggccgccc aactggcgga 23940
 cctcggcgcg cagggcccga tcgtcgctg cgacgtcgcg gatcgcgacc agctgacggc 24000
 gttgctcgac ggcgttcgc tgaccgcggg cgtccacgcc gcgggcgtcc tcgacgacgg 24060
 cctgctcgcc gatctcactc gggaccgatt cgaaaccgtc ctgaggtcca aagtggacgg 24120

cgcaatcctg ctggacgaac tggccggtga cgcccacctc gtgtttcttct cctccgcggc 24180
 cggggtgctc ggcagcgcg ggcaggccaa ctacgcccgc gccaacgccc ccctcgacgc 24240
 ggtggccgcg cgccgcccgg aacggggact acccgcgacc tcgctcgcg gggggctctg 24300
 ggagaccggc gacgggatgg cgggtgcgct cgccgggacc gatcgcgcg ggatggcggg 24360
 ctccgggctg ctgccgcttc cggtcgggga cgccttgacc ctgttcgact tcgccgtcgg 24420
 agcggaggaa gtgctgttcg tgccgatgcg gctcgacgtg cccgctctgc gcgcgagcgc 24480
 cacggacgtg ccgctcctgc gggccttcgc cgggaaatcc cggcggaccg cgtcggccgc 24540
 ccccgccgcg cgggaactgc gtgaccggct ggcgtcgctg ccaccgagg agcggggccg 24600
 ggaactgctc gcgctggtgc gcggccaggt cgccgaggta ctcgccacc gggacgccgg 24660
 ggccgtcgaa ccggtcgtc cgttcgggga actgggcttc gactcgctga ccgcggtgga 24720
 actgcgcaac ggcctcaacg ccgcttcggg gtcgcggtg cccgcgaccg ccgtgttcga 24780
 ccaccccacc ccgaaggcgc tcgcggaact gtcgcccgc gaactgttcg gcgcagcccc 24840
 cgaagccccg gttcaggggc ccgcgatggc ggccgacgag ccgatcgcca tcatcggcac 24900
 ggcatgccgg taccgccggc gggtcgcctc gccggaggac ctctggcggc tggtcgcgga 24960
 gggccgcgac ggcattctgc tcttccggc cgaccgcggc tgggacgtgg acggcctcta 25020
 cgacccggac ccggcaagg cggggaagag ctacgtgcgc gagggcggat tcctccacga 25080
 ggcaggcgat ttcgacgccg gtttcttcgg catctcgccg cgtgaggcac tgggcatgga 25140
 cccacagcag cggctgctgc tggaggtctc gtgggaagcc ttgaacggg ccgggatcga 25200
 ccccggaacg ctgcggggca gcgacaccgg cgtcttcgcc gggcagatgt accacgacta 25260
 cctcaccggc gccacggtcg ttcccacga cgtcgagggt tacctcggca ccggcaactc 25320
 cgggagtgtg ctgtccgggc gggtttctta caccttcggc ctcgaaggtc cggccgtcac 25380
 cgtcgacacg gcgtgttcgt cgtcgctggg ggcgctgcat ctggcggcac aggcgttgcg 25440
 gcgcggcgaa tgctcgctcg cgctggccgg cggggtgacc gtgatggcca cgccggagac 25500
 gttcgtcgac ttcagccgtc agcgagggtt ggcaccggac ggccgctcga agtccttttc 25560
 ggacgggtgc gatggcacgt cctgggtccga aggtgtcggc atgctgctcg tcgagcggct 25620
 ctccgacgcc gagcgcaacg ggcaccggat cctggccgtc gtccgggggt cggcggtgaa 25680
 tcaggacggg gcgtccaacg ggctgaccgc gccgaacggg ccttcgcagc agcgggtgat 25740
 ccggcgagcc ttggccgacg cgcgcctgga accgtccgaa gtggacgccg tcgaggcaca 25800
 cgggaccggg accacgctgg gtgacccgat cgaggcgcaa gcgctgctgg cgacctacgg 25860
 ccagggccgc gaggacgccg cgctgtggct cgggtcgatc aaatcgaaca tcgggcacag 25920

ccaggccgcc gccggggtgg cgggtgtgat caagatggtc gaggcgatgc gccgcggggt 25980
 gctgccgaag acgctgcacg tcaccgaacc gtctgtcat gtggactgga cggcgggccc 26040
 ggtctccctc ctgaccgagg cgcgactctg gccggacgcc ggacgtcccc ggcgtgcggc 26100
 ggtgtcgtcg ttcgggatca gcggtaccaa cgcgcacgtc gtcctggagc agggccccgc 26160
 tccggtggag gccatcgaat ccggtgaggg accggcggcg ttcgtcctgt ccgccgggag 26220
 tgaagcggcc ctgcatgacc aagcgtcgcg gttgagggac ttcctcgccg agacgcctgc 26280
 tgccctggcc gacgtcgcct tctcgttggc gaccacccga gcggccctgg agcaccgggc 26340
 cgccgtcgtg gccgcagacc gggaaaccct gctggccgcg ctggagaacc tcaactgtcac 26400
 cggccgcgcg acggagggcc ggacagcgtt cctgttcacc ggtcagggca gtcagcggct 26460
 cgggatgggc cttcagctgg ccgagcgttt cccggtcttc gccgctgcct acgacgaggt 26520
 gtgttcccgg ttcgagcagc cgctcaggga cctcacggcc gaggagctga accagaccgc 26580
 gaacacgcag tgcgcgttgt tcgcgcttga ggtggcgcgtg ttccgcttgg tcgagagctg 26640
 ggggtgtccgc ccggaacttc tggctgggca ttcggtcggt gagatcgcgg cagctcacgt 26700
 cgcgggtgtg ctttccctcg acgatgcggt gaccctgggtg tcggcgcgag gccgtttgat 26760
 gcaggccttg cctaccggtg gcgcgatggt ggcgttgacg gcgacggaag ccgaggtgac 26820
 gccgctgctg accgagcggg tgctcgtggc ggcgatcaac ggtccggagt cgggtggtcgt 26880
 ttcgggtgag gaggacgccg tcgctgcggt ggtctctcag ttcgagggtc gcaagagcaa 26940
 gcggctcacc gtgagtcacg cgttccactc gccgttgatg gagccgatgc tcgacgagtt 27000
 ccgtgtggtc gccgacagct tgctgtacgc ggcgccgcgg attccgatcg tgtccggtgg 27060
 tctggcggag gtgtccactt cggactattg ggtccgccat gtccgtgacg cgggtgcgatt 27120
 ccacgattcg gtgaagtcc tgggaagcca gggggtcaca cggttcctgg agatcgggcc 27180
 cgacggtgtc ctgaccgcga tggccaagga aactgccgag gacgcggctc tcgttccggc 27240
 actccggcgc gaccggccgg aggtggagac gctgctgacg gcggtcgcgg gcctgcacgt 27300
 ccacggcgtg ggcgtcgatc tgacggcctt gctcggcggg ggaagccccg tcgacctgcc 27360
 cacgtatgcc ttccagcacc gacgtttctg gctttcctcg gcgggcggcg cggcgggcga 27420
 cgtcaccgca gccgggctag gcaccaccga tcaccgctg ctcggcgcgg ccgcggcact 27480
 gccgggacgac ggcgggttcc tgctcaccgg ccggttgctc gggcacgccc agccgtggct 27540
 ggccgaacac cgggtcggcg gcgtggctct gctgccgggc accgcgttcg tcgagatcgc 27600
 cctgcgtgcg ggggatgagg cgggctgcgg ccacctcgaa gacctgacct tcgaagcgcc 27660
 gctcgtcctg cccgagcgcg gtgcgaccca gctgtccgtg ctggtcggcg cggccgacga 27720
 caccggtcgc cggaccatcg agatccactc gcgcgaggaa ggcgaagacg gctggcagag 27780

gcacgcgacc gggctgctat cggccgcgag agccgtcgaa ccggccgggt tgacgacctg 27840
gccgccccag aacgccgaag ccgtcccggg gggtgacgtc tacgagcggc tcgccgccac 27900
cgggtctcgag tacggcccgg cgttccgtgg cctccgtgag gcgtggcgag cgggtgaaga 27960
cctgttcgag gaggtcgaac tcccggagga ccagcactcc gacgcggctc ggttcggcgt 28020
gcatccggcg ctgctcgacg ccgcgctcca caccctcggc ctgcgggcg gcggcgacgg 28080
cacccggtc ccgttcgcct ggtcgggggt gcgcctgcac gccgcccggc cgaccggct 28140
ccgtgtccgg ctgcggccgt ccgggtcccga cgggttcgag gtcctggtcg ccgacggcac 28200
cggccgcccg gtcgtctcag ccgaagagtt gacgctgcgc gagatctcgg gcgacgcctt 28260
ggcccgaag ggacacgact cgtctaccg ggtcgcttg cgtccgggtc cgtcccga 28320
gaccggcgaa accctccccg cggagtcggg tttctccgtg ccgcgcgggt gcgactccgc 28380
cgagcgtgtc cacgaaacga cggccgccgt tctcgaagtc gtccagcggc ggctcgaaga 28440
cgagccgggc ggtccgcttg tcgtccacac ccggggcgga gtcgcccgcg gcgacggcga 28500
agcggtgacc gacctcgcgc accccgcggg ctgggggctg gtgcgtgccg cgcagtcgga 28560
gaaccccggg cggttcctgt tggtcgacgc cgagaccttg cccgatggcc ggatcctggc 28620
catcgacgag cctcagatcg ctttgcgtag cggccgggca ctgcgcgccg gcctggccac 28680
caccgcctcg tccacggaac tgaccccgcc cgagggagcc tggcggctgg acaccaccgg 28740
tcgcggcacc ctggagaacc tcacgtggg gccgtcgccc gaagcagtcg cggcgttggc 28800
tgagggcgag gtccggatcg cggtcggggc cgccgggctc aacttcgcg acgtcctgat 28860
cgcgctgggc atgtaccgg gcgcggccac cctcggcagt gaaggcgcgg gcgtggtcac 28920
cgagatcggg cccgggtgtca ccggcctcga cgtcggcgac cgcgtgttcg gcctgatgtc 28980
gaacggcttc gggccccagg tcgtcaccga tcaccggacg ctggcgaaga tgcccagga 29040
ctggtcgttc gccacggcg cctcgggtccc gatcgtgttc ctcaccgcct actacggcct 29100
gttcgacctc gcgcggctcg aagcgggaga gtcgacctg gtgcacgcgg cggcgggcgg 29160
cgtcggtatg gccgcgaccc agctggcccg tcacgccggg gccgaggtgt tcggcaccgc 29220
cgggtccgggc aaatgggaca cttgctgtgc caacggtttc gacgacacc acctctcgtc 29280
ctcccgtgac ctccgcttcg aggagaagtt ccgcgatgcc accggcggac gcggtgtcga 29340
cgtcgtcttg aactcgctcg ccggcgacta cgtcgacgcg tcaactgcgg tgctggcccc 29400
gggcgggcgg ttcgccgaga tgggcaagac cgacatccgg gaaccggggg agaccggcgt 29460
cgagtaccac cccttcgacg tcatcgacgc cggacccgag cgcacccac agatgctcgc 29520
cgcactgctg gagctgttcg cggccggggc gctgacgccg ttgccgggtc ccggctggga 29580

cgtccggcgc ggccccgacg cgttccgttt cctcagccag gccaaagcacg tcggcaagaa 29640
 cgtcctgacc atgcccgcgc cctcagatcc cgacggcacc gtgctcgtca ccgggggaac 29700
 ggggtgccctc ggcgcgctct tcgcccggca tctggtgcgc gaacgcggcg tccggcggct 29760
 gctgctggcc agcaggcgcg gccacgacgc cccggggcgta cccgagctgg tcgccgaact 29820
 caccgaggca ggcgccctcg tgacggtcga ggcgtgtgac gcggcggatc gcggcgcgct 29880
 cgccgccgtc ctcgccggaa tcccggccgc gcacccgctg accggcgtgg tgcacacggc 29940
 ggggtgtcctg gacgacggcc tcgtcggctc gctgaccccg gagcggctgg cgaagggtgtt 30000
 gcggccgaag gtcgacgcgc cgctgaacct gcacgaactg accagcggcg cggatctcgc 30060
 cgagttcgtc gtcttctcct cggccgcgcg ggtcttcggc aacgccgggc aggcgaacta 30120
 cgccgccgcc aacggtttcc tggacgcgct cagcgtccgg cgcgcggcgc acgggttgcc 30180
 cgcccggctc ctggcggtgg gtctgtgggc cgaaacgggc gggatgggcg ggacgctcgc 30240
 cgaggccgag ctggccagga tggcccagag cggtagccgc gcactgtcca cacaggacgg 30300
 cctggagctc ttcgacgcgc cggcgcgct ggcggaaccg gtcttgggtc cgatgcgcct 30360
 ggacgtcacc gcgatgggcg gggacgggct cccgccgttg ctgcgcggcc tcgcccgcgc 30420
 cccggtaacg cgtgccgcgt ccgccggggc cgccggtgac gcggactcat tgcgagaccg 30480
 gcttctcgcg gtgcccgtcg ccgaccggga gacgctgctg gtcgacctcg tgcgcaccca 30540
 ttccgcgacc gtgctcgggc acaccgcggc ggacgcggtc gaggccacgc ggtccttcca 30600
 ggagatcggc ttcgactccc tgaccgccgt cgagctgcgc aaccggctca ccgccgccac 30660
 cgggctgcgc ctgccggcga cgctgatctt cgactaccgc accccggaag cgctcgcgc 30720
 ccacatcggc gaaggcgctc tgggtgcgca gggcggggcc gagaccgggc aggcggcggc 30780
 gacggccgac gagccgatcg cgatcgtcgc gatgagctgc cggttccccg gccacgccga 30840
 ccccccgaa cggctctggg cctgctggc cgagggccgc gacgcgctgg gcgagttccc 30900
 cgccgaccgc ggctgggacc tggagcggct gtctgacacc gaccggacc gccggggcac 30960
 ctctacacc cgccaaggcg ccttcctcga aaccgccggc gatttcgacg cgggcttctt 31020
 cgggatctcg ccgcgtgagg cgctggcgat ggatccgcag cagcggttgc tgctggagac 31080
 gtctgaggag gcgttcgaac gcgccgggat cgatccggcc accctgcgcg gcagccgcac 31140
 cggcgtgttc gccgggggtga tggacaacga atacgtatcc ggttcggcgc aggtccctga 31200
 cggggctcgc ggctacctgg ccaccggcac ctcggcgagt gtcgcctcgc gccgcgtttc 31260
 ctacaccttc gggctcgaag gtcccgcggc caccgtcgac acggcgtgtt cgctcgtcgt 31320
 ggtcgcgctg catctcgcgc cgcaagcgct gcggcagggc gaggctcgc tggcactggc 31380
 cgggtggagt accgtgatgg ccacaccggg cacgttcgtc gaggtcagcc gtcagcgcgc 31440

actggccgcc gacggccgct gcaaggcggt cgccgacggc gccgacggga cgggctgggg 31500
 cgaaggcgcc gggatgctgc tcgtggagcg gctgtccgac gcccgccgca acgggcatcc 31560
 ggtgctcgcg gtgctgcggg gcagcgcggt caaccaggac ggcgcgtcga acgggctcac 31620
 cgcgccgaac ggtccttcgc agcagcggggt gatccgccag gcgctggcga acgcgcggct 31680
 cgaaccgtcc gaagtggacg cagtcgaagc gcacggaacc gggaccacgc tgggcgaccc 31740
 gatcgaggct caggcgctgc tggcgacctt cggccaggac cgggaacggc cgttgctgct 31800
 cggttcggtc aagtcgaaca tcgggcacac gcaggccgcg gcgggcgctc cgggggtgat 31860
 caagatggtg ctgcgatgc ggcacgggac actgccgcgc acgctgcacg tcgacacgcc 31920
 gacttcgcgc gtcgactggg cggcgggccc gatcgagctc gcgaccgagc cgacccagtg 31980
 gccggagacc ggtggccccg gccgggcggc ggtgtcgctc tcgggatga gcggtaccaa 32040
 cgcgcacgtc gtcctcgaac aggccgaagc ggtcgagaca cgggatgaaa cctcgccggg 32100
 gctgctcggt gacgtcgctc cgtggccgct gtcggcgaag gaaccgagg cgtggccgc 32160
 gcaggcggca cggctgaagt ccttcctgac cggcgaacgt ccggcggacg tggcctactc 32220
 gctggcgacc gcgcggacca cgctggaaca ccgggcggtc gtcgtcggcg aagaccgat 32280
 cgccggggtg gccgcgctgg ccgcgggcga gccgtcgggt tcgggtggtga ccgggaccgc 32340
 gaccagcggg aaggcggtgt tcgtcttccc cggccagggt tcgcagtggg ccgggatggc 32400
 ggtcgagttg ctggcgctcc caccgtgtt cgccgagtcg atggcggagt gcgaagcggc 32460
 tctgctgtcc tatgtggact ggaagctgac cgaggtgctc tcggacgcga ccgcgctgga 32520
 gcgggtcgac gtcgtgcagc ccgccttgtt cgcggtgatg gtgtcgctgg cgaggctgtg 32580
 gcgtgccagt ggcatcgaac cggccgccgt ggtcggatcat tcccagggcg agatcgcggc 32640
 ggcgtgtgtc gccggcgcg cgtcgctcga cgacgcggca cgggtggtct gcctgcgcag 32700
 caaggcgatc acggcgcttt cgggcccggg cggcatggtc tccgtcgccg ctcccgaagc 32760
 ccaggttcgc gagatcctgc ccgagggtgt gtcgctcgcc gcggatgaat gtcccgcgtc 32820
 ggtgggtggtg tcgggtgacg tcgccggtct ggacgcgctc atgaccgctt gcgaggcgag 32880
 cgggctgcgc gcgaagcggga tcccgggtgga ctacgcgctc cattccgcgc acgtcgatgc 32940
 catcgaacaa gacgtcctgg ccgcgctcga cgggatcgag ccgcgggcgc cggagatccc 33000
 gttctattcg acgggtggccg gggagccgct cgatccgggt gtggacgcgg cgtactgggt 33060
 ccggaacctg cgcgggaccg tccacttcgg acaagccgtc cggcggtcgc tcgacgacgg 33120
 gttccggttc ttcgtcgagg cgagcccgc tccggctcct gtcaccggga tcgccgacac 33180
 cgccgaggac gcgggagaa gcgcgctcgc cgtcggcagc ctgcgccggg acgagggagg 33240

gccgctgcgg ttccctcacct cgctggccga agcccacgtc cacggcctca gcccgactg 33300
 ggcgggcgctg gcccccgga cccgcgtcga cctgccgacc tacgccttcc agcacgagca 33360
 ctactggctg cggacgcggt cttcggccga tcccggacag gccggtctgg acgacggcgg 33420
 gcatccgctg ctcgggggccg tcgtcccgtt ggcgggcagc gacggcctgg tggccaccgg 33480
 ccggatctcg gcgcggaacc agacctggct gcccgatcac gccgtcgggg gcgcgctgct 33540
 gctgcccggc gcggcgctcg tggacctggc gctcacgggtg ggggagcgca ccggctgcgg 33600
 ccggatcgcc gaactgacca tcgaggcgcc gctagtcctc ggggagtccg ggagcgcgcg 33660
 gctgcagggtg accgtcggag cgtccgcaga cgacggcacc cgcgaggctc ccgtgtactc 33720
 ccgggacgaa accgctggca cggactggat ccggcacgcg accggcctgc tcgccgcgga 33780
 cggggaaacg cccgtggcgg acctgaccca gtggccgccc gcgggagccg aaccgatctc 33840
 cctcgaaggg cactacgaag gtctcgcgga actgggctac ggctacggtc cggcgttccg 33900
 cgggctgcgt gccgtgtggc gccggggcga cgacgtgttc gccgaagtcg cgctcccgga 33960
 agaccggatc gccgaggccg ccgcgttcgg cctgcacccc gcgctcctcg acgccgccct 34020
 gcacgcgctg ggcttcggca tgctccccga cgacggacgg ctgcggcttc cgttcgcgtg 34080
 gaacgaggtc tcgctgtcgg ccgtcggcgc gccgagcctg cgcgtacggc tctccccgcg 34140
 cggggaggac gcggtggcgg tggacctcgc cgacaccgcc ggggcgcccg tcgcctcgat 34200
 cggctccgtg gtgttcggc cgggtggcga ggcacagctc gccggcgccc ggcgggatcc 34260
 ggcggattcg ctgttccaga tccagtggac ggatctgtcc gcaaaggacg tcgtcgcacc 34320
 ggcggtcgtc gtgctcggcg aggactgcgc ggacctcgcg gagctcgccg cggatctcga 34380
 cgcgggaagg ccggcgcccg acgtggtgct cacgacctgc gcaccgctca ccggcgatat 34440
 cgccgagggc gcgcacgccg ccgcgagggg cgcgctgacg ctgggtccaga actggctggc 34500
 cgatgagcgg ttctccggag ccaggctggc cttccgcact tcgggcgcgg tctcgggtggc 34560
 cgcggacgaa ccggtgtccg acccggccaa cgcgacggtc tggggcctcg tgcgcacggc 34620
 gcaggaggag aatcccggcc ggttcggtct tctcgacacc gatgggtccg aggccgtctt 34680
 ggggtgcggcg ctggcgctcg acgagcccca gctcgcgctg cgggccggaa ccgtgctcgg 34740
 cgcccggctg gtcaaggcgt ccgccgacac cgcgctcgtc ccgcccccg gcagccgcgc 34800
 gtggaccgtc gacaccctcg gcggcggcac cctggagaac ctgggtgctac gggaccggcc 34860
 cgatctgctg gccccgctcg ccgacgggca ggtccgtatc gccgtgcggc cggccgggct 34920
 caacttccgg gacgtcgtgg tggccctcgg gctcgtgcca gggcaggaag gcatcggcgg 34980
 ggaaggcgcg ggcgtgggtc ccgagaccgg ccccggcgtc accgacctgg cgccgggcga 35040
 ccgcgtgctg ggcattgttc acgcgtcgtt cggccccgat gccgtcgccg accggaagct 35100

gatcgcgccc gtcccggacg actggtcggt caccgaagcc gcttcggcgc ccgtcgcggt 35160
cctgaccgcc tacgtcggcc tggctgacct cggcgagctg cggccggggtc agaccgtgct 35220
gatccacgcc gccgccggtg gggtcggcat ggccgcggtc cagctggccc ggcacttcgg 35280
tgccgagatc tacgtgaccg cgagccccgc caagtgggac acgctgcggg cgatgggctt 35340
cgacgacgac cacatcgcgt ccagccggac cctcgatttc gaggacaaga tccgcgaagc 35400
cactggcgga cgcggggtcg acctgggtgct ggactcgctg gcaagggagt tcgtcgacgc 35460
gtcgtcgcg cggtgcgcg aaggcgggcg attcgtcgag atgggcaaga ccgacatccg 35520
cgacgcggac gaggtcgcgg ccgcccattc cggcgtcacc taccgcgcgt tcgacctgat 35580
cgactccggg cacgaccgga tccaggagat cctgggcgaa ctccctggcgc tggcggacaa 35640
ggacgtggtg cggccgctgc cgaccacggc gtgggacgtc cggcgcgccc ccgaagcggt 35700
ccggttcctc agccaggcca agcacacggg caagatcgtg ctggagccgc ccgccgtcct 35760
cgaccccgag ggaacgggtg tgatcaccgg tggcaccggc gtgctgggcg gcctgttcgc 35820
ccgacatctg gtgaccgcgc acggcgtccg gcggctgctg ctgaccagca ggcgcgggct 35880
cgacgccgag ggtgcgcggg aactggtcgc ggacctgacc ggcctcgggg ccacggtgac 35940
cgtcgtggcc tgcgacgtcg ccgatcgcgc cgcggtcgcc ggactgctcg gctcgggtccc 36000
gcccgagcac ccgctgaccg ccgtgggtgca caccgccggc gtgctcgacg acgggctgat 36060
cccggcactc accccggacc ggctcggcac cgtgttcgcgc ccgaaggctc acgccgcgggt 36120
ccatctgcac gaactgacct gcgacctcgg actggccgcg ttcgtgctgt tctcctcgtc 36180
cgcggcgacg ttcggcgccg ccggacaggg gaactacgcg gcggccaacg ccttcctcga 36240
cgactcgcgc cagcaccgcc gggccgaagg gctcgcgggg caggcattgg cgtggggctt 36300
ctggggccgag cggagcgcga tgaccggcca tctcgacgag gcggacgtgg ccaggatgaa 36360
gcgatccggc gtcagtccac tgtcctctgt ggacgggtctt gcgctgttcg acgcggcggc 36420
ggaacgggac gtcgcggcgc tgggtgcccg gcacctggac accgccgccc tccgagggca 36480
gaccgaagtg cccgccctgc ttcgtgttct cgcgggtgct ccggccaagc gggtcgcggg 36540
agcggccgcc acgagcggac cgtcgtcgc ccagcggctg gcggcactgc ccgccgcgga 36600
ccgggagccg ttcctgctgg atctgggtgcg ctgcacgcc gcggccgcgc tcggccacgc 36660
gtcggtcgcc aaggtcggcc cggagctggc ctccgcgac ctcggcttcg actcgtgac 36720
cgcggtcgag ctgcgcaacc ggctcggcgc ggcgaccggg ctgcggctgc cgtccacgct 36780
ggcttctgat cagccgagcc cggccgcgct cgcgggcac ctgctggcgg aactgggcga 36840
accggccggc gccgaaccgc aggtggcggt gctggcagac ctgcaccggc tggagaccgc 36900

actggccgcg gcggtcaccg acgacgagac cgcggaccgg atcaccgacc ggctgcgcgc 36960
 ggtgctcgcc cgggtgaccg aggcccgcgg cccggccgag gacgaggggtg acggcgatct 37020
 ggccgacgcc agcgcgcgacg agctgttcga catcttgac aaggaattcg gaaggctcgtg 37080
 acccgtgtcg ggcgatgaga aactgctgga gaacctgaag tgggcgaccg gcgagctgcg 37140
 gcgcgcgcgg cgcaggctgg tcgagttgga ggaggccggg caccgagcca tcgccgtcgt 37200
 cgggatgagc tgccgcttcc ccggcgggggt ccgctcgccc gaacagctgt gggacctggt 37260
 cgccctccggg accgacgcgc tgctcggagtt ccccggtgac cggggctggg atctgggtgg 37320
 gctcttcgac ccggaccccc acacccccggg caagacctac gtctccgaag gcggattcct 37380
 ctacgaagcc ggggatttcg acgccgcgtt ctccgggac tcgccgcgtg agggccaggc 37440
 gatggatccg cagcagcggc tgctgctcga agcggcgtgg gaggtgctcg aacgcgccgg 37500
 gatcgacccg gccaccctgc gcggcagccg gaccggcgtc tcgccggcg tcatccacaa 37560
 cgactacacc ggcgtgctca ccgacatccc gccggagctg gagccctatc tcggcaacgg 37620
 gaacttcagc agcgtcgctt ccggccggat cgctacacc ctccggcctcg agggccccgc 37680
 ggtctcggtc gatacggcgt gctcgtcttc gctggtcgcg ctgcatctcg ccgcgcagtc 37740
 ttacgtcgc gaggaatgca cgctcgccct cgtcggcggg gtgaacgtga tgacccatcc 37800
 cgccgcgttc gtcgacttca gccgtcagcg cggactggcc gccgacggcc gctgcaaggc 37860
 ctccgccgac gcggccgacg gcaccgggtg gggcgaaggc gtcggaatgc tgctggtcga 37920
 acggctttcc gacgcccagc gcaacggaca ccaggctctc gcggtgctgc ggggcagcgc 37980
 catcaaccag gacggcgcgt cgaacgggct caccgcgccg aacggtcccg ctcagcagcg 38040
 ggtcatccgc caggcactcg ccgacgccag gctctcgccg gggcagggtg acgtcgtcga 38100
 gggacacggc accggcacca ccctcggcga cccgatcgag gcgcaggcgc tgctggcgac 38160
 ctacggccag gaccgggaac gcccgctgct gctgggttcc ctcaaatacga acatcgggca 38220
 tacgcaggcc gccgcccggg tcggcgggggt gatcaagatg gtgcaggcca tccggcacgg 38280
 gatcgccgcg cgcacgctgc acgtcgacgc tccctcgtcg catgtggact ggtcggcggg 38340
 cgaggctctg ctgctgaccg gggaacagcc gtggccggag accggggaac cgcgccgagc 38400
 cggggtgtcg tcgttcggga tcagcggtag caacgcgcac gtgatcctgg agcaagcgcc 38460
 ggccgtcgag gtcgagtccc ttgtggacac tcgggtgctc gactccgcgg tcttgccgtt 38520
 cgtgctttcc ggccgcagtg aagaggcttt ggccgcccag gcgtcgaagc tcgccgcgta 38580
 tctgactggc gagccccgcgc ccaaggccat cgcgcgagcc ctccgccaga cgcggtcggc 38640
 gttgccgcat cgggcggctg tgctcgccga agacctcggc gaactgctcg gcggcttgcg 38700
 tccctcgcc gagggcgaac ccgccgcgcg ggtcctgacc ggtaccgccg aggcgggtaa 38760

ggccgtcttc gtgttcccgg gtcaggggttc gcagtgggtg gggatggcgg aggagttggt 38820
 gttgtcggct ccggtgttcg cggagtcgat ggctgagtgt gagcgcgcgc tttcatcctt 38880
 tgtggattgg aagttgtcgg atgtgttgtc ggatgcggct gcgttgagac gggttgatgt 38940
 ggtgcagcct gttttgttcg cggatgatgg gtcgttggcg cggttgtggc gggcgtgtgg 39000
 ggttgagcct gctgcgggtg tgggtcattc gcaggggtgag atcgcggcgg cgtgtgtggc 39060
 tgggtgcgttgc tcgttggtatg atgctgcgcg gttggtgtgc ctgcggagta aggcgatttt 39120
 ggcgttgtcg ggtcgtgggtg gcatgggtgtc ggtggctgct tcggaggatc gtgttcggga 39180
 gttgctgcct gccggtgtgt cgggtggcagc cgtgaacggc ccgtcggcgg tgggtggtgtc 39240
 cggatgatgtc gcgggcttgg aggcgttgct caagcgggtg gagctgctgg acgtgcgggc 39300
 gaagcggatc ccggtggact atgcctcgca ttcggcgcac gtggatgcga tcgagcagga 39360
 ggtcttgtcg gcgctggcgg gatatctacc gcaggcgcgg gtgatcccggt tttattcgac 39420
 ggtgaccgat gagcctctgg aattggatgc ggcgtactgg ttccggaatc tgcgggggac 39480
 ggtgcgggttc gcggcgacgg tggatcgggt gctggaggac ggtttccgggt ttttcgtgga 39540
 ggcgagtccg catccggtgc tggttccggg gatcagtga gaagccatcg cgttggggag 39600
 tttgcgtcgg ggtgaggggtg gtgcggagcg gttcgtcgcg tcgctggccg aagcccacac 39660
 gcagggcctg agcccctcgt ggtccgcccgt gctgccgccc gccgaacggg tcgacctgcc 39720
 gacgtatgcc ttccagcaca agcggttctg gctcgaagcg ggcaccgcga gcggggacgc 39780
 gtcggcggttc gggcagacgg tggtcgacca cccgctgctc ggcgcgcgcc tgccgctcgc 39840
 ggacggcgac ggcctcgtcc tcaccggccg gatctcgccg gacacgcagc cctggctcgt 39900
 cgaccacacc gtccctggaca ccgtgctcct gccggggacg gcgttcgtcg agctcgtcct 39960
 gcgcgctggg cgggaggcag gctgcgacgg cgtcgacgaa ctgaccttgg aagcgccgct 40020
 cgtccctcgac gggcccgtgg cgctgcaggt cgtgctcggg gagcccagcg agcgcggccg 40080
 tcgtgccgtg tcggtgcact cacggccgga ggattccgac gaaccctgga cccgcaacgc 40140
 tcagggcacg ctgtccgcgg gcaccccatc gacggtttcg ctgcgccagt ggccgccacc 40200
 cggcgccgcc gaagcgccgg agtccgatct ctacgaccgt ttcgccgagc tcggcctcgc 40260
 ctacgggtccg gtgttccagg gactgcgcgc ggcgtggcgc cagggcgacg acgtgttcgc 40320
 cgaggtcgac ctgcccaggg aggaggaggc ggaccgcttc ggcgtgcacc ccgccctgct 40380
 cgacgcggcc ctgcacaccc tcgggctcgg ggcccaggac gagaccgtgc ggctgccgtt 40440
 cacctggtcc ggtgtgaccc tccacgccac gggcgcgctc aaactccggg tccggctcac 40500
 gccgaccgcc gacggcggct cgctcacctg ggccgacgag accggcgccc cggtgctgac 40560

cgtcggggaa ctgggggctgc gcccgatctc cccggcccag ctggggccgcc accgggattc 40620
 gctgttccgg ctcgactggg tccccgctcc tgtggggccg gcgccggaag agccgggggt 40680
 gtggcgctgc cccgaaggcg aactgcggcc ggtcctggaa gaggtcctga agcggatcca 40740
 ggccgattcg acggccacga ccgtcgtgct cacctcgggt gcggtggcga gcgcgtcgcc 40800
 ggatccggtg gcggccgcgg tctgggggtct cgtgcggtcg gccagggccg agcatccggg 40860
 ccggttcgtg ctgatcgacg cgcggaccga ggacgaggtc cgcaccgcgc tggcgaccgg 40920
 ggaagcgcag gtcgccgtcc acgacggcaa accgctggta ccccggtctg cgcgggtggc 40980
 ggccgccgac gcgggcgaac cggactggac gcccgacgac gtcgtcctga tcaccggtgg 41040
 caccggacgg ctcgggcagg cgctggcccg gcacctcgcc gtccggcacg gcgtgcgcgg 41100
 actggtgctg accgggcgga cgggcggggg cgcggaagac ctggtcgcgg acctggcgga 41160
 actgggcacc caggtcaccg tcgcggcctg cgacgtcgcg gatccggacg cgggtgcgcgc 41220
 actgctggcc gcccatccgg tgaccgcggt ggtgcacgcc gcggccgtgc tcgacgacgg 41280
 gctcgtcgac ggtctgacct cggaccggct cggcaccgtg ctggccccga aggccgacgg 41340
 cgcccgcgtg ctgcacgaac tcgccggacc ggtccgccgg ttcgtcacgt tctcctcggc 41400
 ggccggcgtg ttcggcaacc cggggcaagc gggctacgcc gcggcgaacg cctacgccga 41460
 cgctctcatg ctccggcgtc gtgccgaggg gctgcccgga gtgtccctcg cctggggatt 41520
 ctgggcggaa cgcagcaagc tgaccggcga cctcgacgac accgacgtcc gccggatggc 41580
 ccgcgcgggt gtcaccgcgt tgtccacgga ggaaggcctg gcgctgttcg acgccgccgt 41640
 ggccggaggg gacggcctgc tcgtccccgc caagatcgac ctgaccgcct tccggggccg 41700
 cccggccgcc gagatccccg ctctgctgcg cggcctgggt cgcgtccccg cgcgacggtc 41760
 gggggaggcg tcgggcacgg ccgaggcact gaaacgcgac cttgccggga agccggaggc 41820
 cgaacgcgtc cggctgctgg aggaggtcgt gcggatccgg gtggcggccg tgctcgggca 41880
 cgagtcggcc gacgcgatcg ccggggaccg cggattcctc gaactgggct tcgactcgct 41940
 gaccgcggtg gaattgcgca accggctcgc cgaggcgacc ggactgcggt tgccgcccac 42000
 gctcgtcttc gaccggccca acgccggagc gctcgcggcc tacctggcgg ccgaactggc 42060
 caccgagacc gccggaccgg ccctcgacgc cgaactcgac cggttcgccg ccgcgctgac 42120
 cgcggccgac cccggagagg ccgaacgggc ccggctggcc gcccggtgc gggcccttct 42180
 cggcacgctc caaggcgggg aagaccggc cggggaaatc gacggaaaac tcgaatcggc 42240
 ggacgacgag gaaatgttcg cttcatcga caatgtgctt aagccttctt gagtggttaag 42300
 aatggtttcg gcatgggggt cccgggtggt gcgaaagcca ctttcgcaac cttcaacgtt 42360
 gcgaaagtgg ctttcgcaac acccccccg cgggtggctcg accgaacgca cgtgggctga 42420

```

aggctccctt caccgcgtct gatgcggcga aaggagcctt caccgccggc ggatacggtc 42480
tcgaaagcgc ccctggtcgt cgcctattcc ctaaggggac gtaggggcgg ctaggggttg 42540
tccgtctctt cgcagctcac ctagcttttc ttcgagtggc atttcgtttt tcccggcgcg 42600
aagaggttgg ctactgatgc tgaacgagga gaagctgcgc gactacctca agcgggtgtc 42660
ggccgacctg catcggaccc gggcccggct gcgggaggcc gaggcgcggg agcacgagcc 42720
gatcgcgatc atcgggatgg cctgccggta cccgggcggc gtccgcggtc cggagcagtt 42780
gtgggatctc gtggccgcgg gcaccgacgc ggtcggcggg tccccgccg accggggctg 42840
ggatgtcgag gccctctacg accccgaccc cgcgcggcac ggcaagacct acacgcgcga 42900
gggcggtttc ctctacgacg cccacgagtt cgacgccgcg ttcttcggca tcagcccgcg 42960
cgaggcgctc accgtcgacc cgcagcagcg cctcctgctg gagaccgctt gggaggcctt 43020
cgaacgcgcc gggatcgacc cgctttccgt gcgcggcagc cggaccggcg tgttcgccgg 43080
ggtgatgtac aacgactacg gctccaggct cgacccccgc gccgaggaac tgcgcgagtt 43140
cgagggatac ctccggcaacg gcagcgccgg gagcgtcgcc tccggccggg tcgcctacac 43200
cttcggcctc gaaggcccgg ccgtcaccat cgacaccgcg tgttcgtctt cgctggtcgc 43260
gctacacctc gctgccgagt cgctccggcg cggggagtcc acgctcgcgc tggcgggcgg 43320
ggtgaccgtg atggcctcgc cggagacctt cgtggagtcc agccgtcagc gcgggatggc 43380
gcccgaacggc cgctgcaaac ctttcgccga cgcggccgac ggcaccggct gggccgaggg 43440
cgccgggatc ctgctgctcg aacggctttc cgacgcccggt cgccacgggc atcccgtcct 43500
cgccgtggtg cgccggcaccg cgggtcaacca ggacggcgcg agcagcgggc tcaccgcgcc 43560
gaacggccccg tcgcagcagc gggatgatccg gcaggcgctc gacagcgccg gcctcgcgcc 43620
gcaccaggtc gacgtcgtcg aggcacacgg cacggggacg accctgggcg acccgatcga 43680
ggcacaggcc ctgctcgccg cgtacggaca ggagcgcgtc cgtccactgt ggctcggttc 43740
gctgaagtcg aacgtcgggc acagccaggc tgccgccggg gtcggcgggc tgatcaagat 43800
ggtccaggcg atccggcacg ggatcgcccc gatgaccctg cacgtcgaca ccccgacgtc 43860
caaagtggac tgggaagcgg gttcggtcga actgctcacc gaagcccgc cttggccgga 43920
gaccggggaa ccgcgccgcg ccgggatctc ttcgttcggg gtcagcggca ccaacgcga 43980
cgtcacgtc gaacaagcgc cggaggtcga gcccgccgaa cgcgacggcg aatcaccgct 44040
cggcgacgag gtgacgccgc tggtcctgtc cgcccggagc gccgaggctc tgcgcgcga 44100
gtccgcccg ctgcgtgagc accttcgcca gacggaatcc ttgaccgaca ccgccttctc 44160
gctcgcgacg tcccgtgccg cgctggagca ccgcgccgtc gtcgtggccg aagcggacgc 44220

```

gtcgctcgac gccttggccg ccggcgccgc tgccggcaggg ctggtcgaag gtatcgcttt 44280
 gccaccgggc aaggctcgct tcgtctttcc cgggcagggc tcgcaatggg ccgggatggc 44340
 actggagctc aaggactcct cgccggtctt ccgggcccgc ctgctcgact gcgaacgcgc 44400
 tctctcgctc tttgtggact ggaagctcac cgacgtgctc ggcgacgcga cggcgctgga 44460
 gcgcgtcgac gtcgtgcagc ccgcctctt cgcggtcaac gtgtcgctgg cggcgctgtg 44520
 gcgggcgctg ggggtcgaac ccgacgcggt gaccgggcac agtcaggggtg agatcgccgc 44580
 cgcgtaactg tccggcgctg tgctcgctgg cgacgccgc aaggctcgctg ccttgccggc 44640
 caaggccatc ctgcgccttt ccggcgccgc gggcatggtc gcggtcgccc tcggccgcga 44700
 cgacgtgctc cctcggtga cggagtgggg cgaccggatc gccgtggccg cgggtcaacgg 44760
 acccgcgctg gtcgtggtct ccggagaccc agaggcgctc gacgggctcg tctccgcctg 44820
 cgaggcggac ggcgtgctg cccgccggat ccgggtggac tacgcctcgc attcgccgca 44880
 ggtggacgtc ttgcgtgagg aactgctcg cctgctcgac ggcgtcgagc accacgcgtc 44940
 cacggtgccg ttctactcgg cggtgaccgg ggaacccctc gacacggcgg gcctgacccc 45000
 ggagtactgg ttccggaacc tgccggccac cgtccggttc gaccggctccg tccggcggt 45060
 gctcgacgac ggtcaccggt tcttcgtcga agccagcgcg catccggtgc tgaccggcag 45120
 cgtcaccgaa accatcgagg aacggggcgc ccacgcggtc gcgctcggtt cgcttcgccg 45180
 tgacgagggc gggcccccgc ggttcctgac gtcgctggcc gaggtcacg tacgcggcct 45240
 ccgcccggat tgggcccgcg tgtggccac tgccaccagg gtcgacctgc ccacctatgc 45300
 ctccagcgg gtgcgctact ggctcgacgc cgccgtcgtc cggcagggcg gcacggcggc 45360
 cgaactgcgc ttctggggcg ctgtcgacca ggccgacacc ggcgcgctcg acgccgccgt 45420
 gcccgccggg gagggagcct gggacgcggt gcttcccgcg ctttcggcct ggcgccgttc 45480
 cggctctcgac aagtcacag tggacaactg gcggtaccgg atcgactggg tccccgcgac 45540
 cgggacggca gcggccaccc tcgacgggac gtggctgctg gtcgtcccgt ccggaccgat 45600
 gccgcccgtc gcggaggcgc tcacccggct cggcgcccgt gtcttgctcg cgggccccga 45660
 tgacgaactg ccgcacgagc cggtcgacgg cgtgctttcc ctgctggcac tcgacgaacg 45720
 gccgcatccg gaacacccgg tggtagccgc cgggctcgcc gcgaccgcgg acctcgctccg 45780
 ccagctcgcc gacctcgacg ctccactgtg gatcgtcacc tccggcgcgg tcgcccgtcg 45840
 ccggctcggag accccgaacg cgcaggccgc cgtctggggg ctccggccggg cgatcggact 45900
 cgaacacccc gaacgctggg gcggcctcgt cgaccttcg gaggaactcg acgaacgcgc 45960
 cgcgggcccg ctccggggg tgctcgccac cggtcacgag gaccaggtcg ccgtccggtc 46020
 gtccgggggtc tatctgcggc ggctcgtgcg ggcgccgctc ggggacgccg tcgcccggga 46080

atggcgggccc cgtgggaccg tcctgggtcac cggcggcacc ggtgcggtgg ccgcccacgt 46140
 cgcgcggtgg ctcgccggga acggcgccgg gcatctggtg ctcaccagca ggcgcggggc 46200
 ggcggccgag ggtgcgggcg aattgagtga cgaactcgcc ggtctcggtg cgcggggtgac 46260
 ctctcgccgcc tgcgacgtcg ccgatcgtga cgcactggcg gcggtgctgg ccgagtatcc 46320
 gccgaacgcc gtcgtgcaca cggcgggggt cggggccacc gcgtcgctcg ccgagaccgg 46380
 cccggcgga ctcgcccagc cgctcgccgc caaggcgggc ggtgccgctc acctcgacga 46440
 acttctcgaa ggcgccgaac tggacgcctt cgtgctcttt tcctccaacg cgggtgtctg 46500
 gggcgggcgcc gggcaggggt cctacgggtg cgcgaaacgt gccctggacg cgctcgccga 46560
 acgacgtcgt gcccgggggc tgcccggcac ctcggtggcg tgggggctgt ggggcggcgg 46620
 cagcgggctg gccggccagg acgacgtcga ccgcttgccg cgtctcggtat tggccgcgat 46680
 ggacccggcg ctcgccgtgt ccgcgctcgt ccaagccgtc tcgcacgacg agaccttcgt 46740
 cgcggtcgcc gacgtcgact gggcgcggtt cgctcccga ttcgccctcg cccggccccg 46800
 gccgctgctc gacgcgttgc ccgaggtccg cgaggcgctg tccgccgaca ccgcgggacc 46860
 gggcggtcc gaattcgccg ccggactgct ggccgcccc gaggcggacc ggaccgtat 46920
 cgtgctcgac ctggttcgcg cgcaggcagc cgcggtcctc ggccacgggtg gcgccgccgc 46980
 cgtcgagccg gaccgcgcct tccgcgacct cggcttcgac tccctgaccg cggtcgaggt 47040
 ccgcgaccgg ctggccgccc ccaccgggct gcggctgccc gcgaccctgg tcttcgacca 47100
 tccgtcggcc tcggcgcttg ccgggcatct cgtcgccgaa ctcaccggcg acgtcaccgg 47160
 gacacaagcc gcgccggccg tgggtggtgac cgacgacgag ccgatcgca tcgtcgcgat 47220
 gagctgccgg tttcccggcg ggatcacgga tccggagaag ttctgggact tcgtcgcgga 47280
 cggcggggac gcgatggccg ctttccccgg cgaccgcggc tgggacctcg acgcgctcta 47340
 cgacccggac cccgcgcacc tcggcaccac gtacgcccgt gaaggcggct tcctcgacga 47400
 cgcgggcggt ttcgacgcgg cgttcttcgg gatctcgccg cgtgaggcgc tggcgatgga 47460
 tccgcagcag cggttgctgc tggagacgtc gtgggaggcg ttcgaacggg ccgggatcga 47520
 cccggcgacc ctgcggggga gcgcgaccgg cgtcttcgtc ggcgcatcct tccagaacta 47580
 cggcctggac gccgtcgacg cgcccgaagg caccgagggc tacttcctca ccggaaccgc 47640
 caccgcggtc gtctccggcc gcctctccta caccttcggg ctggaaggcc cggcggtgac 47700
 gatcgacacc gcgtgctcgt ctctcgtggt ggcactgcat ctgcggcgcc aggcgctgcg 47760
 gcgcggcgaa tggtcgctgg cgctggcggg cggggtgacc gtgatggcca acccggccgc 47820
 gtctcgtggag ttcagccgtc agcgcgggct cgcgccggac gggcgttgca aggcgttcgc 47880

cgacgcccgc gacggcaccg cgtgggtccga ggggtgccggg atccttcttg tggaaaggct 47940
 ttccgacgcg cgcgcctcg ggcaccccg cctggcgctg gtgcgcggtt cggccgtgaa 48000
 ccaggacggc gcctcgaacg ggctgagcgc gccgaacggg ccgtcacagc agaggggtgat 48060
 ccgccaggcg ctggcgaacg ccgggttcgc accgtccgat gtggacgccg tcgaggcgca 48120
 cggcaccgga accagcctcg gcgacccgat cgaggcacag gccttgctcg ccgcttacgg 48180
 cggggaacgc gagcatccgc tgtgggtcgg ttcggtcaag tcgaacctgg ggcacacaca 48240
 gtcggcgctcg ggtgtggcgg gcgtgatcaa gatggtgcag gcgatccggc acggtgtcct 48300
 gccgcggacc ctgcacgtcg acgcgccgac cacggaggtg gactggacgg cgggtgatgt 48360
 ccggctgctc accgaaccgg tggactggcc ggacaccgga cgtccgcgcc gggcgggct 48420
 ctctctttc ggggtcagcg ggaccaacgt gcacacgctg atcgaagagg tcccggagag 48480
 cgctgcgcct cccgccggcg gggacacgtg ggtgccgtgg gtgctctcgg ccaagaccga 48540
 ggaagcggtg cgggtcccaag cttcccggct gcacgcgcaa ctggaagagc accccgggga 48600
 cgactccgac atcgcgtaca cgctggcgac cgcccgtgcg ggactggaga tccgggccgc 48660
 ggtgaccggg ccggtatcgtc tgcgcgagct ggccctctc gccgagggga cgcgagcgc 48720
 ggcggtgctg cgcggcgcg caccgccgg ggcgccggg ttctgttca ccggtcaggg 48780
 cagccagaaa cccgggatgg gcgccgaact cgcggcccgc tcccgggtgt tcgccgccgc 48840
 gttcgacgag gtgtgcgccc atctggaccc gcgcctcggg ctgtcgtgc gcgaagtcct 48900
 cgaaaccgag cgagtgcacg aaacggcggt cgcgccagtgt gccctgttcg ccgtcgaggt 48960
 cgcgctgttc cggctgctgg agagctgggg tgtccggccc gcgctgctgc tcgggcattc 49020
 ggtcggcgag atcgcggccg cgcacgtcgc cggggtcctg tcgctcgcgg acgcggccac 49080
 gatggtcgag gcgcgcggaa ggctcatggg cgccctgccg tctcgcggcg tgatgatcgc 49140
 cttgcaggcc aatgaagacg aggtgacccc gctgccacc gagcgcgtgt cgatcgccgc 49200
 cgtcaacggc ccggaagcgg tgggtgctgtc cggggacgag gacgccgtta ccgcagtgg 49260
 ggaccgggtc gccgaccgca agagcaagcg gctcgtggtc agtcacgcgt tccactcgcc 49320
 gctgatggaa ccgatgctcg cggacttccg ccgtgtcgtg tccgggcttt ccttcagcga 49380
 gccgaggatc ccgatcgtgt cgacggtgac cggccgctcc gatcccga aa tcgcctcacc 49440
 cggctactgg gtgcggcacg tccgcgaggc ggtgcgggtc cacgacgcga tccggttcgc 49500
 cgaggccgag gccgagggcg tgcgcgcctt cgtcgaactc ggccccgagg gcgtcctttc 49560
 cgccatggcc aaggacttcc tcgaagacac cgtgctgatc ccgaccctgc gcggggaacg 49620
 tccggaggtc gccgcgctgg cgaccacact cggccgcctg cacgtccacg gtgtcgggat 49680
 cgactgggcg ggtgtgttcg acggcgctca ggcgagccgg gtcacgctgc ccacgtatcc 49740

cttcgagcat	cggcacttct	ggctggcgag	caccggcgcg	accacgggcg	acgcggccgc	49800
gttcgggctc	ggcgaggccg	ggcacgcgct	gctcggcgcg	gccgtcccgg	tgcccggcgg	49860
gagcgggata	tcgttcaccg	gaaggctctc	cctgcgggct	cagccgtggc	tcgcggagca	49920
cgtcgtgctc	ggtagggctc	tgcttcccgg	caccgcgttc	gtcgatctcg	cgttgcacgc	49980
gggtgaccgc	gccggctgcg	gaaccgtcgc	cgagctgacc	ttggaagctc	cgctggcgct	50040
gccggaaagt	ggtgacgtcc	ggctgcacgt	caccgtcggc	gagccagggg	aggacggcgg	50100
gcgcacgata	gagatccatt	cccgtgcggg	atccgccgcc	gacgaggaac	cgtggacgcg	50160
gcacgccacc	ggcctcctgg	ccaccggaac	cccggccgcc	agcgggaacc	tggacagctg	50220
gccaccggac	ggcaccgaga	tcccggtcga	ggacttctat	gaccggctcg	acggcaccgg	50280
gttcgagtac	gggccgttgt	tccagggcct	gcgcgcggcg	tggaaggccg	gggacgacgt	50340
ctacgcggag	gtttcgctgc	ccgaggaccg	ctcccgtgac	gccgaaggct	tcggcgctcca	50400
ccccgcgctg	ctggacgccg	cgctgcacgc	gtcgaagctc	cggctggagg	gtgacagcga	50460
gggacctttc	ctaccgttca	cgtggaaggg	tgtctcgctg	gccgcgaccg	gtgcgcggac	50520
gttgcggggtg	cggctgtcct	cgtccgctcc	ggccacgata	tcgctgctgc	tcgccgacgg	50580
tgaaggcgcc	ccggtggcca	ctgtggattc	cctggtgttc	cgccgggttt	cgtccgagca	50640
gctcggaaac	cggcagggga	gcggatcgct	gttccacgtc	gagtggaccg	acgtgcctgc	50700
cgaggaagtg	tccacagagg	atgtcaggat	cggcgccgga	gagtcctatg	tggacgtcgc	50760
ggcactgctc	gccgccaaga	cgcccgaagt	cgcgctgctg	gtctgcccgt	ccggggagac	50820
cgccgaggcg	gtgcacgacg	cgaccgtgtg	ggcgctgcgc	caggtgcggg	actggctcgc	50880
cgacgagcgg	ctggacgcgc	accggctcgt	cctgctgacc	gacggcaccg	acctggccca	50940
ggccgcggtg	cggggactgt	tccggtcggc	ctcgtccgaa	caccccggcc	ggttcggcat	51000
cgccgagacc	accggggata	cggctccgggt	gtcggccgac	gagtccgaac	ttcggctgga	51060
gaacggtgtc	gcgtacgcgc	cgaggctggg	ccgcaagata	gccgcggccg	ctccggtcgc	51120
gctcgatccc	ggcaagacgg	tgctggtcac	cgggtggtacg	ggcgcgctcg	gcgcgctggg	51180
ggcccggcat	ctggtgaccg	cacgcggcgt	gacccggctg	ctgctggtct	cccgctcgtg	51240
gctggaggcc	gaaggcgcca	aggacctggg	ggcggacctg	acggccgcgg	gcgccgacgt	51300
caccgtcgag	gcctgcgacg	tcgccgaccg	cgtgcgctg	gaagcggccc	tcgccgggca	51360
cgagctgacc	gccgtcgtgc	acacggcccg	cgtgctcgac	gacggtctgg	tcgattcgct	51420
gacgccggag	cggctggcga	aggtgctgcg	gccgaaggtc	gacgcggcgc	tgaacctcca	51480
cgagctcgcg	ggtgacgtcg	aggaattcgt	gctgttctcc	tcggcgctcg	ccacgttcgg	51540

caatcccggg caggcgaact acgcggcggc caacgcgttc ctcgacgcgc tcgcccgccca 51600
 ccgccacgca caagggcttc cggccacgtc gctcgccctgg ggactgtggg cgaccgacgg 51660
 cggcatgacg ggcgaactga gcgacaccga cctggccagg atgggcccga ccggtatcgc 51720
 cgcgctgacc ccggaagccg ggctcgccct gttcgacgcg gcgtccggcg ccgggcccgt 51780
 ggtgctgccg atggcgctga cgccatcctc gctccgcgat gtggaacccg cggtgctgcc 51840
 cccgttgctg cggggactgg tgcgggctcc gtcccggcgc gccgcgtccg ctcccgccgg 51900
 tccggcgctg caggacaggc ttccgggcct gaccggcgcg gaacgcgacg acgcggtgct 51960
 ggaggtgggt cgcgagcagg tcgcggccgc gctcggtcac gcgggcccgg gggcgatcga 52020
 tccgggcaag ggcttcgtcg aactcgggat ggattcgctc agcgcggtcg aactgcgcaa 52080
 ccagctgtgc gcgctgagcg ggctgaaact ctcgacgacg gtggtgttcg accaccccaa 52140
 cccggccgcg ctcgccgggc acctcgcggc cgaactgcc gccgaagggg tggccaccac 52200
 cgcgtcgggt cacgccgggc tcgaccggct cgaagcgctg ctggccaccg ccgccccggc 52260
 gaacggggat cgcgccgggg tcaccgcgcg cctgcgcacg ctgctggcga cgtggaccgg 52320
 cgagcccgcc gccgaggccg acgactcgct ggagtcggcc accgcggacg aactgttcga 52380
 cctgctcgat cacgaactcg gcgcgtcctg acccgccctga tactgggaga cccttcctgt 52440
 gcgaacgaag acaagtacct cgactacctc aagcgcgcga ccgccgacct gcgggagacc 52500
 cggcgacggc tgaaggaggc cgaggaccgc ggccacgagc cgatcgccat catcgggatg 52560
 gcctgccggg tccccggcgg cgtgcggtcg ccggaggatc tgtgggagct ggtcgccgag 52620
 ggccgcgacg ggatctccgg gttccccgcc gaccgcggct gggacctgtc cgcgctgtac 52680
 gacccgacgg gggagaagcc cggcacctcg tactgccgcg agggcggttt cctggacggc 52740
 gcgggcgaat tcgaccgggc cttcttcggg atctcgccga gggaaagcgt cgccatggac 52800
 ccccagcagc ggctgctgct ggagatctcc tgggagacct tcgagcgcgc gggcatcgac 52860
 cccggctccc tgcggggcag ccggaccggg gtgttcgccg gggatgatga ccacgactac 52920
 gtctcccggc tcgccgccat cccggaggaa ctcgagggtc acctcggcac cgggaactcg 52980
 ggcagcgtcg ttccggggcg ggtcgccctac acgttcgggc tggaaaggccc ggcggtgacg 53040
 atcgacaccg cttgctcgtc ctcactcgtc gcgctgcac tcgcagcgca ggcgctgcgg 53100
 cagggcgaat gctcgatggc gctcgccggc ggtgtcgcg tgatgtccac accggacacg 53160
 ttcgtcgact tcagccgtca gcgcgggctc gccgcggacg gccgctgcaa gtcctattcg 53220
 gacggagcgg acggcacgtc gtgggcccag ggcgtcggga tgctcctggg ggagaagctc 53280
 tccgacgcgc ggcggctcgg ccacgaagtg ctcgcgggtc tcagcggcag cgcggtcaac 53340
 caggacgggg cgagcagcgg gctcagcgtg ccgaacggcc cgtcacagca gcgggtcatc 53400

cggcaggccc tggagaacgc gcggctctcg gccggacaga tcgacgtcgt ggagggccac 53460
 ggcaccggga ccaccctggg cgacccgatc gaggcgcagg cgctgctcgc cacctacggc 53520
 cgggagaaat ccgcggaccg gccgttgttg ctgggctcgc tgaagtcgaa catcgggcac 53580
 tcccagtcg cgcgggggt cggcggcgtg atcaagatgg tgcaggcgat ccggcacggg 53640
 atcttgccgc gtaccctgca cgcgaggac ccgtcgtcca aagtggactg gtcggccggt 53700
 gccgtcgaac tgctcaccga agcacgcggg tggccggaga ccgggcagcc gcgccgcgcg 53760
 ggcgtgtcct cgttcggcgt cagcggcacc aacgcgcaca ccatcatcga gcaagcccc 53820
 gagagcgaag agtccccggc cgtgccaccc accggcgccg tgcccgcggt gttgtctggc 53880
 aagaccgccg aggcgctgcg cgaccaggtc gtgcggctgc gctcgacat cctcgcccgg 53940
 ccggagctga gcgtcgccga cgtcgccgcg tcgctcgcca ccaccgcgt cctgcacgag 54000
 caccggggcg cgatcgtcgc ggccgaccgc gaccagctgc tcgcggggct ggacatcctc 54060
 gccgccggcg ccacgaccgc cggggtctct caaggtgtcg ccaccgacgg ccggacggcg 54120
 ttctgttca ccggccaggg cagccagcgc cgcgggatgg ggcgggaact ggccgagcgt 54180
 ttcccgggtg tcgccgaggc cttcgacgac gtctgtgcc ccggtcgaac gccgatcaag 54240
 gaactgtcca ccgaggaact gaaccagacg gcgaacacgc agtgccgcgt cttcgccttc 54300
 gaggtggcgc tggtccggct ggtcgaaagc tggggcgtgc ggctgactt cctggcgggg 54360
 cactcgatcg gcgagatcg gccagctcat gtcgcaggtg tggtcaacct cgatgacgcc 54420
 gtgaagctgg tcgcggcgcg aggccggtt atgcaggcgt tgcccaccgg cggcgcgatg 54480
 gtggccttgc aggcgacgga ggccgaggtc ttcccgttgc tgacggaccg ggtgtcgctg 54540
 gccgcgatca acggcccgga gtcggtggtc ctctccggcg acgaagacgc cgtcgccgct 54600
 gtggtgtccc gcttcgaggg ccgtaagcac aaacggctcg ccgtgagtca cgcgttccac 54660
 tcgccgctga tggagccgat gctcgacgac ttccgcgcgg tcgcggacag tctctcgat 54720
 gcggcgccac ggatcccgat cgtgtccggc ggtctggcgg atgtgtccac ttcggactac 54780
 tgggtccgcc atgtccgtga cgcggtgcgg ttccacgatt cggtcgaagt cctggaaacc 54840
 gaaggggtca ccgcttctt ggagatcggg ccggacgccg tcctcaccgc gatggcccag 54900
 gaaagcaccg agggcgcggt cgtcgtcgcg gcctcgcgcc gcaaccgcgc ggaggacgtc 54960
 accctgctcg ccgcggtctc cacgctgcac gtccacgggg cgtccgtcga ctggacgccg 55020
 ctgctcgccg gagcccgccg cgtcgacctg cccacgtacg ccttcagca ccgccgtttc 55080
 tggctggacg gcccgctgaa cgcggagggt gacgcggcga gcctgggcct gggcgccacc 55140
 gatcaccgc tgctcggcgc cgtcgtcacg atggccgacg cgcacggcgt cctgctcacc 55200

gggcggcttt ccctcgcggc gcagccgtgg ctggccgggc acgtggtcgc ggggcacgtc 55260
 ctgctgccgg gcaccgcctt cgtcgacctc gtctgcacg ccggggacaa ggtcgactgc 55320
 gggatcgtgg aggaactgac cctgcgggaa cccctcgctc tgcccgaaca cgacgccctc 55380
 agcctgcaac tcgtcgtcgg cgcgccggac gagaccggca ggcgcacggc cggcgctccac 55440
 tcccgccccg aggccgccga cgcagaatgg tcgtgccacg cgaccgggtg cctcgcccc 55500
 ggtttccccg acaccgactt cagcctcgcc gcctggcctc ccgaaggcgc cgcgccggtc 55560
 gcgatcgacg gcctctacgg cgcgctcgcg gaggtcggcc tcgactatgg gcccgccctc 55620
 cagtgcgtgc gcgccgcctg gaccacgat tcggccgtct acgccgaaat cgagctggcc 55680
 gacgccgaga aggccgacgc ggcccgggtc ggtatccatc cggccctgct cgactcggca 55740
 ctgcacgccg ccggtctcgg cgcgctggac gccaccgagg cgcgtcttcc gttctcgtgg 55800
 tccgggtgtga gcctgcgggc gtccggagcg acgacgatcc gcgtgcggct gaccccggcg 55860
 gggccggaca cgatcgcgct ggccgtcgcg gatccggagg gacggccggc gttcgccgcc 55920
 gacggcctcc tcgtccgcgc ggtcccgtcc ggtgccctca cctcgcgaaa cccgggtgcgc 55980
 gacgggttgt tccgggtgga ctggcagccg ctcaccatcc ccgccgaagc cgccgcggag 56040
 tacgtcgtcg cctcgttcac cgggtacacc ggcgacctgc tcggcgacgc ccacgcggcc 56100
 gcggtcgcgc cactcgaact ggtgcatgcc gacagcggcg gcccgaaact ggtcttcctg 56160
 accagcgggt ccgtcgggga cgccgtgccg cgtccggcgc aggccaccgt ctgggggtctc 56220
 gtccgcaccg cgcaggagga gttcccggac cggttcgtcc tcctcgacgc cgacaccgag 56280
 cccacgcccg aattcatcgc ggccgccgtc gccaccgggtg aacccgagct cctgctccgc 56340
 gaagggtgtc tgccgggtgc ccgtctcgtc cgcgccccgc gtgcctccgc cgagcccggc 56400
 gacatcgacg ggacgggtgt cgtcaccggc ggcaccggcg cgtcggcgc ggatctcgcc 56460
 cggcacctcg tccggtcgcg cgggtgtccg cggctgctgc tcaccagccg tcgcgggtgcg 56520
 gcggcaccag gcgcggacac cctcaccctg gagctgaccg cgtcggcgc cgaagtccgg 56580
 atcgaagcct gcgacgccgc cgaccgcgac gctctcgccg ccctgctggc cgatcagccg 56640
 atcaccctcg ccgtgcacgc cgcgggtgtc ctggacgacg gcctcatcgg tgacctgtcc 56700
 gcagaacgcc tcaccgccgt cttgaggtcc aaagtggacg ccgccgtgca tctgcacgaa 56760
 ctgctcggcg acaccgaact cgtcctgttc tcctccgccg ccggtgtgtt cggcaacgaa 56820
 gggcaggcga actacgccgc cgcgaacgcc ttctcgacg ccctcgcccg gcaccggcag 56880
 gcgaacggcc tgcccggcac ggcactggcc tgggggatgt gggcctccgg catgggtgac 56940
 gcgctcaccg ctgcgccggg ctttcccgcg ctgtccacag aagacggtat ggcgctcttc 57000
 gacgccgcga cggcgctcga cgacgccgca ctcgtcccga tccggctcga tctgcccgcg 57060

ttgcgagcgc ggctcggcgg tgacgtgccg cctctgttcc gcggcctgat ccggcccacc 57120
 cgccgtgccg ccgtcaccgg ttcggccggc gcgctcgccg accggctggc cgcgctcgcc 57180
 ccggccgaac ggagccggga actgctggag atcgtgcgga cgcacgtcgc catcgtgctg 57240
 gggcacctcg gttcggaggc gatcgacgcc gggaaacct tccaggagct cggcttcgac 57300
 tcgctggcgg cggtcgaact gcgcaaccgg ctgaccgagg tcaccggcct gcggctggcc 57360
 gcgacctcg tcttcgacta cccgaccccg ctctgtctcg ccgaacacct gctggaaggg 57420
 ctgcgccggg gcggactcgc cgagacgccg gacgcgccgg tgcgcaccgg tccggtcgac 57480
 gagccgatcg cgatcatcgg catggcttgc cgctaccgg gcggtgtcac ttctccggaa 57540
 gagctgtggg acctggtcgc cgccggccgg gacggggttt cggagtccc ggtcaaccgg 57600
 ggctgggaag acgtctacga cgccgacccc ggcaagggtg gcaagagtta cgcccgcgag 57660
 ggcggttcc tgcacgacgc gggcgaattc gacgcggcgt tcttcgggat ctgcgccgt 57720
 gaggcgctgg cgatggatcc gcagcagcgt ctgctgctgg agacgtcgtg ggaggtcttc 57780
 gaacgcgccg ggatcgatcc gcacgcggtg cggggcagca agaccggcgt ctgcgccggc 57840
 gtgatgtacc acgactacgc ggcacggctg aactccgtac cggaggacgt cgagggctac 57900
 ctcggcacgg ggaactcggg cagtgtgatc tcggggcggc tggcctacac gttcgggctg 57960
 gaaggccccg cggtcagcat cgacacggcc tgttcgtcgt cgctggtcgc gatgcacctc 58020
 gccggacagg cgctgcggca gggcgaatgt tcgctcgcgg tcgccggcgg cgtgaccgtg 58080
 atggcgacgc cgaacacctt catcgagttc agccgccagc gcgggatggc cactgatggc 58140
 cggtgcaaat ccttcgccga ggccgcggac ggcaccggct ggggcgaggg cgtcggcatg 58200
 ctctgctgg agcggctttc ggacgcccgc cgcaacggtc accgggtgct ggccgtgggtt 58260
 cgcggtcgg cggtaacca ggacggcgcg tcgaacgggc tgacggcgcc gaacgggccc 58320
 tcgcagcagc gggatgatcc tcaagccttg gcgcaggcgg ggttgcgctc gtccgatgtg 58380
 gacgccgtcg aggcgcacgg tacgggaacg aactcgggtg acccgatcga ggcacaggcc 58440
 ttgctcgcca cctatggcca ggatcgcgag gagccgttgt ggctggggtc ggtgaagtcg 58500
 aacctcgggc acacgcaggc cgccgccggc gtcgcggggc tgatcaagat ggtcgaggcg 58560
 atgcgtcacg gcgtgctgcc tcggacgttg cacgtcgatg agccttcgtc ccatgtggac 58620
 tggaccggtg gcgcggtgtc cctgggtgac gagtcgcggg agtggccgga caccggccgt 58680
 ccgcgccgcg ccgggggtgtc gtcgttcggg atcagcggga ccaacgcgca caccatcatc 58740
 gaggccgtcg agccggaagc cgccgagccg tccggaaacc cggacgtccc gccgtggccg 58800
 ctgtccggca agaccgagga agcgttgcca gcgcaggcgt ccgcctcca cgaccacctg 58860

ctggccactc ccgaggtgac cgcggcggac gtcgcgctct ccctcacggc gcgggcggac 58920
 ttggagcatc gtgccgtgct cgtggccggt gaccgtgacg gtctcctcgc cacgctcgac 58980
 gcgctcgcgc acggcgagac caccgagggg atcgtccggg gaacggcgcg gcacaccggc 59040
 cggacggcgt tcctgttcac cggtcagggc agtcagcggc tcgggatggg ccgtgagctg 59100
 gccgagcgtt tcccgggtgtt cgccgaggtc tatgacgagg tgtgttcccg gttegagcag 59160
 ccgctcaggg acttgtcggc cgaggagctg aaccagaccg cgaacacgca gtgcgcgttg 59220
 ttcgcccttg aggtggccct gtccgcctg gtggagagct ggggtgtccg gccggatttc 59280
 ctggccgggc actcggtcgg cgagatcgcg gccgccacg tcgcgggtgt gctttccctc 59340
 gacgatgcgg tgacgctggt gtcggcgcgc ggccgcctga tgcaggcgt gcccacgggc 59400
 ggcgcgatgg tggcgcctgc ggcgaccgaa gcggaggtga ccccgctgct gacggagcgg 59460
 gtgtegatcg ccgccatcaa cggcccggag tcggtcgtcg tctcaggtga cgaagatgcc 59520
 gtcgccgctg tggtcgaggg ccgcaagcac aagcgactta ccgtgagtca cgcgttccat 59580
 tcgccgctga tggagccgat gctggacgag ttccgcaccg tgggtggaggg cctgacgttc 59640
 gcggcgccgc ggatcccgat cgtgtcgggt ggcttggcgg aggtgtccac ttcggactat 59700
 tgggtccgtc atgtccgtga cgcggtgcgg ttccatgatt cgggtgaagt cctggaagcc 59760
 gagggcgta cgcggttcct ggagatcggc ccggacggtg tgctgaccgc gatggcgag 59820
 gacagcctgg aggacgcggt cgtcgtcccc gccctgcggc gcgacaagcc cgaggtcacg 59880
 accctgctga cggcggtcgc cggactgcac gtccacggcg ccggcgtcga ctggagcccg 59940
 ctgtccgccg gggcccgcgg ggtggacctg cccacgtatg ccttccagcg cacggagttc 60000
 tggctcgacg cgggtgccgc ggctggcgat ctgaccgcgg cgggactgtc cgacgccgga 60060
 catccgctgc tcggtggcgc ggtgacctg ccggactccg gcgggaccgt gttcacccgg 60120
 aggctgtcgc tcgcggccca gccctggctc gccgaccacg ccgtcgggga gaccgtgctc 60180
 ctgcccggta ccgcgttcgt cgatctggcg ctcgccgccg gacgacggca cggccgcgtc 60240
 gtctcgcacg aactcacct ggagagcccg ctggctcctgc cggagcacgg cgggtgtcgat 60300
 ctgcgcgtgt gggtcgcga accggacgac accggcgcgt gcgcggtcag cgtgcattcc 60360
 cgtgccgacg acgagccctg gatccgccac gcggtcggaa cgctgaccga ggacaccggc 60420
 gccacgcccg ccgacctcac gtcattggcg cccgccgcgg aggagaccga cgtcgacggg 60480
 ctgtacgacg cgctcgccga cgcgggcctg aactacggcc cggctctcca aggcgtccgc 60540
 gcggcctggc tcgacggcac caccgtgtac gccgagatcg acctcgacga acgcatcac 60600
 ggcgacgccg cccggttcgg cctgcacccg gcgctgctgg acgcggccct gcacaccgcc 60660
 ggactcggcg cgctgagcac cgaaggcggg gcacggctgc ctttctgtg gtcgggcgtc 60720

tcgctcaccg gcctcggcgc caccgagcctg cgcgtccggc tcaccgggtc gggcgacacg 60780
 ctctccctgg cgatcgcgga cgggacgggt gcgccggtgg cgaccgtcgc cgggctgacc 60840
 gtccgtcagg tcgaccccg cgcgttcggt ggtggcggcg actcgctgtt ccgggtggag 60900
 tgggtcccgg tccgcgcccg tgccgcggac accgcgcccg ccgtccggtc cgaagtggac 60960
 agtctggtga acgtgcgcga agcgaccgcg caaacgcttg cggcgctcca atcctggctc 61020
 gccgacgaaa gcaacgccga cccccactg gtcgtgctga ccagcggcgc ggtgtcggtg 61080
 gcgggggagg acacgcgtga tctcgcccgc gccgccgtct gggggctggt gcggtcggcg 61140
 cagtccgagc acccgggccg gttcgtgctc atcgacaccg ataccgaacc agcggacctg 61200
 gccggagccg tcgccaccgg cgaggcacag cttgccatcc gcgacgggaa gctgtgggcg 61260
 ccgcgtctgg tgaagagcgc accctccagt gccacaccgc gtttcgacct ggaaggcacc 61320
 gtgctgctca ccggggcgac cgggtgcgtg gcccgatcgc tggccagtca cctggtctcc 61380
 ggacacgggg tgccgcatct gctgctggtc agccgcagcg gcgcggccgc acacggtgcc 61440
 aaggacctgc tggcggaact gaccgggctc ggccctccg tggtcctgga gtcctgcgac 61500
 gtcgccgacc gggaagccct cgcggggctg ctggccggga tcgaccccg gcatccgctc 61560
 accggggctc tgacgcggc cggcgtctc gacgacggcc tgatcgacag cctgactccc 61620
 gaacgggttc acgccgtgct gcggcccaag gccgacgcgg cgctgaacct gcacgagctg 61680
 gcgggcgacg tcgacgagtt cgtcctgttc tcctcggcgg cgggcacgtt cggcaacgcc 61740
 ggacaggcga actacgcgc gccgaacgcc ttcttgagc cgttggcaca gcaccgccag 61800
 gccaacggcc ttccggcccg gtccctggcc tggggtctgt gggacaccga cgacgggatg 61860
 gacgcttccg ccgccgtcgc caggctcacc gggtcggcc tcaccaccga agaagggtg 61920
 cacctgttcg acaccgcggg tgacggtgtc gtctgcccga tgaagctcga cctcgccgcg 61980
 ctccgcgccg aactcggttc cgacgtgccg tcgctgctgc gcggtctgat caaggcgccc 62040
 gcgcggcggt ccgcgggagc gtcggcgtgg aagcggcagc tcgcgggact gtccgaagag 62100
 gaccgtgacg cagcctgct cgaactcgtg cgggcacagg tcgccgcggt gctgggctac 62160
 tcgggcccgg aggacgtgcc gtcggaccgg gcgttcaccg aactcggtt cgattcgctc 62220
 acgtcggtgg atctgcggaa ccggctgaac tccgcgaccg gcctgcgcct gcccgccacc 62280
 ctcggtgttcg accacccgaa ctccgacgcg gtcgtcgcgc ggctgcggga ggaactgtcc 62340
 ggcaccgtgg tcgcggccgc cgtcgtcacc acggcgccgg tggacgaacc gatcgccatc 62400
 gtcggcatgg cctgccggtt ccccgccggg gtccgctcgc cggaagacct ctggcggtg 62460
 gtcagcgaag gccgcgacgg catcaccocg ttccccgcgg accggggatg ggacgtcgaa 62520

ggccctgtacg accccgaggc ctcccggccc ggcacctcct gcacccgcta cggcggattc 62580
 ctgcacgacg ccggggactt cgaccccggc ttcttcggga tctcgccgcg ggaggcgctg 62640
 gcgatggacc cgcagcagcg gttgctgctg gagacgtcct gggaaagcctt cgaacgcgcc 62700
 gggatcgacc cggccaccct gcgcggctcc gcgaccggcg ttttcgcccgg ggcgatgtac 62760
 cacgactacg tttcgcggtt caccgagatc ccggcggatc tggagggcta cctcggcacg 62820
 gggaactcgg gcagcgtgat ctcggggcgc ctgcctacg ccttcgggct ggaggggccc 62880
 gcggtcagca tcgacacggc gtgctcgtct tcgctggtcg cgatgcatct cgcggcgag 62940
 gcgctgcggc agggcgaatg cggcctggcg ctggccggcg gcgtcgcggt gatgtccact 63000
 ccggacactt tcatcgagtt cagccgccag cgcgggatgg cgcggacgg ccggatcaag 63060
 gcgttctccg agaccgccga cggcacggcc tggggcgagg gcgtcggcat gctgctgctg 63120
 gagcgccctt cggacgcccg ccgcaacgga caccgggtgc tggccgtcct gcgtggcacg 63180
 gcggtgaacc aggacggcgc gtcgaacggg ttgacggcgc cgaacgggccc gtcgcagcag 63240
 cgggtgatcc ggcaggcttt ggcgcaggcc ggtttgcgac catccgatgt ggacgctgtc 63300
 gaggcgcacg gaaccgggac cacgctcggc gatccgatcg aggcgcaggc tctgctcgcc 63360
 acctacgggc aggaccgtga agagccgttg tggctcggtt cgggtgaagtc gaacctgggc 63420
 cacacgcagg ccgcgcggg ggtggcgagc gtgatcaaga tggtcgaggc gatgcgtcac 63480
 ggcgctcctgc ccaggacact gcacgtcgac gagccgtcgt cccatgtgga ctggacggaa 63540
 ggcgcctctt ccctgctcac cgaaacgcgg gactggccgg acaccggacg cccacggcgt 63600
 gccgggggtgt cgtcgttcgg gatcagcggg accaacgcgc acgtcgtcct cgaagcggac 63660
 ggcgcggcg acgcggcacc gcccgacag ccggatgtac ttgccttccc gttgtccgcc 63720
 aagaccagg acgctctgcg cgagcaggcc gccaggttgc gtgcccgggt gctgaccgga 63780
 cacgcacccg agctcgccga cgtcgcgcaa acgcttgcca cacgggggct tttcgagcac 63840
 cgggcgggtgg tcaccgcggg cgaccgcgac ggactgctcg acgcgtcgc cgcgtggcc 63900
 gggggagAAC cgggcgactt cgtcaccggt ctgcgaaac cgggcgggaa actcgcgttc 63960
 ctcttcaccg gtcagggcag ccagcgcgcc gggatggccg acgaactctc cgccgccttc 64020
 ccggtgttcg ctgaaacctt cggcgagatc tgcgcgcgtt tcgataccct gctggaccgt 64080
 ccgctgcgcg aggcgctcgc cggtgacctg gtcgaccgca ccgaatacac ccagtgcgcg 64140
 atgttcgccc tcgaggtcgc gctgttccgg ctgctcgaga gccggggcgt gcggccggac 64200
 ttcttgcccg ggcactcgat cggggaactg gcggcgccc acgtcgccgg ggtctggtcg 64260
 ctggaggacg cctgcaccgt ggtcgccgcg cgcggcaggc tcatgcaggc gctgccgtcg 64320
 ggcggcgca tgatcgcggt ccaggccacc gaagaggagg tccggccgct gatcgacgac 64380

gagaccgtgt cgatcgccgc gatcaacggc ccggtgtcgg tcgtcgtctc cggcgaagaa 64440
 gccgccgtga ccgcgctggc cgccgggttc gccgaacgtg gccgcaagac caagcggctc 64500
 accgtgagcc acgcgttcca ctgcgcgtc atggacggga tgctcggcga attccgcgcc 64560
 gtgctcgacg ggatcgccgc ggccgaccca cggatcccgc tgggtgtccac gctgaccggt 64620
 gacccgctga ccggcgatca ggcgcgatcg agcgagtact ggggtccggca cgtgcgggac 64680
 gcgggtccggt tctgcgacgc gatccggacc ctggaggcgc aggggtgtccg gcgttacctg 64740
 gagctcggcc cggacgcgcc gctgaccgcc ctcggcgagc actgcgtcac gaacgagtcc 64800
 acagtggacg ctacgtgtt cgtgccgtcg ctgcgggccg gtcgatccga cgtcgagtcg 64860
 ttcgtcaccg cgctagcgcg gttgcacgtc gacggcgtcc gggtcgactg ggcgaaggca 64920
 ctccccggcc ggaagatcga tctgcccacc tacgccttcc agcacgagcg gttctggctg 64980
 cggcccgcgc cgcccgcggt gggagacgtc accgggctgg ggcagtcgcc cgccgggcat 65040
 ccgctgctcg gcgcggcggt cgaggcgccg gacagcggcg cgggtgctgtt caccggcagg 65100
 ctgtcgggtgc aggagcagcc gtggctggcc gaccacgtcg tcgccgggac gacccttctc 65160
 ccgggcacgg cgttcgtcga gctcgcgttg cgggccgggg agctgaccgg ctgcgcggcc 65220
 gtcgacgaac tgaccctgga agcaccgctg gtgctgccgg accacgggtgg cacggcactg 65280
 cggatcgtcg ccgccgcgcc ggacgagacc ggcaggcgcg cgttgacgt ctactcccgc 65340
 cccgacgacg gcgactggat ccgtcacgcc accgggaccg tgtcgcccct ggcggcgggc 65400
 gcaccgttcg atctgtcggc ctgggcggcc gccgatgccg agaccgtcga aaccgacggc 65460
 ctctacgacg gattggccgc cgccgggctc gagtacggtc cggctcttcca gggacttcgc 65520
 tccgcccggc ggcgagggga cgacatctgg gccgaggtcg acctccccga ggacaccacg 65580
 accgaggggt tcggcctgca tccggccttg ctgcacgcc ccttgacgc cctgggcttc 65640
 gccgaagggg gtgagcagga ggccgacgtg gcggccgggg ggggtgcgcct gcccttcgcc 65700
 tgggtccggtg tccggctcca cgcctccggt gcgcgtgccc tcgggggtccg gctgtcgccg 65760
 gcgggggaga acgcggtctc cctggccgcg gcggacgaga ccggcaggct ggtggccaca 65820
 gtggacgctc tgacgtgcg cccggtctcg ctggagcaac tcggcgggcg gcagggcagc 65880
 cacgagtcgc tggtcgggtc ggagtgggcg ccggttcgc tctaccccac cgccgccgtg 65940
 gccgcgagct gggcggtcgt cgggtgtcgac gactacaaac tcgacgcgc gctcaccgcc 66000
 gccggctatc gcggccaggc ttacgccgat ctgcgcgcgc tggccgaggc gatggatcgc 66060
 gcgccagagc tgggtcttcgt gtctgcgcg ccggaccacc gccaaagggt ggcagccgcc 66120
 gcgcacaccg ccgcccaccg cgcgctagag ctgggtccgtg cgtgggtggc cgaggaccgg 66180

ttgcgcgggtt cccggctggt gctggtcacc ggcggcgcgcg tcggcggaacc ggcgagggcg 66240
 gtgatctggg gcctgatccg ctcgggcgag tccgagcacc ccggccgggt cgtgctgggtg 66300
 gacctcgacg aacaggacgc gtcgtaccgt gtgctggtgc ccgcgctcgc ctccggcgaa 66360
 ccgcagctgg agttgcgcga gggaacgggtg aaggcgccgc ggctgggtcaa accggccgtg 66420
 acggccgcgcg aaggcaaggc tcggaccgac ggcgccgtgc tgatcaccgg cggcaccggc 66480
 gcgctcggcg cggcactggc ccggcatctg gtcaccgcgc acgggaagac ccggctgggtg 66540
 ctgcgcgggtc gccgcggccc ggacgcgcgcg ggcgcgggcg aactggccga cgaactgcgg 66600
 ggtctggggcg ccgaggtcgc tgtgatcgt tgcgacgcgg ccgatcgtga agcgctgcga 66660
 cgccttctgg ccgagcaccg ggtgaccggg gtgggtgcacg ccgccgggtg tctcgacgac 66720
 gtcgtcctcg acggcctcac ccggaccgg ctcgacgcgc tcctgcggcc gaaggtcgac 66780
 gccgcgggtga acctgcacga actggcgga gacgtcgacg agttcgtgct gttctcctcg 66840
 gcggcgggca ccttcggcaa tccggggcag gcgaattacg cggcgggcaa cgccttctc 66900
 gacgcgctcg ccggcatcg tcacgcacac gggctgcccg cgacctcgt cgcctgggga 66960
 ctctggggcg gtgacgggat ggcgggcggt atgtccgggc gcgatctgga ccgatgtcc 67020
 gcctccggcg cgggcgcact gtccacagag gagggctctg cgttgttcga cctcgcggtg 67080
 acggcgggcg aaccgggtgct gttgccgatg cggtggacc tcgccaccgt gcgggcgggc 67140
 ctcggcaccg acgtcccgc cctgctgcgc ggctgatcc gcggtaccag aaaacgcgc 67200
 gagaccgcgc gttcaccgac cggggacgcg ctcaaggcgg agctggccgg gatgaccggc 67260
 gaggaacgcg ccgcggcact gctgaacctc gtcgccacgc acgtcgccgg tgcctcggg 67320
 cacgccgggtc ccgagcaggt cgatccggac aaggcggtca cggaactcgg gttcgactcg 67380
 ctgcgcgcgg tcgaactgcg caaccgggtc aacgaggcca ccggtctccg gctgcccgc 67440
 acgctgggtct tcgaccatcc gaccaccacc gcggtggcg aactggtcgg cgcggagatc 67500
 gtcgtggagg acgcgccacc gccgctgggg gtgctggcg aactcgaccg gctggaggcc 67560
 gcgttcgcgc ggggaagccc ggacgacgcg atccgcggca aggtcaagga ccggctgcgc 67620
 gccctgctcg cggcctgcga tccgggcgag ggcaccgaat ccgtggcgga tcggctcgaa 67680
 gacgcctcgg acgacgaaat gttcgaattc atcggcaagg aactcgggat ctctgactt 67740
 gggggcgga atgaaagaca ccgaggacaa actccggtac ttctcaagc aggtcaccgc 67800
 ggatcttcac gaaaccggga aacgcctgaa ggagaccgaa gccgcgggca gcgaaccgat 67860
 cgccatcgtc gggatggcct gccgctatcc cggcggggtg gcctcgcccg aggatctgtg 67920
 gcggatggtc gaaaccggcg gcgacgggat cagcggattc ccggtcgacc gcggctggga 67980
 cctcgaagcg ctgtacgacc cggatccgga caagcagggc acgagctacg tttcgcaggg 68040

tggtttctc caccagctcg ccgagttcga cccggcgctt ttcgggatct cgccgcgtga 68100
 ggcgctggcg atggatccgc agcagcggct cctgctggag acgtcgtggg aggccatcga 68160
 gcgggcgggt atcgatccgg gctcgtgaa gggcagccgg accgggggtgt tcgccgggtt 68220
 gatgtaccac gactacgtct ccgggctgac cgagatcccc gacgaggtcg gcggctacct 68280
 cggcaccggg aactccggca gcatcgctc cggccgggtg tcctacacct tcgggttcga 68340
 aggccccgcg ctaccgtgg acaccgcgtg ctgctcgtcg ctggtgacct tccacctcgc 68400
 cgcgcaggcg ctgcggcggg gcgagtgcga cctcgccctg tccggcgggg tgacggtgat 68460
 gttcaccccc gggacgttcg tggagttcag ccgccagcgc gggatggcgc cggacggccg 68520
 ctgcaaaccg ttcgccgaag aggcggacgg caccggctgg tccgaggggtg tcgggatgct 68580
 gctggtggaa cggctttccg acgcgcggcg caacggccat ccggtgctgg cggtcctcgc 68640
 cgggtcggcg gtgaaccagg acggcgcgtc gaacggcctg accgccccga acggcccgtc 68700
 ccagcagcgg gtgatccgcg aggcgctcgc cgacgcccg ctgacgacgg cggacgtcga 68760
 cgtcgtcgag gcgcacggaa ccggcaccac cctgggcgac ccgatcgagg cgcaggcgct 68820
 gctcgcgacc tacggcaagg gcaggccgtc ggaccggccg ctgtggctcg ggtcgatcaa 68880
 gtcgaacctc gggcacaccc aggcgcgccg cggagtcgcc gggatcatca agatggtgca 68940
 ggcgctgcga agcgggatcc tgccccggag cctgcacgcg gagaccccgt cgtcgcgtgt 69000
 ggactggagc gcgggcgcgg tctcgttgct ggccgaggcg cggccgtggc cggagctcga 69060
 ccgtcctcgc cgggccgcgg tgctcgtcgtt cggcatcagc gggaccaacg cgcacgtcgt 69120
 cctcgaagcg gccccggctg ccgaggtcga gccccggcag ccggtgggtga ccggtgcgac 69180
 gccgtggctg ttgtcggcgc ggacgccgga ggccttgctg gccagggctg cacagcttcg 69240
 gtccctttgtg gaccttcag gcgccgtgc cacactggcc gcgcggccgc tgttcgggca 69300
 ccgggcggcc atcgtcgggtg atccgcgtgc cgcgctggac gcgctcgcca ccggaaagcc 69360
 ctogaacctg ctgatcgagg gcaccgcgca gtcgggtaag gctgttttcg tgttcccggg 69420
 tcagggttcg cagtgggtgg ggatggcgga ggagttgttg ttgtcggctc cgggtgttcgc 69480
 ggagtcgatg gctgagtgtg agcaggcgct ttcgtccttt gtggattgga agttgtccga 69540
 tgtgttgctg gatgcggctg cgttgagcgc ggttgatgtg gtgcagcctg ttttgttcgc 69600
 ggtgatggtt tctctggcgc ggttggtggc ggcgtgtggg gttgagcctg ctgcgggtgg 69660
 tggtcattcg cagggtgaga tcgcggcggc gtgtgtggcg ggtgcgttgt cgttggtatga 69720
 cgctgcgcgc gtggtgtgcc tacggagtaa ggcgattctg gcgttgctcg ggctcgggtg 69780
 catggtgtcg gtggctgcct cggaggaccg ggtgcgggag ctattgcctg ccggtgtgtc 69840

ggtggcagca gtgaacggcc cgtcggcggc ggtggtgtcc ggtgatgtcg cgggcttgga 69900
 ggcggtgctc aagcgggtgtg agttgctgga tgtgcgggcg aagcggatcc cggaggacta 69960
 tgccctcgcat tcggcgcatg tggatgcatg cgagcaggag gtcttggtcg cgctggcggg 70020
 tatctcaccg caggcgccgg tgatcccgtt ttattcgacg gtgaccgatg agcctctgga 70080
 attggatgct ggggtattggt tccggaatct gcgggggacg gtgcgggttcg cggcgacggc 70140
 ggatcgggtg ctggaggacg gtttcgggtt ctctgtggag acgagtcgc atccgggtct 70200
 ggtcccggga atcagcgaag acgctgtcg tctggggagt ttgcgtcggg gtgaggggtg 70260
 tgccggagcgg ttcgtcgcgt cactggccga agcccatgtg cacggcctga gcccggcgtg 70320
 gtcttcgacg ctgccgacgg cggactgggt cgatctgccg acgtatccgt tccagcgcaa 70380
 gcgggttctg ctggaagccg ggaccgccgc cggggacgcg tcggcggttcg ggcagacggc 70440
 ggtggaccac ccgctgctcg gcgccgtcgt cgcgggtccc gggaccggcg ggctgctgta 70500
 caccggccgg atctcgctgg agacgcctcc ctggctcgcc gatcacgcg tgtccgggac 70560
 ggtactggtg cccgggtaccg ctttcgtgga actcgcgctg gccgccggca ctcaggtgga 70620
 ctgcgcgctg ctcgacgaat tgaccctcga agcaccgctc gtgctcgaag aaggcacgga 70680
 cgtccggctc tcggtcgaac tcggtgacgc ggacgtcgac ggccgtcgcg aggtcggcgt 70740
 gtactcccgc cgcggcgacg aacctggac ccggcacggc aacgggtgtc tgctgcccga 70800
 aacggacggc gtgcccacgc cgctcgcgga gtggccgccc gccggggcg aacgcgtcgg 70860
 cgctcgaggcg ctgtacgacg agctcgcgaa cgcgggcctc gaatacggcc cggcggtcca 70920
 aggactccgc gccgcatggc gtcgcgagaa cgaggtcttc gccgagatcg acctgcccga 70980
 agcccagacc ggcgaggctc cggccttcgg cctgcctccc gcgttgctgg acggcgcgct 71040
 ccacgggacg gcgctgggtg tgcttcccga cgacggggag ggactccggc ttccgttcgc 71100
 gttctccggg gtccggctgt ggtcgcgggg cgcgacggca ctgcgagtgc ggctgcgacc 71160
 ggcggcgacg ggggtcgcgc tgaccgtcgc cgacgggtgag ggcctaccgg tcgcccagct 71220
 ggacgggtctg ctgctgcggc cgggtgtcgt gtccggcctc ggtgggtatc gagagtcctt 71280
 gttcggcctg gattgggtgc ccgcgggccc gaccgaaccg cacgacgcga cgggtgtggca 71340
 ctgcgaatcc ggggatctcc gcaccgtgct ggggtgcggcg ctcgaacgcg tccggacgtg 71400
 gctcgacgag cctggggacg gtccgctcgt ggtggccacg cgaggcggga tcgcgaccga 71460
 acgcccggat ccggtgacgg ccgcggtatg ggggctcgtg cgctcggcgc agtcggagca 71520
 ccccgacggc ttcgtgctcg tggacggcga cgtcccggcg gcgctgcccg ccgggggaatc 71580
 gcaggtcgtg gtccgtgacg gggtcggctt cgtcccaggc ctgctccggg tcccgggaacc 71640
 cggcccggcc cggccgtgga gcgacgatga tgctgtgctg atcaccggag gcaccggcct 71700

cctcgggtgcg gccgtcgcga aacacctggt ggtgacgcac ggcgtccgtt cgctgggtgct 71760
 gctgagccgt tccggtgctt ccgcgcccgg tgcggcggca ctggcggacg aactcaccgg 71820
 gatgggtgcc gaggtccgga tcctcgcgtg cgacgcggcc gaccgggagg cgctgcgcca 71880
 ggtgctggcc gcgcatccgg tgaccggtgt cgtgcacgcc gccggtgtcc tcgacgacgg 71940
 gctgatcacc gcgcagaccc ccgaacggct cgaccgggtg ctgcgcgcca aggtggacgc 72000
 cgcggtgaac ctgcacgaac tcttgcccga tgccgcgccg ttcgtgatgt tctcctcggc 72060
 ggccggggtc ttcgggaatc cggggcagtc cggttacgcc gcagccaacg ctttcgtgga 72120
 cgccctggtg gaacgccgcc gcgcggacgg cgccgccgcg gcgtcactgg cgtggggcct 72180
 gtgggcgacc accagcgcca tgaccggttc cgccgacgtg gaccggatgg cgagggcggg 72240
 actcaccgga ctgtccacag aggaggggtct cgacctgctc gacgccgcgc tcgccaccgg 72300
 gcggacgctg accgtcccca tggggctcga cctcgccgcg ctccgcgccg aggaggtgcc 72360
 gccgttgctg cgcgggctcg tccgcgctcg tgcccggcgc gcgcccgcgc gcggcggcgc 72420
 gttccgcgcc cggctcgccg gactcgacgc ggacggccgc gacgcggaga tcctggaact 72480
 ggtgcgcggt caggtcgcgg ccgtcctcgg ccacgacggt gccgacgcga tcgacgccgg 72540
 tgtcgcgttc ctogaactcg gcttcgactc gctcaccgcc gtcgacctgc gtaaccggct 72600
 ggcggcctcg accggcctgc ggctcccgcc gtcgctggtg ttcgaccacc cgacgccgct 72660
 cgccgtcgcg gaacggatct ccggtgactt cgcggttccc gaccaggccg agccggtgcc 72720
 agcgccacc gacgtcttcg gcgcgatgtt cgcccgcgcg atcgaactcg acgaggtcgc 72780
 gcagttcgtc gcgctagccg cgcaggcttc gcgctaccgg ccgtcgttca ccgtcgaaac 72840
 cgcgcgggaa cagaacctgc aacccgctcg gctcgcgaag ggcccgtccg gcccogaact 72900
 ggtctgcgtc ccctccctgc tggccggctc gggggcgcac gaatacgcgc ggttcgcggc 72960
 gtcgttccgg gacgtgcagg acgtttccgt cgttccgggtg cccggtttcg gccacgggca 73020
 gccgctgccg gactcgatcg aggcggctct ccacgcgcag gcggacgcga tcctccgcga 73080
 aggcggtgac ccggtgggtc tgggtggcca ctctcttggc ggcccgtcgc cccacgcgct 73140
 ggctcggcac ctggaggaag cgggctccgc gccgcgcgcg ctcgctgctga tcgacgtcta 73200
 cccgcaggac gagcacgcgc tggacggcat ccgtgaccgg ctacgcggcg gcctcggcga 73260
 cgacacgcgg ctaccgcca tgggcgccta cctgcgcttg ttcgccgact atgtgcccgc 73320
 gccgaccggt gtgccgactc tgctcgtgcg ggcgtcggag cccctggaag cgtggcgtga 73380
 ccggaccgaa tggcgggtccg gctgggcctt gccgcacgac acggtggacg tcgaggggga 73440
 tcacttcacg atgctggagc ggcattgccg gacgaccgcc gaggccgtcc gggagtggct 73500

ggggcggctg gggtaacggc tgcgcgtgaa ccggtcgtgg gctgaaggct cccttcgccg 73560
cgtcttaagc ggtgaaagga gccttcgccc gcggcacag 73599

<210> 25
<211> 162
<212> PRT
<213> Amycolatopsis orientalis

<400> 25

Val Asp Thr Ser Thr Leu Ile Asn Ile Ala Val Ala Ile Ala Val Val
1 5 10 15
Val Tyr Val Ile Tyr Gln Arg Met Ser Trp Lys Pro Leu Glu Asn Val
20 25 30
Glu Ile Trp Gly Gly Pro Leu Thr Leu Val Ala Ile Gly Val Ile Gln
35 40 45
Met Arg His Leu Asp Thr Thr Ile Ser Val Thr Asp Ile Val Phe Leu
50 55 60
Gly Val Gly Leu Leu Val Ser Leu Leu Gly Gly Ala Ala Met Gly Ala
65 70 75 80
Met Thr Gln Leu Gln Arg Arg Gly Asp Lys Val Tyr Gln Arg Ile Gly
85 90 95
Val Val Gly Leu Ala Val Trp Val Gly Leu Leu Leu Val Arg Gly Val
100 105 110
Leu Gly Val Ile Gly His Phe Ala Gly Ala Thr Leu Thr Ser Gly Gly
115 120 125
Gly Thr Ile Leu Leu Ser Leu Gly Ala Asn Leu Met Ala Met Thr Leu
130 135 140
Val Leu Ser Ala Arg Leu Gly Gly Ala Lys Val Pro Gly Gly Ser Pro
145 150 155 160
Gln Arg

<210> 26
<211> 486
<212> DNA
<213> Amycolatopsis orientalis

<400> 26

gcgctgcggg ctgccgccgg ggaccttggc gccgccgagg cgggcggaca gcacgagcgt 60
catcgccatc aggttcgcgc ccagcgagag caggatggtg ccgccgccgg aggtcagcgt 120
cgcgccggcg aagtgcccgga tcacgccgag cacgccgcgg acgagcagca ggcccaccca 180
gacggcgagg ccgaccacgc cgatccgctg gtagaccttg tcgccgcgcc gctgcagctg 240
cgtcacgcgc cccatcgccg cgccgccgag gagcgagacc agcaggccca ccccgaggaa 300

gacgatgtcg gtcacgctga tgggtggtgtc cagatgccgc atctggatga ccccgatggc 360
gaccaggggtg agcggcccgc cccagatctc cacgttctcc agcggcttcc agctcatgcg 420
ctggtagatc acgtagacga cgacggcgat ggcgaccgcg atgttgatca gcgtgctggt 480
gtccac 486

<210> 27
<211> 441
<212> PRT
<213> Amycolatopsis orientalis

<400> 27

Val Ala Val Val Gly Ala Gly Tyr Val Gly Leu Thr Thr Ala Ala Cys
1 5 10 15
Leu Ala Ser Leu Gly His Arg Val Arg Cys Thr Asp Ser Asp Arg Gly
20 25 30
Lys Leu Ala Arg Leu Lys Arg Gly Glu Val Asp Ile Leu Glu Lys Gly
35 40 45
Leu Pro Gly Leu Val Ala Glu Gly Ile Ala Ala Gly Arg Leu Gly Phe
50 55 60
Val Glu Ser Ala Ala Glu Ala Val Glu Thr Ala Glu Ala Val Phe Leu
65 70 75 80
Cys Val Pro Thr Pro Met Gly Glu Gly Gly Met Ala Asp Leu Ser Ala
85 90 95
Val Ile Asp Val Ala Thr Lys Val Arg Asp Val Leu Ser Pro Gly Cys
100 105 110
Val Leu Val Asn Lys Ser Thr Val Pro Val Gly Thr Ala Ala Arg Val
115 120 125
Ala Ala Leu Leu Gly Arg Asp Asp Val Ala Val Val Ser Asn Pro Glu
130 135 140
Phe Leu Arg Glu Gly Thr Ala Val His Asp Phe Leu Asn Pro Asp Arg
145 150 155 160
Ile Val Val Gly Ser Asp Thr Arg Gly Pro Ala Glu Arg Val Ala Ala
165 170 175
Leu Tyr Ala Arg Leu Gly Ala Pro Thr Val Leu Thr Asp Ala Ala Ser
180 185 190
Ala Glu Met Val Lys Tyr Ala Ala Asn Cys Phe Leu Ala Thr Lys Leu
195 200 205
Ser Tyr Val Asn Ala Ile Ala Glu Leu Cys Glu Arg Leu Gly Ala Asp
210 215 220
Ile Gly Asp Val Thr Glu Gly Met Gly Tyr Asp Arg Arg Ile Gly Pro
225 230 235 240

Thr Phe Leu Ser Pro Gly Pro Gly Trp Gly Gly Ser Cys Leu Pro Lys
 245 250 255
 Asp Thr Met Ala Leu Lys Gln Val Ala Glu Val Ala Gly Phe Glu Phe
 260 265 270
 Gly Leu Leu Asp Glu Val Ile Ser Gly Asn Ala Lys Gln Ala Ser Arg
 275 280 285
 Val Val Glu Arg Ile Ala Val Ala Cys Gly Leu Asp Ala Asp Ala Asp
 290 295 300
 Leu Thr Gly Leu Arg Ile Gly Leu Leu Gly Leu Thr Phe Lys Ala Gly
 305 310 315 320
 Thr Asn Asp Leu Arg Asp Ser Pro Ala Leu Ser Val Ala Arg Leu Leu
 325 330 335
 Ala Glu Arg Gly Ala Glu Leu Thr Gly Tyr Asp Pro Gly Leu Thr Gly
 340 345 350
 Ala Glu Pro Pro Ile Pro Gly Val Arg Val Val Asp Asp Pro Tyr Tyr
 355 360 365
 Ile Ala Lys Asp Ala His Ala Leu Val Leu Leu Thr Asp Trp Pro Gln
 370 375 380
 Phe Arg Ala Leu Asp Trp Pro Arg Ile Ala Gly Leu Leu Glu Gly Pro
 385 390 395 400
 Val Val Ile Asp Thr Arg Asn His Leu Asp Pro Asp Ala Leu Ser Arg
 405 410 415
 Ala Gly Ile Ala Trp Arg Gly Phe Gly Arg Pro Pro Val Asp Pro Val
 420 425 430
 Arg Thr Pro Ser Leu Asp Pro Val Pro
 435 440

<210> 28

<211> 1326

<212> DNA

<213> Amycolatopsis orientalis

<400> 28

gtggcgcgtcg tcggcgccgg atacgtcggg ctgaccaccg cggcgtgtct cgcctcgctc 60
 gggcaccggg tccgatgcac cgattccgat cgcggcaaat tggcccggct caaacgaggc 120
 gaggtcgaca tcctggaaaa gggcctgccc ggtctggtcg ccgagggaat cgccgccgga 180
 cggctcggtt tcgtcgagtc ggccgcggag gccgtcgaga ccgcggaggc cgtgttcctt 240
 tgtgtaccca ccccgatggg cgagggcggg atggccgatc tgtcggccgt catcgacgtc 300
 gcgaccaagg tccgtgacgt gctttcgccg ggttggtgtac tgggtgaaca gtcgaccgtg 360
 ccggtcggga ccgcggccag ggtcgccgcg ctgctcggcc gggacgacgt cgcggtggtg 420
 agcaatccgg agttcctccg cgagggcacc gccgtccacg acttcctcaa cccggaccgg 480

```

atcgtcgctcg gttccgacac gcgcggcccg gcggaacggg tcgcggcgct ctacgcccgg 540
ctcggcgccc cgacggtgct gaccgacgcg gcgagcgcg agatgggtcaa gtacgccgcc 600
aactgtttcc tcgcgacgaa actgtcctat gtgaacgcca tcgccgaact gtgcgagcg 660
ctcggcgccg acatcggcga cgtcaccgaa ggcattgggt acgaccgccg gatcggcccg 720
acgttcctct cgccggggcc gggctggggc ggttcctgcc tgcccaagga caccatggcg 780
ctcaaacagg tcgccgaggt cgcggtttc gagttcggcc tgctcgacga ggtcatctcg 840
ggcaacgcga aacaggcgtc ccgagtggtc gaacggatcg ccgtcgctg tggactcgac 900
gcggacgcgg acctcaccgg cctgcggatc ggcctgctcg ggctgacctt caaggcgggc 960
accaacgacc tccgggattc cccggcgctc agcgtcgccc ggctgctggc cgagcgcggc 1020
gcggagctga ccggatacga ccccggtctc accggcgccg aacctccgat ccccggcgtc 1080
cgggtcgctc acgacccta ctacatcgcg aaggacgcgc acgcgctcgt cctgctgacc 1140
gattggccgc agttccgtgc cctcgactgg ccgcggatcg ccggtctgct cgaaggaccg 1200
gtcgtcatcg acaccgcaa ccacctcgac cccgacgcgc tcagccgggc cggcatcgcc 1260
tggcgcggct tcggcaggcc cccggtcgac ccggtgcgca cgccgtccct cgaccccggt 1320
ccctga 1326

```

```

<210> 29
<211> 407
<212> PRT
<213> Amycolatopsis orientalis

```

```

<400> 29

```

```

Met Arg Val Leu Cys Thr Val Thr Gly Ser Gln Gly His Ala Arg Ala
1          5          10          15

Val Leu Pro Leu Ala Arg Ala Ala Lys Ala Gly His Glu Val Leu
20          25          30

Val Val Thr Pro Pro Glu Leu Ala Asp Val Phe Glu Pro Gly Leu Met
35          40          45

Arg Ile Glu Pro Val Leu Pro Gly Met Val Glu Ala Ile Gly Arg Met
50          55          60

Val Gln Glu Arg Gln Glu Ala Glu Ala Ala Gly Thr Pro Arg Arg Val
65          70          75          80

Leu Asp Thr Arg Glu Gln Leu Ile Ala Thr Ala Ser Gly Pro His Val
85          90          95

Thr Thr Ala Tyr Gln Lys Leu Tyr Pro Leu Ala Lys Glu Phe Gln Pro
100         105         110

Asp Ile Val Leu Arg Asp Gly Ala Glu Leu Ser Gly Ala Leu Val Ala
115         120         125

```

Glu Gln Leu Gly Val Pro Tyr Ile Ser Ala Pro Ser Gly Ala Gly Asn
 130 135 140
 Leu Ile Asp Pro Ala Gly Leu Val Glu Pro Leu Asn Glu Arg Arg Gln
 145 150 155 160
 Glu Leu Gly Leu Ala Ala Glu Pro Asp Ala Gly Met Val His Arg Tyr
 165 170 175
 Gly Arg Phe Asp Cys Leu Pro Ala Asp Thr Ser Phe Ala Ala Phe Asp
 180 185 190
 Leu Pro Thr Pro Phe Thr Tyr Arg Gln Pro Ser Glu Val Ala Thr Gly
 195 200 205
 Glu Val Leu Pro Pro Glu Ile Ala Ala Leu Pro Ala Asp Arg Pro Leu
 210 215 220
 Val Leu Ala Ser Val Gly Thr Ala Leu Pro Met Leu Gly Ala Phe Lys
 225 230 235 240
 Ala Phe Gly Ile Asp Pro Pro Glu Glu Met Glu Asp Pro Asp Val Thr
 245 250 255
 Val Arg Ala Leu Ile Glu Gly Leu Ser Ser Val Asp Cys Ser Ala Val
 260 265 270
 Val Ala Thr Ala Gly Phe Pro Ile Gly Asp Val Glu Val Gly Asp Asn
 275 280 285
 Val Leu Val Val Glu Arg Met Pro Gln Pro Leu Leu Leu Glu Cys Ala
 290 295 300
 Gln Leu Phe Leu Thr His Ala Gly Tyr Asn Ser Ile Arg Glu Ala Leu
 305 310 315 320
 Arg Ala Gly Val Pro Met Ala Thr Leu Pro Gln Phe Gly Asp Gln Pro
 325 330 335
 His Asn Ala Arg Arg Ile Glu Glu Leu Gly Phe Gly Lys Gln Ile Pro
 340 345 350
 Ala Thr Thr Pro Glu Ala Val Ala Glu Thr Cys Arg Ala Val Leu Ala
 355 360 365
 Asp Ala Thr Ile Ala Ala Thr Val Ala Arg Ala Gln Arg Arg Ser Leu
 370 375 380
 Thr Met Pro Gly Val Glu Ser Ala Val Ala His Leu Glu Glu Leu Ala
 385 390 395 400
 Gly Arg Ala Ala Gly Thr Glu
 405

<210> 30
 <211> 1224
 <212> DNA
 <213> Amycolatopsis orientalis
 <400> 30

```

atgcggggttt tgtgcaccgt gaccggctcg cagggccacg cacgggcggt gctgcccttg      60
gccagggcg   cggcgaaggc gggccacgaa gtgctcgtcg tgaccccgcc ggaactggcc      120
gacgtcttcg  aaccggggt  gatgcggatc gaaccgggtg tcccgggggat ggtcgaggcg      180
atcgggcgga  tgggccagga acgccaggag gccgaagcgg ccgggacccc gcgccgggtg      240
ctggacacgc  gcgaacagct gatcgccacc gcgagcggcc cgcacgtcac caccgcctac      300
cagaagctct  acccactggc caaggagt   cagcccgaca tcgtgctgcg cgacggcgcg      360
gagctgtccg  gcgcgctggc cggcgagcag ctgggcgtgc cctacatcag cgcgccgctg      420
ggtgcgggca  acctgatcga cccggcgggc ctgggtggag cgctgaacga gcgccgccag      480
gagctggggc  tcgccgccga acccgacgcc gggatgggtg accgctacgg ccgtttcgac      540
tgctgccccg  ccgacacctc gttcgccgcc ttcgatctgc cgacgccgtt cacctaccgc      600
cagccgtcgg  aggtggccac cggtgaggtc ctgccgccgg agatcgccgc attgcccgcg      660
gaccggccgc  tggtgctcgc ctcggtcggc accgcgctgc ccatgctcgg cgcgttcaag      720
gccttcggca  tcgacccgcc ggaggagatg gaagatcccc acgtcacggt gcgcgccttg      780
atcgaaggac  tgtccagtgt ggactgttcg gcggtggtgg cgacggccgg gttcccgatc      840
ggcgacgtcg  aggtcggcga caacgtgctc gtcgtcgaac ggatgccgca gccgctgctg      900
ctcgaatgcg  cgcagctgtt cctgaccac  gccgggtaca acagcatccg cgaggcgctg      960
cgtgccggag  tcccgatggc cacgctgccg cagttcggcg accagccgca caacgcgcgc     1020
cgcacgagg  agctcggggt cggcaagcag atccccgcca ccacgccgga agcggtcgcc     1080
gagacctgcc  gcgcggtgct ggccgacgcc acgatcgcg  ccaccgtcgc acgggcccaa     1140
cggcggagcc  tgaccatgcc gggcgtggaa tccgccgtgg cccatctcga agagctcgcc     1200
ggccgggccc  cgggaacgga gtag                                     1224

```

```

<210> 31
<211> 521
<212> PRT
<213> Amycolatopsis orientalis

```

```
<400> 31
```

```

Val Gln Ile Asp His Tyr Val Ser Gln Leu Leu Asp Val Leu Ser Thr
1              5              10              15

Arg Pro Asp Glu Ile Ala Leu Arg Tyr Gly Asp Glu Ala Leu Thr Ser
                20              25              30

Ala Glu Phe Ala Ala Ala Ile Thr Gly Ala Ala Ala Ala Leu Arg Asp
                35              40              45

Arg Gly Thr Gly Glu Gly Gly Val Val Ala Leu Leu Thr Val Gly Asn
50              55              60

```

Ser	Pro	Ala	Thr	Leu	Ile	Gly	Arg	Tyr	Ala	Ala	Asn	Leu	Ile	Gly	Ala	65	70	75	80
Thr	Val	Val	His	Leu	Arg	Gly	Ile	Asn	Ala	Ala	Asp	Pro	Leu	Asp	Glu		85	90	95
Leu	Pro	Val	Ala	Thr	Gln	Val	Glu	Ile	Val	Asp	Asp	Thr	Gly	Thr	Thr		100	105	110
Val	Leu	Leu	Thr	Asp	Ala	Ala	Asn	Leu	Asp	Arg	Ala	Arg	Lys	Ile	Arg		115	120	125
Asp	Ala	Met	Ala	Glu	Pro	Ala	Ala	Leu	Ala	Ala	Phe	Gly	Asp	Phe	Gly		130	135	140
Asp	Asp	Val	Ala	Asp	Leu	Thr	Gly	Thr	Ala	Ser	Glu	Val	Glu	Pro	Arg	145	150	155	160
Ala	Glu	Gly	Thr	Ala	Val	Leu	Thr	Tyr	Thr	Ser	Gly	Thr	Thr	Gly	Arg		165	170	175
Pro	Lys	Gly	Ile	Gly	Arg	Gly	Phe	Gly	Gly	Leu	Gly	Ala	Val	Val	Thr		180	185	190
Lys	Ala	Arg	His	Met	Thr	Glu	Arg	Cys	Thr	Met	Leu	Val	Thr	Thr	Pro		195	200	205
Leu	Ser	His	Ser	Val	Ser	Ser	Thr	Val	Asp	Asp	Ala	Val	Ala	Ser	Gly	210	215	220	
Gly	Met	Ile	Val	Leu	His	Glu	Gly	Phe	Asp	Ala	Gly	Ala	Val	Leu	Glu	225	230	235	240
Ala	Val	Glu	Arg	His	Arg	Val	Asn	Arg	Val	Tyr	Leu	Ala	Thr	Pro	Gln		245	250	255
Leu	Tyr	Asp	Leu	Leu	Asp	His	Pro	Ala	Leu	Gly	Thr	Thr	Asp	His	Ser		260	265	270
Ser	Leu	Arg	Glu	Leu	Tyr	Tyr	Gly	Gly	Ser	Pro	Ala	Ser	Pro	Val	Arg	275	280	285	
Leu	Ser	Arg	Ala	Ala	Glu	Val	Phe	Gly	Ala	Lys	Leu	Ile	Gln	Ile	Tyr	290	295	300	
Gly	Thr	Thr	Glu	Ser	Trp	Val	Ile	Ala	Ala	Leu	Ser	Pro	Glu	Glu	His	305	310	315	320
Leu	Lys	Pro	Glu	Leu	Leu	Thr	Thr	Val	Gly	Lys	Ala	Val	Pro	Phe	Val		325	330	335
Gln	Val	Gly	Ile	Arg	Asp	Pro	His	Val	Arg	His	Glu	Leu	Pro	Ala	Gly		340	345	350
Lys	Thr	Gly	Glu	Ile	Cys	Val	Arg	Ser	Pro	Met	Met	Met	Asp	Gly	Tyr		355	360	365
Trp	Lys	Arg	Pro	Asp	Leu	Thr	Ser	Lys	Val	Leu	Ile	Asp	Gly	Trp	Leu	370	375	380	

His Thr Gly Asp Val Gly Tyr Leu Asp Glu Asn Gly Tyr Leu Tyr Leu
385 390 395 400

Val Asp Arg Leu Ala Asp Met Ile Lys Thr Asn Gly Ile Lys Val Tyr
405 410 415

Pro Ala Glu Val Glu Asn Ala Leu Leu Ala His Pro Asp Val Ala Gln
420 425 430

Ala Ala Val Phe Gly Val Ala Asp Glu Asp Asn Val Glu Tyr Met His
435 440 445

Ala Ile Ala Val Pro Arg Arg Gly Arg Asp Val Asp Pro Ala Asp Leu
450 455 460

Ala Ala His Val Ala Arg Val Leu Ser Pro Ser His Val Pro Ala Glu
465 470 475 480

Ile Arg Leu Arg Ala Glu Leu Pro Leu Thr Asp Ala Gly Lys Pro Asp
485 490 495

Lys Leu Arg Leu Arg Glu Glu Ala Lys Pro Ala Thr Lys Ser Ser His
500 505 510

Ala Glu Pro Glu Ser Glu Leu Thr Ser
515 520

<210> 32

<211> 1563

<212> DNA

<213> *Amycolatopsis orientalis*

<400> 32

```
gtgcagatcg accactacgt cagccagctg ctggacgtgc tttccacccg cccggacgag      60
atcgcgttgc gctacggcga cgaagcgctg acgtcggcgg aattcgccgc ggcgatcacc      120
gggtgccgccg ccgcgctgcg cgaccgcggg accggcgaag gcgggggtggt ggccctgctg      180
accgtgggga acagcccggc gacgctgata ggccggtagc ccgccaacct gatcggcgcc      240
accgtggtgc acctgcgcgg gatcaacgcc gccgatccgc tggacgaact cccggtcgcc      300
acgcaggteg agatcgtcga cgacaccggc accaccgtcc tgetcaccga cgcggcgaac      360
ctcgaccggg ccaggaagat ccgcgacgcc atggcggaac cggcggcact ggcggctttc      420
ggggacttcg gtgacgacgt cgccgacctc accgggaccg cgagcgaggt cgagccgcga      480
gccgagggca ccgccgtgct gacctacacc agtgggacca ccggcaggcc caagggcatc      540
ggccgcgggt tcggcgggct gggcgcgggtg gtcaccaagg cccggcacat gaccgagcgc      600
tgcacgatgc tggtcaccac gccgctcagc cattccgtct cgtccacagt ggacgacgcg      660
gtcgcctccg gcgggatgat cgtcctgcac gaggggttcg acgccggcgc cgtgctcgaa      720
gccgtggaac gccaccgggt caaccgggtc tacctggcca ccccgagct ctacgacctg      780
ctcgaccatc cggcactggg caccaccgac cattccagcc tgcgcgagct gtactacggc      840
```

```

gggagcccgg cctccccggg gcggtctctc cgggcccggg aggtgttcgg cgcgaagctg      900
atccagatct acggcaccac cgaaagctgg gtgatcgccg cgcttttcgcc ggaagagcac      960
ctgaaaccgg aactgctcac cacggtcggc aaggcgggtcc cgttcgtcca ggtcggcatc     1020
cgcgacccgc atgtgcgga cagagctgccc gccgggaaga ccggggagat ctgcggtccgg     1080
tcgccgatga tgatggacgg ttactggaag cggcccggacc tgacctcgaa ggtcctcatc     1140
gacggctggc tgcacaccgg cgacgtcggc tacctcgacg agaacggcta cctgtacctg     1200
gtcgaccggc tcgccgacat gatcaagacc aacggcatca aggtgtatcc ggccgaggtc     1260
gagaacgcgc tgctggccca tccggacgtc gcgcaggccg cgggtgttcgg ggtcgccgac     1320
gaggacaacg tcgagtacat gcacgcgatc gcggtgccac gccgcggcag ggacgtggat     1380
cccgccgacc ttgccgcgca tgcgcgcgg gtgctgtccc cgagccacgt gccggcggag     1440
atccggctcc gcgcgagct tccgctgacc gacgcgggga agccggacaa gctccgcctc     1500
cgcgaagagg cgaaacccgc caccaagtcc agccacgccg agccagagag cgagttgacg     1560
tca                                                                    1563

```

```

<210> 33
<211> 402
<212> PRT
<213> Amycolatopsis orientalis

```

```
<400> 33
```

```

Met Thr Thr Tyr Leu Glu Ser Phe Gln Arg Thr Leu Gln Gly Glu Val
1              5              10              15

Leu Gln Lys Arg Asp Phe Leu Glu Ile Gly Arg Gln Ala Gly Arg Phe
20              25              30

Pro Ala Ala Ser Arg Tyr Glu Glu Ala Glu Ala Val Ala Glu Ile Asn
35              40              45

Val Trp Cys Ser Asn Asp Tyr Leu Gly Met Gly Gln His Pro Asp Val
50              55              60

Leu Ser Ala Met Lys Glu Ala Val Glu Arg Phe Gly Ala Gly Ala Gly
65              70              75              80

Gly Ser Arg Asn Ile Ala Gly Thr Asn His Tyr His Val Ala Leu Glu
85              90              95

Arg Glu Leu Ala Glu Leu His Gly Lys Glu Asp Ala Leu Leu Phe Thr
100             105             110

Ser Gly Tyr Thr Ala Asn Asp Gly Ser Leu Thr Val Leu Ala Gly Arg
115             120             125

Pro Glu Asp Cys Ile Val Phe Ser Asp Glu Lys Asn His Ala Ser Ile
130             135             140

```

Ile Asp Gly Leu Arg His Ser Gly Val Glu Lys Lys Ile Phe Arg His
 145 150 155 160
 Asn Asp Val Ala His Leu Ala Glu Leu Leu Ala Ala Ala Pro Ala Asp
 165 170 175
 Arg Pro Lys Met Ile Val Phe Glu Ser Val Tyr Ser Met Asn Gly Asp
 180 185 190
 Ile Ala Pro Leu Ala Glu Phe Ala Ala Leu Ala Lys Gln Tyr Asp Ala
 195 200 205
 Met Thr Tyr Val Asp Glu Val His Ala Val Gly Met Tyr Gly Pro Glu
 210 215 220
 Gly Ala Gly Ile Ala Ala Arg Glu Gly Ile Ala Asp Glu Phe Thr Val
 225 230 235 240
 Val Met Gly Thr Leu Ala Lys Gly Phe Gly Thr Thr Gly Gly Tyr Ile
 245 250 255
 Ala Gly Pro Ala Ala Leu Ile Asp Ala Val Arg Thr His Ser Arg Ser
 260 265 270
 Phe Ile Phe Thr Thr Ala Leu Pro Pro Ala Val Ala Ala Gly Ala Leu
 275 280 285
 Ala Ala Val Arg His Leu Arg Ser Ser Glu Arg Glu Arg Glu Ile Leu
 290 295 300
 Ala Asp Asn Ala Gln Leu Leu His Lys Leu Leu Ala Glu Arg Gly Ile
 305 310 315 320
 Pro Phe Leu Ser Asp Glu Ser His Ile Val Ser Ile Leu Val Gly Asp
 325 330 335
 Asp Ala Leu Cys Lys Lys Val His Glu Leu Leu Leu Gln Arg His Gly
 340 345 350
 Ile Tyr Ile Gln Ser Ile Asn Ala Pro Ser Val Pro Phe Gly Gln Glu
 355 360 365
 Ile Leu Arg Thr Ala Pro Ser Ala Val His Thr Gly Ser Asp Val Gln
 370 375 380
 Lys Met Val Glu Ala Leu Asp Gln Ile Trp Leu Asp Leu Gly Leu Pro
 385 390 395 400

Arg Gly

<210> 34
 <211> 1206
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 34
 atgaccacct acctggagtc cttccagcgc accctgcaag gcgaagtgct gcagaaacgc 60
 gacttcctgg agatcgggcg gcaggcgggc cggttcccgg cggccagccg gtacgaggag 120

```

gccgaagcgg tcgccgagat caacgtctgg tgcagcaacg actacctcgg catggggccag 180
caccgcggacg tgctctccgc gatgaaggag gccgtcgagc ggttcggcgc cggggcgggc 240
ggttcacgca acatcgcggg caccaaccac taccacgtgg cgctcgaacg cgaactggcc 300
gaactgcacg gcaaagagga cgcgctgctc ttcacctccg gctacaccgc caacgacggt 360
tcgctgaccg tgctggcggg ccgccccgag gactgcatcg tgttctccga cgagaagaac 420
cacgcctcca tcatcgacgg gttgcggcac agtggtgtgg agaagaagat cttccgccac 480
aacgacgtcg cccatctggc cgagctgctc gccgccgccc cggcggaccg gccgaagatg 540
atcgtgttcg agtcggtcta ctcgatgaac ggcgacatcg cgccgctggc cgaattcgcc 600
gcgttggcga agcagtacga cgccatgacc tatgtggacg aagtgcacgc cgtcggaatg 660
tacgggccccg aaggtgccgg gatcgccgcg cgcgagggga tcgccgacga gttcaccgtc 720
gtgatgggca cgctggccaa gggtttcggc accaccggcg gatacatcg cgggcccgcc 780
gcgctgatcg acgccgtgcg cacgcattcg cgatcgttca tcttcaccac cgcgctgccg 840
ccgcgcgtgg ccgccggagc gctcgccgcc gtccggcacc tgcgttcgtc ggagcgggag 900
cgcgagatcc tcgccgacaa cgcgcagctg ctgcacaaac tgctcgccga acgcggcatc 960
cccttcctct cggacgagtc gcatatcgtg tcgatacctgg tcggcgacga cgcgctctgc 1020
aagaagggtgc acgaactcct gttgcagcgg cacgggatct acatccagtc gatcaacgcg 1080
ccgagtgtcc cgttcggaca ggagatcctg cgcacggccc cgtcggcggt gcacaccggc 1140
agcgacgtgc agaagatggg cgaggcgctg gaccagatct ggctggatct cggctctgccg 1200
cgcggc 1206

```

```

<210> 35
<211> 511
<212> PRT
<213> Amycolatopsis orientalis

```

```
<400> 35
```

```

Val Ser Leu Ser Leu Ala Ala Val Leu Ala Asp Ser Ala Gly Arg Arg
1          5          10         15
Pro Asp His Pro Ala Leu Val Phe Asp Gly Glu Pro Phe Ser Tyr Arg
20         25         30
Glu Leu Trp Ala Gly Ala Lys Arg Tyr Ala Ser Ala Leu Arg Asp Gln
35         40         45
Gly Val Ala Ala Gly Asp Arg Val Val Leu Leu Leu Pro Asn Thr Pro
50         55         60
Glu Phe Pro Met Val Tyr Phe Gly Ala Leu Ala Leu Gly Ala Val Val
65         70         75         80

```

Val	Pro	Val	His	Thr	Leu	Leu	Val	Ala	Glu	Glu	Ile	His	Tyr	Ile	Leu	
				85					90					95		
Thr	Asp	Cys	Asp	Ala	Arg	Val	Leu	Ile	Cys	Gly	Ala	Ala	Leu	Leu	Glu	
			100					105					110			
Gln	Gly	Gly	Glu	Ala	Ala	Asp	Ala	Ala	Gly	Val	Glu	Val	Leu	Thr	Met	
		115					120					125				
Leu	Glu	Asp	Ser	Asp	Thr	Gly	Arg	Val	Arg	Leu	Asp	Val	Leu	Ala	Gly	
	130					135					140					
Asp	Ala	Ala	Glu	Ile	Glu	Arg	Tyr	Glu	Pro	Arg	Glu	Pro	Ser	Asp	Leu	
145					150					155					160	
Ala	Leu	Ile	Leu	Tyr	Thr	Ser	Gly	Thr	Thr	Gly	Lys	Pro	Lys	Gly	Ala	
				165					170					175		
Met	Leu	Thr	His	Leu	Ser	Ile	Val	Leu	Asn	Val	Ser	Thr	Thr	Met	Leu	
			180					185					190			
Ser	Pro	Phe	Asp	Phe	His	Ala	Asp	Asp	Val	Leu	Leu	Gly	Cys	Leu	Pro	
		195					200					205				
Leu	Phe	His	Thr	Phe	Gly	Gln	Ile	Cys	Gly	Met	Ala	Thr	Cys	Phe	Arg	
	210					215					220					
Ala	Gly	Ala	Thr	Met	Val	Leu	Met	Ser	Arg	Phe	Asp	Ala	Arg	Ala	Ala	
225					230					235					240	
Leu	Glu	Leu	Met	Val	Glu	Gln	Asn	Cys	Ser	Leu	Phe	Met	Gly	Val	Pro	
			245					250					255			
Thr	Met	Tyr	Val	Ala	Leu	Leu	Glu	Ala	Ala	Glu	Asp	Glu	Pro	Arg	Arg	
			260					265					270			
Pro	Lys	Leu	Asp	Arg	Ala	Phe	Ser	Gly	Gly	Ser	Ser	Leu	Pro	Val	Ala	
		275					280					285				
Leu	Leu	Glu	Arg	Phe	Glu	Ala	Val	Phe	Asp	Cys	Pro	Ile	Tyr	Glu	Gly	
	290					295					300					
Tyr	Gly	Leu	Thr	Glu	Thr	Ser	Pro	Val	Val	Ala	Tyr	Asn	Gln	Arg	Ala	
305					310					315					320	
Trp	Pro	Thr	Arg	Ala	Gly	Thr	Val	Gly	Lys	Pro	Ile	Trp	Gly	Val	Asp	
				325					330				335			
Val	Ala	Ile	Ala	Arg	Ala	Glu	Thr	Glu	Asp	Arg	Ile	Glu	Pro	Val	Pro	
			340					345				350				
Pro	Gly	Glu	Val	Gly	Glu	Ile	Val	Val	Arg	Gly	His	Asn	Val	Met	Ala	
		355					360					365				
Gly	Tyr	Leu	Asn	Arg	Pro	Glu	Ala	Thr	Ala	Ala	Ala	Ile	Val	Asp	Gly	
	370					375					380					
Trp	Phe	Arg	Ser	Gly	Asp	Leu	Gly	Phe	Leu	Asp	Asp	Asp	Gly	Tyr	Leu	
385					390					395					400	
Ser	Ile	Val	Asp	Arg	Lys	Lys	Asp	Met	Ile	Leu	Arg	Gly	Gly	Tyr	Asn	

405	410	415
Val Tyr Pro Arg Glu Ile Glu Glu	Val Leu Ala Arg His Pro Ala Ile	
420	425	430
Ala Gln Val Ala Val Val Gly Val	Pro Asp Glu Arg Tyr Gly Glu Glu	
435	440	445
Ile Cys Ala Val Val Val Ala Ala	Ser Asp Arg Glu Pro Gly Pro Glu	
450	455	460
Leu Ala Ala Glu Leu Val Ala Trp Ser	Lys Lys Arg Val Ala Ala Tyr	
465	470	480
Lys Tyr Pro Arg Arg Val Glu Phe Leu	Asp Ala Met Pro Leu Gly Pro	
485	490	495
Ser Gly Lys Ile Leu Lys Arg Glu Leu	Ala Glu Leu Leu Gly His	
500	505	510

<210> 36
 <211> 1533
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 36
 gtgtccttgt ccctagcggc cgtcctcgcc gactcggcgg gcaggcggcc ggaccacccc 60
 gcgctcgtgt tcgacgggga accgttctcc taccgggaac tctgggcccgg ggcgaagagg 120
 tacgcctccg cgctccggga ccaggggggtc gccgccggcg accgggtcgt gctgctcctg 180
 ccgaacacgc cggagtcccc gatggtctac ttccggcgcgc tggcgctcgg cgcggtcgtc 240
 gtgccgggtgc acacgttgct cgtcgcggag gagatccact acatcctcac cgactgtgac 300
 gcccggggtgc tgatctgcgg agccgccctg ctggagcagg gcggcgaggc cggcgacgcg 360
 gccggtgtcg aagtcctgac gatgctggag gactccgaca ccggccgcgt ccgcctcgac 420
 gtccctcgccg gggacgcggc cgagatcgag cggtagaac cgcgtgaacc ctccggacctc 480
 gcgctgatcc tctacacctc ggggaccacc ggcaaaccac agggcgcgat gctgaccac 540
 ctgagcatcg tgctgaacgt ttccaccacg atgctgtcgc cgttcgactt ccacgccgac 600
 gacgtgctgc tcggctgcct gccgctgttc cacaccttcg gccagatctg cgggatggcg 660
 acctgtttcc gcgccggcgc gacgatggtg ctgatgtcgc ggttcgacgc gcgagccgcg 720
 ctggaactga tggtaggagca gaactgctcg ctgttcatgg gcgtgccgac gatgtacgtc 780
 gcgttgctgg aggccgccga ggacgagccg cggcggccca aactcgaccg ggccttctcc 840
 ggtgggttcgt cgctgcccgt agcgtgctg gagcggttcg aggccgtgtt cgactgcccg 900
 atctacgagg gatacggcct caccgagacc tcgcccgtgg tggcctacaa ccagcgcgcg 960
 tggccgaccc gcgcgggcac cgtcggcaaa ccgatctggg gcgtggacgt cgccatcgcg 1020
 cgcgccgaga ccgaagaccg gatcgaaccc gtgccgccgg gtgaggtcgg cgagatcgtc 1080

```

gtccggggcc acaacgtgat ggcgggctac ctgaaccgtc ccgaggccac ggcggccgcg 1140
atcgtggacg gctgggtccg cagcggcgac ctaggcttcc tcgacgacga cggctatctg 1200
tccattgtgg accgtaagaa ggacatgac cttcgcggcg gctacaacgt gtatccgcgc 1260
gagatcgagg aagtgctggc caggcatccc gcgatcgccc aggtcgcggt cgtcggcgtg 1320
ccggacgaac ggtacggcga ggagatctgc gccgtcgtgg tggccgcttc cgatcgggaa 1380
cccgggccgg aactggcggc ggaactcgtg gcgtggagca agaagcgcgt ggcggcctac 1440
aagtatccgc gccgcgtgga gttcctggac gcgatgccgc tcgggcccag cgggaagatc 1500
ctcaagcggg agctggcgga gctcctcggg cac 1533

```

```

<210> 37
<211> 3834
<212> PRT
<213> Amycolatopsis orientalis

```

```

<400> 37

```

```

Met Arg Thr Met Arg Asp Glu Leu Ile Leu Arg Thr Arg Arg Val Arg
1           5           10           15
Pro Asp Trp Ala Thr Val Leu Ala Ala Phe Asp Glu Thr Pro Asp Gly
20           25           30
Glu Arg Arg Arg Ala Leu Ala Ala Leu Val Val Ala Glu Thr Glu Ala
35           40           45
Val Leu Glu Ala Lys Pro Gly Ala Gly Thr Ala Ala Pro Gly Thr Pro
50           55           60
Phe Ala Glu Leu Gly Phe Asp Ser Leu Ala Ala Val Glu Leu His Arg
65           70           75           80
Arg Ile Ser Ala Ala Thr Ala Leu Glu Leu Pro Val Thr Leu Val Phe
85           90           95
Asp His Pro Thr Pro Ser Ala Leu Ala Gly His Leu Arg Asp Leu Leu
100          105          110
Ala Gly Glu Ala Val Ala Glu Ile Glu Asp Tyr Gln Ala Ile Ala Asp
115          120          125
Asp Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg Tyr Pro Gly Gly
130          135          140
Ile Gly Ser Pro Glu Asp Leu Trp Arg Leu Val Thr Glu Gly Gly Asp
145          150          155          160
Ala Thr Ser Asp Phe Pro Ala Asp Arg Gly Trp Asp Val Glu Ser Leu
165          170          175
Tyr Asp Pro Asp Pro Gly Val Pro Gly Lys Thr Tyr Thr Arg Arg Gly
180          185          190

```

Gly Phe Leu Asp Gly Ala Gly Asp Phe Asp Ala Gly Phe Phe Gly Ile
 195 200 205
 Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Leu
 210 215 220
 Glu Thr Ser Trp Glu Ala Phe Glu Arg Ala Gly Ile Asp Pro Ala Thr
 225 230 235 240
 Leu Arg Gly Ser Ala Thr Gly Val Phe Val Gly Ala Glu Thr Gln Glu
 245 250 255
 Tyr Gly Pro Arg Leu Gly Gly Ala Glu Glu Gly Leu Glu Gly Tyr Leu
 260 265 270
 Leu Thr Gly Asn Ala Ala Ser Val Ala Ser Gly Arg Val Ser Tyr Ala
 275 280 285
 Phe Gly Phe Glu Gly Pro Thr Val Thr Val Asp Thr Ala Cys Ser Ser
 290 295 300
 Ser Leu Val Ala Leu His Leu Ala Gly Gln Ala Leu Arg Leu Gly Glu
 305 310 315 320
 Cys Pro Ile Ala Val Ala Gly Gly Val Ala Val Met Ser Ser Pro Gly
 325 330 335
 Gly Phe Leu Ala Phe Ser Arg Gln Arg Gly Leu Ala Pro Asp Gly Arg
 340 345 350
 Cys Lys Pro Phe Ser Ala Ala Ala Asp Gly Thr Gly Trp Ser Glu Gly
 355 360 365
 Val Gly Met Leu Val Leu Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly
 370 375 380
 His Arg Val Leu Ala Val Val Arg Gly Thr Ala Ile Asn Ser Asp Gly
 385 390 395 400
 Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Ala Ala Gln Gln Arg Val
 405 410 415
 Ile Arg Arg Ala Leu Ala Asn Ala Gly Leu Ala Pro Ser Glu Val Asp
 420 425 430
 Ala Val Glu Ala His Gly Thr Gly Thr Val Leu Gly Asp Pro Ile Glu
 435 440 445
 Ala Gln Ala Leu Leu Ala Thr Tyr Gly Arg Asp Arg Glu Arg Pro Leu
 450 455 460
 Leu Leu Gly Ser Val Lys Ser Asn Ile Gly His Thr Gln Ser Ala Ala
 465 470 475 480
 Gly Val Ala Gly Val Ile Lys Met Val Gln Ala Met Arg His Gly Val
 485 490 495
 Leu Pro Lys Thr Leu His Ala Asp Glu Pro Thr Pro Lys Val Ala Trp
 500 505 510
 Ser Ser Gly Ala Val Glu Leu Leu Asn Glu Thr Val Ala Trp Pro Glu

515	520	525
Asn Gly Ala Pro Arg Arg Ala Ala Val Ser Ser Phe Gly Met Ser Gly 530 535 540		
Thr Asn Ala His Ala Val Leu Glu Gln Ala Pro Ala Glu Asp Glu Pro 545 550 555 560		
Glu Pro Ser Pro Glu Ala Trp Pro Thr Trp Leu Phe Pro Val Ser Gly 565 570 575		
Arg Asp Glu Lys Ala Leu Arg Arg Gln Ala Ala Arg Leu Arg Glu Ala 580 585 590		
Leu Pro Asp Ser Asp Leu Pro Ala Ile Ala Ala Ala Leu Ala Thr Thr 595 600 605		
Arg Ser Ala Leu Glu Trp Arg Ala Val Val Thr Val Ala Asp Arg Ala 610 615 620		
Gly Leu Leu Ala Gly Leu Asp Ala Leu Ala Thr Gly Glu Ala Leu Pro 625 630 635 640		
Ser Leu Val His Gly Thr Ala Arg Ile Gly Ile Val Phe Ser Gly Gln 645 650 655		
Gly Ser Gln Arg Ala Gly Met Gly Arg Glu Leu His Arg Arg Phe Pro 660 665 670		
Val Phe Ala Ala Ala Phe Asp Asp Ala Cys Gly His Leu Asp Leu Gln 675 680 685		
Leu Asp Arg Pro Leu Ala Glu Ile Val Phe Ala Asp Glu Gly Thr Glu 690 695 700		
Glu Ala Gly Leu Leu His Arg Thr Glu Tyr Ala Gln Cys Ala Leu Phe 705 710 715 720		
Ala Val Glu Val Ala Leu Phe Arg Leu Tyr Glu His Trp Gly Leu Arg 725 730 735		
Pro Asp Tyr Val Ala Gly His Ser Ile Gly Glu Leu Ala Ala Ala His 740 745 750		
Val Ser Gly Met Leu Ser Leu Ser Asp Ala Ala Ala Leu Val Ala Ala 755 760 765		
Arg Gly Arg Leu Met Gln Asp Thr Arg Glu Gly Gly Ala Met Leu Ala 770 775 780		
Val Gln Ala Thr Glu Asp Glu Val Leu Pro Leu Leu Asp Glu Arg Leu 785 790 795 800		
Ala Ile Ala Ala Val Asn Gly Pro Arg Ser Val Val Val Ser Gly Asp 805 810 815		
Glu Ala Ala Val Glu Glu Val Ala Ala Ala Phe Ala Arg Arg Lys Thr 820 825 830		
Lys Arg Leu Lys Val Ser His Ala Phe His Ser His His Met Asp Gly 835 840 845		

Met Leu Asp Glu Phe Arg Arg Phe Ala Glu Ile Leu Thr Phe Arg Lys
 850 855 860
 Pro Val Ile Pro Leu Val Ser Thr Val Ser Gly Glu Leu Leu Thr Glu
 865 870 875 880
 Ala Thr Ala Pro Glu Tyr Trp Val Glu His Val Arg Arg Pro Val Arg
 885 890 895
 Phe Ala Asp Gly Val Arg Arg Leu Asp Glu Leu Gly Val Asp Val Leu
 900 905 910
 Leu Glu Leu Gly Pro Asp Ala Val Leu Thr Pro Met Ala Ala Glu Val
 915 920 925
 Leu Asp Gly Glu Gly Ala Ala Leu Val Pro Ser Leu Arg Gly Ser Arg
 930 935 940
 Pro Glu Ala Glu Ala Leu Ala Ala Ser Leu Ala Glu Leu Trp Val Arg
 945 950 955 960
 Gly Ala Glu Leu Gly Trp Pro Gln Val Phe Gly Ala His Pro Arg Ala
 965 970 975
 Asp Leu Pro Thr Tyr Ala Phe Glu Arg Gln Arg Tyr Trp Leu Ile Asp
 980 985 990
 Gln Asp Thr Ala Gly Asp Pro Gly Ala Tyr Gly Leu Gly Asp Thr Gly
 995 1000 1005
 His Pro Leu Leu Arg Ala Ser Val Thr Thr Ala Glu Asp Gly Ala
 1010 1015 1020
 Leu Leu Leu Ser Gly Arg Leu Ser Pro Leu Thr Gln Pro Trp Leu
 1025 1030 1035
 Ala Asp His Val Val Gly Gly Asp Val Val Leu Pro Gly Thr Ala
 1040 1045 1050
 Leu Leu Glu Leu Ala Leu Arg Ala Ala Glu Leu Ala Gly Ala Gly
 1055 1060 1065
 Gly Val Glu Glu Leu Thr Leu Glu Val Pro Met Val Leu Ser Glu
 1070 1075 1080
 Ala Gly Val Gln Val Gln Val Ser Val Arg Asp Ser Gly Leu Leu
 1085 1090 1095
 Ile Phe Phe Arg Asp Thr Glu Asp Asp Glu Trp Thr Arg Cys Ala
 1100 1105 1110
 Ser Gly Thr Leu Gly Ala Ala Ala Pro Ala Pro Gly Phe Gly Ala
 1115 1120 1125
 Trp Pro Pro Ala Gly Glu Pro Leu Asp Leu Ser Asp Leu Tyr Asp
 1130 1135 1140
 Arg Leu Ala Asp Ser Gly Leu Asp Tyr Gly Pro Ala Phe Arg Cys
 1145 1150 1155

Leu	Arg	Ala	Ala	Trp	Arg	Ser	Gly	Asp	Asp	Leu	Tyr	Ala	Glu	Val
1160						1165					1170			
Ala	Ala	Val	Pro	Glu	Thr	Gln	Gly	Gly	Phe	Gly	Val	His	Pro	Ala
1175						1180					1185			
Leu	Leu	Asp	Ala	Ala	Leu	His	Val	Leu	Glu	Leu	Gly	Ser	Gly	Gly
1190						1195					1200			
Gly	Gly	Gly	Pro	Ala	Ala	Leu	Pro	Phe	Ala	Trp	Ser	Gly	Val	Thr
1205						1210					1215			
Leu	His	Ala	Arg	Gly	Ala	Asp	Val	Leu	Arg	Val	Lys	Leu	Glu	Asn
1220						1225					1230			
His	Val	Ala	Gly	Ala	Glu	Ala	Gly	Thr	Tyr	Ser	Val	Ser	Leu	Lys
1235						1240					1245			
Val	Ala	Asp	Gly	Ala	Gly	Glu	Pro	Val	Ala	Ser	Val	Glu	Ser	Leu
1250						1255					1260			
Ala	Leu	Arg	Pro	Leu	Ser	Thr	Ala	Pro	Arg	Ala	Gln	Asp	Gly	Ala
1265						1270					1275			
Leu	Tyr	Gly	Val	Asp	Trp	Ile	Ser	Leu	Pro	Gly	Thr	Pro	Gly	Val
1280						1285					1290			
Ala	Glu	Tyr	Arg	Leu	Tyr	Pro	Asp	Leu	Thr	Ala	Val	Asp	Asp	Val
1295						1300					1305			
Pro	Pro	Val	Val	Ala	Val	Arg	Cys	Thr	Thr	Leu	Glu	Ser	Val	Leu
1310						1315					1320			
Asp	Leu	Val	Gln	Thr	Trp	Leu	Ala	Asp	Asp	Arg	Phe	Ala	Pro	Ala
1325						1330					1335			
Arg	Leu	Ala	Leu	Leu	Thr	Asp	Gly	Ala	Val	Ala	Thr	Glu	Asn	Pro
1340						1345					1350			
Asp	Pro	Ala	Ala	Ala	Ala	Met	Trp	Gly	Leu	Val	Arg	Ser	Ala	Gln
1355						1360					1365			
Ala	Glu	His	Pro	Asp	Arg	Leu	Val	Leu	Ala	Asp	Val	Thr	Gly	Glu
1370						1375					1380			
Asp	Gly	Leu	Ala	Ala	Gly	Leu	Ala	Ser	Gly	Glu	Pro	Glu	Phe	Ala
1385						1390					1395			
Ala	Arg	Asp	Gly	Ala	Val	Leu	Val	Pro	Arg	Leu	Thr	Arg	Val	Pro
1400						1405					1410			
Ser	Pro	Ala	Pro	Ala	Ser	Phe	Thr	Thr	Gly	Gly	Thr	Val	Leu	Ile
1415						1420					1425			
Thr	Gly	Gly	Thr	Gly	Gly	Leu	Ala	Gly	Leu	Leu	Ala	Arg	His	Leu
1430						1435					1440			
Val	Glu	Arg	His	Glu	Val	Arg	Ser	Leu	Leu	Leu	Val	Ser	Arg	Arg
1445						1450					1455			
Gly	Ala	Ala	Gly	Pro	Leu	Val	Asp	Asp	Leu	Thr	Ala	Leu	Gly	Ala

1460		1465		1470
Asp Val Thr Val Ala Ala Cys Asp Ile Ala Asp Arg Glu Ser Val				
1475		1480		1485
Ala Ala Leu Leu Ala Glu His Pro Val Ser Ala Val Val His Ala				
1490		1495		1500
Ala Gly Val Leu Asp Asp Ala Thr Ile Thr Thr Leu Asp His Glu				
1505		1510		1515
Arg Leu Ala Ala Val Leu Arg Pro Lys Val Thr Gly Ala Leu Val				
1520		1525		1530
Leu Asp Glu Leu Thr Arg Asp Leu Asp Leu Ser Ala Phe Val Leu				
1535		1540		1545
Phe Ser Ser Ser Ala Ala Thr Phe Asp Gly Ala Gly Gln Ala Asn				
1550		1555		1560
Tyr Ala Ala Ala Asn Ala Phe Leu Glu Ala Leu Ala Leu Arg Arg				
1565		1570		1575
Arg Ala Glu Gly Arg Pro Gly Val Ala Leu Gly Trp Gly Leu Trp				
1580		1585		1590
Ala Thr Gly Met Gly Ala Arg Leu Asp Glu Ala Gly Leu Arg Arg				
1595		1600		1605
Ile Glu Arg Ser Gly Gln Arg Ala Leu Ser Glu Val Asp Gly Leu				
1610		1615		1620
Ala Leu Phe Asp Ala Ala Leu Ala Ala Asp Arg Pro Val Leu Leu				
1625		1630		1635
Pro Met Arg Met His Arg Ala Ala Leu Arg Ala Arg Ala Ser Ala				
1640		1645		1650
Glu Gly Leu Pro Ala Val Leu Gly Gly Leu Val Arg Val Thr Arg				
1655		1660		1665
Pro Ala Pro Ser Ala Ala Pro Arg Gly Leu Asp Glu Ala Ala Leu				
1670		1675		1680
Leu Asp Leu Val Arg Thr Thr Val Ala Ala Val Leu Gly His Pro				
1685		1690		1695
Asp Ala His Ala Ile Asp Pro Asp Arg Ala Phe Thr Glu Val Gly				
1700		1705		1710
Phe Asp Ser Leu Ala Ala Val Glu Leu Arg Asn Arg Leu Ile Ala				
1715		1720		1725
Ala Thr Gly Leu Lys Ile Ala Pro Thr Leu Val Phe Asp His Pro				
1730		1735		1740
Asn Pro Arg Ala Val Ala Ala Phe Leu Ala Ala Gly Ser Ala Pro				
1745		1750		1755
Val Arg Asp Glu Pro Ala Ala Pro Ala Glu Ala Asp Glu Pro Ile				
1760		1765		1770

Ala	Ile	Ile	Gly	Met	Ala	Cys	Arg	Tyr	Pro	Gly	Gly	Val	Ser	Thr
1775						1780					1785			
Pro	Asp	Asp	Leu	Trp	Arg	Leu	Val	Ala	Asp	Gly	Asn	Asp	Gly	Ile
1790						1795					1800			
Thr	Arg	Phe	Pro	Glu	Asn	Arg	Gly	Trp	Asp	Thr	Asp	Gly	Val	Tyr
1805						1810					1815			
His	Pro	Asp	Ala	Asp	His	Arg	Gly	Thr	Thr	Tyr	Val	Arg	Glu	Gly
1820						1825					1830			
Gly	Phe	Leu	His	Asp	Ala	Gly	Gln	Phe	Asp	Pro	Gly	Phe	Phe	Gly
1835						1840					1845			
Ile	Ser	Pro	Arg	Glu	Ala	Leu	Ala	Met	Asp	Pro	Gln	Gln	Arg	Leu
1850						1855					1860			
Leu	Leu	Glu	Ile	Ser	His	Glu	Ala	Val	Glu	Arg	Ala	Gly	Ile	Asp
1865						1870					1875			
Pro	Lys	Ser	Leu	Arg	Gly	Ser	Gly	Thr	Gly	Val	Phe	Ala	Gly	Val
1880						1885					1890			
Met	Tyr	His	Asp	Tyr	Ala	Thr	Gly	Leu	Asn	Arg	Val	Pro	Asp	Asp
1895						1900					1905			
Val	Glu	Gly	Tyr	Leu	Gly	Asn	Gly	Thr	Ser	Ala	Ser	Ile	His	Ser
1910						1915					1920			
Gly	Arg	Val	Ala	Tyr	Thr	Phe	Gly	Leu	Glu	Gly	Pro	Ala	Val	Thr
1925						1930					1935			
Ile	Asp	Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala	Leu	His	Leu	Ala
1940						1945					1950			
Ala	Gln	Ala	Leu	Arg	Arg	Gly	Glu	Cys	Ser	Met	Ala	Leu	Ala	Gly
1955						1960					1965			
Gly	Val	Thr	Val	Met	Ala	Thr	Pro	Glu	Val	Phe	Val	Asp	Phe	Ser
1970						1975					1980			
Arg	Gln	Arg	Gly	Leu	Ala	Pro	Asp	Gly	Arg	Cys	Lys	Ser	Phe	Ser
1985						1990					1995			
Asp	Glu	Ala	Asp	Gly	Thr	Val	Trp	Ser	Glu	Gly	Val	Gly	Met	Leu
2000						2005					2010			
Leu	Val	Glu	Arg	Leu	Ser	Asp	Ala	Arg	Arg	Asn	Gly	His	Arg	Val
2015						2020					2025			
Leu	Ala	Ile	Val	Arg	Gly	Ser	Ala	Val	Asn	Gln	Asp	Gly	Ala	Ser
2030						2035					2040			
Asn	Gly	Leu	Thr	Ala	Pro	Ser	Gly	Pro	Ser	Gln	Gln	Arg	Val	Ile
2045						2050					2055			
Arg	Arg	Ala	Leu	Ala	Asp	Ala	Gly	Leu	Lys	Pro	Ser	Glu	Val	Asp
2060						2065					2070			

Ala	Val	Glu	Ala	His	Gly	Thr	Gly	Thr	Pro	Leu	Gly	Asp	Pro	Ile
2075						2080					2085			
Glu	Ala	Gln	Ala	Met	Leu	Ala	Thr	Tyr	Gly	Gln	Asp	Arg	Asp	Arg
2090						2095					2100			
Pro	Leu	Trp	Leu	Gly	Ser	Leu	Lys	Ser	Asn	Leu	Gly	His	Thr	Gln
2105						2110					2115			
Ala	Ala	Ala	Gly	Val	Gly	Gly	Ile	Ile	Lys	Met	Val	Gln	Ala	Met
2120						2125					2130			
His	His	Gly	Val	Leu	Pro	Arg	Thr	Leu	Asn	Leu	Gly	Thr	Pro	Thr
2135						2140					2145			
Thr	Lys	Val	Asp	Trp	Thr	Ser	Gly	Asn	Val	Ser	Leu	Leu	Ser	Glu
2150						2155					2160			
Pro	Val	Ala	Trp	Pro	Glu	Thr	Gly	Gly	Pro	Arg	Arg	Ala	Ala	Val
2165						2170					2175			
Ser	Ser	Phe	Gly	Ile	Ser	Gly	Thr	Asn	Ala	His	Val	Val	Leu	Glu
2180						2185					2190			
Gln	Ala	Glu	Pro	Val	Glu	Lys	Ser	Thr	Ser	Asp	Thr	Ser	Pro	Leu
2195						2200					2205			
Gly	Gly	Asp	Val	Leu	Pro	Phe	Val	Leu	Ser	Gly	Lys	Thr	Ser	Ala
2210						2215					2220			
Ala	Leu	Ala	Ala	Gln	Ala	Asp	Arg	Leu	Ala	Gly	His	Leu	Ala	Gly
2225						2230					2235			
Asp	Val	Ser	Leu	Pro	Ala	Val	Ala	Arg	Ala	Leu	Ala	Val	Thr	Arg
2240						2245					2250			
Ser	Ala	Leu	Asp	His	Arg	Ala	Val	Val	Val	Ala	Gly	Asp	Arg	Ala
2255						2260					2265			
Gly	Leu	Thr	Ala	Gly	Leu	Arg	Ala	Leu	Ala	Asp	Ala	Val	Pro	Ala
2270						2275					2280			
Pro	His	Val	Val	Asp	Gly	Val	Ala	Glu	Asn	Gly	Lys	Ala	Val	Phe
2285						2290					2295			
Val	Phe	Pro	Gly	Gln	Gly	Ser	Gln	Trp	Thr	Gly	Met	Ala	Val	Asp
2300						2305					2310			
Leu	Leu	Gly	Ser	Ser	Ala	Val	Phe	Ala	Glu	Ala	Met	Ala	Asp	Cys
2315						2320					2325			
Glu	Ala	Ala	Leu	Leu	Ser	His	Leu	Asp	Trp	Lys	Leu	Thr	His	Val
2330						2335					2340			
Leu	Ser	Asp	Ala	Ala	Ala	Leu	Glu	Arg	Val	Asp	Val	Val	Gln	Pro
2345						2350					2355			
Val	Leu	Phe	Ala	Val	Met	Val	Ser	Leu	Ala	Arg	Leu	Trp	Arg	Ala
2360						2365					2370			
Cys	Gly	Ile	Glu	Pro	Ala	Ala	Val	Val	Gly	His	Ser	Gln	Gly	Glu

2375	2380	2385
Ile Ala Ala Ala Cys Val	Ala Gly Ala Leu Ser	Leu Glu Asp Ala
2390	2395	2400
Ala Arg Val Val Cys Leu	Arg Ser Lys Ala Ile	Leu Ala Leu Ser
2405	2410	2415
Gly Leu Gly Gly Met Val	Ser Val Ala Ala Ser	Glu Asp Arg Val
2420	2425	2430
Arg Glu Leu Leu Pro Asp	Gly Val Ser Val Ala	Val Val Asn Gly
2435	2440	2445
Pro Ala Ser Val Val Val	Ser Gly Asp Val Ala	Gly Leu Glu Ala
2450	2455	2460
Leu Leu Lys Arg Cys Glu	Leu Leu Asp Val Arg	Ala Lys Arg Val
2465	2470	2475
Pro Val Asp Tyr Ala Ser	His Ser Ala His Val	Asp Ala Ile Glu
2480	2485	2490
Gln Gln Val Val Thr Ala	Leu Ser Gly Ile Met	Pro Arg Glu Ala
2495	2500	2505
Glu Leu Pro Met Tyr Ser	Thr Val Thr Gly Glu	Pro Ile Asp Thr
2510	2515	2520
Thr Thr Leu Asp Ala Ala	Tyr Trp Phe Arg Asn	Leu Arg Ala Thr
2525	2530	2535
Val Arg Phe Asp Gln Ala	Val Arg Arg Leu Ile	Ala Asp Gly Phe
2540	2545	2550
Arg Phe Phe Val Glu Thr	Ser Pro His Pro Val	Leu Val Ala Gly
2555	2560	2565
Leu Thr Glu Leu Val Glu	Glu Ala Ala Val Pro	Ala Val Ala Leu
2570	2575	2580
Ala Ser Leu Arg Arg Asp	Glu Gly Gly Pro Thr	Arg Phe Val Thr
2585	2590	2595
Ser Leu Ala Glu Ala His	Val His Gly Leu Ser	Pro Asp Trp Ala
2600	2605	2610
Ala Leu Leu Pro Glu Ala	Gly Trp Val Asp Leu	Pro Pro Tyr Ala
2615	2620	2625
Phe Gln His Gln Glu Phe	Trp Leu Thr Asp Ala	Gly Glu Pro Gly
2630	2635	2640
Asp Ala Ala Gly Phe Gly	Leu Gly Ala Thr Gly	His Pro Leu Leu
2645	2650	2655
Thr Ala Ala Thr Ala Leu	Pro Gly Ser Gly Gly	Leu Leu Leu Thr
2660	2665	2670
Gly Arg Ile Ser Thr Ala	Ala Gln Pro Trp Leu	Ala Asp His Ala
2675	2680	2685

Val	Gln	Gly	Val	Val	Leu	Leu	Pro	Gly	Thr	Ala	Phe	Val	Glu	Leu
2690						2695					2700			
Ala	Leu	Gln	Ala	Gly	Thr	His	Ala	Gly	Cys	Gly	Arg	Ile	Asp	Glu
2705						2710					2715			
Leu	Thr	Leu	Glu	Ala	Pro	Leu	Pro	Leu	Pro	Glu	Gln	Gly	Gly	Val
2720						2725					2730			
Arg	Val	Gln	Val	Val	Leu	Gly	Ser	Glu	Val	Asn	Gly	Arg	Arg	Glu
2735						2740					2745			
Val	Thr	Val	His	Ser	Gln	Ala	Glu	Ser	Gly	Asp	Asp	Thr	Trp	Val
2750						2755					2760			
Arg	His	Ala	Ser	Gly	Phe	Leu	Thr	Ser	Ala	Glu	Thr	Pro	Gly	Glu
2765						2770					2775			
Gly	Leu	Thr	Glu	Trp	Pro	Pro	Ala	Gly	Ala	Thr	Ser	Ala	Asp	Leu
2780						2785					2790			
Asp	Gly	Phe	Tyr	Ala	Asp	Ala	Glu	Ala	Gln	Gly	Tyr	Gly	Tyr	Gly
2795						2800					2805			
Pro	Ala	Phe	Gln	Gly	Leu	Arg	Ala	Ala	Trp	Thr	Leu	Gly	Ser	Asp
2810						2815					2820			
Val	Phe	Ala	Glu	Val	Val	Leu	Pro	Asp	Ala	Glu	Gly	Ala	Asp	Arg
2825						2830					2835			
Phe	Gly	Leu	His	Pro	Ala	Leu	Leu	Asp	Ala	Ala	Leu	His	Ala	Leu
2840						2845					2850			
Gly	Thr	Val	Arg	Ser	Gly	Asp	Gly	Ala	Glu	Leu	Pro	Phe	Ala	Trp
2855						2860					2865			
Thr	Gly	Val	Thr	Val	His	Ala	Val	Gly	Ala	Thr	Ala	Leu	Arg	Val
2870						2875					2880			
Arg	Leu	Thr	Val	Gly	Thr	Asp	Thr	Val	Ala	Val	Thr	Ala	Ala	Asp
2885						2890					2895			
Pro	Ala	Gly	Ala	Pro	Val	Ala	Thr	Val	Glu	Gly	Leu	Val	Thr	Arg
2900						2905					2910			
Pro	Ala	Ala	Leu	Pro	Gly	Ser	Arg	Arg	Pro	Asp	Ser	Leu	Phe	Arg
2915						2920					2925			
Val	Asp	Trp	Thr	Pro	Val	Ser	Thr	Pro	Glu	Ala	Val	Glu	Thr	Pro
2930						2935					2940			
Thr	Val	Thr	Val	Leu	Ser	Asp	Gly	Asp	Leu	Thr	Ala	Leu	Ala	Glu
2945						2950					2955			
Ile	Pro	Asp	Val	Val	Leu	Val	Pro	Val	Gly	Ala	Glu	Ala	Gly	Asp
2960						2965					2970			
Leu	Thr	Glu	Ser	Val	His	Arg	Thr	Thr	Ala	Arg	Val	Leu	Asp	Leu
2975						2980					2985			

Leu	Arg	Thr	Trp	Leu	Asp	Asp	Glu	Arg	Phe	Ala	Asp	Ala	Arg	Leu
2990						2995					3000			
Val	Leu	His	Thr	Arg	Gly	Ala	Val	Ala	Asp	Val	Arg	Asp	Leu	Pro
3005						3010					3015			
Ala	Ala	Ala	Ala	Trp	Gly	Leu	Val	Arg	Ser	Ala	Gln	Ala	Glu	Asn
3020						3025					3030			
Pro	Asp	Arg	Ile	Val	Leu	Leu	Asp	Ser	Asp	Thr	Asp	Leu	Pro	Pro
3035						3040					3045			
Ala	Leu	Leu	Ala	Glu	Val	Leu	Ala	Thr	Gly	Glu	Ala	Gln	Leu	Ala
3050						3055					3060			
Trp	Arg	Asp	Gly	Glu	Leu	Leu	Val	Pro	Arg	Leu	Ala	Lys	Val	Ser
3065						3070					3075			
Thr	Asp	Gly	Thr	Leu	Thr	Pro	Pro	Glu	Gly	Pro	Trp	Val	Leu	Asp
3080						3085					3090			
Ala	Pro	Arg	Arg	Gly	Thr	Leu	Glu	Glu	Leu	Ala	Leu	Val	Pro	Ala
3095						3100					3105			
Pro	Thr	Ala	Ala	Arg	Pro	Leu	Ala	Asp	Gly	Glu	Val	Arg	Ile	Gln
3110						3115					3120			
Val	Arg	Ala	Ala	Gly	Ile	Asn	Phe	Arg	Asp	Val	Leu	Ile	Thr	Leu
3125						3130					3135			
Asp	Met	Tyr	Pro	Glu	Asp	Lys	Ala	Val	Met	Gly	Ser	Glu	Gly	Ala
3140						3145					3150			
Gly	Ile	Val	Thr	Glu	Ile	Gly	Ser	Gly	Val	Thr	Gly	Leu	Lys	Pro
3155						3160					3165			
Gly	Asp	Arg	Val	Phe	Gly	Leu	Phe	Asp	Gly	Ala	Phe	Gly	Pro	Val
3170						3175					3180			
Ala	Ile	Ala	Asp	Arg	Arg	Thr	Val	Thr	Glu	Met	Pro	Val	Asp	Trp
3185						3190					3195			
Thr	Phe	Ala	Glu	Ala	Ala	Ala	Leu	Pro	Val	Val	Phe	Leu	Thr	Ala
3200						3205					3210			
Tyr	Tyr	Gly	Leu	Val	Asp	Leu	Gly	Gly	Leu	Arg	Pro	Gly	Glu	Lys
3215						3220					3225			
Val	Leu	Ile	His	Gly	Ala	Thr	Gly	Gly	Val	Gly	Met	Ala	Ala	Val
3230						3235					3240			
Gln	Leu	Ala	Arg	His	Leu	Gly	Ala	Glu	Val	Phe	Ala	Thr	Ala	Ser
3245						3250					3255			
Pro	Gly	Lys	Trp	Glu	Val	Leu	Arg	Gly	Leu	Gly	Phe	Asp	Asp	Glu
3260						3265					3270			
His	Ile	Ala	Ser	Ser	Arg	Thr	Leu	Asp	Phe	Glu	Asp	Arg	Phe	Gly
3275						3280					3285			
Arg	Met	Asp	Val	Val	Leu	Asp	Ser	Leu	Ala	Lys	Glu	Phe	Val	Asp

3290	3295	3300
Ala Ser Leu Arg Leu Leu Gly Glu Gly Gly Arg Phe Val Glu Met		
3305	3310	3315
Gly Lys Thr Asp Ile Arg Asp Ala Asp Glu Val Ala Ala Ala His		
3320	3325	3330
Pro Gly Val Thr Tyr Arg Ala Phe Asp Leu Leu Asp Ala Gly Arg		
3335	3340	3345
Pro Arg Ile Gly Glu Ile Leu Ala Glu Leu Leu Asp Leu Phe Gly		
3350	3355	3360
Ala Gly Ser Leu Thr Val Pro Arg Pro Thr Val Trp Asp Ala Arg		
3365	3370	3375
Arg Ala Pro Glu Val Phe Arg Phe Met Ser Gln Ala Lys His Ile		
3380	3385	3390
Gly Lys Asn Val Leu Thr Ile Pro Ser Thr Met Asp Gly Asn Gly		
3395	3400	3405
Thr Val Leu Ile Thr Gly Ala Thr Gly Thr Leu Gly Ala Leu Val		
3410	3415	3420
Ala Arg His Leu Val Thr Val Arg Gly Val Arg His Leu Leu Leu		
3425	3430	3435
Val Gly Arg Arg Gly Arg Ala Ala Ala Gly Met Ala Glu Leu Glu		
3440	3445	3450
Ala Glu Leu Thr Ala Ala Gly Ala Ser Val Thr Ile Ala Ala Cys		
3455	3460	3465
Asp Ala Ala Asp Arg Ala Ala Leu Ala Ala Leu Leu Ala Thr Val		
3470	3475	3480
Pro Ala Glu His Pro Leu Ala Gly Val Val His Ala Ala Gly Val		
3485	3490	3495
Leu Asp Asp Gly Leu Val Ala Thr Leu Thr Pro Glu Arg Leu Ala		
3500	3505	3510
Lys Val Leu Arg Pro Lys Val Asp Ala Ala Val Asn Leu His Glu		
3515	3520	3525
Leu Thr Arg Asp Ala His Leu Ala Glu Phe Val Leu Phe Ser Ser		
3530	3535	3540
Ala Ala Gly Ala Phe Gly Asp Ala Gly Gln Gly Asn Tyr Ala Ala		
3545	3550	3555
Ala Asn Ser Phe Leu Asp Ser Leu Ala Arg His Arg Arg Ala Gln		
3560	3565	3570
Gly Leu Pro Ala Val Ser Leu Ala Trp Gly Phe Trp Ala Glu Leu		
3575	3580	3585
Ser Gly Met Thr Gly His Leu Gly Glu Ala Asp Leu Ala Arg Leu		
3590	3595	3600

Lys Arg Ser Gly Met Ser Pro Leu Ser Thr Glu Asp Gly Leu Leu
 3605 3610 3615
 Leu Met Asp Ala Ala Arg Ala Gly Tyr Glu Pro Ala Pro Leu Pro
 3620 3625 3630
 Met His Ile Asp Leu Ala Ala Leu Arg Gly Glu Glu Val His Pro
 3635 3640 3645
 Leu Leu Arg Gly Leu Val Lys Ala Pro Val Arg Arg Ala Ala Ala
 3650 3655 3660
 Ala Thr Gly Thr Gln Ser Glu Gly Leu Ala Asp Arg Leu Ala Gly
 3665 3670 3675
 Leu Ala Pro Ala Ala Arg Gly Arg Ala Leu Leu Asp Leu Ile Arg
 3680 3685 3690
 Ala Asn Val Ala Ala Val Leu Gly Phe Gly Ser Pro Glu Gln Val
 3695 3700 3705
 Gly Val Arg Gln Ala Phe Arg Glu Leu Gly Phe Asp Ser Leu Ser
 3710 3715 3720
 Ala Val Glu Leu Arg Asn Arg Leu Asn Ala Ala Thr Gly Leu Arg
 3725 3730 3735
 Leu Pro Ala Thr Val Val Phe Asp His Pro Thr Pro Thr Ala Leu
 3740 3745 3750
 Ala Glu Thr Leu Gly Asp Arg Leu Ala Pro Ala Glu Glu Ala Val
 3755 3760 3765
 Asp Asp Glu Val Ala Arg Ile Gly Ala Val Leu Ala Ser Val Pro
 3770 3775 3780
 Ala Asp Arg Leu Arg Glu Ala Gly Val Leu Asp Leu Leu Thr Arg
 3785 3790 3795
 Leu Ala Asp Pro Gly Tyr Arg Pro Thr Glu Ser Pro Asp Gly Ala
 3800 3805 3810
 Asp Ile Asp Glu Met Asp Ala Asp Arg Leu Ile Ala Leu Ala Phe
 3815 3820 3825
 Asp Ala Ser Asp Pro Ala
 3830

<210> 38
 <211> 11505
 <212> DNA
 <213> *Amycolatopsis orientalis*

<400> 38
 atgcggacca tgcgagacga actgattctg cgaactcgac gtgttcggcc ggactgggcc 60
 acggtgctgg ccgctttcga cgaaaccccg gacggggagc ggccggcgggc gctcgccgcg 120
 ctggtcgtcg ccgagaccga agcgggtgctg gaggcgaagc cgggtgcggg gaccgcccgcg 180

cccggcacgc ccttcgccga actcgggttc gattccctcg cggcgggtgga actgcaccgg	240
cggatctccg cggccaccgc gctggagctg ccggtgacgc tcgtcttcga ccacccgaca	300
ccgtcggcgc tcgccggtca tctgcgcgat ctgctcgccg gtgaggccgt ggccgagatc	360
gaggactacc aggcgatcgc cgacgacgag ccgatcgcca tcgtcggcat ggcttgccgt	420
taccccggtg ggatcgggttc gccggaggac ctctggcggc tggtcaccga gggtagggac	480
gcgacgtcgg acttcccggc cgaccgcggc tgggacgtgg aatcgctgta cgaccccgac	540
cccgggggtgc ccggcaagac ctacaccggc cgaggcgggt tcctcgacgg cgccggggat	600
ttcgacgcgg gattcttcgg gatctcgccg cgtgaggcgc tggcgatgga tccgcaacag	660
cggctcctgc tggagacgtc gtgggaggcc ttcgagcggg cggggatcga ccccgcgacc	720
ttgcggggaa gcgcgaccgg cgtgttcgtc ggcgcggaga cccaggagta cggaccgcgt	780
ctcggtaggc cggaagaagg tctcgaaggc tatctgctga ccggtaacgc ggcgagtgtc	840
gcgtcgggcc gcgtctcgta cgccttcggg ttcgagggcc cgacggtcac cgtggacacc	900
gcatgctcgt cgtcgctggt ggccctgcac ctggcagggc aggcgctgcg gctgggggag	960
tgcccgatcg cggtaggcgg cggcgtcgcg gtgatgtcga gcccggcgg tttcctcgcc	1020
ttcagccgtc agcgcgggct cgcgccggac gggcgctgca agccgttctc cgccgcggcg	1080
gacggcacccg gctgggtccga aggtgtcggg atgctggtgc tggaaaggct ttccgacgcc	1140
cggcgcaacg ggcaccgggt gctcgccgtc gtccgcggca ccgcgatcaa ctccgacggc	1200
gccagcaacg gtctcaccgc gcccaacggc gccgctcagc agagggtgat ccggcgcgcg	1260
ctggcgaacg ccgggctcgc accgtccgaa gtggacgccc tcgaagcaca cggcaccggt	1320
accgtcctcg gcgacccgat cgaggcgcag gcaactgctg ccacctacgg ccgcgaccgt	1380
gagcgcccgt tgctcctcgg ctcggtcaag tcgaacatcg ggcacacca gtcggccgcc	1440
ggggtggccg gggtagtcaa gatggtgcag gcgatgcggc acggtgtgct gcccaagacc	1500
ctgcacgccc acgagcccac cccgaaggtc gcctggctct ccggtgccgt cgaactgctc	1560
aacgagaccg ttgcttggcc ggagaatggc gcgcctcgcc gcgcggcggg gtcgtcgttc	1620
gggatgagcg ggaccaacgc gcacgccgtc ctggaacagg ccccgccga ggacgagccc	1680
gagccgtcgc cggaagcgtg gccacactgg ctgttccccg tcagcggccc cgacgagaag	1740
gccctgcgcc gtcaggccgc ccggctgcgt gaagccctgc cggacagtga cctccccgcc	1800
atcgccgccc cgctcgccac caccgggtcc gccctggagt ggccggccgt ggtgacggtc	1860
gccgatcgcg cgggattggt ggccggggtg gacgcgttgg ccaccggtga agctctgccg	1920
agcctgggtcc acgggacggc gcggatcggg atcgtcttca gcggccaggg cagccagcgc	1980
gccgggatgg gccgcgaact gcaccgccgg ttcccggtgt tcgccgccgc cttcgacgac	2040

gcctgcgggc atctcgacct gcaactggac cggccgctgg ccgagatcgt gttcgccgac	2100
gagggcaccg aggaagccgg cctgttgac cgcaccgaat acgcgcagtg cgcgttggtc	2160
gccgtcgagg tcgcgctggt ccggctgtac gagcattggg gcctgcgccc cgattacgtc	2220
gccgggcact cgatcggcga gctggccgcc gcgcacgttt cgggcatgct ttcgctctcc	2280
gacgccgccg cgctcgtcgc cgcgcgggga cgcctgatgc aggacacgcg cgagggcggc	2340
gcgatgctcg cggcgcaggc gacggaggac gaggtcctgc cgctgcttga cgaacgcctc	2400
gcgatcgcgg ccgtcaacgg cccgcggtcg gtggctcgtc cgggcgacga ggccgcggtc	2460
gaggaggtcg ccgccgcgtt cgccaggcgc aagaccaaac ggctcaaggc gagtcacgcc	2520
ttccactcgc atcacatgga cgggatgctc gacgagttcc gccggttcgc cgagatcctc	2580
accttccgga agccggtgat cccgctggtg tccactgtgt ccggtgagct gctcaccgag	2640
gcgacggcgc cgggaatactg ggtggagcac gtgcgccgcc cggcgcgggtt cgccgacggc	2700
gtgcggcggc tggacgagct cggcgtcgac gtgctcctgg aactcggccc ggacgcggtg	2760
ctgacgccga tggccgccga agtcctcgac ggcgagggag cggcgtggt gccgagcctg	2820
cgcgggtcgc ggccggaggc ggaggcgtc gccgcgtcgc tggccgaact gtgggtccgc	2880
ggcgcgaac tcggctggcc tcagggtgtt ggtgcacacc cgagggccga tttgccgact	2940
tatgccttcg aacggcagcg gtactggctg atcgaccagg acaccgccgg ggatcccgcc	3000
gcctacggtc tgggcgacac cgggcatccg ctcttcgccc cgtcggtcac cacggccgaa	3060
gacggtgcgc tgctgctctc cggcagggtg tccccgctca cccagccctg gctcgccgac	3120
cacgtcgtcg gtggcgacgt ggtgctgccg ggtaccgcgc tgctcgaact ggcgctgcgg	3180
gccgcggaac tcgcgggggc cgggggcgtc gaggaactga ccctcgaagt gccgatggtg	3240
ctttccgaag cgggcgttca ggttcagggt tcgggtccggg acagcgggct cctgatcttc	3300
ttccgtgaca ccgaggacga cgagtggacg cgctgcgctt cgggcacgct cggcgccgcg	3360
gcgcccgtc ccggcttcgg ggcgtggccg cccgccggtg agcccctcga cctttccgat	3420
ctctacgacc ggttggccga ctccggcctc gactacgggc cggcgttccg ctgcctgcgt	3480
gccgcatggc gctccggtga cgacctctac gccgaggtcg ccgccgtgcc ggagaccag	3540
ggcgggttcg gcgtgcatcc ggcgctgctg gacgcggcgc tgcacgtgct cgaactcggc	3600
tccgggggcg gtggaggccc cgcggcgtg ccgttcgcgt ggtccggcgt gacgttgac	3660
gcgcgcggcg ccgacgttct gcgcgtcaag ctcgagaacc acgtcgcggg tgccgaagcc	3720
gggacgtact cggcgtccct gaaggcggc gacggcgcgg gcgaaccggt cgcgtcggtc	3780
gaatccttag ccctgcgacc tctttccaca gctcctcgcg cgcaggacgg cgcgctttac	3840

ggcgtcgact ggatttcgct tcccgggaacg ccggggcgctg ccgagtagccg gctctatccg	3900
gacctcaccg ccgtcgacga cgtgccaccg gtcgtcgccg tccgttgac cactctcgaa	3960
agcgtgctgg atctcgcca gacgtggctc gccgacgacc ggttcgcccc ggccaggctg	4020
gcgctgctca ccgacggcgc cgtcgccacc gaaaaccccc atcccgccgc ggccgccatg	4080
tgggggcttg tgcgttcgc gcaggccgag cacccgacc ggctggatt ggccgacgtc	4140
acgggagaag acggcctcgc cggcggactg gcttcggcg aaccgagtt cggcgccgc	4200
gacggcgcgg tgctggccc caggctgacg cgtgtgccga gcccgcccc ggcgctgttc	4260
accaccggcg gcacgggtgt gatcaccggc gggaccggcg gtctcgccgg gctgctggcc	4320
cggcatctgg tcgagcggca cgaggtagc agcctgcttc tcgtgagccg tcgcggtgcc	4380
gcggggccgc tcgtcgacga cctcaccgc ctgggtgccg acgtcaccgt cggcgctgc	4440
gacatcgccg acccgagtc cgtcgcgga ctgctcgccg agcatccggt gtcggcggtc	4500
gtccacgccg ccggtgtgt cgacgacgc accatcacca cgctcgacca cgagcggctc	4560
gcggccgtcc tgcgccgaa ggtcaccggc gcgctcgctc tggacgaact caccgggac	4620
ctcgacctgt cggcgctcgt gctgttctct tcgtccggcg ccaccttcga cggcgcggt	4680
caggccaact acgtgcggc caatgccttc ctgaagcgc tcgccctccg ccgccgtgcg	4740
gaaggccgcc ccggcgtcgc actgggctgg ggcctctggg ccaccgggat gggagcacgg	4800
ctcgacgagg cggggctgc ccggatcgag cgctccggcc agcgtgcact atccgaagta	4860
gacgggctcg cgctgttcga cgcggcactg gcggcggacc ggccgggtact gctgccgatg	4920
cggatgcacc gtgccgcgtt gcgtgccgc gcctccggcg aaggacttc ggcagtcctc	4980
ggcggactcg tccgggtcac ccgcccggcg ccgtcggccg caccgcgcgg actggacgag	5040
gcggccctgc tcgacctcgt ccggacgacg gtcgccgcg tcctgggcca cccggacgcg	5100
cacgcgatcg acccggatcg cgcgttcacc gaggtgggtt tcgactcgct cggcgccgtg	5160
gaactgcgca accggctgat cgcggccacc ggactgaaga tcgcgccgac gctgggtgttc	5220
gatcaccga acccgcgtc ggtcgccgc ttctcgccg ccggctccgc tccggtccgg	5280
gacgagcccg ccgtccggc cgaagccgac gagccgatcg cgatcatcg catggcctgc	5340
cgctatccgg gcgggggtgag cacacccgac gacttgtggc gtctggtcgc cgacgggaac	5400
gacggcatca cccggttccc cgagaaccgc ggctgggaca ccgacggcgt ctaccacccc	5460
gacgccgacc acccgggcac gacctacgtg cgcgagggcg gtttcttgca cgacgccgga	5520
cagttcgatc ccggcttctt cgggatctcg ccccggaag cgctggcgat ggaccgcag	5580
cagcggctgc tgctggagat ctcccacgaa gccgtcgaac gggccgggat cgaccggaag	5640
tccttgccgc gcagtggaa cggcgtgttc gccgggggtga tgtaccacga ctacgcgacc	5700

gggctgaacc gcgtccccga cgacgtcgag ggttacctcg gcaacgggac ctcggccagc 5760
 attcactccg gccgggtcgc ctacaccttc gggctggaag gcccggccgt cacgatcgac 5820
 acggcctggt cgtcgtcgct ggtggcgctg cacctggccg cgcaggcgct gcggcgcggt 5880
 gagtgtcga tggcgctggc gggcggggtg accgtgatgg ccacgcccga ggtcttcgtg 5940
 gacttcagcc gtcagcgcg cctcgctccc gatggccgt gcaagtcctt ttcggacgaa 6000
 gcagacggca cgggtgtggag cgaaggcgtc gggatgctcc tgggtggaacg cctttccgac 6060
 gcccgccgca acggccatcg cgtcctcgcg atcgtgcggg ggagcgcggt caaccaggac 6120
 ggcgcgcca acggcctcac cgccccgagc ggtccgtcgc agcaacgggt gatccgccgg 6180
 gccttggcgg acgcgggtct caaacgtcc gaagtggacg ctgtggaggc ccacggcacc 6240
 gggacgccgt tgggtgatcc gatcgaggcg caggcgatgc tcgccaccta cggccaggac 6300
 cgggaccggc cgctgtggct cgggtcgctg aagtcgaacc tcggccacac ccaggccgcc 6360
 gccggcgctc gcgggatcat caagatggtg caggcgatgc accacggtgt gctgccccgc 6420
 acgtcaacc tcggcacgcc gacgaccaag gtcgactgga catccgggaa cgtgtccttg 6480
 ctacgcgagc ccgtggcctg gccggaaacc ggcgggcccc ggcgtgcggc tgtctcgtcg 6540
 ttcgggatca gcgggaccaa cgcgcacgtc gtcctggagc aggcggaacc ggtcgaaaag 6600
 tccacttcgg acacatcgcc gtcgggtggt gacgtgctgc cgttcgtcct gtccggaaag 6660
 acgtccgccg ccctggccgc gcaggccgac cggctcgccg ggcacctggc cggcgacgtc 6720
 tccctgcccg ccgtggcccg cgcgctcgcg gtgaccaggc ccgcgctgga ccaccgtgcc 6780
 gtggtggtgg cgggcgaccg cgccgggttg accgccgggc tgcgcgcgct ggccgacgcc 6840
 gtccccgcgc cccacgtggt cgatggggtc gccgagaacg gcaaggccgt cttcgtcttt 6900
 ccaggccagg gatcgagtg gaccgggatg gcggtggatc tgctgggatc gtcggcggtc 6960
 ttcgccgaag cgatggccga ctgcgaggcc gcacttctgt cccatctgga ctggaagctg 7020
 acgcacgtcc tgtccgacgc ggcggcgctg gaacgggtgg acgtcgcca gccggtgctg 7080
 ttcgcggtga tgggtgcgct ggccccgctc tggcgggcgt gcggcatcga acccgccgcc 7140
 gtggtcgggc attcgaggg tgagatcgcg gccgcgtgtg tcgcgggcgc gctgtcgctg 7200
 gaagacgccg cacgcgtggt ctgcctgcgc agcaaggcga tcctggcgct gtccggattg 7260
 ggcgggatgg tgtcggtcgc ggcctctgag gatcgcgctc gggaactgct gcccgatggc 7320
 gtttccgtgg ccgtggtgaa cggccccggt tccgtcgtcg tgtccggtga cgtcgccggg 7380
 ctggaggcgc tgctcaagcg atgcgaactg ctcgacgtgc gggcgaagcg ggtcccgggtg 7440
 gactacgcgt cgcactcggc tcacgtcgac gcgatcgaac agcaggctcg gacggcgctg 7500

agcggaatca tgccgcgcga agccgaactg ccgatgtact cgaccgtcac cggtagagccg 7560
 atcgacacga ccaccctcga cgcggcctat tggttccgca atctccgggc caccgtccgg 7620
 ttcgaccagg cggtagcggcg gctgatcgcg gacgggttcc ggttcttcgt cgagacgagc 7680
 ccgcatccgg tgctggtcgc cgggctgacc gaactcgtcg aagaggccgc cgtgcccgcc 7740
 gtcgcgctcg cgagccttcg ccgtgacgag ggtggaccga cccggttcgt cacctccctg 7800
 gccgaggcgc acgtccacgg tctcagcccc gattggggccg cgtgctgcc cgaggcgggg 7860
 tgggtggatc tgccgcccta tgccttcag catcaggagt tctggctcac cgacgccggg 7920
 gaaccgggtg acgccgccgg attcgggtctc ggcgccaccg ggcattccgt gctcaccgcc 7980
 gcgaccgcgc tgccgggctc cggcggcctg ctgctcaccg gccggatctc gacggccgcc 8040
 cagccgtggc tggccgacca cgcggtgcag ggcgtgggtgc tgctgccggg tacggcgttc 8100
 gtggagctgg cgtgcaggc cggaaccac gcgggctcg ggcggatcga cgagctgact 8160
 ctgaagccc cgtgccgt tcccagcag ggcggcgtcc gcgtccaggc cgtcctgggg 8220
 tccgaagtga acggacgccg cgaggtcacc gtgcactccc aggccgaatc cggtagacgac 8280
 acctgggtgc ggcacgcac cggcttcctg acttcggcgg aaaccccggg agagggactg 8340
 accgaatggc cccccgccg cgcgacgagc gccgacctc acggctttta cgccgacgcc 8400
 gaggcgcagg gctacggcta cggtagcggc ttccaagggc tgcgagcggc ctggaccctg 8460
 ggttccgacg tcttcgccga ggtcgtcctg cccgatgccg agggcgcgga ccggttcggt 8520
 ctgcatccgg cgttgctcga cgcgcctc cacgcctcgt gtaccgtccg gtccggcgac 8580
 ggcgcggaac tgccgttcgc gtggaccggg gtcaccgtgc acgccgtcgg cgccaccgcg 8640
 ctgcgggtcc ggctcaccgt ggggacggac accgtcgcgg tgacggcggc cgatccggcg 8700
 ggcgcgccgg tcgcgaccgt cgaaggcctc gtcacgcggc ccgccgccct gcccggatcc 8760
 cggcggccgg actcgtgtt ccgcgtcgac tggactccgg tctccacgcc ggaagccgtc 8820
 gagacgccga ccgtcaccgt cctgtccgac ggcgacctga ccgcgctcgc cgagatcccc 8880
 gacgtggtgc tggtagccgt gggagccgag gccggggacc tcaccgagag cgtccatcgc 8940
 acgaccgcc gggtgctcga tctgctccgg acctggctcg acgacgagcg gttagccgac 9000
 gcgcggctgg tgctgcacac ccgcggcgcg gtcgcggacg tccgcgacct gccggccgcg 9060
 gcggcctggg gcctgggtccg gtccgcgcag gccgagaacc ccgaccggat cgtcctgctc 9120
 gacagcgaca ccgaccttc gccggcggtg ctgcgccgaag tgctggccac cggtagggcg 9180
 cagctcgcgt ggcgcgacgg ggaactgctc gtgccgaggc tcgccaaggt ctccaccgac 9240
 ggcacgctga cccgcgccga agggccctgg gtgctggacg cgcgccgccg cggcacgctg 9300
 gaagagctcg cgctcgtccc ggcgcccacg gccgcccggc cgctcgccga cggcgaggtc 9360

cggatccagg	tccgggcccgc	cgggatcaac	ttccgcgacg	tgctcatcac	gctcgacatg	9420
tatcccgagg	acaaggcggg	gatgggcagc	gagggcgcg	gtatcgtcac	cgaaatcggg	9480
tccggcggtca	ccggcctgaa	gcccggcgac	cgggtcttcg	gcctgttcga	cggcgcggtc	9540
ggaccgggtcg	cgatcgccga	ccggcggacg	gtcacggaaa	tgcccgtgga	ctggacgttc	9600
gccgaagcgg	ccgctctgcc	ggtcgtcttc	ctcaccgcct	actacgggct	ggtcgacctc	9660
ggcggggtcc	ggccggggga	gaaggtgctg	atccacggag	cgaccggcgg	tgtcggcatg	9720
gccgcgggtcc	agctggcccc	ccacctcggc	gccgaggtgt	tcgccacggc	gagccccggc	9780
aagtgggaag	tgctgcgggg	cctcggtttc	gacgacgagc	acatcgcttc	ctcccgcacg	9840
ctggacttcg	aggaccgggt	cggccggatg	gacgtcgtcc	tggactcgct	cgccaaggag	9900
ttcgtcgacg	cgtcgctgcg	gctgctgggc	gagggcgggc	ggttcgtgga	gatgggcaag	9960
accgacatcc	gtgacgcgga	cgaggtcgcg	gccgcgcata	ccggcgtcac	ctaccgcgcg	10020
ttcgacctgc	tcgacgccgg	acggccgagg	atcggcgaga	tcctggccga	actgctggac	10080
ctgttcggcg	ccgggtcgtc	caccgtgccc	cggccgacgg	tgtgggacgc	gcgccgcgca	10140
cccgaggtct	tccggttcat	gagccaggcc	aagcacatcg	gcaagaacgt	gctcaccata	10200
ccgtccacaa	tggacgggaa	cgggacgggt	ctgatcaccg	gcgccaccgg	gacactcggc	10260
gcgctgggtcg	cccggcatac	ggtcaccgtg	cgcggtgtcc	ggcacctgct	gctcgtcggc	10320
cgccgggggtc	gtgcggcggc	cgggatggcc	gaactcgaag	cggaactgac	cgccgccggg	10380
gcgtccgtca	ccatcgccgc	ctgcgacgcg	gccgaccggg	cggcgctggc	cgccctgctc	10440
gccaccgtcc	cggccgagca	tccgctggcc	ggggtggtgc	acgccgccgg	tgtcctggac	10500
gacggcctcg	tcgccacgct	gacccccgag	cggctggcga	aggtgctgcg	cccgaaggtc	10560
gacgccgcgg	tcaacctgca	cgaactgacc	cgcgacgcgc	atctcgccga	gttcgtcctg	10620
ttctcctcgg	ccgccggcgc	gttcggcgac	gccggacagg	gcaactacgc	cgccgcgaac	10680
agtttcctcg	actcgctcgc	ccggcacctg	cgggcgcagg	ggttgccccg	ggtctcgctc	10740
gcgtgggggtt	tctgggcccga	gctgagcggg	atgaccggcc	acctcgggtga	agcggatctg	10800
gcccgggtca	agcgggtccg	gatgagccct	ctgtccactg	aggacggact	actgttgatg	10860
gacgccgccc	gtgccgggta	cgaaccggcg	ccgctcccga	tgcacatcga	cctcgccgcc	10920
ctgcggggcg	aggaagtgca	cccgttgctg	cgggggctgg	tgaaggcacc	ggtgcgccgg	10980
gccgccgcgg	ccaccggcac	acagtccgag	ggactagccg	accggctggc	cgggctcgcc	11040
ccggccgccc	gcggccgggc	cctgctggac	ctgatccgcg	cgaacgtcgc	cgcggtgctc	11100
ggtttcggct	caccggagca	ggtcgggggtc	cggcaggcct	tccgggagct	cgggttcgac	11160

tcgctcagcg cggtcgaact ccgcaaccgg ctcaacgcgg cgaccggtct gcggctgccc 11220
gccacggtcg tgttcgacca tccgacgccc accgcgctcg ccgaaaccct cggcgaccgg 11280
ctggcacccg ccgaagaagc cgttgacgac gaggtcgccc gstatcggcgc ggtcctcgct 11340
tcggtgcccc ccgaccgggt ccgcgaagcc ggcgtgctgg acctgctgac ccggctggcc 11400
gaccccggtt accgccccac cgagtcgccc gacggcgcgg acatcgacga gatggacgcc 11460
gaccgcctga tcgcactcgc ttctgacgct tccgaccccg cctga 11505

<210> 39
<211> 5723
<212> PRT
<213> Amycolatopsis orientalis

<400> 39

Val	Lys	His	Pro	Gly	Ala	Ala	Met	Ser	Thr	Ser	Glu	Asn	Lys	Val	Val	1	5	10	15
Glu	Ala	Leu	Arg	Ala	Ala	Leu	Lys	Glu	Ala	Asp	Arg	Leu	Arg	Gly	Glu	20	25	30	
Asn	Arg	Arg	Leu	Thr	Gly	Glu	Pro	Ile	Ala	Ile	Ile	Gly	Met	Ala	Cys	35	40	45	
Arg	Tyr	Pro	Gly	Gly	Val	Arg	Ser	Pro	Glu	Glu	Leu	Trp	Asp	Leu	Val	50	55	60	
Ala	Gly	Glu	Arg	Thr	Gly	Leu	Thr	Gly	Phe	Pro	Val	Asp	Arg	Gly	Trp	65	70	75	80
Asp	Leu	Asp	Gly	Leu	Tyr	Asp	Pro	Glu	Gln	Gly	Lys	Pro	Gly	Lys	Ser	85	90	95	
Tyr	Val	Arg	Glu	Gly	Gly	Phe	Leu	His	Asp	Ala	Ala	Arg	Phe	Asp	Pro	100	105	110	
Ala	Phe	Phe	Gly	Ile	Ser	Pro	Arg	Glu	Ala	Leu	Ala	Met	Asp	Pro	Gln	115	120	125	
Gln	Arg	Leu	Leu	Leu	Glu	Ile	Ser	Trp	Glu	Ala	Ile	Glu	Arg	Ala	Gly	130	135	140	
Ile	Ala	Pro	Asp	Ser	Leu	Arg	Gly	Ser	Arg	Thr	Gly	Val	Phe	Ala	Gly	145	150	155	160
Val	Ile	His	Asn	Glu	Tyr	Ser	Ala	Ile	Ala	Gly	Thr	Pro	Pro	Ala	Asp	165	170	175	
Leu	Glu	Pro	Tyr	Leu	Gly	Asn	Gly	Ser	Phe	Ala	Ser	Ile	Ala	Ser	Gly	180	185	190	
Arg	Val	Ser	Tyr	Thr	Phe	Gly	Leu	Glu	Gly	Pro	Ala	Val	Thr	Val	Asp	195	200	205	
Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala	Leu	His	Leu	Ala	Ala	Gln	Ala	210	215	220	

Leu Arg Gln Gly Glu Cys Ser Leu Ala Leu Ala Gly Gly Val Thr Val
 225 230 235 240
 Met Ala Asn Pro Ala Ala Phe Val Asp Phe Ser Arg Gln Arg Gly Leu
 245 250 255
 Ala Ala Asp Gly Arg Ile Lys Ala Phe Ala Glu Ala Ala Asp Gly Thr
 260 265 270
 Ala Trp Gly Glu Gly Ala Gly Met Leu Leu Val Glu Arg Leu Ser Asp
 275 280 285
 Ala Arg Arg Asn Gly His Arg Val Leu Ala Val Val Arg Gly Ser Ala
 290 295 300
 Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Leu
 305 310 315 320
 Ser Gln Gln Arg Val Ile Arg Gln Ala Leu Ala Asn Ala Arg Leu Ala
 325 330 335
 Pro Ser Asp Val Asp Ala Met Glu Ala His Gly Thr Gly Thr Arg Leu
 340 345 350
 Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Asp
 355 360 365
 Arg Thr Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Ile Gly His
 370 375 380
 Ser Gln Ala Ala Ala Gly Val Ala Ser Ile Ile Lys Leu Val Glu Ala
 385 390 395 400
 Met Arg His Gly Val Leu Pro Lys Thr Leu His Val Asp Ala Pro Thr
 405 410 415
 Ser His Val Asp Trp Ser Glu Gly Ala Val Ser Leu Leu Thr Glu Ala
 420 425 430
 Glu Pro Trp Pro Lys Thr Asp Arg Pro Arg Arg Ala Ala Val Ser Ser
 435 440 445
 Phe Gly Ile Ser Gly Thr Asn Ala His Val Val Leu Glu Gln Pro Thr
 450 455 460
 Ala Glu Glu Glu Pro Pro Ser Thr Phe Ala Gly Pro Val Pro Phe Val
 465 470 475 480
 Leu Ser Gly Lys Thr Glu Ala Ala Leu His Glu Gln Val Ala Arg Val
 485 490 495
 Arg Glu Leu Ala Arg Asp Ser Asp Val Thr Ala Ala Asp Leu Ala Phe
 500 505 510
 Ser Leu Ala Thr Thr Arg Thr Ala Leu Asp His Arg Ala Ala Leu Val
 515 520 525
 Gly Thr Leu Asp Asp Leu Leu Thr Ala Thr Leu Val Glu Gly Arg Ala
 530 535 540

Thr	Asp	Gly	Gly	Thr	Ala	Phe	Leu	Phe	Thr	Gly	Gln	Gly	Ser	Gln	Arg	545	550	555	560
Leu	Gly	Met	Gly	Arg	Glu	Leu	Ala	Glu	Arg	Phe	Pro	Val	Phe	Ala	Gln		565	570	575
Ala	Phe	Asp	Asp	Val	Ser	Ser	Arg	Phe	Glu	Arg	Pro	Ile	Ala	Glu	Leu		580	585	590
Ser	Ala	Glu	Glu	Leu	Asn	Gln	Thr	Ala	Asn	Thr	Gln	Cys	Ala	Leu	Phe		595	600	605
Ala	Phe	Glu	Val	Ala	Leu	Phe	Arg	Leu	Val	Glu	Asn	Trp	Gly	Leu	Arg		610	615	620
Pro	Asp	Phe	Leu	Ala	Gly	His	Ser	Val	Gly	Glu	Ile	Ala	Ala	Ala	His		625	630	635
Val	Ala	Asp	Val	Leu	Ser	Leu	Asp	Asp	Ala	Val	Thr	Leu	Val	Ser	Ala		645	650	655
Arg	Gly	Arg	Leu	Met	Gln	Ala	Leu	Pro	Thr	Gly	Gly	Ala	Met	Val	Ala		660	665	670
Leu	Gln	Ala	Thr	Glu	Ala	Glu	Val	Ala	Pro	Leu	Leu	Thr	Asp	Arg	Val		675	680	685
Ser	Leu	Ala	Ala	Ile	Asn	Gly	Pro	Glu	Ser	Val	Val	Val	Ser	Gly	Asp		690	695	700
Glu	Glu	Ala	Val	Ala	Ala	Val	Val	Ser	His	Phe	Glu	Gly	Arg	Lys	Ser		705	710	715
Lys	Arg	Leu	Thr	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu	Met	Glu	Pro		725	730	735
Met	Leu	Asp	Asp	Phe	Arg	Ala	Val	Val	Glu	Gly	Leu	Thr	Phe	Ala	Glu		740	745	750
Pro	Arg	Ile	Pro	Ile	Val	Ser	Gly	Gly	Leu	Ala	Glu	Val	Ser	Thr	Ser		755	760	765
Asp	Tyr	Trp	Val	Arg	His	Val	Arg	Asp	Ala	Val	Arg	Phe	His	Asp	Ser		770	775	780
Val	Glu	Phe	Leu	Lys	Ala	Glu	Gly	Val	Thr	Arg	Phe	Leu	Glu	Ile	Gly		785	790	795
Pro	Asp	Ala	Val	Leu	Thr	Ala	Met	Ala	Lys	Glu	Ser	Ala	Glu	Asp	Ala		805	810	815
Val	Val	Leu	Pro	Ala	Ser	Arg	Arg	Asp	Arg	Pro	Glu	Val	Thr	Thr	Leu		820	825	830
Leu	Thr	Ala	Val	Ala	Gly	Leu	His	Val	His	Gly	Ala	Glu	Val	Asp	Trp		835	840	845
Ala	Pro	Leu	Phe	Asp	Gly	Ala	Arg	Arg	Val	Asp	Leu	Pro	Thr	Tyr	Pro		850	855	860
Phe	Gln	Tyr	Glu	His	Phe	Trp	Leu	Glu	Ser	Gly	Ala	Ala	His	Arg	Asp				

865		870		875		880
Val Ser Ala Ala Gly Leu Asp Ala Ser Pro His Ala Leu Leu Ala Ala						
		885		890		895
Ala Val Arg Pro Ala Gly Glu Asp Glu Ile Leu Leu Thr Gly Arg Ile						
		900		905		910
Ser Leu Ser Thr Leu Pro Trp Leu Ala Asp His Val Val Gly Gly Asn						
		915		920		925
Val Leu Leu Pro Gly Thr Ala Phe Ala Glu Leu Ala Leu Ala Ala Ala						
		930		935		940
Asp Glu Ala Gly Cys Glu Ala Val Glu Glu Leu Asn Leu Glu Ala Pro						
		945		950		955
						960
Leu Val Leu Pro Glu Lys Gly Gly Val Gln Leu Gln Val Ala Val Gly						
		965		970		975
Ala Ala Asp Asp Gln Gly Arg Arg Ser Val Thr Val His Ala Arg Pro						
		980		985		990
Glu Asp Asp Gly Phe Trp Val Arg His Ala Ser Gly Val Leu Gly Thr						
		995		1000		1005
Ala Val Ser Thr Gln Asp Glu Met Ile Glu Trp Pro Pro Ser Gly						
		1010		1015		1020
Ala Glu Pro Val Asp Leu Glu Gly Phe Tyr Pro Asn Leu Ala Ala						
		1025		1030		1035
Glu Gly Leu Gly Tyr Gly Pro Ala Phe Gln Gly Val Arg Ala Val						
		1040		1045		1050
Trp Thr Arg Asp Gly Asp Val Phe Ala Glu Val Gln Val Asp Asp						
		1055		1060		1065
Thr Pro Gly Thr Phe Gly Ile His Pro Ala Leu Phe Asp Ser Ala						
		1070		1075		1080
Leu His Ala Ile Gly Val Gly Glu Ser Arg Gly Leu Glu Ile Pro						
		1085		1090		1095
Phe Ala Trp Ser Asp Leu Arg Leu His Ala Asp Gly Ala Thr Val						
		1100		1105		1110
Leu Arg Val Arg Leu Ser Pro Ala Gly Asp Gly Ala Val Ser Val						
		1115		1120		1125
Phe Ala Thr Asp Pro Ala Gly Ala Pro Val Leu Ser Val Gly Ser						
		1130		1135		1140
Leu Ser Leu Arg Ala Pro Val Ala Ala Thr Ala Ser Leu Pro Arg						
		1145		1150		1155
Asp Ser Leu Phe Arg Val Thr Trp Thr Pro Val Thr Val Pro Ala						
		1160		1165		1170
Gly Ala Gly Glu Pro Thr Val Glu Ser Phe Val Asp Phe Asp Asp						
		1175		1180		1185

Val	Arg	Gln	Ala	Thr	Ala	His	Ala	Arg	Gln	Ile	Ala	Val	Glu	Pro
1190						1195					1200			
Gly	Glu	Ala	Pro	Val	Val	Phe	Leu	Thr	Ser	Gly	Ala	Phe	Thr	Asp
1205						1210					1215			
Pro	Ala	Gln	Ala	Ser	Val	Trp	Gly	Leu	Met	Arg	Ser	Ala	Arg	Glu
1220						1225					1230			
Glu	Tyr	Pro	Gly	Arg	Phe	Val	Leu	Val	Asp	Ala	Asp	Asp	Pro	Ala
1235						1240					1245			
Thr	Leu	Thr	Ala	Gly	Leu	Leu	Ala	Gly	Ile	Val	Ala	Ser	Gly	Glu
1250						1255					1260			
Thr	Glu	Ala	Ile	Val	Arg	Glu	Gly	Glu	Val	Arg	Val	Pro	Arg	Leu
1265						1270					1275			
Thr	Pro	Val	Arg	Gly	Gly	Glu	Thr	Gly	Pro	Gly	Trp	Asp	Pro	Glu
1280						1285					1290			
Gly	Thr	Val	Leu	Ile	Thr	Gly	Gly	Thr	Gly	Ala	Leu	Ala	Thr	Glu
1295						1300					1305			
Leu	Ala	Arg	His	Leu	Val	Thr	Arg	Arg	Gly	Val	Arg	Asn	Leu	Ile
1310						1315					1320			
Leu	Ala	Gly	Arg	Arg	Gly	Pro	Ala	Ala	Glu	Gly	Ala	Ser	Glu	Leu
1325						1330					1335			
Ala	Ala	Glu	Leu	Ala	Asp	Leu	Gly	Ala	Gln	Ala	Arg	Ile	Val	Ala
1340						1345					1350			
Cys	Asp	Val	Ala	Asp	Arg	Asp	Gln	Leu	Thr	Ala	Leu	Leu	Asp	Gly
1355						1360					1365			
Val	Pro	Leu	Thr	Ala	Val	Val	His	Ala	Ala	Gly	Val	Leu	Asp	Asp
1370						1375					1380			
Gly	Leu	Leu	Ala	Asp	Leu	Thr	Arg	Asp	Arg	Phe	Glu	Thr	Val	Leu
1385						1390					1395			
Arg	Ser	Lys	Val	Asp	Gly	Ala	Ile	Leu	Leu	Asp	Glu	Leu	Ala	Gly
1400						1405					1410			
Asp	Ala	His	Leu	Val	Phe	Phe	Ser	Ser	Ala	Ala	Gly	Val	Leu	Gly
1415						1420					1425			
Ser	Ala	Gly	Gln	Ala	Asn	Tyr	Ala	Ala	Ala	Asn	Ala	Ala	Leu	Asp
1430						1435					1440			
Ala	Val	Ala	Ala	Arg	Arg	Arg	Glu	Arg	Gly	Leu	Pro	Ala	Thr	Ser
1445						1450					1455			
Leu	Ala	Trp	Gly	Leu	Trp	Glu	Thr	Gly	Asp	Gly	Met	Ala	Gly	Ala
1460						1465					1470			
Leu	Ala	Gly	Thr	Asp	Arg	Ala	Arg	Met	Ala	Gly	Ser	Gly	Leu	Leu
1475						1480					1485			

Pro	Leu	Pro	Val	Gly	Asp	Ala	Leu	Thr	Leu	Phe	Asp	Phe	Ala	Val
1490						1495					1500			
Gly	Ala	Glu	Glu	Val	Leu	Phe	Val	Pro	Met	Arg	Leu	Asp	Val	Pro
1505						1510					1515			
Ala	Leu	Arg	Ala	Ser	Ala	Thr	Asp	Val	Pro	Leu	Leu	Arg	Ala	Phe
1520						1525					1530			
Ala	Gly	Lys	Ser	Arg	Arg	Thr	Ala	Ser	Ala	Ala	Pro	Ala	Ala	Arg
1535						1540					1545			
Glu	Leu	Arg	Asp	Arg	Leu	Ala	Ser	Leu	Pro	Thr	Glu	Glu	Arg	Gly
1550						1555					1560			
Arg	Glu	Leu	Leu	Ala	Leu	Val	Arg	Gly	Gln	Val	Ala	Glu	Val	Leu
1565						1570					1575			
Gly	His	Arg	Asp	Ala	Gly	Ala	Val	Glu	Pro	Ala	Arg	Pro	Phe	Arg
1580						1585					1590			
Glu	Leu	Gly	Phe	Asp	Ser	Leu	Thr	Ala	Val	Glu	Leu	Arg	Asn	Gly
1595						1600					1605			
Leu	Asn	Ala	Ala	Ser	Gly	Leu	Arg	Leu	Pro	Ala	Thr	Ala	Val	Phe
1610						1615					1620			
Asp	His	Pro	Thr	Pro	Lys	Ala	Leu	Ala	Asp	Leu	Leu	Ala	Ala	Glu
1625						1630					1635			
Leu	Phe	Gly	Ala	Ala	Pro	Glu	Ala	Pro	Val	Gln	Gly	Pro	Ala	Met
1640						1645					1650			
Ala	Ala	Asp	Glu	Pro	Ile	Ala	Ile	Ile	Gly	Met	Ala	Cys	Arg	Tyr
1655						1660					1665			
Pro	Gly	Gly	Val	Ala	Ser	Pro	Glu	Asp	Leu	Trp	Arg	Leu	Val	Ala
1670						1675					1680			
Glu	Gly	Arg	Asp	Gly	Ile	Ser	Leu	Phe	Pro	Ala	Asp	Arg	Gly	Trp
1685						1690					1695			
Asp	Val	Asp	Gly	Leu	Tyr	Asp	Pro	Asp	Pro	Gly	Lys	Ala	Gly	Lys
1700						1705					1710			
Ser	Tyr	Val	Arg	Glu	Gly	Gly	Phe	Leu	His	Glu	Ala	Gly	Asp	Phe
1715						1720					1725			
Asp	Ala	Gly	Phe	Phe	Gly	Ile	Ser	Pro	Arg	Glu	Ala	Leu	Gly	Met
1730						1735					1740			
Asp	Pro	Gln	Gln	Arg	Leu	Leu	Leu	Glu	Val	Ser	Trp	Glu	Ala	Phe
1745						1750					1755			
Glu	Arg	Ala	Gly	Ile	Asp	Pro	Gly	Thr	Leu	Arg	Gly	Ser	Asp	Thr
1760						1765					1770			
Gly	Val	Phe	Ala	Gly	Gln	Met	Tyr	His	Asp	Tyr	Leu	Thr	Gly	Ala
1775						1780					1785			
Thr	Val	Val	Pro	Asp	Asp	Val	Glu	Gly	Tyr	Leu	Gly	Thr	Gly	Asn

1790		1795		1800
Ser Gly 1805	Ser Val Leu Ser	Gly 1810	Arg Val Ser Tyr	Thr 1815 Phe Gly Leu
Glu Gly 1820	Pro Ala Val Thr	Val 1825	Asp Thr Ala Cys	Ser 1830 Ser Ser Leu
Val Ala 1835	Leu His Leu Ala	Ala 1840	Gln Ala Leu Arg	Arg 1845 Gly Glu Cys
Ser Leu 1850	Ala Leu Ala Gly	Gly 1855	Val Thr Val Met	Ala 1860 Thr Pro Glu
Thr Phe 1865	Val Asp Phe Ser	Arg 1870	Gln Arg Gly Leu	Ala 1875 Pro Asp Gly
Arg Ser 1880	Lys Ser Phe Ser	Asp 1885	Gly Ala Asp Gly	Thr 1890 Ser Trp Ser
Glu Gly 1895	Val Gly Met Leu	Leu 1900	Val Glu Arg Leu	Ser 1905 Asp Ala Glu
Arg Asn 1910	Gly His Arg Ile	Leu 1915	Ala Val Val Arg	Gly 1920 Ser Ala Val
Asn Gln 1925	Asp Gly Ala Ser	Asn 1930	Gly Leu Thr Ala	Pro 1935 Asn Gly Pro
Ser Gln 1940	Gln Arg Val Ile	Arg 1945	Arg Ala Leu Ala	Asp 1950 Ala Arg Leu
Glu Pro 1955	Ser Glu Val Asp	Ala 1960	Val Glu Ala His	Gly 1965 Thr Gly Thr
Thr Leu 1970	Gly Asp Pro Ile	Glu 1975	Ala Gln Ala Leu	Leu 1980 Ala Thr Tyr
Gly Gln 1985	Gly Arg Glu Asp	Ala 1990	Ala Leu Trp Leu	Gly 1995 Ser Ile Lys
Ser Asn 2000	Ile Gly His Ser	Gln 2005	Ala Ala Ala Gly	Val 2010 Ala Gly Val
Ile Lys 2015	Met Val Glu Ala	Met 2020	Arg Arg Gly Val	Leu 2025 Pro Lys Thr
Leu His 2030	Val Thr Glu Pro	Ser 2035	Ser His Val Asp	Trp 2040 Thr Ala Gly
Ala Val 2045	Ser Leu Leu Thr	Glu 2050	Ala Arg Leu Trp	Pro 2055 Asp Ala Gly
Arg Pro 2060	Arg Arg Ala Ala	Val 2065	Ser Ser Phe Gly	Ile 2070 Ser Gly Thr
Asn Ala 2075	His Val Val Leu	Glu 2080	Gln Gly Pro Ala	Pro 2085 Val Glu Ala
Ile Glu 2090	Ser Gly Glu Gly	Pro 2095	Ala Ala Phe Val	Leu 2100 Ser Ala Gly

Ser	Glu	Ala	Ala	Leu	His	Asp	Gln	Ala	Ser	Arg	Leu	Arg	Asp	Phe
2105						2110					2115			
Leu	Ala	Glu	Thr	Pro	Ala	Ala	Leu	Ala	Asp	Val	Ala	Phe	Ser	Leu
2120						2125					2130			
Ala	Thr	Thr	Arg	Ala	Ala	Leu	Glu	His	Arg	Ala	Ala	Val	Val	Ala
2135						2140					2145			
Ala	Asp	Arg	Glu	Thr	Leu	Leu	Ala	Ala	Leu	Glu	Asn	Leu	Thr	Val
2150						2155					2160			
Thr	Gly	Arg	Ala	Thr	Glu	Gly	Arg	Thr	Ala	Phe	Leu	Phe	Thr	Gly
2165						2170					2175			
Gln	Gly	Ser	Gln	Arg	Leu	Gly	Met	Gly	Leu	Gln	Leu	Ala	Glu	Arg
2180						2185					2190			
Phe	Pro	Val	Phe	Ala	Ala	Ala	Tyr	Asp	Glu	Val	Cys	Ser	Arg	Phe
2195						2200					2205			
Glu	Gln	Pro	Leu	Arg	Asp	Leu	Thr	Ala	Glu	Glu	Leu	Asn	Gln	Thr
2210						2215					2220			
Ala	Asn	Thr	Gln	Cys	Ala	Leu	Phe	Ala	Leu	Glu	Val	Ala	Leu	Phe
2225						2230					2235			
Arg	Leu	Val	Glu	Ser	Trp	Gly	Val	Arg	Pro	Asp	Phe	Leu	Ala	Gly
2240						2245					2250			
His	Ser	Val	Gly	Glu	Ile	Ala	Ala	Ala	His	Val	Ala	Gly	Val	Leu
2255						2260					2265			
Ser	Leu	Asp	Asp	Ala	Val	Thr	Leu	Val	Ser	Ala	Arg	Gly	Arg	Leu
2270						2275					2280			
Met	Gln	Ala	Leu	Pro	Thr	Gly	Gly	Ala	Met	Val	Ala	Leu	Gln	Ala
2285						2290					2295			
Thr	Glu	Ala	Glu	Val	Thr	Pro	Leu	Leu	Thr	Glu	Arg	Val	Ser	Leu
2300						2305					2310			
Ala	Ala	Ile	Asn	Gly	Pro	Glu	Ser	Val	Val	Val	Ser	Gly	Glu	Glu
2315						2320					2325			
Asp	Ala	Val	Ala	Ala	Val	Val	Ser	Gln	Phe	Glu	Gly	Arg	Lys	Ser
2330						2335					2340			
Lys	Arg	Leu	Thr	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu	Met	Glu
2345						2350					2355			
Pro	Met	Leu	Asp	Glu	Phe	Arg	Val	Val	Ala	Asp	Ser	Leu	Ser	Tyr
2360						2365					2370			
Ala	Ala	Pro	Arg	Ile	Pro	Ile	Val	Ser	Gly	Gly	Leu	Ala	Glu	Val
2375						2380					2385			
Ser	Thr	Ser	Asp	Tyr	Trp	Val	Arg	His	Val	Arg	Asp	Ala	Val	Arg
2390						2395					2400			

Phe	His	Asp	Ser	Val	Lys	Phe	Leu	Glu	Ala	Glu	Gly	Val	Thr	Arg
2405						2410					2415			
Phe	Leu	Glu	Ile	Gly	Pro	Asp	Gly	Val	Leu	Thr	Ala	Met	Ala	Lys
2420						2425					2430			
Glu	Thr	Ala	Glu	Asp	Ala	Val	Val	Val	Pro	Ala	Leu	Arg	Arg	Asp
2435						2440					2445			
Arg	Pro	Glu	Val	Glu	Thr	Leu	Leu	Thr	Ala	Val	Ala	Gly	Leu	His
2450						2455					2460			
Val	His	Gly	Val	Gly	Val	Asp	Leu	Thr	Ala	Leu	Leu	Gly	Gly	Gly
2465						2470					2475			
Ser	Pro	Val	Asp	Leu	Pro	Thr	Tyr	Ala	Phe	Gln	His	Arg	Arg	Phe
2480						2485					2490			
Trp	Leu	Ser	Ser	Ala	Gly	Gly	Ala	Ala	Gly	Asp	Val	Thr	Ala	Ala
2495						2500					2505			
Gly	Leu	Gly	Thr	Thr	Asp	His	Pro	Leu	Leu	Gly	Ala	Ala	Ala	Ala
2510						2515					2520			
Leu	Pro	Gly	Asp	Gly	Gly	Phe	Leu	Leu	Thr	Gly	Arg	Leu	Ser	Gly
2525						2530					2535			
His	Ala	Gln	Pro	Trp	Leu	Ala	Glu	His	Arg	Val	Gly	Gly	Val	Val
2540						2545					2550			
Leu	Leu	Pro	Gly	Thr	Ala	Phe	Val	Glu	Ile	Ala	Leu	Arg	Ala	Gly
2555						2560					2565			
Asp	Glu	Ala	Gly	Cys	Gly	His	Leu	Glu	Asp	Leu	Thr	Leu	Glu	Ala
2570						2575					2580			
Pro	Leu	Val	Leu	Pro	Glu	Arg	Gly	Ala	Thr	Gln	Leu	Ser	Val	Leu
2585						2590					2595			
Val	Gly	Ala	Ala	Asp	Asp	Thr	Gly	Arg	Arg	Thr	Ile	Glu	Ile	His
2600						2605					2610			
Ser	Arg	Glu	Glu	Gly	Glu	Asp	Gly	Trp	Gln	Arg	His	Ala	Thr	Gly
2615						2620					2625			
Leu	Leu	Ser	Ala	Ala	Gly	Ala	Val	Glu	Pro	Ala	Gly	Leu	Thr	Thr
2630						2635					2640			
Trp	Pro	Pro	Gln	Asn	Ala	Glu	Ala	Val	Pro	Val	Gly	Asp	Val	Tyr
2645						2650					2655			
Glu	Arg	Leu	Ala	Ala	Thr	Gly	Leu	Glu	Tyr	Gly	Pro	Ala	Phe	Arg
2660						2665					2670			
Gly	Leu	Arg	Ala	Ala	Trp	Arg	Ala	Gly	Glu	Asp	Leu	Phe	Ala	Glu
2675						2680					2685			
Val	Glu	Leu	Pro	Glu	Asp	Gln	His	Ser	Asp	Ala	Ala	Arg	Phe	Gly
2690						2695					2700			
Val	His	Pro	Ala	Leu	Leu	Asp	Ala	Ala	Leu	His	Thr	Leu	Gly	Leu

2705		2710		2715
Ala Gly Gly Gly Asp Gly Thr Arg Leu Pro Phe Ala Trp Ser Gly				
2720		2725		2730
Val Arg Leu His Ala Ala Gly Ala Thr Arg Leu Arg Val Arg Leu				
2735		2740		2745
Arg Pro Ser Gly Pro Asp Gly Phe Glu Val Leu Val Ala Asp Gly				
2750		2755		2760
Thr Gly Arg Pro Val Val Ser Ala Glu Glu Leu Thr Leu Arg Glu				
2765		2770		2775
Ile Ser Gly Asp Ala Leu Ala Arg Lys Gly His Asp Ser Leu Tyr				
2780		2785		2790
Arg Val Ala Trp Arg Pro Val Pro Leu Pro Glu Thr Gly Glu Thr				
2795		2800		2805
Leu Pro Ala Glu Ser Val Phe Ser Val Pro Arg Gly Gly Asp Ser				
2810		2815		2820
Ala Glu Arg Val His Glu Thr Thr Ala Ala Val Leu Glu Val Val				
2825		2830		2835
Gln Arg Arg Leu Glu Asp Glu Pro Gly Gly Pro Leu Val Val His				
2840		2845		2850
Thr Arg Gly Gly Val Ala Ala Gly Asp Gly Glu Ala Val Thr Asp				
2855		2860		2865
Leu Ala His Ala Ala Val Trp Gly Leu Val Arg Ala Ala Gln Ser				
2870		2875		2880
Glu Asn Pro Gly Arg Phe Leu Leu Val Asp Ala Glu Thr Leu Pro				
2885		2890		2895
Asp Gly Arg Ile Leu Ala Ile Asp Glu Pro Gln Ile Ala Leu Arg				
2900		2905		2910
Asp Gly Arg Ala Leu Ala Pro Arg Leu Ala Thr Thr Ala Ser Ser				
2915		2920		2925
Thr Glu Leu Thr Pro Pro Glu Gly Ala Trp Arg Leu Asp Thr Thr				
2930		2935		2940
Gly Arg Gly Thr Leu Glu Asn Leu Thr Leu Val Pro Ser Pro Glu				
2945		2950		2955
Ala Val Ala Pro Leu Ala Glu Gly Glu Val Arg Ile Ala Val Arg				
2960		2965		2970
Ala Ala Gly Leu Asn Phe Arg Asp Val Leu Ile Ala Leu Gly Met				
2975		2980		2985
Tyr Pro Gly Ala Ala Thr Leu Gly Ser Glu Gly Ala Gly Val Val				
2990		2995		3000
Thr Glu Ile Gly Pro Gly Val Thr Gly Leu Asp Val Gly Asp Arg				
3005		3010		3015

Val	Phe	Gly	Leu	Met	Ser	Asn	Gly	Phe	Gly	Pro	Gln	Val	Val	Thr
3020						3025					3030			
Asp	His	Arg	Thr	Leu	Ala	Lys	Met	Pro	Glu	Asp	Trp	Ser	Phe	Ala
3035						3040					3045			
Thr	Ala	Ala	Ser	Val	Pro	Ile	Val	Phe	Leu	Thr	Ala	Tyr	Tyr	Gly
3050						3055					3060			
Leu	Phe	Asp	Leu	Ala	Arg	Leu	Glu	Ala	Gly	Glu	Ser	Ile	Leu	Val
3065						3070					3075			
His	Ala	Ala	Ala	Gly	Gly	Val	Gly	Met	Ala	Ala	Thr	Gln	Leu	Ala
3080						3085					3090			
Arg	His	Ala	Gly	Ala	Glu	Val	Phe	Gly	Thr	Ala	Gly	Pro	Gly	Lys
3095						3100					3105			
Trp	Asp	Thr	Leu	Arg	Ala	Asn	Gly	Phe	Asp	Asp	Thr	His	Leu	Ser
3110						3115					3120			
Ser	Ser	Arg	Asp	Leu	Gly	Phe	Glu	Glu	Lys	Phe	Arg	Asp	Ala	Thr
3125						3130					3135			
Gly	Gly	Arg	Gly	Val	Asp	Val	Val	Leu	Asn	Ser	Leu	Ala	Gly	Asp
3140						3145					3150			
Tyr	Val	Asp	Ala	Ser	Leu	Arg	Leu	Leu	Ala	Pro	Gly	Gly	Arg	Phe
3155						3160					3165			
Ala	Glu	Met	Gly	Lys	Thr	Asp	Ile	Arg	Glu	Pro	Gly	Glu	Thr	Gly
3170						3175					3180			
Val	Glu	Tyr	His	Pro	Phe	Asp	Val	Ile	Asp	Ala	Gly	Pro	Glu	Arg
3185						3190					3195			
Ile	His	Glu	Met	Leu	Ala	Ala	Leu	Leu	Glu	Leu	Phe	Ala	Ala	Gly
3200						3205					3210			
Ala	Leu	Thr	Pro	Leu	Pro	Val	Thr	Gly	Trp	Asp	Val	Arg	Arg	Gly
3215						3220					3225			
Pro	Asp	Ala	Phe	Arg	Phe	Leu	Ser	Gln	Ala	Lys	His	Val	Gly	Lys
3230						3235					3240			
Asn	Val	Leu	Thr	Met	Pro	Ala	Ala	Leu	Asp	Pro	Asp	Gly	Thr	Val
3245						3250					3255			
Leu	Val	Thr	Gly	Gly	Thr	Gly	Ala	Leu	Gly	Ala	Leu	Phe	Ala	Arg
3260						3265					3270			
His	Leu	Val	Arg	Glu	Arg	Gly	Val	Arg	Arg	Leu	Leu	Leu	Ala	Ser
3275						3280					3285			
Arg	Arg	Gly	His	Asp	Ala	Pro	Gly	Val	Pro	Glu	Leu	Val	Ala	Glu
3290						3295					3300			
Leu	Thr	Glu	Ala	Gly	Ala	Ser	Val	Thr	Val	Glu	Ala	Cys	Asp	Ala
3305						3310					3315			

Ala 3320	Asp	Arg	Gly	Ala	Leu	Ala 3325	Ala	Val	Leu	Ala	Gly 3330	Ile	Pro	Ala
Ala 3335	His	Pro	Leu	Thr	Gly	Val 3340	Val	His	Thr	Ala	Gly 3345	Val	Leu	Asp
Asp 3350	Gly	Leu	Val	Gly	Ser	Leu 3355	Thr	Pro	Glu	Arg	Leu 3360	Ala	Lys	Val
Leu 3365	Arg	Pro	Lys	Val	Asp	Ala 3370	Ala	Leu	Asn	Leu	His 3375	Glu	Leu	Thr
Ser 3380	Gly	Ala	Asp	Leu	Ala	Glu 3385	Phe	Val	Val	Phe	Ser 3390	Ser	Ala	Ala
Gly 3395	Val	Phe	Gly	Asn	Ala	Gly 3400	Gln	Ala	Asn	Tyr	Ala 3405	Ala	Ala	Asn
Gly 3410	Phe	Leu	Asp	Ala	Leu	Ser 3415	Val	Arg	Arg	Ala	Ala 3420	His	Gly	Leu
Pro 3425	Ala	Arg	Ser	Leu	Ala	Trp 3430	Gly	Leu	Trp	Ala	Glu 3435	Thr	Gly	Gly
Met 3440	Gly	Gly	Thr	Leu	Gly	Glu 3445	Ala	Glu	Leu	Ala	Arg 3450	Met	Ala	Gln
Ser 3455	Gly	Thr	Ala	Ala	Leu	Ser 3460	Thr	Gln	Asp	Gly	Leu 3465	Glu	Leu	Phe
Asp 3470	Ala	Ala	Gly	Ala	Leu	Ala 3475	Glu	Pro	Val	Leu	Val 3480	Pro	Met	Arg
Leu 3485	Asp	Val	Thr	Ala	Met	Gly 3490	Gly	Asp	Gly	Leu	Pro 3495	Pro	Leu	Leu
Arg 3500	Gly	Leu	Ala	Arg	Gly	Pro 3505	Val	Arg	Arg	Ala	Ala 3510	Ser	Ala	Gly
Ala 3515	Ala	Gly	Asp	Ala	Asp	Ser 3520	Leu	Arg	Asp	Arg	Leu 3525	Leu	Ala	Val
Pro 3530	Val	Ala	Asp	Arg	Glu	Thr 3535	Leu	Leu	Val	Asp	Leu 3540	Val	Arg	Thr
His 3545	Ser	Ala	Thr	Val	Leu	Gly 3550	His	Thr	Ala	Ala	Asp 3555	Ala	Val	Glu
Ala 3560	Thr	Arg	Ser	Phe	Gln	Glu 3565	Ile	Gly	Phe	Asp	Ser 3570	Leu	Thr	Ala
Val 3575	Glu	Leu	Arg	Asn	Arg	Leu 3580	Thr	Ala	Ala	Thr	Gly 3585	Leu	Arg	Leu
Pro 3590	Ala	Thr	Leu	Ile	Phe	Asp 3595	Tyr	Pro	Thr	Pro	Glu 3600	Ala	Leu	Ala
Ala 3605	His	Ile	Gly	Glu	Gly	Val 3610	Leu	Gly	Ala	Gln	Gly 3615	Gly	Pro	Glu
Thr	Gly	Gln	Ala	Ala	Val	Thr	Ala	Asp	Glu	Pro	Ile	Ala	Ile	Val

3620	3625	3630
Ala Met Ser Cys Arg Phe Pro Gly His Ala Asp Thr Pro Glu Arg		
3635	3640	3645
Leu Trp Ala Leu Leu Ala Glu Gly Arg Asp Ala Leu Gly Glu Phe		
3650	3655	3660
Pro Ala Asp Arg Gly Trp Asp Leu Glu Arg Leu Phe Asp Thr Asp		
3665	3670	3675
Pro Asp Arg Arg Gly Thr Ser Tyr Thr Arg Gln Gly Ala Phe Leu		
3680	3685	3690
Glu Thr Ala Gly Asp Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro		
3695	3700	3705
Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Leu Glu		
3710	3715	3720
Thr Ser Trp Glu Ala Phe Glu Arg Ala Gly Ile Asp Pro Ala Thr		
3725	3730	3735
Leu Arg Gly Ser Arg Thr Gly Val Phe Ala Gly Val Met Asp Asn		
3740	3745	3750
Glu Tyr Val Ser Gly Ser Ala Glu Val Pro Asp Gly Val Glu Gly		
3755	3760	3765
Tyr Leu Ala Thr Gly Thr Ser Ala Ser Val Ala Ser Gly Arg Val		
3770	3775	3780
Ser Tyr Thr Phe Gly Leu Glu Gly Pro Ala Val Thr Val Asp Thr		
3785	3790	3795
Ala Cys Ser Ser Ser Leu Val Ala Leu His Leu Ala Ala Gln Ala		
3800	3805	3810
Leu Arg Gln Gly Glu Cys Ser Leu Ala Leu Ala Gly Gly Val Thr		
3815	3820	3825
Val Met Ala Thr Pro Gly Thr Phe Val Glu Phe Ser Arg Gln Arg		
3830	3835	3840
Gly Leu Ala Ala Asp Gly Arg Cys Lys Ala Phe Ala Asp Gly Ala		
3845	3850	3855
Asp Gly Thr Gly Trp Gly Glu Gly Ala Gly Met Leu Leu Val Glu		
3860	3865	3870
Arg Leu Ser Asp Ala Arg Arg Asn Gly His Pro Val Leu Ala Val		
3875	3880	3885
Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu		
3890	3895	3900
Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Gln Ala		
3905	3910	3915
Leu Ala Asn Ala Arg Leu Glu Pro Ser Glu Val Asp Ala Val Glu		
3920	3925	3930

Ala	His	Gly	Thr	Gly	Thr	Thr	Leu	Gly	Asp	Pro	Ile	Glu	Ala	Gln
3935						3940					3945			
Ala	Leu	Leu	Ala	Thr	Tyr	Gly	Gln	Asp	Arg	Glu	Arg	Pro	Leu	Leu
3950						3955					3960			
Leu	Gly	Ser	Val	Lys	Ser	Asn	Ile	Gly	His	Thr	Gln	Ala	Ala	Ala
3965						3970					3975			
Gly	Val	Ala	Gly	Val	Ile	Lys	Met	Val	Leu	Ala	Met	Arg	His	Gly
3980						3985					3990			
Thr	Leu	Pro	Arg	Thr	Leu	His	Val	Asp	Thr	Pro	Thr	Ser	Arg	Val
3995						4000					4005			
Asp	Trp	Ala	Ala	Gly	Arg	Ile	Glu	Leu	Ala	Thr	Glu	Pro	Thr	Gln
4010						4015					4020			
Trp	Pro	Glu	Thr	Gly	Gly	Pro	Arg	Arg	Ala	Ala	Val	Ser	Ser	Phe
4025						4030					4035			
Gly	Met	Ser	Gly	Thr	Asn	Ala	His	Val	Val	Leu	Glu	Gln	Ala	Glu
4040						4045					4050			
Ala	Val	Glu	Thr	Arg	Asp	Glu	Thr	Ser	Pro	Gly	Leu	Leu	Gly	Asp
4055						4060					4065			
Val	Val	Ala	Trp	Pro	Leu	Ser	Ala	Lys	Glu	Pro	Glu	Ala	Val	Ala
4070						4075					4080			
Ala	Gln	Ala	Ala	Arg	Leu	Lys	Ser	Phe	Leu	Thr	Gly	Glu	Arg	Pro
4085						4090					4095			
Ala	Asp	Val	Ala	Tyr	Ser	Leu	Ala	Thr	Ala	Arg	Thr	Thr	Leu	Glu
4100						4105					4110			
His	Arg	Ala	Val	Val	Val	Gly	Glu	Asp	Pro	Ile	Ala	Gly	Leu	Ala
4115						4120					4125			
Ala	Leu	Ala	Ala	Gly	Glu	Pro	Ser	Gly	Ser	Val	Val	Thr	Gly	Thr
4130						4135					4140			
Ala	Thr	Ser	Gly	Lys	Ala	Val	Phe	Val	Phe	Pro	Gly	Gln	Gly	Ser
4145						4150					4155			
Gln	Trp	Ala	Gly	Met	Ala	Val	Glu	Leu	Leu	Ala	Ser	Ala	Pro	Val
4160						4165					4170			
Phe	Ala	Glu	Ser	Met	Ala	Glu	Cys	Glu	Ala	Ala	Leu	Leu	Ser	Tyr
4175						4180					4185			
Val	Asp	Trp	Lys	Leu	Thr	Glu	Val	Leu	Ser	Asp	Ala	Thr	Ala	Leu
4190						4195					4200			
Glu	Arg	Val	Asp	Val	Val	Gln	Pro	Ala	Leu	Phe	Ala	Val	Met	Val
4205						4210					4215			
Ser	Leu	Ala	Arg	Leu	Trp	Arg	Ala	Ser	Gly	Ile	Glu	Pro	Ala	Ala
4220						4225					4230			

Val	Val	Gly	His	Ser	Gln	Gly	Glu	Ile	Ala	Ala	Ala	Cys	Val	Ala
4235						4240					4245			
Gly	Ala	Leu	Ser	Leu	Asp	Asp	Ala	Ala	Arg	Val	Val	Cys	Leu	Arg
4250						4255					4260			
Ser	Lys	Ala	Ile	Thr	Ala	Leu	Ser	Gly	Arg	Gly	Gly	Met	Val	Ser
4265						4270					4275			
Val	Ala	Ala	Pro	Glu	Ala	Gln	Val	Arg	Glu	Ile	Leu	Pro	Glu	Gly
4280						4285					4290			
Val	Ser	Leu	Ala	Ala	Val	Asn	Gly	Pro	Ala	Ser	Val	Val	Val	Ser
4295						4300					4305			
Gly	Asp	Val	Ala	Gly	Leu	Asp	Ala	Leu	Met	Thr	Ala	Cys	Glu	Ala
4310						4315					4320			
Ser	Gly	Leu	Arg	Ala	Lys	Arg	Ile	Pro	Val	Asp	Tyr	Ala	Ser	His
4325						4330					4335			
Ser	Ala	His	Val	Asp	Ala	Ile	Glu	Gln	Asp	Val	Leu	Ala	Ala	Leu
4340						4345					4350			
Asp	Gly	Ile	Glu	Pro	Arg	Ala	Pro	Glu	Ile	Pro	Phe	Tyr	Ser	Thr
4355						4360					4365			
Val	Ala	Gly	Glu	Pro	Leu	Asp	Pro	Val	Val	Asp	Ala	Ala	Tyr	Trp
4370						4375					4380			
Phe	Arg	Asn	Leu	Arg	Gly	Thr	Val	His	Phe	Gly	Gln	Ala	Val	Arg
4385						4390					4395			
Arg	Leu	Leu	Asp	Asp	Gly	Phe	Arg	Phe	Phe	Val	Glu	Ala	Ser	Pro
4400						4405					4410			
His	Pro	Val	Leu	Val	Thr	Gly	Ile	Ala	Asp	Thr	Ala	Glu	Asp	Ala
4415						4420					4425			
Gly	Glu	Arg	Ala	Val	Ala	Val	Gly	Ser	Leu	Arg	Arg	Asp	Glu	Gly
4430						4435					4440			
Gly	Pro	Leu	Arg	Phe	Leu	Thr	Ser	Leu	Ala	Glu	Ala	His	Val	His
4445						4450					4455			
Gly	Leu	Ser	Pro	Asp	Trp	Ala	Ala	Leu	Ala	Pro	Gly	Thr	Arg	Val
4460						4465					4470			
Asp	Leu	Pro	Thr	Tyr	Ala	Phe	Gln	His	Glu	His	Tyr	Trp	Leu	Arg
4475						4480					4485			
Thr	Arg	Ser	Ser	Ala	Asp	Pro	Gly	Gln	Ala	Gly	Leu	Asp	Asp	Gly
4490						4495					4500			
Gly	His	Pro	Leu	Leu	Gly	Ala	Val	Val	Pro	Leu	Ala	Gly	Ser	Asp
4505						4510					4515			
Gly	Leu	Val	Ala	Thr	Gly	Arg	Ile	Ser	Ala	Arg	Asn	Gln	Thr	Trp
4520						4525					4530			
Leu	Pro	Asp	His	Ala	Val	Gly	Gly	Ala	Leu	Leu	Leu	Pro	Gly	Ala

4535	4540	4545
Ala Leu Val Asp Leu Ala	Leu Thr Val Gly Glu Arg	Thr Gly Cys
4550	4555	4560
Gly Arg Ile Ala Glu Leu	Thr Ile Glu Ala Pro Leu	Val Leu Gly
4565	4570	4575
Glu Ser Gly Ser Ala Arg	Leu Gln Val Thr Val Gly	Ala Ser Ala
4580	4585	4590
Asp Asp Gly Thr Arg Glu	Val Ala Val Tyr Ser Arg	Asp Glu Thr
4595	4600	4605
Ala Gly Thr Asp Trp Ile	Arg His Ala Thr Gly Leu	Leu Ala Ala
4610	4615	4620
Asp Gly Glu Thr Pro Val	Ala Asp Leu Thr Gln Trp	Pro Pro Ala
4625	4630	4635
Gly Ala Glu Pro Ile Ser	Leu Glu Gly His Tyr Glu	Gly Leu Ala
4640	4645	4650
Glu Leu Gly Tyr Gly Tyr	Gly Pro Ala Phe Arg Gly	Leu Arg Ala
4655	4660	4665
Val Trp Arg Arg Gly Asp	Asp Val Phe Ala Glu Val	Ala Leu Pro
4670	4675	4680
Glu Asp Arg Ile Ala Glu	Ala Ala Ala Phe Gly Leu	His Pro Ala
4685	4690	4695
Leu Leu Asp Ala Ala Leu	His Ala Leu Gly Phe Gly	Met Leu Pro
4700	4705	4710
Asp Asp Gly Arg Leu Arg	Leu Pro Phe Ala Trp Asn	Glu Val Ser
4715	4720	4725
Leu Ser Ala Val Gly Ala	Pro Ser Leu Arg Val Arg	Leu Ser Pro
4730	4735	4740
Ala Gly Glu Asp Ala Val	Ala Val Asp Leu Ala Asp	Thr Ala Gly
4745	4750	4755
Ala Pro Val Ala Ser Ile	Gly Ser Val Val Phe Arg	Pro Val Ala
4760	4765	4770
Glu Ala Gln Leu Ala Gly	Ala Arg Arg Asp Pro Ala	Asp Ser Leu
4775	4780	4785
Phe Gln Ile Gln Trp Thr	Asp Leu Ser Ala Lys Asp	Val Val Ala
4790	4795	4800
Pro Ala Val Val Val Leu	Gly Glu Asp Cys Ala Asp	Leu Ala Glu
4805	4810	4815
Leu Ala Ala Asp Leu Asp	Ala Gly Arg Pro Ala Pro	Asp Val Val
4820	4825	4830
Leu Thr Thr Cys Ala Pro	Val Thr Gly Asp Ile Ala	Glu Gly Ala
4835	4840	4845

His	Ala	Ala	Ala	Arg	Asp	Ala	Leu	Thr	Leu	Val	Gln	Asn	Trp	Leu
4850						4855					4860			
Ala	Asp	Glu	Arg	Phe	Ser	Gly	Ala	Arg	Leu	Val	Phe	Arg	Thr	Ser
4865						4870					4875			
Gly	Ala	Val	Ser	Val	Ala	Ala	Asp	Glu	Pro	Val	Ser	Asp	Pro	Ala
4880						4885					4890			
Asn	Ala	Thr	Val	Trp	Gly	Leu	Val	Arg	Thr	Ala	Gln	Glu	Glu	Asn
4895						4900					4905			
Pro	Gly	Arg	Phe	Gly	Leu	Leu	Asp	Thr	Asp	Gly	Ser	Glu	Ala	Val
4910						4915					4920			
Leu	Gly	Ala	Ala	Leu	Ala	Leu	Asp	Glu	Pro	Gln	Leu	Ala	Leu	Arg
4925						4930					4935			
Ala	Gly	Thr	Val	Leu	Gly	Ala	Arg	Leu	Val	Lys	Ala	Ser	Ala	Asp
4940						4945					4950			
Thr	Ala	Leu	Val	Pro	Pro	Pro	Gly	Ser	Arg	Ala	Trp	Thr	Val	Asp
4955						4960					4965			
Thr	Leu	Gly	Gly	Gly	Thr	Leu	Glu	Asn	Leu	Val	Leu	Arg	Asp	Arg
4970						4975					4980			
Pro	Asp	Leu	Leu	Ala	Pro	Leu	Ala	Asp	Gly	Gln	Val	Arg	Ile	Ala
4985						4990					4995			
Val	Arg	Ser	Ala	Gly	Leu	Asn	Phe	Arg	Asp	Val	Val	Val	Ala	Leu
5000						5005					5010			
Gly	Leu	Val	Pro	Gly	Gln	Glu	Gly	Ile	Gly	Gly	Glu	Gly	Ala	Gly
5015						5020					5025			
Val	Val	Thr	Glu	Thr	Gly	Pro	Gly	Val	Thr	Asp	Leu	Ala	Pro	Gly
5030						5035					5040			
Asp	Arg	Val	Leu	Gly	Met	Phe	Asp	Ala	Ser	Phe	Gly	Pro	Ile	Ala
5045						5050					5055			
Val	Ala	Asp	Arg	Lys	Leu	Ile	Ala	Pro	Val	Pro	Asp	Asp	Trp	Ser
5060						5065					5070			
Phe	Thr	Glu	Ala	Ala	Ser	Ala	Pro	Val	Ala	Phe	Leu	Thr	Ala	Tyr
5075						5080					5085			
Val	Gly	Leu	Ala	Asp	Leu	Gly	Glu	Leu	Arg	Pro	Gly	Gln	Thr	Val
5090						5095					5100			
Leu	Ile	His	Ala	Ala	Ala	Gly	Gly	Val	Gly	Met	Ala	Ala	Val	Gln
5105						5110					5115			
Leu	Ala	Arg	His	Phe	Gly	Ala	Glu	Ile	Tyr	Val	Thr	Ala	Ser	Pro
5120						5125					5130			
Ala	Lys	Trp	Asp	Thr	Leu	Arg	Ala	Met	Gly	Phe	Asp	Asp	Asp	His
5135						5140					5145			

Ile	Ala	Ser	Ser	Arg	Thr	Leu	Asp	Phe	Glu	Asp	Lys	Ile	Arg	Glu
5150						5155					5160			
Ala	Thr	Gly	Gly	Arg	Gly	Val	Asp	Leu	Val	Leu	Asp	Ser	Leu	Ala
5165						5170					5175			
Arg	Glu	Phe	Val	Asp	Ala	Ser	Leu	Arg	Leu	Val	Arg	Glu	Gly	Gly
5180						5185					5190			
Arg	Phe	Val	Glu	Met	Gly	Lys	Thr	Asp	Ile	Arg	Asp	Ala	Asp	Glu
5195						5200					5205			
Val	Ala	Ala	Ala	His	Pro	Gly	Val	Thr	Tyr	Arg	Ala	Phe	Asp	Leu
5210						5215					5220			
Ile	Asp	Ser	Gly	His	Asp	Arg	Ile	Gln	Glu	Ile	Leu	Gly	Glu	Leu
5225						5230					5235			
Leu	Ala	Leu	Ala	Asp	Lys	Asp	Val	Val	Arg	Pro	Leu	Pro	Thr	Thr
5240						5245					5250			
Ala	Trp	Asp	Val	Arg	Arg	Ala	Pro	Glu	Ala	Phe	Arg	Phe	Leu	Ser
5255						5260					5265			
Gln	Ala	Lys	His	Thr	Gly	Lys	Ile	Val	Leu	Glu	Pro	Pro	Ala	Val
5270						5275					5280			
Leu	Asp	Pro	Glu	Gly	Thr	Val	Leu	Ile	Thr	Gly	Gly	Thr	Gly	Val
5285						5290					5295			
Leu	Gly	Gly	Leu	Phe	Ala	Arg	His	Leu	Val	Thr	Ala	His	Gly	Val
5300						5305					5310			
Arg	Arg	Leu	Leu	Leu	Thr	Ser	Arg	Arg	Gly	Leu	Asp	Ala	Glu	Gly
5315						5320					5325			
Ala	Arg	Glu	Leu	Val	Ala	Asp	Leu	Thr	Gly	Leu	Gly	Ala	Thr	Val
5330						5335					5340			
Thr	Val	Val	Ala	Cys	Asp	Val	Ala	Asp	Arg	Ala	Ala	Val	Ala	Gly
5345						5350					5355			
Leu	Leu	Gly	Ser	Val	Pro	Pro	Glu	His	Pro	Leu	Thr	Ala	Val	Val
5360						5365					5370			
His	Thr	Ala	Gly	Val	Leu	Asp	Asp	Gly	Leu	Ile	Pro	Ala	Leu	Thr
5375						5380					5385			
Pro	Asp	Arg	Leu	Gly	Thr	Val	Phe	Arg	Pro	Lys	Val	Asp	Ala	Ala
5390						5395					5400			
Val	His	Leu	His	Glu	Leu	Thr	Arg	Asp	Leu	Gly	Leu	Ala	Ala	Phe
5405						5410					5415			
Val	Leu	Phe	Ser	Ser	Ser	Ala	Ala	Thr	Phe	Gly	Ala	Ala	Gly	Gln
5420						5425					5430			
Gly	Asn	Tyr	Ala	Ala	Ala	Asn	Ala	Phe	Leu	Asp	Ala	Leu	Ala	Gln
5435						5440					5445			
His	Arg	Arg	Ala	Glu	Gly	Leu	Ala	Gly	Gln	Ala	Leu	Ala	Trp	Gly

5450	5455	5460
Phe Trp Ala Glu Arg Ser	Ala Met Thr Gly His	Leu Asp Glu Ala
5465	5470	5475
Asp Val Ala Arg Met Lys	Arg Ser Gly Val Ser	Pro Leu Ser Ser
5480	5485	5490
Val Asp Gly Leu Ala Leu	Phe Asp Ala Ala Ala	Glu Arg Asp Val
5495	5500	5505
Ala Ala Leu Val Pro Val	His Leu Asp Thr Ala	Ala Leu Arg Gly
5510	5515	5520
Gln Thr Glu Val Pro Ala	Leu Leu Arg Val Leu	Ala Gly Ala Pro
5525	5530	5535
Ala Lys Arg Val Ala Gly	Ala Ala Thr Ser Gly	Pro Ser Leu
5540	5545	5550
Ala Gln Arg Leu Ala Ala	Leu Pro Ala Ala Asp	Arg Glu Pro Phe
5555	5560	5565
Leu Leu Asp Leu Val Arg	Ser His Ala Ala Ala	Ala Leu Gly His
5570	5575	5580
Ala Ser Val Ala Lys Val	Gly Pro Glu Leu Ala	Phe Arg Asp Leu
5585	5590	5595
Gly Phe Asp Ser Leu Thr	Ala Val Glu Leu Arg	Asn Arg Leu Gly
5600	5605	5610
Ala Ala Thr Gly Leu Arg	Leu Pro Ser Thr Leu	Val Phe Asp Gln
5615	5620	5625
Pro Ser Pro Ala Ala Leu	Ala Arg His Leu Leu	Ala Glu Leu Gly
5630	5635	5640
Glu Pro Ala Gly Ala Glu	Pro Glu Val Ala Val	Leu Ala Asp Leu
5645	5650	5655
Asp Arg Leu Glu Thr Ala	Leu Ala Ala Ala Val	Thr Asp Asp Glu
5660	5665	5670
Thr Ala Asp Arg Ile Thr	Asp Arg Leu Arg Ala	Val Leu Ala Arg
5675	5680	5685
Trp Thr Glu Ala Arg Gly	Pro Ala Glu Asp Glu	Gly Asp Gly Asp
5690	5695	5700
Leu Ala Asp Ala Ser Ala	Asp Glu Leu Phe Asp	Ile Leu His Lys
5705	5710	5715
Glu Phe Gly Arg Ser		
5720		

<210> 40
 <211> 17172
 <212> DNA
 <213> Amycolatopsis orientalis

<400> 40

gtgaaacacc ctggagctgc gatgtccaca tccgagaaca aggtcgtcga ggccctgcgg	60
gcggcgctga aggaagccga ccgcctgcgc ggggagaacc ggcgcctgac cggcgagccc	120
atcgcgatca tcggcatggc ctgccgttac ccgggcgggg tccgctcgcc ggaagagctg	180
tgggatctgg tcgccggaga acgcaccggc ctcaccggat tcccggtcga ccgcggctgg	240
gacctcgacg ggctctacga ccccgagcag gggaaaccgg gcaagagcta tgtccgggaa	300
ggcggtttcc tgcacgacgc cgcccgggtc gaccggcggt tcttcgggat ctcgccgcgt	360
gaggcgctgg cgatggaccc gcagcagcga ctgctgctgg agatctcctg ggaggcgatc	420
gaacgcgcgg ggatcgcgcc ggattccctg cggggcagcc ggaccggcggt gttcgcgggc	480
gtcatccaca acgagtactc ggccatcgcg ggcacgcgc ccgcggatct cgagccgtac	540
ctcggcaacg ggagtttcgc gagcatcgcc tccgggcggg tttcctacac cttcgggctc	600
gaaggcccgg cggtcaccgt cgacacggcg tgttcgtcgt cgctgggtggc gctgcatctg	660
gcggcacagg cgctgcggca gggcgaatgt tcgctggcgt tggcgggtgg ggtgaccgtg	720
atggccaacc cggcggcggt cgtggacttc agccgtcagc gcgggctcgc ggcggacggg	780
cggatcaagg cgttcgccga agccgccgac ggcaccgcct ggggcgaagg cgcgggcatg	840
ctgctcgtcg agcggctctc cgacgcccgg cgcaacgggc accgcgtcct cgccgtcgtg	900
cgcggatccg cggatgaacca ggacggcgcc tcgaacgggc tcaccgcgcc caacggctctt	960
tcccagcaac gggatcatccg gcaggcactc gcgaacgcgc ggctcgcacc gtccgatgtg	1020
gacgccatgg aggcgcacgg cacgggcacc cggctcggcg acccgatcga ggcacaggct	1080
ttgctggcca cctacggcca ggaccggacc accccgctct ggctcggctc ggtgaagtcc	1140
aacatcgggc acagccaggc cgcggccggg gtcgcgtcga tcatcaaact cgtcgaggcg	1200
atgcggcacg gtgtgctgcc gaagacgctg cacgtcgacg cgccgacgtc gcatgtggac	1260
tggatccgagg gcgcgggtctc gttgctgacc gaggccgagc cgtggccgaa gacggatcga	1320
ccccggcggg ccgcgggtgtc ctcgttcggg atcagcggga cgaacgcgca cgtcgtcctc	1380
gaacagccca ccgcggaaga ggaaccgccg tccacgtttg cggggccgggt gccgttcgtg	1440
ctgtccggca agaccgaagc cgccctgcac gagcagggtg cccgcgtgcg ggaactcgcg	1500
cgggattcgg acgtcaccgc ggcggacctg gcgttctcgc tggccaccac gcggaccgcg	1560
ctggatcatc gggccgcctt ggtcggcacg ctggacgatc tgctgaccgc cactttggtg	1620
gaagggcggg cgacggacgg cgggacggcg ttcctgttca cgggccaggg cagtcagcgg	1680
ctgggggatgg gccgcgagct cgccgagcgt tccccgggtg tcgctcaagc cttcgacgac	1740
gtctcttcgc ggttcgagcg accgatcgcg gagctgtccg ccgaggaact gaaccagacg	1800

gcgaacacgc agtgcgcggtt gttcgccttc gaggtggcgc tcttccggct ggtcgagaac	1860
tggggcctcc ggccggactt cctggccggg cattcggtcg gggagatcgc ggccggctcat	1920
gtcgcggacg tgctctctct cgacgacgcg gtgacgttgg tgtcggctcg tggccgcctg	1980
atgcaggcgt tgccgaccgg tggggcgatg gtggcgcttc aggcgaccga ggcggaggtc	2040
gccccgctcc tgaccgaccg ggtgtcgctg gccgcgatca acggccccga gtcggtggtc	2100
gtctcgggtg acgaagaagc cgtcgccgcg gtggtgtccc acttcgaggg ccggaagagc	2160
aagcgcctta cggtagagtca cgcgttccat tcgcccttga tggagccgat gctcgacgac	2220
ttccgcgcgg tggtaggggg gctgaccttc gccgaaccgc ggatcccgat cgtgtccggc	2280
ggcctggctg aagtgtccac ttcggactat tgggtccggc acgtccgtga cgcggtgcgg	2340
ttccacgatt cggtcgaatt cctgaaggcc gagggcgctca cccggttccct ggagatcggg	2400
cccgcgcgcg tcttgaccgc catggccaag gaaagcgccg aggacgcggt cgtcctcccg	2460
gcttcgcgac gggaccgccc cgaggtagcg acgctgctga cggcggtcgc cggactgcac	2520
gtccatgggg ccgaggtcga ctgggcgcgc ctgttcgacg gtgcgcggcg cgtcgatctg	2580
ccgacgtatc cgttccagta cgagcacttc tggctcgaat ccggtgccgc tcaccgcgac	2640
gtgtccgccc ccgggctgga cgcgtcgccg cacgccttgc tcgccgcgcg ggtccggccc	2700
gcgggcgagg acgagatcct cctgacgggc aggatctcgc tgagcacact gccgtggctg	2760
gcggaccacg tcgtcggcgg aaacgtcctt ctgcccggtg ccgcgttcgc cgaactcgcg	2820
ctcgcggccc ccgacgaggc cggttgtgag gccgtcgagg aactgaacct ggaagcgccc	2880
ctggtgctgc ccgagaaggg cgggggtccag ttgcaggtcg cggtcggcgc ggctgacgac	2940
cagggcaggc gtcgggtcac cgtgcacgcc cggccggagg acgacggctt ctgggtgcgg	3000
cacgcctccg gcgtcctcgg taccgcagtg tccacacagg acgagatgat cgagtggccc	3060
ccctcgggcg cggagcctgt cgacctcgaa ggcttctacc cgaacctggc ggccgaaggg	3120
ctcggctatg gccctgcctt tcagggcgtc cgtgccgtct ggacccgcga tggcgacgtg	3180
ttcgccgaag tccagggtgga cgacactccc ggcaccttcg ggatccaccc cgcgttgttc	3240
gactccgccc tgcacgccat cggcgtcggc gagtcgcggg ggctggagat ccccttcgcc	3300
tggtcggatc tccgcctgca cggcgacggc gcgacgggtg tccgggttcg cctcagcccc	3360
gcgggcgacg gtgccgtctc cgttttcgcg accgaccccg ccggagcgcc ggtgttgctg	3420
gtcggctcgc tcagcctgcg ggctccggtc gccgcgaccg cctcgcttcc ccgtgactcg	3480
ctgttcgcgc tcacctggac gccggtgacg gtgcccgtg gtgctgggga acccaccgtg	3540
gagtcctttg tggacttcga tgacgtccgg caagcgacgg cgcacgcccg gcagatcgcc	3600
gtggagcccc gcgaggcccc cgtggtgttc ctgaccagcg gcgcgttcac cgatcctgcg	3660

caggcgctcgg	tctggggact	catgcgttcg	gcgcgggagg	agtaccccgg	ccggttcgtg	3720
ctcgtcgacg	ccgacgaccc	cgccacgctc	acggccggcc	tgctggccgg	catcgtggcc	3780
tccggcgaga	ccgaagccat	cgtgcgtgag	ggcgagggtcc	gtgtcccgcg	gctcaccgcc	3840
gtgcgcgggg	gcgaaaccgg	accgggctgg	gacccggaag	gcacggtcct	gatcaccggc	3900
ggcaccggcg	cgctcgccac	cgaactcgcc	cggcacctcg	tcacacgacg	cggtgtgcgg	3960
aacctgatcc	tcgccggacg	ccgcgggtccc	gccgcggaag	gcgcgagcga	gctggccgcc	4020
gaactggcgg	acctcggcgc	gcaggcccg	atcgtcgctt	gcgacgtcgc	ggatcgcgac	4080
cagctgacgg	cgttgctcga	cggcggttcg	ctgaccgcgg	tcgtccacgc	cgcgggcgctc	4140
ctcgacgacg	gcctgctcgc	cgatctcact	cgggaccgat	tcgaaaccgt	cctgaggtcc	4200
aaagtggacg	gcgcaatcct	gctggacgaa	ctggccgggtg	acgcccacct	cgtgtttcttc	4260
tcctccgcgg	ccgggggtgct	cggcagcgcg	gggcaggcca	actacgccgc	cgccaacgcc	4320
gccctcgacg	cggtggccgc	gcgcgcgcgg	gaacggggac	taccgcgac	ctcgctcgcg	4380
tgggggctct	gggagaccgg	cgacgggatg	gcgggtgcgc	tcgccgggac	cgatcgcgcg	4440
cggatggcgg	gctccgggct	gctgccgctt	ccggtcgggg	acgccttgac	cctgttcgac	4500
ttcgccgtcg	gagcggagga	agtgtgttct	gtgccgatgc	ggctcgacgt	gcccgtctctg	4560
cgcgcgagcg	ccacggacgt	gccgtctctg	cgggccttcg	ccgggaaatc	ccggcggacc	4620
gcgtcggccg	ccccgcgcgc	gcgggaactg	cgtgaccggc	tggcgctcgt	gcccaccgag	4680
gagcggggcc	gggaactgct	cgcgctgggtg	cgcggccagg	tcgccgaggt	actcggccac	4740
cgggacgccg	gggccgtcga	accggctcgt	ccgttcgggg	aactgggctt	cgactcgctg	4800
accgcgggtg	aactgcgcaa	cggcctcaac	gccgcttcgc	ggctccggct	gcccgcgacc	4860
gccgtgttcg	accaccccac	cccgaaggcg	ctcgcggaac	tgctcgccgc	cgaactgttc	4920
ggcgcagccc	ccgaagcccc	ggttcagggg	cccgcgatgg	cggccgacga	gccgatcgcc	4980
atcatcgcca	tggcatgccg	gtaccccggc	ggggtcgcct	cgccggagga	cctctggcgg	5040
ctggtcgcgg	agggccgcga	cggcatctcg	ctcttcccgg	ccgaccgcgg	ctgggacgtg	5100
gacggcctct	acgaccggga	ccccggcaag	gcggggaaga	gctacgtgcg	cgagggcgga	5160
ttcctccacg	aggcaggcga	tttcgacgcc	ggttttcttcg	gcatctcgcc	gcgtgaggca	5220
ctgggcatgg	accacagca	gcggctgctg	ctggaggtct	cgtgggaagc	cttcgaacgg	5280
gccgggatcg	accccggaac	gctgcggggc	agcgacaccg	gcgtcttcgc	cgggcagatg	5340
taccacgact	acctcaccgg	cgccacggtc	gttcccgcgc	acgtcgaggg	ttacctcggc	5400
accggcaact	ccgggagtgt	gctgtccggg	cgggtttcct	acaccttcgc	cctcgaaggt	5460

ccggccgtca ccgtcgacac ggcggtgttcg tcgtcgctgg tggcgctgca tctggcggca 5520
 caggcgttgc ggcgcggcga atgctcgctc gcgctggccg gcgggggtgac cgtgatggcc 5580
 acgccggaga cgttcgtcga cttcagccgt cagcgaggtt tggcaccgga cggccgctcg 5640
 aagtcctttt cggacggtgc ggatggcacg tcctgggtccg aaggtgtcgg catgctgctc 5700
 gtcgagcggc tctccgacgc cgagcgcaac gggcaccgga tcctggccgt cgtccgggggt 5760
 tcggcggtga atcaggacgg tgcgtccaac gggctgaccg cgccgaacgg tccttcgcag 5820
 cagcgggtga tccggcgagc cttggccgac gcgcgcctgg aaccgtccga agtggacgcc 5880
 gtcgaggcac acgggaccgg taccacgctg ggtgaccoga tcgaggcgca agcgctgctg 5940
 gcgacctacg gccagggccg cgaggacgcc gcgctgtggc tcgggtcgat caaatcgaac 6000
 atcgggcaca gccaggccgc cgccgggggtg gcgggtgtga tcaagatggg cgaggcgatg 6060
 cgccgcgggg tgctgccgaa gacgctgcac gtcaccgaac cgtcgtctca tgtggactgg 6120
 acggcgggcg cgggtctccct cctgaccgag gcgcgactct ggccggacgc cggacgtccc 6180
 cggcgtgcgg cgggtgtcgtc gttcgggatc agcggtacca acgcgcacgt cgtcctggag 6240
 caggggccccg ctccggtgga ggccatcgaa tccggtgagg gaccggcggc gttcgtcctg 6300
 tccgccggga gtgaagcggc cctgcatgac caagcgtcgc ggttgaggga cttcctcgcc 6360
 gagacgcctg ctgccttggc cgacgtcgcc ttctcgttgg cgaccacccg agcggccctg 6420
 gagcaccggg ccgccgtcgt ggccgcagac cgggaaaccc tgctggccgc gctggagAAC 6480
 ctactgtca ccggccgcgc gacggagggc cggacagcgt tcctgttcac cggtcagggc 6540
 agtcagcggc tcgggatggg ccttcagctg gccgagcgtt tcccggctct cgccgctgcc 6600
 tacgacgagg tgtgttcccc gttcagacag ccgctcaggg acctcacggc cgaggagctg 6660
 aaccagaccg cgaacacgca gtgcgcgttg ttcgcgcttg aggtggcgct gttccgcttg 6720
 gtcgagagct ggggtgtccg cccggacttc ctggctgggc attcggtcgg tgagatcgcg 6780
 gcagctcacg tcgcgggtgt gctttccctc gacgatgcgg tgaccctggg gtcggcgcga 6840
 ggccgtttga tgcaggcctt gcctaccggt ggcgcgatgg tggcgttgca ggcgacggaa 6900
 gccgaggtga cgccgctgct gaccgagcgg gtgtcgctgg cggcgatcaa cggtcgggag 6960
 tcgggtggctc tttcgggtga ggaggacgcc gtcgctgcgg tggctctctca gttcagagggt 7020
 cgcaagagca agcggctcac cgtgagtcac gcgttccact cgccgttgat ggagccgatg 7080
 ctcgacgagt tccgtgtggg cgccgacagc ttgtcgtagc cggcgccgcg gattccgata 7140
 gtgtccgggtg gtctggcgga ggtgtccact tcggactatt gggtcgcga tgtccgtgac 7200
 gcggtgcgat tccacgattc ggtgaagttc ctggaagccg aggggggtcac acggttcctg 7260
 gagatcgggc ccgacggtgt cctgaccgcg atggccaagg aaactgccga ggacgcggtc 7320

gtcgttccgg cactccggcg cgaccggccg gaggtggaga cgctgctgac ggcggtcgcg	7380
ggcctgcacg tccacggcgt gggcgtcgat ctgacggcct tgctcggcgg tggaagcccc	7440
gtcgacctgc ccacgtatgc cttccagcac cgacgtttct ggctttcctc ggcgggaggc	7500
gcggcggggc acgtcaccgc agccgggcta ggcaccaccg atcaccgcgt gctcggcgcg	7560
gccgcggcac tgccggggcg cggcgggttc ctgctcaccg gccggttgtc cgggcacgcc	7620
cagccgtggc tggccgaaca ccgggtcggc ggcgtggctc tgctgccggg caccgcgttc	7680
gtcgagatcg ccctgcgtgc gggggatgag gcgggctgcg gccacctcga agacctgacc	7740
ctcgaagcgc cgctcgtcct gcccagagcg ggtgcgacct agctgtccgt gctggtcggc	7800
gcggccgacg acaccggtcg ccggaccatc gagatccact cgcgcgagga aggcgaagac	7860
ggctggcaga ggcacgcgac cgggctgcta tcggccggcg gagccgtcga accggccggg	7920
ttgacgacct ggccgccccg gaacgccgaa gccgtcccgg tgggtgacgt ctacgagcgg	7980
ctcgccgcca ccggtctcga gtacggcccc gcgttccgtg gcctccgtgc ggcgtggcga	8040
gcgggtgaag acctgttcgc ggaggtcgaa ctcccggagg accagcactc cgacgcggct	8100
cggttcggcg tgcattccggc gctgctcgac gccgcgctcc acaccctcgg cctcgcgggc	8160
ggcggcgacg gcacccggct cccgttcgcc tggtcggggg tgcgcctgca cgccgccggc	8220
gcgacccggc tccgtgtccg gctgcggccg tccgggtccc acgggttcga ggtcctggtc	8280
gccgacggca ccggccgccc ggtcgtctca gccgaagagt tgacgctgcg cgagatctcg	8340
ggcgacgcct tggcccgcaa gggacacgac tcgctctacc gggtcgcctg gcgtccggtc	8400
ccgtcccgg agaccggcga aaccctcccc gcggagtcgg ttttctccgt gccgcgcggc	8460
ggcgactccg ccgagcgtgt ccacgaaacg acggccggcg ttctcgaagt cgtccagcgg	8520
cggctcgaag acgagccggg cgggtccgctt gtcgtccaca cccggggcgg agtcgccgcg	8580
ggcgacggcg aagcggtgac cgacctcgcg caccgcgcgg tctgggggct ggtgcgtgcc	8640
gcgcagtcgg agaaccgccg tcggttcctg ttggtcgacg ccgagacctt gcccgatggc	8700
cggatcctgg ccatcgacga gcctcagatc gctttgctg acggccgggc actcgcgccg	8760
cgcctggcca ccaccgcctc gtccacggaa ctgaccccg cccagggagc ctggcggctg	8820
gacaccaccg gtcgcggcac cctggagaac ctcacgctgg tgccgtcgcc cgaagcagtc	8880
gcgccgttgg ctgagggcga ggtccggatc gcggtgccgg ccgccgggct caacttccgc	8940
gacgtcctga tcgcgctggg catgtaccgc ggcgcggcca ccctcggcag tgaaggcgcg	9000
ggcgtggtea ccgagatcgg gcccggtgac accggcctcg acgtcggcga ccgcgtgttc	9060
ggcctgatgt cgaacggctt cgggccccag gtcgtcaccg atcaccggac gctggcgaag	9120

atgcccgagg actggtcgtt cgccacggcg gcctcgggtcc cgatcgtgtt cctcaccgcc 9180
 tactacggcc tgttcgacct cgcgcggttc gaagcgggag agtcgatcct ggtgcacgcg 9240
 gcggcgggcg gcgtcgggtat ggccgcgacc cagctggccc gtcacgccgg ggccgaggtg 9300
 ttcggcaccg ccggtccggg caaatgggac accttgctg ccaacggttt cgacgacacc 9360
 cacctctcgt cctcccgtga cctcgggttc gaggagaagt tccgcgatgc caccggcgga 9420
 cgcggtgtcg acgtcgtctt gaactcgttc gccggcgact acgtcgacgc gtcactgcgg 9480
 ctgctggccc cgggcgggcg gttcgccgag atgggcaaga ccgacatccg ggaaccgggg 9540
 gagaccggcg tcgagtacca ccccttcgac gtcacgcacg ccggacccga gcgcatccac 9600
 gagatgctcg ccgcactgct ggagctgttc gcggccgggg cgctgacgcc gttgccggtc 9660
 accggctggg acgtccggcg cggccccgac gcgttccgtt tcctcagcca ggccaagcac 9720
 gtcggcaaga acgtcctgac catgcccgcc gccctcgatc ccgacggcac cgtgctcgtc 9780
 accgggggaa cgggtgccct cggcgcgctc ttcgcccggc atctgggtgc cgaacgcggc 9840
 gtccggcggc tgctgctggc cagcaggcgc ggccacgacg ccccgggcgt acccgagctg 9900
 gtcgccgaac tcaccgaggc aggcgcctcg gtgacggtcg aggcgtgtga cgcggcggat 9960
 cgcggcgcg ctcgcccggt cctcgccgga atcccggccg cgcacccgct gaccggcgtg 10020
 gtgcacacgg cgggtgtcct ggacgacggc ctgctcggct cgctgacccc ggagcggctg 10080
 gcgaaggtgt tgcggccgaa ggtcgacgcg gcgctgaacc tgcacgaact gaccagcggc 10140
 gcggatctcg ccgagttcgt cgtcttctcc tcggccgccc gggctcttcg caacgccggg 10200
 caggcgaact acgccgcgc caacggtttc ctggacgcgc tcagcgtccg gcgcgcggcg 10260
 cacgggttgc ccgccggtc gctggcgtgg ggtctgtggg ccgaaacggg cgggatgggc 10320
 gggacgctcg gcgaggccga gctggccagg atggcccaga gcggtaccgc cgcactgtcc 10380
 acacaggacg gcctggagct cttcgacgcc gccggcgcg tggcggaacc ggtcctgggtg 10440
 ccgatgcgcc tggacgtcac cgcgatgggc ggggacgggc tcccgccgtt gctgcgcggc 10500
 ctgcccgcg gcccggtacg ccgtgccgcg tccgccgggg ccgccggtga cgcggactca 10560
 ttgcgagacc ggcttctcgc ggtgcccgtc gccgaccggg agacgctgct ggtcgacctc 10620
 gtgcgcaccc attccgcgac cgtgctcggg cacaccgcgg cggacgcggt cgaggccacg 10680
 cggtccttcc aggagatcgg cttcgactcc ctgaccgccg tcgagctgcg caaccggctc 10740
 accgccgcca ccgggctgcg gctgccggcg acgtgatct tcgactaccc gaccccgga 10800
 gcgctcgccg ccacatcgg cgaaggcgtc ctgggtgcgc agggcgggcc cgagaccggg 10860
 caggcggcg tgacggccga cgagccgac gcgatcgtcg cgatgagctg ccggttcccc 10920
 ggccacgccg acacccccga acggctctgg gccctgctgg ccgagggccg ggacgcgctg 10980

ggcgagttcc ccgccgaccg cggctgggac ctggagcggc tgttcgacac cgacccggac 11040
 cgccggggca cctcctacac ccgccaaggc gccttcctcg aaaccgccgg cgatttcgac 11100
 gcgggcttct tcgggatctc gccgcgtgag gcgctggcga tggatccgca gcagcgggtg 11160
 ctgctggaga cgtcgtggga ggcgttcgaa cgcgccggga tcgatccggc caccctgcgc 11220
 ggcagccgca ccggcgtggt cgccgggggtg atggacaacg aatacgtatc cggttcggcg 11280
 gaggtccctg acggggtcga gggctacctg gccaccggca cctcggcgag tgcgcctcg 11340
 ggccgcgttt cctacacctt cgggctcgaa ggtcccgcgg tcaccgtcga cacggcgtgt 11400
 tcgtcgtcgc tggtcgcgct gcatctcgcg gcgcaagcgc tgcggcaggg cgagtgcctg 11460
 ctggcactgg ccggtggagt gaccgtgatg gccacaccgg gcacgttcgt cgagttcagc 11520
 cgtcagcgcg gactggccgc cgacggccgc tgcaaggcgt tcgccgacgg cgccgacggg 11580
 acgggctggg gcgaaggcgc cgggatgctg ctctgaggag ggctgtccga cgcccgccgc 11640
 aacgggcatc cggtgctcgc ggtgctgcgg ggcagcgcgg tcaaccagga cggcgcgtcg 11700
 aacgggctca ccgcgccgaa cggtccttcg cagcagcggg tgatccgcca ggcgctggcg 11760
 aacgcgcggc tcgaaccgtc cgaagtggac gcagtcgaag cgcacggaac cgggaccacg 11820
 ctgggcgacc cgatcgaggc tcaggcgctg ctggcgacct acggccagga ccgggaacgg 11880
 ccgttgctgc tcggttcggg caagtcgaac atcgggcaca cgcaggccgc ggcgggcgtc 11940
 gccggggtga tcaagatggg gctcgcgatg cggcacggga cactgccgcg cacgctgcac 12000
 gtcgacacgc cgacttcgcg cgtcgactgg gcggcgggccc ggatcgagct cgcgaccgag 12060
 ccgacccagt ggccggagac cggtgggccc cgccggggcg cggtgctcgtc gttcgggatg 12120
 agcggtagca acgcgcacgt cgtcctcgaa caggccgaag cggtcgagac acgggatgaa 12180
 acctcgccgg ggctgctcgg tgacgtcgtc gcgtggccgc tgcggcgaa ggaacccgag 12240
 gccgtggccg cgcaggcggc acggctgaag tccttcctga ccggcgaacg tccggcggac 12300
 gtggcctact cgctggcgac cgcgcggacc acgctggaac accgggcggg cgtcgtcggc 12360
 gaagacccga tcgccggggt ggccgcgctg gccgcgggcg agccgtcggg ttcggtggtg 12420
 accgggaccg cgaccagcgg gaaggcgggt ttcgtcttcc ccggccaggg ttcgcagtgg 12480
 gccgggatgg cggtcgagtt gctggcgtcc gcacccgtgt tcgccgagtc gatggcggag 12540
 tgcgaagcgg ctctgctgtc ctatgtggac tggaagctga ccgaggtgct ctcggaacgcg 12600
 accgcgctgg agcgggtcga cgtcgtgcag cccgccttgt tcgcggtgat ggtgtcgtcg 12660
 gcgaggctgt ggcggtccag tggcatcgaa ccggccggcc tggtcgggtca ttcccagggc 12720
 gagatcgcgg cggcgtgtgt cgccggcgcg ctgtcgtcgt acgacgcggc acgggtgggtc 12780

tgcctgcgca gcaaggcgat cacggcgctt tcgggcccggg gcggcatggt ctccgtcgcc 12840
 gctcccgaag cccaggttcg cgagatcctg cccgaggggtg tgctcgctcgc cgcgggtgaat 12900
 ggtcccgcgt cgggtggtggt gtcgggtgac gtcgccggtc tggacgcgct catgaccgct 12960
 tgcgaggcga gcgggctgcg cgcgaagcgg atcccgggtg actacgcgtc gcattccgcg 13020
 cacgtcgatg ccatcgaaca agacgtcctg gccgcgctcg acgggatcga gccgcgggcg 13080
 ccggagatcc cgttctattc gacggtggcc ggggagccgc tcgatccggg ggtggacgcg 13140
 gcgtactggt tccggaacct gcgcgggacc gtccacttcg gacaagccgt ccggcggctg 13200
 ctcgacgacg ggttccgggt ctctcgtcgag gcgagccgc atccggtcct ggtcaccggg 13260
 atcgccgaca ccgccgagga cgcgggagaa cgcgccgtcg ccgtcggcag cctgcgccgg 13320
 gacgagggag ggccgctgcg gttcctcacc tcgctggccg aagcccacgt ccacggcctc 13380
 agcccggact gggcggcgct ggcccccgga acccgcgctc acctgccgac ctacgccttc 13440
 cagcacgagc actactggct gcggacgcgg tcttcggccg atcccggaca ggccgggtctg 13500
 gacgacggcg ggcatccgct gctcggggcc gtcgtcccgc tggcgggcag cgacggcctg 13560
 gtggccaccg gccggatctc ggcgcggaac cagacctggc tgcccgatca cgccgtcggg 13620
 ggcgcgctgc tgctgcccgg cgcggcgctc gtggacctgg cgctcacggt gggggagcgc 13680
 accggctgcg gccggatcgc cgaactgacc atcgaggcgc cgctagtcct cggggagtcc 13740
 gggagcgcgc ggctgcaggt gaccgtcgga gcgtccgcag acgacggcac ccgcgaggtc 13800
 gccgtgtact cccgggacga aaccgctggc acggactgga tccggcacgc gaccggcctg 13860
 ctgcgccgcg acggggaaac gcccggtggcg gacctgacct agtggccgcc cgcgggagcc 13920
 gaaccgatct ccctcgaagg gcactacgaa ggtctcgcgg aactgggcta cggctacggt 13980
 ccggcgttcc gcgggctgcg tgccgtgtgg cgcggggcg acgacgtgtt cgccgaagtc 14040
 gcgctcccgg aagaccggat cgccgaggcc gccgcgttcg gcctgcacct cgcgctcctc 14100
 gacgccgccc tgcacgcgct gggcttcggc atgctccccg acgacggacg gctgcggctt 14160
 ccgttcgcgt ggaacgaggt ctcgctgtcg gccgtcggcg cgccgagcct gcgcgtacgg 14220
 ctctcccccg ccggggagga cgcggtggcg gtggacctcg ccgacaccgc cggggcgccg 14280
 gtcgcctcga tcggctccgt ggtgttccgg ccggtggccg aggcacagct cgccggcgcc 14340
 cggcgggatc cggcggattc gctgttccag atccagtgga cggatctgtc cgcaaaggac 14400
 gtcgtcgcac cggcggtcgt cgtgctcggc gaggactgcg cggacctgc ggagctcgcc 14460
 gcggatctcg acgcgggaag gccggcgccc gacgtggtgc tcacgacctg cgcacccgtc 14520
 accggcgata tcgccgaggg cgcgcacgcc gccgcgaggg acgcgctgac gctgggtccag 14580
 aactggctgg ccgatgagcg gttctccgga gccaggctgg tcttccgcac ttccggcgcg 14640

gtctcgggtgg ccgcggacga accggtgtcc gacccggcca acgcgacggt ctggggcctc 14700
 gtgcgcacgg cgcaggagga gaatcccggc cggttcggtc ttctcgacac cgatgggttcc 14760
 gaggccgtct tgggtgcggc gctggcgctc gacgagcccc agctcgcgct gcgggccgga 14820
 acggtgctcg gcgcccggct ggtcaaggcg tccgccgaca ccgcgctcgt cccgcccccg 14880
 ggcagccgcg cgtggaccgt cgacaccctc ggcgggcgga ccctggagaa cctggtgcta 14940
 cgggaccggc ccgatctgct ggccccgctc gccgacgggc aggtccgtat cgccgtgcgg 15000
 tcggccgggc tcaacttccg ggacgtcgtg gtggccctcg ggctcgtgcc agggcaggaa 15060
 ggcatcggcg gggaaggcg gcggcgtggc accgagaccg gccccggcgt caccgacctg 15120
 gcgcggggcg accgcgtgct gggcatgttc gacgcgtcgt tcggcccgat cgccgtcgcc 15180
 gaccggaagc tgatcgcgcc cgtcccggac gactggctgt tcaccgaagc cgcttcggcg 15240
 cccgtcgcgt tcctgaccgc ctacgtcggc ctggctgacc tcggcgagct gcggccgggt 15300
 cagaccgtgc tgatccacgc cgccgccggt ggggtcggca tggccgcggt ccagctggcc 15360
 cggcacttcg gtgccgagat ctacgtgacc gcgagccccg ccaagtggga cacgctgcgg 15420
 gcgatgggct tcgacgacga ccacatcgcg tccagccgga ccctcgattt cgaggacaag 15480
 atccgcgaag ccaactggcg acgcggggtc gacctggtgc tggactcgtt ggcaaggag 15540
 ttctcgcacg cgtcgtcgcg gctgggtgcg gaaggcgggc gattcgtcga gatgggcaag 15600
 accgacatcc gcgacgcgga cgaggtcgcg gccgcccata ccggcgtcac ctaccgcgcg 15660
 ttcgacctga tcgactccgg gcacgaccgg atccaggaga tcctggggca actcctggcg 15720
 ctggcggaca aggacgtggc gcggccgctg ccgaccacgg cgtgggacgt ccggcgcgcc 15780
 cccgaagcgt tccggttcct cagccaggcc aagcacacgg gcaagatcgt gctggagccg 15840
 ccgcgcgtcc tcgaccccga gggaacgggtg ctgatcaccg gtggcaccgg cgtgctgggc 15900
 ggctgttcg cccgacatct ggtgaccgcg cacggcgtcc ggcggtcgt gctgaccagc 15960
 aggcgcgggc tcgacgccga ggggtgcgcg gaactggctc cggacctgac cggcctcggg 16020
 gccacgggtga ccgtcgtggc ctgcgacgtc gccgatcgcg ccgcggtcgc cggactgctc 16080
 ggctcggtec cgcccagca cccgctgacc gccgtgggtg acaccgccgg cgtgctcgac 16140
 gacgggctga tcccggcact caccgccgac cggctcggca ccgtgttcg cccgaaggtc 16200
 gacgccgcgg tccatctgca cgaactgacc cgcgacctc gactggccgc gttcgtgctg 16260
 ttctcctcgt ccgcggcgac gttcggcgcc gccggacagg ggaactacgc ggcgccaac 16320
 gccttcctcg acgcactcgc ccagcaccgc cgggccgaag ggctcggcgg gcaggcattg 16380
 gcgtggggct tctggggcga gcggagcgcg atgaccggcc atctcgacga ggcggacgtg 16440

```

gccaggatga agcgatccgg cgtcagtcca ctgtcctctg tggacgggtct tgcgctgttc 16500
gacgcggcgg cggaacggga cgtcgcggcg ctggtgcccc tgcacctgga caccgccgcc 16560
ctccgagggc agaccgaagt gcccgccttg cttcgtgttc tcgcgggtgc tccggccaag 16620
cgggtcgcgg gagcggccgc cacgagcgga ccgtcgctcg cccagcggct ggcggcactg 16680
cccgccgcgg accgggagcc gttcctgctg gatctgggtgc gctcgcacgc cgcggccgcg 16740
ctcggccacg cgtcggtcgc caaggtcggc ccggagctgg ccttcgcga cctcggcttc 16800
gactcgctga ccgcggtcga gctgcgcaac cggctcggcg cggcgaccgg gctgcggctg 16860
ccgtccacgc tggctcttca tcagccgagc ccggccgcgc tcgcccggca cctgctggcg 16920
gaactgggcg aaccggccgg cgccgaacc gaggtggcgg tgctggcaga cctcgaccgg 16980
ctggagaccg cactggccgc ggcggtcacc gacgacgaga ccgcggaccg gatcaccgac 17040
cggctgcgcg cgggtgctgc ccggtggacc gagggccgcg gcccgggcca ggacgagggt 17100
gacggcgatc tggccgacgc cagcgccgac gagctgttcg acatcttgca caaggaattc 17160
ggaaggtcgt ga 17172

```

```

<210> 41
<211> 1735
<212> PRT
<213> Amycolatopsis orientalis

```

```
<400> 41
```

```

Val Ser Gly Asp Glu Lys Leu Leu Glu Asn Leu Lys Trp Ala Thr Gly
1          5          10          15
Glu Leu Arg Arg Ala Arg Arg Arg Leu Val Glu Leu Glu Glu Ala Gly
20          25          30
His Glu Pro Ile Ala Val Val Gly Met Ser Cys Arg Phe Pro Gly Gly
35          40          45
Val Arg Ser Pro Glu Gln Leu Trp Asp Leu Val Ala Ser Gly Thr Asp
50          55          60
Ala Leu Ser Glu Phe Pro Gly Asp Arg Gly Trp Asp Leu Gly Gly Leu
65          70          75          80
Phe Asp Pro Asp Pro Asp Thr Pro Gly Lys Thr Tyr Val Ser Glu Gly
85          90          95
Gly Phe Leu Tyr Glu Ala Gly Asp Phe Asp Ala Ala Phe Phe Gly Ile
100         105         110
Ser Pro Arg Glu Ala Gln Ala Met Asp Pro Gln Gln Arg Leu Leu Leu
115         120         125
Glu Ala Ala Trp Glu Val Leu Glu Arg Ala Gly Ile Asp Pro Ala Thr
130         135         140

```

Leu	Arg	Gly	Ser	Arg	Thr	Gly	Val	Phe	Ala	Gly	Val	Ile	His	Asn	Asp	145	150	155	160
Tyr	Thr	Gly	Val	Leu	Thr	Asp	Ile	Pro	Pro	Glu	Leu	Glu	Pro	Tyr	Leu	165	170	175	
Gly	Asn	Gly	Asn	Phe	Ser	Ser	Val	Ala	Ser	Gly	Arg	Ile	Ala	Tyr	Thr	180	185	190	
Leu	Gly	Leu	Glu	Gly	Pro	Ala	Val	Ser	Val	Asp	Thr	Ala	Cys	Ser	Ser	195	200	205	
Ser	Leu	Val	Ala	Leu	His	Leu	Ala	Ala	Gln	Ser	Leu	Arg	Arg	Glu	Glu	210	215	220	
Cys	Thr	Leu	Ala	Leu	Val	Gly	Gly	Val	Asn	Val	Met	Thr	His	Pro	Ala	225	230	235	240
Ala	Phe	Val	Asp	Phe	Ser	Arg	Gln	Arg	Gly	Leu	Ala	Ala	Asp	Gly	Arg	245	250	255	
Cys	Lys	Ala	Phe	Ala	Asp	Ala	Ala	Asp	Gly	Thr	Gly	Trp	Gly	Glu	Gly	260	265	270	
Val	Gly	Met	Leu	Leu	Val	Glu	Arg	Leu	Ser	Asp	Ala	Gln	Arg	Asn	Gly	275	280	285	
His	Gln	Val	Leu	Ala	Val	Leu	Arg	Gly	Ser	Ala	Ile	Asn	Gln	Asp	Gly	290	295	300	
Ala	Ser	Asn	Gly	Leu	Thr	Ala	Pro	Asn	Gly	Pro	Ala	Gln	Gln	Arg	Val	305	310	315	320
Ile	Arg	Gln	Ala	Leu	Ala	Asp	Ala	Arg	Leu	Ser	Pro	Gly	Gln	Val	Asp	325	330	335	
Val	Val	Glu	Gly	His	Gly	Thr	Gly	Thr	Thr	Leu	Gly	Asp	Pro	Ile	Glu	340	345	350	
Ala	Gln	Ala	Leu	Leu	Ala	Thr	Tyr	Gly	Gln	Asp	Arg	Glu	Arg	Pro	Leu	355	360	365	
Leu	Leu	Gly	Ser	Leu	Lys	Ser	Asn	Ile	Gly	His	Thr	Gln	Ala	Ala	Ala	370	375	380	
Gly	Val	Gly	Gly	Val	Ile	Lys	Met	Val	Gln	Ala	Ile	Arg	His	Gly	Ile	385	390	395	400
Ala	Pro	Arg	Thr	Leu	His	Val	Asp	Ala	Pro	Ser	Ser	His	Val	Asp	Trp	405	410	415	
Ser	Ala	Gly	Glu	Val	Ser	Leu	Leu	Thr	Gly	Glu	Gln	Pro	Trp	Pro	Glu	420	425	430	
Thr	Gly	Glu	Pro	Arg	Arg	Ala	Gly	Val	Ser	Ser	Phe	Gly	Ile	Ser	Gly	435	440	445	
Thr	Asn	Ala	His	Val	Ile	Leu	Glu	Gln	Ala	Pro	Ala	Val	Glu	Val	Glu	450	455	460	
Ser	Leu	Val	Asp	Thr	Arg	Val	Leu	Asp	Ser	Ala	Val	Leu	Pro	Phe	Val				

465					470						475				480
Leu	Ser	Gly	Arg	Ser	Glu	Glu	Ala	Leu	Ala	Ala	Gln	Ala	Ser	Lys	Leu
				485					490					495	
Ala	Ala	Tyr	Leu	Thr	Gly	Glu	Pro	Ala	Pro	Lys	Ala	Ile	Ala	Arg	Ala
			500					505					510		
Leu	Ala	Glu	Thr	Arg	Ser	Ala	Leu	Pro	His	Arg	Ala	Val	Val	Leu	Ala
		515					520					525			
Glu	Asp	Leu	Gly	Glu	Leu	Leu	Gly	Gly	Leu	Arg	Ser	Leu	Ala	Glu	Gly
	530					535				540					
Glu	Pro	Ala	Ala	Arg	Val	Leu	Thr	Gly	Thr	Ala	Glu	Ala	Gly	Lys	Ala
545					550					555					560
Val	Phe	Val	Phe	Pro	Gly	Gln	Gly	Ser	Gln	Trp	Val	Gly	Met	Ala	Glu
				565					570					575	
Glu	Leu	Leu	Leu	Ser	Ala	Pro	Val	Phe	Ala	Glu	Ser	Met	Ala	Glu	Cys
			580					585					590		
Glu	Arg	Ala	Leu	Ser	Ser	Phe	Val	Asp	Trp	Lys	Leu	Ser	Asp	Val	Leu
	595						600					605			
Ser	Asp	Ala	Ala	Ala	Leu	Glu	Arg	Val	Asp	Val	Val	Gln	Pro	Val	Leu
	610					615					620				
Phe	Ala	Val	Met	Val	Ser	Leu	Ala	Arg	Leu	Trp	Arg	Ala	Cys	Gly	Val
625					630					635					640
Glu	Pro	Ala	Ala	Val	Val	Gly	His	Ser	Gln	Gly	Glu	Ile	Ala	Ala	Ala
				645					650					655	
Cys	Val	Ala	Gly	Ala	Leu	Ser	Leu	Asp	Asp	Ala	Ala	Arg	Leu	Val	Cys
			660					665					670		
Leu	Arg	Ser	Lys	Ala	Ile	Leu	Ala	Leu	Ser	Gly	Arg	Gly	Gly	Met	Val
	675					680						685			
Ser	Val	Ala	Ala	Ser	Glu	Asp	Arg	Val	Arg	Glu	Leu	Leu	Pro	Ala	Gly
	690					695					700				
Val	Ser	Val	Ala	Ala	Val	Asn	Gly	Pro	Ser	Ala	Val	Val	Val	Ser	Gly
705					710					715					720
Asp	Val	Ala	Gly	Leu	Glu	Ala	Leu	Leu	Lys	Arg	Cys	Glu	Leu	Leu	Asp
				725					730					735	
Val	Arg	Ala	Lys	Arg	Ile	Pro	Val	Asp	Tyr	Ala	Ser	His	Ser	Ala	His
			740					745					750		
Val	Asp	Ala	Ile	Glu	Gln	Glu	Val	Leu	Ser	Ala	Leu	Ala	Gly	Ile	Ser
	755						760					765			
Pro	Gln	Ala	Pro	Val	Ile	Pro	Phe	Tyr	Ser	Thr	Val	Thr	Asp	Glu	Pro
	770					775					780				
Leu	Glu	Leu	Asp	Ala	Ala	Tyr	Trp	Phe	Arg	Asn	Leu	Arg	Gly	Thr	Val
785					790					795					800

Arg Phe Ala Ala Thr Val Asp Arg Leu Leu Glu Asp Gly Phe Arg Phe
 805 810 815
 Phe Val Glu Ala Ser Pro His Pro Val Leu Val Pro Gly Ile Ser Glu
 820 825 830
 Glu Ala Ile Ala Leu Gly Ser Leu Arg Arg Gly Glu Gly Gly Ala Glu
 835 840 845
 Arg Phe Val Ala Ser Leu Ala Glu Ala His Thr Gln Gly Leu Ser Pro
 850 855 860
 Ser Trp Ser Ala Val Leu Pro Pro Ala Glu Arg Val Asp Leu Pro Thr
 865 870 875 880
 Tyr Ala Phe Gln His Lys Arg Phe Trp Leu Glu Ala Gly Thr Ala Ser
 885 890 895
 Gly Asp Ala Ser Ala Phe Gly Gln Thr Val Val Asp His Pro Leu Leu
 900 905 910
 Gly Ala Ala Leu Pro Leu Ala Asp Gly Asp Gly Leu Val Leu Thr Gly
 915 920 925
 Arg Ile Ser Pro Asp Thr Gln Pro Trp Leu Val Asp His Thr Val Leu
 930 935 940
 Asp Thr Val Leu Leu Pro Gly Thr Ala Phe Val Glu Leu Val Leu Arg
 945 950 955 960
 Ala Gly Arg Glu Ala Gly Cys Asp Gly Val Asp Glu Leu Thr Leu Glu
 965 970 975
 Ala Pro Leu Val Leu Asp Gly Pro Val Ala Leu Gln Val Val Leu Gly
 980 985 990
 Glu Pro Asp Glu Arg Gly Arg Arg Ala Val Ser Val His Ser Arg Pro
 995 1000 1005
 Glu Asp Ser Asp Glu Pro Trp Thr Arg Asn Ala Gln Gly Thr Leu
 1010 1015 1020
 Ser Ala Gly Thr Pro Ser Thr Val Ser Leu Ala Glu Trp Pro Pro
 1025 1030 1035
 Pro Gly Ala Ala Glu Ala Pro Glu Ser Asp Leu Tyr Asp Arg Phe
 1040 1045 1050
 Ala Glu Leu Gly Leu Ala Tyr Gly Pro Val Phe Gln Gly Leu Arg
 1055 1060 1065
 Ala Ala Trp Arg Gln Gly Asp Asp Val Phe Ala Glu Val Asp Leu
 1070 1075 1080
 Pro Glu Glu Glu Glu Ala Asp Arg Phe Gly Val His Pro Ala Leu
 1085 1090 1095
 Leu Asp Ala Ala Leu His Thr Leu Gly Leu Gly Ala Gln Asp Glu
 1100 1105 1110

Thr	Val	Arg	Leu	Pro	Phe	Thr	Trp	Ser	Gly	Val	Thr	Leu	His	Ala
1115						1120					1125			
Thr	Gly	Ala	Ser	Lys	Leu	Arg	Val	Arg	Leu	Thr	Pro	Thr	Ala	Asp
1130						1135					1140			
Gly	Gly	Ser	Leu	Thr	Val	Ala	Asp	Glu	Thr	Gly	Ala	Pro	Val	Leu
1145						1150					1155			
Thr	Val	Gly	Glu	Leu	Gly	Leu	Arg	Pro	Ile	Ser	Pro	Ala	Gln	Leu
1160						1165					1170			
Gly	Arg	His	Arg	Asp	Ser	Leu	Phe	Arg	Leu	Asp	Trp	Val	Pro	Ala
1175						1180					1185			
Pro	Val	Gly	Pro	Ala	Pro	Glu	Glu	Pro	Gly	Val	Trp	Arg	Cys	Pro
1190						1195					1200			
Glu	Gly	Glu	Leu	Arg	Pro	Val	Leu	Glu	Glu	Val	Leu	Lys	Arg	Ile
1205						1210					1215			
Gln	Ala	Asp	Ser	Thr	Ala	Thr	Thr	Val	Val	Leu	Thr	Ser	Gly	Ala
1220						1225					1230			
Val	Ala	Ser	Ala	Ser	Pro	Asp	Pro	Val	Ala	Ala	Ala	Val	Trp	Gly
1235						1240					1245			
Leu	Val	Arg	Ser	Ala	Gln	Ala	Glu	His	Pro	Gly	Arg	Phe	Val	Leu
1250						1255					1260			
Ile	Asp	Ala	Arg	Thr	Glu	Asp	Glu	Val	Arg	Thr	Ala	Leu	Ala	Thr
1265						1270					1275			
Gly	Glu	Ala	Gln	Val	Ala	Val	His	Asp	Gly	Lys	Pro	Leu	Val	Pro
1280						1285					1290			
Arg	Leu	Ala	Arg	Val	Ala	Ala	Ala	Asp	Ala	Gly	Glu	Pro	Asp	Trp
1295						1300					1305			
Thr	Pro	Asp	Asp	Val	Val	Leu	Ile	Thr	Gly	Gly	Thr	Gly	Arg	Leu
1310						1315					1320			
Gly	Gln	Ala	Leu	Ala	Arg	His	Leu	Ala	Val	Arg	His	Gly	Val	Arg
1325						1330					1335			
Gly	Leu	Val	Leu	Thr	Gly	Arg	Thr	Gly	Gly	Gly	Ala	Glu	Asp	Leu
1340						1345					1350			
Val	Ala	Asp	Leu	Ala	Glu	Leu	Gly	Thr	Gln	Val	Thr	Val	Ala	Ala
1355						1360					1365			
Cys	Asp	Val	Ala	Asp	Pro	Asp	Ala	Val	Arg	Ala	Leu	Leu	Ala	Ala
1370						1375					1380			
His	Pro	Val	Thr	Ala	Val	Val	His	Ala	Ala	Ala	Val	Leu	Asp	Asp
1385						1390					1395			
Gly	Leu	Val	Asp	Gly	Leu	Thr	Pro	Asp	Arg	Leu	Gly	Thr	Val	Leu
1400						1405					1410			
Ala	Pro	Lys	Ala	Asp	Gly	Ala	Arg	Val	Leu	His	Glu	Leu	Ala	Gly

1415		1420		1425
Pro Val Arg Arg Phe Val	Thr Phe Ser Ser Ala Ala	Gly Val Phe		
1430	1435	1440		
Gly Asn Pro Gly Gln Ala	Gly Tyr Ala Ala Ala	Asn Ala Tyr Ala		
1445	1450	1455		
Asp Ala Leu Met Leu Arg	Arg Arg Ala Glu Gly	Leu Pro Gly Val		
1460	1465	1470		
Ser Leu Ala Trp Gly Phe	Trp Ala Glu Arg Ser	Lys Leu Thr Gly		
1475	1480	1485		
Asp Leu Asp Asp Thr Asp	Val Arg Arg Met Ala	Arg Ala Gly Val		
1490	1495	1500		
Thr Ala Leu Ser Thr Glu	Glu Gly Leu Ala Leu	Phe Asp Ala Ala		
1505	1510	1515		
Val Ala Gly Gly Asp Gly	Leu Leu Val Pro Ala	Lys Ile Asp Leu		
1520	1525	1530		
Thr Ala Phe Arg Gly Arg	Pro Ala Ala Glu Ile	Pro Ala Leu Leu		
1535	1540	1545		
Arg Gly Leu Val Arg Val	Pro Ala Arg Arg Ser	Gly Glu Ala Ser		
1550	1555	1560		
Gly Thr Ala Glu Ala Leu	Lys Arg Asp Leu Ala	Gly Lys Pro Glu		
1565	1570	1575		
Ala Glu Arg Val Arg Leu	Leu Glu Glu Val Val	Arg Ile Arg Val		
1580	1585	1590		
Ala Ala Val Leu Gly His	Glu Ser Ala Asp Ala	Ile Ala Gly Asp		
1595	1600	1605		
Arg Gly Phe Leu Glu Leu	Gly Phe Asp Ser Leu	Thr Ala Val Glu		
1610	1615	1620		
Leu Arg Asn Arg Leu Ala	Glu Ala Thr Gly Leu	Arg Leu Pro Pro		
1625	1630	1635		
Thr Leu Val Phe Asp Arg	Pro Asn Ala Gly Ala	Leu Ala Ala Tyr		
1640	1645	1650		
Leu Ala Ala Glu Leu Ala	Thr Glu Thr Ala Gly	Pro Ala Leu Asp		
1655	1660	1665		
Ala Glu Leu Asp Arg Phe	Ala Ala Ala Leu Thr	Ala Ala Asp Pro		
1670	1675	1680		
Gly Glu Ala Glu Arg Ala	Arg Leu Ala Ala Arg	Leu Arg Ala Leu		
1685	1690	1695		
Leu Gly Thr Leu Gln Gly	Gly Glu Asp Pro Ala	Gly Glu Ile Asp		
1700	1705	1710		
Gly Lys Leu Glu Ser Ala	Asp Asp Glu Glu Met	Phe Ala Phe Ile		
1715	1720	1725		

Asp Asn Val Leu Lys Pro Ser
 1730 1735

<210> 42
 <211> 5208
 <212> DNA
 <213> *Amycolatopsis orientalis*

<400> 42
 gtgtcgggcg atgagaaact gctggagaac ctgaagtggg cgaccggcga gctgcggcgc 60
 gcgcggcgca ggctggtcga gttggaggag gccgggcacg agccgatcgc cgtcgtcggg 120
 atgagctgcc gcttccccgg cggggtccgc tcgcccgaac agctgtggga cctggtcgcc 180
 tccgggaccg acgcgctgtc ggagttcccc ggtgaccggg gctgggatct ggggtgggctc 240
 ttcgaccggg accccgacac cccgggcaag acctacgtct ccgaaggcgg attcctctac 300
 gaagccgggg atttcgacgc cgcgttcttc gggatctcgc cgcgtgaggc ccaggcgatg 360
 gatccgcagc agcggctgct gctcgaagcg gcgtgggagg tgctcgaacg cgccgggata 420
 gaccggcca ccttgcgcgg cagccggacc ggcgtcttcg ccggcgtcat ccacaacgac 480
 tacaccggcg tgctcaccga catcccgccg gagctggagc cctatctcgg caacgggaac 540
 ttcagcagcg tcgcctccgg ccggatcgcc tacaccctcg gcctcgaggg ccccgcggtc 600
 tcggtcgata cggcgtgctc gtcttcgctg gtcgcgctgc atctcgccgc gcagtcttta 660
 cgtcgcgagg aatgcacgct cgccctcgtc ggcggggtga acgtgatgac ccatcccgcc 720
 gcgttcgctc acttcagccg tcagcgcgga ctggccgccc acggccgctg caaggccttc 780
 gccgacgcgg ccgacggcac cggttggggc gaaggcgctc gaatgctgct ggtcgaacgg 840
 ctttccgacg cccagcgcaa cggacaccag gtccctcgcg tgctgcgggg cagcgccatc 900
 aaccaggacg gcgcgtcgaa cgggctcacc gcgccgaacg gtcccgtca gcagcgggtc 960
 atccgccagg cactcgccga cgccaggctc tcgccggggc aggtggacgt cgtcgaggga 1020
 cacggcaccg gcaccaccct cggcgacccg atcgaggcgc aggcgctgct ggcgacctac 1080
 ggccaggacc gggaacgccc gctgctgctg ggttcctca aatcgaacat cgggcatacg 1140
 caggccgccc ccggggtcgg cggggtgatc aagatggtgc aggcctccg gcacgggatc 1200
 gcgccgcgca cgctgcacgt cgacgctccc tcgtcgcatg tggactggtc ggcgggagcg 1260
 gtctcgctgc tgaccgggga acagccgtgg ccggagaccg gggaaccgcg ccgagccggg 1320
 gtgtcgtcgt tcgggatcag cggtaaccaac gcgcacgtga tcctggagca agcgccggcc 1380
 gtcgaggctc agtcccttgt ggacactcgg gtgctcgact ccgcggtctt gccgttcgtg 1440
 ctttccggcc gcagtgaaga ggctttggcc gccagggcgt cgaagctcgc cgcgtatctg 1500
 actggcgagc ccgcgcccaa ggccatcgcg cgagccctcg ccgagacgcg gtcggcgctt 1560

ccgcatcggg	cggtcgtgct	cgccgaagac	ctcggcgaac	tgctcggcgg	cttgcgttcc	1620
ctcgccgagg	gcgaacccgc	cgcgcgggtc	ctgaccggta	ccgccgaggc	gggtaaggcc	1680
gtcttcgtgt	tcccgggtca	gggttcgcag	tgggtgggga	tggcggagga	gttggtgttg	1740
tcggctccgg	tgttcgcgga	gtcgatggct	gagtgtgagc	gcgcgctttc	atcctttgtg	1800
gattggaagt	tgtcggatgt	gttgtcggat	gcggctgcgt	tggagcgggt	tgatgtggtg	1860
cagcctgttt	tgttcgcggt	gatggtgtcg	ttggcgcggt	tgtggcgggc	gtgtgggggt	1920
gagcctgctg	cggtgggtggg	tcattcgcag	ggtgagatcg	cggcggcgtg	tgtggctggt	1980
gcgttgctgt	tggatgatgc	tgccgcggtt	gtgtgcctgc	ggagtaaggc	gattttggcg	2040
ttgtcgggtc	gtggtggcat	ggtgtcgggt	gctgcttcgg	aggatcgtgt	tcgggagttg	2100
ctgcctgccg	gtgtgtcggg	ggcagccgtg	aacggcccgt	cggcgggtgg	ggtgtccggg	2160
gatgtcgcgg	gcttgagggc	gttgctcaag	cggtgtgagc	tgctggacgt	gcgggcgaag	2220
cggatcccgg	tggactatgc	ctcgcatteg	gcgcattgtg	atgcgatcga	gcaggaggtc	2280
ttgtcggcgc	tggcgggtat	ctcaccgcag	gcgccgggtg	tcccgtttta	ttcgacgggtg	2340
accgatgagc	ctctggaatt	ggatgcggcg	tactggttcc	ggaatctgcg	ggggacgggtg	2400
cggttcgcgg	cgacgggtga	tcggttgctg	gaggacgggt	tccggttttt	cgtggaggcg	2460
agtccgcata	cggtgctggt	tccggggatc	agtgaagaag	ccatcgcggt	ggggagtttg	2520
cgtcgggggtg	aggggtggtgc	ggagcggttc	gtcgcgtcgc	tggccgaagc	ccacacgcag	2580
ggcctgagcc	cctcgtgggtc	cgccgtgctg	ccgcccgcgc	aacgggtcga	cctgccgacg	2640
tatgccttcc	agcacaagcg	gttctgggtc	gaagcgggca	ccgcgagcgg	ggacgcgtcg	2700
gcgttcgggc	agacgggtgg	cgaccacccg	ctgctcggcg	ccgccctgcc	gctcgcggac	2760
ggcgacggcc	tcgtcctcac	cggccggatc	tcgccggaca	cgcagccctg	gctcgtcgac	2820
cacaccgtcc	tggacaccgt	gctcctgccg	gggacggcgt	tcgtcgagct	cgtcctgcgc	2880
gctgggcggg	aggcaggctg	cgacggcgtc	gacgaactga	ccttggaagc	gccgctcgtc	2940
ctcgacgggc	ccgtggcgct	gcaggtcgtg	ctcggggagc	ccgacgagcg	cggccgctcg	3000
gccgtgtccg	tgcactcacg	gccggaggat	tccgacgaac	cctggaccgc	caacgctcag	3060
ggcacgctgt	ccgcgggcac	cccacgcagc	gtttcgctcg	ccgagtggcc	gccaccgggc	3120
gccgccgaag	cgcgggagtc	cgatctctac	gaccgtttcg	ccgagctcgg	cctcgcctac	3180
ggtccgggtgt	tccagggaact	gcgcgcggcg	tggcgccagg	gcgacgacgt	gttcgccgag	3240
gtcgacctgc	ccgaggagga	ggaggcggac	cgttcgggcg	tgcaccccg	cctgctcgac	3300
gcggccctgc	acaccctcgg	gctcggggcc	caggacgaga	ccgtgcggct	gccgttcacc	3360

tggtccggtg	tgaccctcca	cgccacgggc	gcgtcgaaac	tccgggtccg	gctcacgccg	3420
accgccgacg	gcggctcgct	caccgtggcc	gacgagaccg	gcgccccggt	gctgaccgtc	3480
ggggaactgg	ggctgcgccc	gatctccccg	gcccagctgg	gccgccaccg	ggattcgctg	3540
ttccggctcg	actgggtccc	cgctcctgtg	gggccggcgc	cggaagagcc	gggggtgtgg	3600
cgctgccccg	aaggcgaact	gcggccggtc	ctggaagagg	tcctgaagcg	gatccaggcc	3660
gattcgacgg	ccacgaccgt	cgtgctcacc	tcgggtgcgg	tggcgagcgc	gtcgccggat	3720
ccggtggcgg	ccgcggtctg	gggtctcgtg	cggtcggccc	aggccgagca	tccgggcccg	3780
ttcgtgctga	tcgacgcgcg	gaccgaggac	gaggtccgca	ccgcgctggc	gaccggggaa	3840
gcgcaggctg	ccgtccacga	cggcaaaccg	ctggtacccc	ggctcgcgcg	ggtggcggcc	3900
gccgacgcgg	gcgaaccgga	ctggacgccc	gacgacgtcg	tcctgatcac	cggtggcacc	3960
ggacggctcg	ggcaggcgct	ggccccggac	ctcgccgtcc	ggcacggcgt	gcgcggactg	4020
gtgctgaccg	ggcggacggg	cgggggcgcg	gaagacctgg	tcgcggacct	ggcggaaactg	4080
ggcaccacgg	tcaccgtcgc	ggcctgcgac	gtcgcggate	cggacgcggt	gcgcgcactg	4140
ctggccgccc	atccggtgac	cgcggtggtg	cacgccgcgg	ccgtgctcga	cgacgggctc	4200
gtcgacggtc	tgaccccgga	ccggctcggc	accgtgctgg	ccccgaaggc	cgacggcgcc	4260
cgcgtgctgc	acgaactcgc	cggaccggtc	cgccggttcg	tcacgttctc	ctcggcggcc	4320
ggcgtgttcg	gcaaccgggg	gcaagcgggc	tacgccgcgg	cgaacgccta	cgccgacgct	4380
ctcatgctcc	ggcgtcgtgc	cgaggggctg	cccggagtgt	ccctcgcttg	gggattcttg	4440
gcggaacgca	gcaagctgac	cggcgacctc	gacgacaccg	acgtccgccg	gatggcccgc	4500
gcgggtgtca	ccgcgttgtc	cacggaggaa	ggcctggcgc	tgttcgacgc	cgccgtggcc	4560
ggaggggacg	gcctgctcgt	ccccgccaa	atcgacctga	ccgccttcgg	gggccgcccc	4620
gccgccgaga	tccccgctct	gctgcgcggc	ctggtgcgcg	tccccgcgcg	acggtcgggg	4680
gaggcgtcgg	gcacggccga	ggcactgaaa	cgcgaccttg	ccgggaagcc	ggaggccgaa	4740
cgcgtccggc	tgctggagga	ggtcgtgcgg	atccgggtgg	cggccgtgct	cgggcacgag	4800
tcggccgacg	cgatcgccgg	ggaccgcgga	ttcctcgaac	tgggcttcga	ctcgctgacc	4860
gcggtggaat	tgcgcaaccg	gctcgccgag	gcgaccggac	tgcggttgcc	gcccacgctc	4920
gtcttcgacc	ggcccaacgc	cggagcgctc	gcggcctacc	tggcgggcca	actggccacc	4980
gagaccgccg	gaccggccct	cgacgccgaa	ctcgaccggc	tcgccgccgc	gctgaccgcg	5040
gccgaccccc	gagaggccga	acgggccccg	ctggccgccc	ggctgcgggc	ccttctcggc	5100
acgctccaag	gcggggaaga	cccggccggg	gaaatcgacg	gaaaactcga	atcggcggac	5160
gacgaggaaa	tgttcgcctt	catcgacaat	gtgcttaagc	cttcttga		5208

<210> 43
 <211> 3264
 <212> PRT
 <213> Amycolatopsis orientalis

<400> 43

```

Met Leu Asn Glu Glu Lys Leu Arg Asp Tyr Leu Lys Arg Val Ser Ala
1          5          10          15

Asp Leu His Arg Thr Arg Ala Arg Leu Arg Glu Ala Glu Ala Arg Glu
          20          25          30

His Glu Pro Ile Ala Ile Ile Gly Met Ala Cys Arg Tyr Pro Gly Gly
          35          40          45

Val Arg Gly Pro Glu Gln Leu Trp Asp Leu Val Ala Ala Gly Thr Asp
          50          55          60

Ala Val Gly Gly Phe Pro Ala Asp Arg Gly Trp Asp Val Glu Ala Leu
65          70          75          80

Tyr Asp Pro Asp Pro Ala Arg His Gly Lys Thr Tyr Thr Arg Glu Gly
          85          90          95

Gly Phe Leu Tyr Asp Ala His Glu Phe Asp Ala Ala Phe Phe Gly Ile
          100          105          110

Ser Pro Arg Glu Ala Leu Thr Val Asp Pro Gln Gln Arg Leu Leu Leu
          115          120          125

Glu Thr Ala Trp Glu Ala Phe Glu Arg Ala Gly Ile Asp Pro Leu Ser
          130          135          140

Val Arg Gly Ser Arg Thr Gly Val Phe Ala Gly Val Met Tyr Asn Asp
145          150          155          160

Tyr Gly Ser Arg Leu Asp Pro Arg Ala Glu Glu Leu Arg Glu Phe Glu
          165          170          175

Gly Tyr Leu Gly Asn Gly Ser Ala Gly Ser Val Ala Ser Gly Arg Val
          180          185          190

Ala Tyr Thr Phe Gly Leu Glu Gly Pro Ala Val Thr Ile Asp Thr Ala
          195          200          205

Cys Ser Ser Ser Leu Val Ala Leu His Leu Ala Ala Glu Ser Leu Arg
          210          215          220

Arg Gly Glu Ser Thr Leu Ala Leu Ala Gly Gly Val Thr Val Met Ala
225          230          235          240

Ser Pro Glu Thr Phe Val Glu Phe Ser Arg Gln Arg Gly Met Ala Pro
          245          250          255

Asp Gly Arg Cys Lys Pro Phe Ala Asp Ala Ala Asp Gly Thr Gly Trp
          260          265          270

Ala Glu Gly Ala Gly Ile Leu Leu Leu Glu Arg Leu Ser Asp Ala Arg

```

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__


NOTE: For additional volumes please contact the Canadian Patent Office.

3010-5PCT-7CA

-111-

We claim:


1. A compound of Formula I, or a pharmaceutically acceptable salt thereof:



wherein,

A is selected from $-C(NH)NHR^1$, CH_3 , H and

10




R^1 is selected from H, C_{1-6} alkyl, C_{6-10} aryl, $C(O)C_{1-6}$ alkyl and $C(O)C_{6-10}$ aryl;

R^2 and R^3 are each independently selected from H, C_{1-6} alkyl, C_{2-7} alkene and C_{6-10} aryl;

R^4 is selected from H and CH_3 ;

Z is OH; or Z is O when taken with adjacent carbon atom to form a carbonyl; or Z is a tetrahydropyranoxy of formula:



20

R^5 is selected from H, COOH, C_{1-6} alkyl and $C(O)OC_{1-6}$ alkyl;

R^6 , R^7 and R^8 are each independently selected from H, C_{1-6} alkyl and


3010-5PCT-7CA

-112-

$C(O)C_{1-6}$ alkyl; or

R^6 , R^7 and R^8 may each independently be absent when the adjacent oxygen and carbon atoms are taken together to form a carbonyl; or


R^6 , R^7 and R^8 may each independently be a bond when any of two neighboring R^6 , R^7 and R^8 are taken together with attached oxygen and carbon atoms to form a 1,3-dioxolane ring of formula:



R^9 and R^{10} are each independently selected from H, C_{1-6} alkyl, C_{2-7} alkene
10 and C_{6-10} aryl; or


R^9 and R^{10} are taken together with adjacent carbon atom to form a ring having from 5 to 7 carbons;

D is selected from OH, NH_2 , $NH(C_{1-3}alkyl)$, $N(C_{1-3}alkyl)_2$, $OC_{1-3}alkyl$ and



R^{11} is selected from H and C_{1-3} alkyl.

2. An isolated compound of Formula II, or a pharmaceutically acceptable salt thereof:



3010-5PCT-7CA


-113-

wherein, R^1 is selected from H and $C(O)C_{1-3}alkyl$;

R^4 is selected from H and CH_3 ;

R^5 is selected from $C(O)OH$ and $C(O)OC_{1-3}alkyl$;


D is selected from OH and the cyclopentenone of the formula:



wherein R^{11} is selected from H and $C_{1-3}alkyl$.

3. A compound of claim 2 wherein


wherein D is



10


R^1 and R^{11} are H; R^4 is CH_3 ; and R^5 is $C(O)OH$, or a pharmaceutically acceptable salt thereof.

4. A compound of claim 2 wherein D is



R^1 , R^4 and R^{11} are H and R^5 is $C(O)OH$, or a pharmaceutically acceptable salt thereof.

5. A compound of claim 2 wherein D is




3010-5PCT-7CA

-114-


R^1 and R^{11} are H, R^4 is CH_3 and R^5 is $\text{C}(\text{O})\text{OCH}_3$, or a pharmaceutically acceptable salt thereof.

6. A compound of claim 2 wherein D is



R^1 is H; R^4 and R^{11} are CH_3 ; and R^5 is $\text{C}(\text{O})\text{OH}$; or a pharmaceutically acceptable salt thereof.


7. A compound of claim 2 wherein D is



R^1 is H; R^4 and R^{11} are CH_3 ; and R^5 is $\text{C}(\text{O})\text{OCH}_3$; or a pharmaceutically acceptable salt thereof.

10

8. A compound of claim 2 wherein
wherein D is




R^1 is $\text{C}(\text{O})\text{CH}_3$; R^4 is CH_3 ; R^5 is $\text{C}(\text{O})\text{OH}$; and R^{11} is H; or a pharmaceutically acceptable salt thereof.

9. The compound of claim 2, wherein D is OH, R^1 is H, R^4 is CH_3 and R^5 is $\text{C}(\text{O})\text{OH}$, or a pharmaceutically acceptable salt thereof.


3010-5PCT-7CA

-115-


10. A compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:




Compound 1;



Compound 2;




Compound 3;




Compound 4;

3010-5PCT-7CA


-116-




Compound 5;




Compound 6;



Compound 7;




Compound 8;




Compound 9;

3010-5PCT-7CA


-117-




Compound 10;




Compound 11;



Compound 12;




Compound 13;




Compound 14;

3010-5PCT-7CA


-118-




Compound 15;




Compound 16;



Compound 17;




Compound 18;




Compound 19;

3010-5PCT-7CA


-119-




Compound 20;



Compound 21;




Compound 22;




Compound 23;

3010-5PCT-7CA


-120-




Compound 24;



Compound 25;




Compound 26;



Compound 27; and


3010-5PCT-7CA

-121-




Compound 28.


11. A compound of claim 2, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:



Compound 1;




Compound 2;




Compound 3;

3010-5PCT-7CA


-122-




Compound 4;



Compound 5;



Compound 6; and



Compound 7.

- 10 12. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising a compound of claim 2 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.


14. A pharmaceutical composition comprising a compound of claim 10 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a compound of claim 11 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

16. A polyene polyketide selected from Compounds 1, 2 and 7 as defined in claim 11, wherein said polyene polyketide is obtained by a method comprising:

- a) cultivating a *Amycolatopsis orientalis* strain, wherein said cultivation is performed under aerobic conditions in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms; and
- b) isolating a polyene polyketide of claim 11 selected from Compounds 1, 2 and 7, from the bacteria cultivated in step (a).

17. A polyene polyketide of Formula I




wherein,

A is selected from $-\text{C}(\text{NH})\text{NHR}^1$, CH_3 , H and

3010-5PCT-7CA


-124-



R¹ is selected from H, C₁₋₆alkyl, C₆₋₁₀aryl, C(O)C₁₋₆alkyl and C(O)C₆₋₁₀aryl;
 R² and R³ are each independently selected from H, C₁₋₆ alkyl, C₂₋₇ alkene and C₆₋₁₀ aryl;


R⁴ is selected from H and CH₃;

Z is OH; or Z is O when taken with adjacent carbon atom to form a carbonyl; or Z is a tetrahydropyranoxy of formula:



; wherein


- 10 R⁵ is selected from H, COOH, C₁₋₆ alkyl and C(O)OC₁₋₆ alkyl;
 R⁶, R⁷ and R⁸ are each independently selected from H, C₁₋₆ alkyl and C(O)C₁₋₆ alkyl; or
 R⁶, R⁷ and R⁸ may each independently be absent when the adjacent oxygen and carbon atoms are taken together to form a carbonyl; or
 R⁶, R⁷ and R⁸ may each independently be a bond when any of two neighboring R⁶, R⁷ and R⁸ are taken together with attached oxygen and carbon atoms to form a 1,3-dioxolane ring of formula:



- 20 R⁹ and R¹⁰ are each independently selected from H, C₁₋₆ alkyl, C₂₋₇ alkene and C₆₋₁₀ aryl; or

R^9 and R^{10} are taken together with adjacent carbon atom to form a ring having from 5 to 7 carbons;

D is selected from OH, NH_2 , $NH(C_{1-3}alkyl)$, $N(C_{1-3}alkyl)_2$, $OC_{1-3}alkyl$ and



R^{11} is selected from H and C_{1-3} alkyl,

10 wherein said polyene polyketide is obtained by a method comprising:

- a) cultivating a *Amycolatopsis orientalis* strain, under aerobic conditions in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms; and
- b) isolating a polyene polyketide of claim 11 selected from compounds 1, 2 and 7, from the bacteria cultivated in step (a); and
- c) chemically modifying the polyene polyketide of paragraph (b) to obtain a polyene polyketide of Formula I.

20 18. The polyene polyketide of claim 16 that generates a ^1H NMR spectra essentially as shown in Figure 4.

19. The polyene polyketide of claim 16 that generates a ^1H NMR spectra essentially as shown in Figure 5.

20. The polyene polyketide of claim 16 that generates a ^1H NMR spectra essentially as shown in Figure 10.

21. The polyene polyketide of claim 17 that generates a ^1H NMR spectra essentially as shown in Figure 6.

30 22. The polyene polyketide of claim 17 that generates a ^1H NMR spectra essentially as shown in Figure 7.

23. The polyene polyketide of claim 17 that generates a ^1H NMR spectra essentially as shown in Figure 8.

3010-5PCT-7CA

-126-

24. The polyene polyketide of claim 17 that generates a ^1H NMR spectra essentially as shown in Figure 9.

25. A process of producing a compound of claim 1 comprising the steps of:

- a) cultivating an *Amycolatopsis* strain in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms;
- b) isolating a compound selected from the group consisting of Compound 1, 2, 7, 8 and 15 as defined in claim 10; and
- c) chemically modifying the compound of paragraph b) to produce a compound of claim 1.

26. A process of producing a compound of claim 10 selected from the group consisting of Compounds 1, 2, 7, 8 and 15 comprising the steps of:

- a) cultivating an *Amycolatopsis* strain in a nutrient medium comprising at least one source of carbon atoms and nitrogen atoms; and
- b) isolating the compound of claim 10 selected from the group consisting of Compounds 1, 2, 7, 8 and 15.

27. The process of claims 25 or 26 wherein the *Amycolatopsis* strain is *Amycolatopsis orientalis*.


28. The process of any one of claim 25-27, wherein the *Amycolatopsis* strain is *Amycolatopsis orientalis* ATCC 43491 or a mutant or variant thereof.

29. The process of any one of claim 25-28, wherein the *Amycolatopsis* strain is *Amycolatopsis orientalis* having accession number IDAC 220604-01, or a mutant or variant thereof.

3010-5PCT-7CA

-127-

30. The process of any one of claims 25-29, wherein the cultivating step occurs under aerobic conditions.
31. The process of any one of claims 25-30, wherein said cultivation is carried out at a temperature ranging from 18°C to 40°C.
32. The process of any one of claims 25-31, wherein said cultivation is carried out at a pH ranging from 6 to 9.
33. *Amycolatopsis orientalis* sp. having IDAC Accession No. 220604-01.
34. Use, as an antibacterial agent, of a compound of Formula II:



10


Formula II

wherein, R¹ is selected from H and C(O)C₁₋₃alkyl;

R⁴ is selected from H and CH₃;

R⁵ is selected from C(O)OH and C(O)OC₁₋₃alkyl;

D is selected from OH and the cyclopentenone of the formula:



wherein R¹¹ is selected from H and C₁₋₃alkyl.


35. Use of a compound of any one of claims 3-9 and 11 to inhibit bacterial growth.

20

3010-5PCT-7CA

-128-

36. Use, in the treatment of bacterial infection, of a compound of Formula II:




Formula II

wherein, R¹ is selected from H and C(O)C₁₋₃alkyl;

R⁴ is selected from H and CH₃;

R⁵ is selected from C(O)OH and C(O)OC₁₋₃alkyl;

D is selected from OH and the cyclopentenone of the formula:



wherein R¹¹ is selected from H and C₁₋₃alkyl.

10

37. Use of a compound of claim 3-9 and 11 in the treatment of bacterial infection in a subject.


38. Use of a compound of claim 11 in the treatment of bacterial infection in a mammal.

39. Use of a compound of any one of claims 3-9 and 11 in the preparation of a medicament to treat bacterial infection.

40. Use in the preparation of a medicament for the treatment of bacterial infection, of a compound of Formula II:

3010-5PCT-7CA

-129-




Formula II

wherein, R^1 is selected from H and $C(O)C_{1-3}alkyl$;

R^4 is selected from H and CH_3 ;

R^5 is selected from $C(O)OH$ and $C(O)OC_{1-3}alkyl$;

D is selected from OH and the cyclopentenone of the formula:



wherein R^{11} is selected from H and $C_{1-3}alkyl$.

10 41. Use according to any one of claims 35-40 wherein the bacterial growth or bacterial infection involves a bacterial strain selected from the group consisting of *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Enterococcus faecium*, *Klebsiella pneumoniae*, *Enterobacter spp.*, *Proteus spp.*, *Pseudomonas aeruginosa*, *E. coli*, *Serratia marcesens*, *Staphylococcus aureus*, Coagulase negative *Staphylococcus*, *Haemophilus influenzae*, *Bacillus anthracis*, *Mycoplasma pneumoniae*, and *Staphylococcus epidermidis*.

42. Use according to any one of claims 35-40 wherein the bacterial growth or bacterial infection involves a strain selected from the group consisting of *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Bacillus subtilis*, *Bacillus*
20 *megaterium*, *Enterococcus faecalis* and *Micrococcus luteus*.

43. Use of any one of claims 41 or 42 wherein the bacterial strain is *Staphylococcus aureus*.

3010-5PCT-7CA


-130-


44. Use of a pharmaceutical composition according to claim 15 in the treatment of bacterial infection.

45. Use of a pharmaceutical composition according to claim 15 in the preparation of a medicament for the treatment of bacterial infection.

46. Use according to claim 44 or 45 wherein the bacterial infection involves a strain selected from the group consisting of *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Enterococcus faecium*, *Klebsiella pneumoniae*, *Enterobacter* spp., *Proteus* spp., *Pseudomonas aeruginosa*, *E. coli*, *Serratia marcesens*, *Staphylococcus aureus*, Coagulase negative *Staphylococcus*, *Haemophilus influenzae*, *Bacillus anthracis*, *Mycoplasma pneumoniae*, and *Staphylococcus epidermidis*.

47. Use according to claim 44 or 45 wherein the bacterial infection involves a strain selected from *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Bacillus subtilis*, *Bacillus megaterium*, *Enterococcus faecalis* and *Micrococcus luteus*.








Figure 4

Compound 1 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.752 MHz
Number of Transients = 64
Temperature = 25°C




Figure 5

Compound 2 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.752 MHz
Number of Transients = 64
Temperature = 25°C




Figure 6

Compound 3 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.572 MHz
Number of Transients = 64
Temperature = 25°C




Figure 7

Compound 4 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.572 MHz
Number of Transients = 64
Temperature = 25°C




Figure 8

Compound 5 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.572 MHz
Number of Transients = 64
Temperature = 25°C




Figure 9

Compound 6 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.572 MHz
Number of Transients = 64
Temperature = 25°C




Figure 10

Compound 7 ^1H NMR Spectrum
Solvent = CD_3OD
Observe Transmitter Frequency = 499.572 MHz
Number of Transients = 256
Temperature = 25°C




Figure 11

Biosynthetic locus for production of
the compound of Formula I




Figure 12a

```

ORF 22_KS02      PIAIIGMACRYPGGVTSPEELWDLVAAGRDGVSEFPVNRGW--EDVYDAD
ORF 22_KS03      PIAIVGMACRFPGGVRSPEDLWRLVSEGRDGITPFPADRGWDVEGLYDPE
ORF 19_KS01      PIAIIGMACRYPGGVRSPPEELWDLVAGERTGLTGFPVDRGWDLDGLYDPE
ORF 18_KS02      PIAIIGMACRYPGGVSTPDDLWRLVADGNDGITRFPENRGWDTDGVYHPD
ORF 19_KS02      PIAIIGMACRYPGGVASPEDLWRLVAEGRDGISLFPADRGWDVDGLYDPD
ORF 23_KS01      PIAIVGMACRYPGGVASPEDLWRMVETGGDGISGFPPVDRGWDLEALYDPD
ORF 20_KS01      PIAVVGMSCRFPGGVRSPEQLWDLVASGTDALSEFPGDRGWDLGGLFDPD
ORF 21_KS01      PIAIIGMACRYPGGVRGPEQLWDLVAAGTDAVGGFPADRGWDVEALYDPD
ORF 22_KS01      PIAIIGMACRFPGGVRSPEDLWELVAEGRDGISGFPPADRGWDLSELYDPT
ORF 19_KS03      PIAIVAMSCRFPGHADTPERLWALLAEGRDALGEFPADRGWDLERLFDTD
ORF 18_KS01      PIAIVGMACRYPGGIGSPEDLWRLVTEGGDATSDFPADRGWDVESLYDPD
ORF 21_KS02      PIAIVAMSCRFPGGITDPEKFWDFVADGGDAMAAPGDRGWDLDALYDPD
                  ***::.*:***:**      *: :*  :.      .      ** :***      :...

ORF 22_KS02      PGKVGKSYAREGGFLHDAGEFDAAFFGISPREALAMDPQQRLLLETSWEV
ORF 22_KS03      ASRPGTSCTRYGGFLHDAGDFDPGFFGISPREALAMDPQQRLLLETSWEA
ORF 19_KS01      QGKPGKSYVREGGFLHDAARFDPAFFGISPREALAMDPQQRLLLEISWEA
ORF 18_KS02      ADHRGTTYVREGGFLHDAGQFDPGFFGISPREALAMDPQQRLLLEISHEA
ORF 19_KS02      PGKAGKSYVREGGFLHEAGDFDAGFFGISPREALGMDPQQRLLLEVSWEA
ORF 23_KS01      PDKQGTSYVSQGGFLHDVAEFDPAFFGISPREALAMDPQQRLLLETSWEA
ORF 20_KS01      PDTPGKTYVSEGGFLYEAGDFDAAFFGISPREAQAMDPQQRLLLEAAWEV
ORF 21_KS01      PARHGKTYTREGGFLYDAHEFDAAFFGISPREALTVDPPQQRLLLETAWEA
ORF 22_KS01      GEKPGTSYCREGGFLDGAGEFDPAFFGISPREALAMDPQQRLLLEISWET
ORF 19_KS03      PDRRGTSYTRQGAFLTAGDFDAGFFGISPREALAMDPQQRLLLETSWEA
ORF 18_KS01      PGVPGKTYTRGGFLDGAGDFDAGFFGISPREALAMDPQQRLLLETSWEA
ORF 21_KS02      PAHLGTTYAREGGFLDDAGGFDAFFGISPREALAMDPQQRLLLETSWEA
                  *:      *.**      .      *.*****      :*****      :*.

ORF 22_KS02      FERAGIDPHAVRGSKTGVFAGVMYHDYAARLNSVPEDV---EGYLGTGNS
ORF 22_KS03      FERAGIDPATLRGSATGVFAGAMYHDYVSRLTEIPADL---EGYLGTGNS
ORF 19_KS01      IERAGIAPDSLGRSRTGVFAGVIHNEYSIAIAGTPPADL---EPYLGNGSF
ORF 18_KS02      VERAGIDPKSLRSGTGTFAGVMYHDYATGLNRVPDDV---EGYLGNGTS
ORF 19_KS02      FERAGIDPGTLRGSdTGVFAGQMYHDYLTGATVVPDDV---EGYLGTGNS
ORF 23_KS01      IERAGIDPGSLKGSRTGVFAGLMYHDYVSGLTEIPDEV---GGYLGTGNS
ORF 20_KS01      LERAGIDPATLRGSRTGVFAGVIHNDYTGVLTDIPPEL---EPYLGNGNF
ORF 21_KS01      FERAGIDPLSVRGSRTGVFAGVMYNDYGSRLDPRAEELREFEGYLGNGSA
ORF 22_KS01      FERAGIDPGSLRGSRTGVFAGVMYHDYVSRLAAIPEEL---EGYLGTGNS
ORF 19_KS03      FERAGIDPATLRGSRTGVFAGVMDNEYVSGSAEVPDGV---EGYLATGTS
ORF 18_KS01      FERAGIDPATLRGSATGVFVGAETQEYGPRLGGAEGL---EGYLLTGNA
ORF 21_KS02      FERAGIDPATLRGSATGVFVGASFQNYGLDAVDAPEGT---EGYFLTGTA
                  .***** * :::** ***** ::*      *: .*.

ORF 22_KS02      GSVISGRLAYTFGLEGPAVSIDTAQSSSLVAMHLAGQALRQGECSLAVAG
ORF 22_KS03      GSVISGRLAYAFGLEGPAVSIDTAQSSSLVAMHLAAQALRQGECSLALAG
ORF 19_KS01      ASIASGRVSYTFGLEGPAVTVDTAQSSSLVALHLAAQALRQGECSLALAG
ORF 18_KS02      ASIHSGRVAYTFGLEGPAVTIDTAQSSSLVALHLAAQALRRGECSMALAG
ORF 19_KS02      GSVLSGRVSYTFGLEGPAVTVDTAQSSSLVALHLAAQALRRGECSLALAG
ORF 23_KS01      GSIASGRVSYTFGFEGPALTVDTAQSSSLVTLHLAAQALRRGECDLALSG
ORF 20_KS01      SSVASGRIAYTLGLEGPAVSVDTAQSSSLVALHLAAQSLRREECTLALVG
ORF 21_KS01      GSVASGRVAYTFGLEGPAVTIDTAQSSSLVALHLAAESLRRGESTLALAG
ORF 22_KS01      GSVVSGRVAYTFGLEGPAVTIDTAQSSSLVALHLAAQALRQGECSMALAG
ORF 19_KS03      ASVASGRVSYTFGLEGPAVTVDTAQSSSLVALHLAAQALRQGECSLALAG
ORF 18_KS01      ASVASGRVSYAFGFEGPTVTVDTAQSSSLVALHLAGQALRLGECPIAVAG
ORF 21_KS02      TAVVSGRLSYTFGLEGPAVTIDTAQSSSLVALHLAAQALRRGECSLALAG
                  :: *****::*:***:::**********::***.::**      *. :*: *

```

Figure 12b

```

ORF 22_KS02      GVTVMATPNTFIEFSRQRGMATDGRCKSF AEAAADGTGWGEGVGMLLLERL
ORF 22_KS03      GVAVMSTPDTFIEFSRQRGMADGRIKAFSETADGTAWGEGVGMLLLERL
ORF 19_KS01      GVTVMANPAAFVDFSRQRGLAADGRICKAF AEAAADGTAWGEGAGMLLVERL
ORF 18_KS02      GVTVMATPEVFVDFSRQRGLAPDGRCKSFSD EADGTWSEG VGMLLVERL
ORF 19_KS02      GVTVMATPETFVDFSRQRGLAPDGRCKSFSD GADGTSWSEG VGMLLVERL
ORF 23_KS01      GVTVMFTPGTFVEFSRQRGMADGRCCKPFAEEADGTGW SEG VGMLLVERL
ORF 20_KS01      GVNVMTHPAAFVDFSRQRGLAADGRCKAFADAADGTGW GEG VGMLLVERL
ORF 21_KS01      GVTVMASPETFVEFSRQRGMADGRCCKPFADAADGTGWA EGAGILLERL
ORF 22_KS01      GVAVMSTPDTFVDFSRQRGLAADGRCKSYSDGADGT SWAEG VGMLLVEKL
ORF 19_KS03      GVTVMATPGTFVEFSRQRGLAADGRCKAFADGADGTGW GEGAGMLLVERL
ORF 18_KS01      GVAVMSSPGGFLAFSRQRGLAPDGRCKPFSAADGTGW SEG VGMLVLERL
ORF 21_KS02      GVTVMANPAAFVEFSRQRGLAPDGRCKAFADAADGTAW SEGAGILLERL
                  **  **  *  *: *****:*.*** *.: :  **** *.**.*:*.**:**

ORF 22_KS02      SDARRNGHRVLAVVRGSAVNQDGASNGLTAPNGPSQQRVIRQALAQAGLR
ORF 22_KS03      SDARRNGHRVLAVLRGTAVNQDGASNGLTAPNGPSQQRVIRQALAQAGLR
ORF 19_KS01      SDARRNGHRVLAVVRGSAVNQDGASNGLTAPNGLSQQRVIRQALANARLA
ORF 18_KS02      SDARRNGHRVLAIVRGSAVNQDGASNGLTAPSGPSQQRVIRRALADAGLK
ORF 19_KS02      SDAERNNGHRILAVVRGSAVNQDGASNGLTAPNGPSQQRVIRRALADARLE
ORF 23_KS01      SDARRNGHPVLAVLRGSAVNQDGASNGLTAPNGPSQQRVIREALADARLT
ORF 20_KS01      SDAQRNHGQVLAVLRGSAINQDGASNGLTAPNGPAQQRVIRQALADARLS
ORF 21_KS01      SDARRHGHPVLAVVRGTAVNQDGASSGLTAPNGPSQQRVIRQALDSAGLA
ORF 22_KS01      SDARRLGHEVLAVVSGSAVNQDGASSGLSVPNGPSQQRVIRQALENARLS
ORF 19_KS03      SDARRNGHPVLAVLRGSAVNQDGASNGLTAPNGPSQQRVIRQALANARLE
ORF 18_KS01      SDARRNGHRVLAVVRGTAINSDGASNGLTAPNGAAQQRVIRRALANAGLA
ORF 21_KS02      SDARRLGHPVLALVRGSAVNQDGASNGLSAPNGPSQQRVIRQALANAGFA
                  ***.* ** :*: : *: :*.*****.**:.*.* :*****.*. * :

ORF 22_KS02      PSDVDAVEAAGTGTTLGDP IEAQALLATY GQDR--EEPLWLGSVKS NLGH
ORF 22_KS03      PSDVDAVEAAGTGTTLGDP IEAQALLATY GQDR--EEPLWLGSVKS NLGH
ORF 19_KS01      PSDVDAMEAAGTGTRLGDP IEAQALLATY GQDR--TTPLWLGSVKS NIGH
ORF 18_KS02      PSEVDAVEAAGTGTP LGDP IEAQAMLATY GQDR--DRPLWLGS LKSNLGH
ORF 19_KS02      PSEVDAVEAAGTGTT LGDP IEAQALLATY GQGRE--DAALWLGS IKS NIGH
ORF 23_KS01      TADVDVVEAAGTGTT LGDP IEAQALLATY GKGRPSDRPLWLGS IKS NLGH
ORF 20_KS01      PGQVDVVEAAGTGTT LGDP IEAQALLATY GQDR--ERPLLLGSLKS NIGH
ORF 21_KS01      PHQVDVVEAAGTGTT LGDP IEAQALLAAYGQER--VRPLWLGS LKSNVGH
ORF 22_KS01      AGQIDVVEAAGTGTT LGDP IEAQALLATY GREKSADRPLWLGS LKSNIGH
ORF 19_KS03      PSEVDAVEAAGTGTT LGDP IEAQALLATY GQDR--ERPLLLGSVKS NIGH
ORF 18_KS01      PSEVDAVEAAGTGTV LGDP IEAQALLATY GRDR--ERPLLLGSVKS NIGH
ORF 21_KS02      PSDVDAVEAAGTGTS LGDP IEAQALLAAYGGER--EHPLWLGSVKS NLGH
                  . :*: :*. ***** :*: :* : . * ***:***:***

ORF 22_KS02      TQAAAGVAGVIKMVEAMRHGVL PRTLHVDEPSSHVDWTGGAVSLV TESRE
ORF 22_KS03      TQAAAGVASVIKMVEAMRHGVL PRTLHVDEPSSHVDWTEGAVSLLTETR D
ORF 19_KS01      SQAAAGVASIIKLVEAMRHGVL PRTLHVDAPTSHVDWSEGAVSLLTEAEP
ORF 18_KS02      TQAAAGVGGIIMVQAMHHGVL PRTLNLGTPPTTKVDWTSGNV SLLSEPVA
ORF 19_KS02      SQAAAGVAGVIKMVEAMRRGVLPKTLHVTEPSSHVDWTAGAVSLLTEARL
ORF 23_KS01      TQAAAGVAGIIKMVQALRSGILPRSLHAETPSSHVDWSAGAVSLLAEARP
ORF 20_KS01      TQAAAGVGGVIMVQAIRHGIAPRTLHVDA PSSHVDWSAGEVSLLTGEQP
ORF 21_KS01      SQAAAGVGGVIMVQAIRHGIAPMTLHVDTPTSKVDWEAGSVELLTEARP
ORF 22_KS01      SQSAAGVGGVIMVQAIRHGILPRTLHAEDPSSKVDWSAGAVELLTEARG
ORF 19_KS03      TQAAAGVAGVIKMVLAMRHGTL PRTLHVDTPTSRVDWAAGRIELATEPTQ
ORF 18_KS01      TQSAAGVAGVIKMVQAMRHGVL PKTLHADEPTPKVAWSSGAVELLNETVA
ORF 21_KS02      TQSASGVAGVIKMVQAIRHGVL PRTLHVDAPTTEVDWTAGDVRLLETPVD
                  :*: :*: :*: :* *: : * * :*: * :. . * * * : *

ORF 22_KS02      WPD TGRPRRAGVSSFGISGTNAHTII EAV
ORF 22_KS03      WPD TGRPRRAGVSSFGISGTNAHV VLEAD
ORF 19_KS01      WPK TDRPRRAAVSSFGISGTNAHV VLEQP
ORF 18_KS02      WPETGGPRRAAVSSFGISGTNAHV VLEQA
ORF 19_KS02      WPDAGRPRRAAVSSFGISGTNAHV VLEQG
ORF 23_KS01      WPELDRPRRAAVSSFGISGTNAHV VLEAA
ORF 20_KS01      WPETGEPRRAGVSSFGISGTNAHV ILEQA
ORF 21_KS01      WPETGEPRRAGISSFGVSGTNAHV IVEQA
ORF 22_KS01      WPETGQPRRAGVSSFGVSGTNAHTII EQA
ORF 19_KS03      WPETGGPRRAAVSSFGMSGTNAHV VLEQA
ORF 18_KS01      WPENGAPRRAAVSSFGMSGTNAHV VLEQA
ORF 21_KS02      WPD TGRPRRAGVSSFGVSGTNVHTLIEEV
                  ** . . *****:*****:*****.*.: :*

```

Figure 13a

```

ORF_19_AT01      GPVPFVLSGKTEAALHEQVARVR-ELARDSDVTAADLAFSLATTRTALDH
ORF_22_AT01      GAVPAVLSGKTAEALRDQVVRLRSHILARPELSVADVAASLATTRVLHEH
ORF_19_AT02      GPAAFVLSAGSEAAALHDQASRLR-DFLAETPAALADVAFSLATTRAALEH
ORF_22_AT02      DVPPWPLSGKTEEALRAQASRLHDHLLATPEVTAADVALSLT-ARADLEH
ORF_21_AT02      TWVPWVLSAKTEEALRSQASRLHAQLEEHP-GDDSDIAYTLATARAGLEI
AAF71776_ATMA03|NYST GVVPLPLSGKSPEALRDQAARLLAGLAERPALRPLDLGYSLATTRSAFDH
ORF_22_AT03      DVLAFPLSAKTQDALREQAARLRARLLTGHAPELADVAQTLA-TRGLFEH
ORF_18_AT01      PTWLFPVSGRDEKALRRQAARLR---EALPDSDLPAIAAALATTRSALEW
ORF_20_AT01      -VLPFVLSGRSEEALAAQASKLAAYLTGEP--APKAIARALAETRSLALPH
ORF_23_AT01      -ATPWLLSARTPEALRARAQAQLRSFVDLPG--AAATLA-----ARPLFGH
ORF_18_AT02      -VLPFVLSGKTSAAALAAQADRLAGHLAGDV--SLPAVARALAVTRSALDH
ORF_19_AT03      -VVAWPLSAKEPEAVAAQAARLKSFLTGE--RPADVAYSLATARTTLEH
ORF_21_AT01      -VTPLVLSARSAEALRAQASRLREHLRQTE--SLTDTAFSLATSRAALEH
AAF71775_ATMM01|NYST -ALPWIVSGHSPQALRDQAAALAAARVETDPALRPQDIGHTLHTARALLER
                    :*.      *:      :      :      :      :      :*

ORF_19_AT01      RAALVGT-LDDLLT-----ATLVEGRA-TDGGTAFLFTGQGSQR
ORF_22_AT01      RGAIVAADDRDQLLAGLDILAAGATTAGVSQGVA-TDGRTAFLFTGQGSQR
ORF_19_AT02      RAAVVAADRETLLAALEN-----LTVTGRA-TEGRTAFLFTGQGSQR
ORF_22_AT02      RAVLVAGDRDGLLATLDALAHGETTEGIVRGRTARHTGRTAFLFTGQGSQR
ORF_21_AT02      RAAVTGPDRLRELALLAEG----TPSAAVLRGALTAGAPGFLFTGQGSQK
AAF71776_ATMA03|NYST RAVVLATDRADAVRALTAALAAADADLSAVVGD-RTGRHAVLFSGQGSQR
ORF_22_AT03      RAVVTAGDRDGLLDALAALAGG-EPGDFVTGLAKPGGKLAFLFTGQGSQR
ORF_18_AT01      RAVVTVADRAGLLAGLDALATGEALPSLVHGTA----RIGIVFSGQGSQR
ORF_20_AT01      RAVVLAEDLGELLGGLRSLAECEPAARVLTGTAEA-GKAVFVFPQGGSQW
ORF_23_AT01      RAAIVGDPR----AALDALATGKPSNLLIEGTAQS-GKAVFVFPQGGSQW
ORF_18_AT02      RAVVVAGDRAGLTAGLRALADAVPAPHVVDGVAEN-GKAVFVFPQGGSQW
ORF_19_AT03      RAVVVGEDP---IAGLAALAAAGEPSGSVVTGTATS-GKAVFVFPQGGSQW
ORF_21_AT01      RAVVVAEAD---ASLDALAAGAPAAGLVEGIALPPGKVAFVFPQGGSQW
AAF71775_ATMM01|NYST RAVVVAPDRAELLAATHELAAGRSANAVVEGLADVEGRTVFVFPQGGSQW
                    *...:      :      :*.***

ORF_19_AT01      LGMGRELAERFPVFAQAFDDVSSRFERPI-----AELSAEE--LN
ORF_22_AT01      RGMGRELAERFPVFAEAFDDVCARFERPI-----KELSTEE--LN
ORF_19_AT02      LGMGLQLAERFPVFAAAAYDEVCSRFEQPL-----RDLTAE--LN
ORF_22_AT02      LGMGRELAERFPVFAEVYDEVCSRFEQPL-----RDLSAEE--LN
ORF_21_AT02      PGMGAELAARFPVFAAAFDEVCAHLDPRLGLSL----REVLETER--VH
AAF71776_ATMA03|NYST LGMGRELYERFPVFAEALDVAIDHLDAALPAQASLREVMWGDDVEL--LD
ORF_22_AT03      AGMADELSAAFPVFARTFGEICARFDTLDDRPLR-----EALAGDL--VD
ORF_18_AT01      AGMGRELHRRFPVFAAAFDDACGHLDLQLDRPLAEIVFADEGTEEAGLLH
ORF_20_AT01      VGMAEELLLSAPVFAESMAECERALSSFVDWKLS---DVLS---DAAALE
ORF_23_AT01      VGMAEELLLSAPVFAESMAECEQALSSFVDWKLS---DVLS---DAAALE
ORF_18_AT02      TGMVAVLLGSSAVFAEAMADCEAALLSHLDWKLT---HVLS---DAAALE
ORF_19_AT03      AGMAVELLASAPVFAESMAECEAALLSYVDWKLT---EVLS---DATALE
ORF_21_AT01      AGMALELKDSSPVFRAALLDCERALSSFVDWKLT---DVLG---DATALE
AAF71775_ATMM01|NYST VGMGAQLLDES AVFAERIAECAALAEFTDWSLV--DVLRGVVGAPSLE
                    **. :*      .**      :      :.

M1      M2      M3
-----
ORF_19_AT01      QTANTQCALFAFEVALFRLVENWGLRPDFLAGHSVGEIAAAHVADVLSLD
ORF_22_AT01      QTANTQCALFAFEVALFRLVESWGVRPDLFLAGHSIGEIAAAHVAGVFNLD
ORF_19_AT02      QTANTQCALFAFEVALFRLVESWGVRPDLFLAGHSVGEIAAAHVAGVLSLD
ORF_22_AT02      QTANTQCALFAFEVALFRLVESWGVRPDLFLAGHSVGEIAAAHVAGVLSLD
ORF_21_AT02      ETAFACALFAFEVALFRLLESWGVRPALLLGHVGEIAAAHVAGVLSLA
AAF71776_ATMA03|NYST ETGWTQPALFAFEVALFRLVESWGVRPDLFVAGHSIGEIAAAHVGVFSLE
ORF_22_AT03      RTEYTQCAMFAFEVALFRLVESRGVRPDLFLAGHSIGELAAAHVAGVWSLE
ORF_18_AT01      RTEYAQCALFAFEVALFRLYEHWGLRPDYVAGHSIGELAAAHVSGMLSLS
ORF_20_AT01      RVDVVQPVLFAVMVSLARLWRACGVEPAAVVGHSQGEIAAACVAGALSLE
ORF_23_AT01      RVDVVQPVLFAVMVSLARLWRACGVEPAAVVGHSQGEIAAACVAGALSLE
ORF_18_AT02      RVDVVQPVLFAVMVSLARLWRACGIEPAAVVGHSQGEIAAACVAGALSLE
ORF_19_AT03      RVDVVQPALFAVMVSLARLWRASGIEPAAVVGHSQGEIAAACVAGALSLE
ORF_21_AT01      RVDVVQPALFAVMVSLAALWRACGVEPDAVTGHSQGEIAAAVSGALSLE
AAF71775_ATMM01|NYST RVDVVQPASFVMVSLAALWGRGVLPAVVGHSQGEIAAAVSGALSLE
                    .. .* . ** .*: *      *: *      : ** **:* ** * . .*

```

Figure 13b

ORF_19_AT01	DAVTLVSAAGRLM-QALPTGGAMVALQATEAEVAPLLTDR--VSLAAIN
ORF_22_AT01	DAVKLVAAAGRLM-QALPTGGAMVALQATEAEVFPLLTD--VSLAAIN
ORF_19_AT02	DAVTLVSAAGRLM-QALPTGGAMVALQATEAEVTPLLTER--VSLAAIN
ORF_22_AT02	DAVTLVSAAGRLM-QALPTGGAMVALRATEAEVTPLLTER--VSIAAIN
ORF_21_AT02	DAATMVEAAGRLM-GALPSRGVMIALQANEDEVTPLP--VSIAAVN
AAF71776_ATMA03 NYST	DACRLVAAATATLM-QALPTGGAMIAIQAAEDEVTOHLTDD--VSIAAVN
ORF_22_AT03	DACTVVAAAGRLM-QALPSGGAMIAVQATEEEVRPLIDDET--VSIAAIN
ORF_18_AT01	DAAALVAAAGRLM-QDTREGGAMLAVQATEDEVLP--LAIAAVN
ORF_20_AT01	DAARLVCLPSKAI-LALSGRGGMVSVAAASEDRVRELLPAG--VSVAAVN
ORF_23_AT01	DAARVVCLPSKAI-LALSGLGGMVSVAAASEDRVRELLPAG--VSVAAVN
ORF_18_AT02	DAARVVCLPSKAI-LALSGLGGMVSVAAASEDRVRELLPDG--VSVAVVN
ORF_19_AT03	DAARVVCLPSKAI-TALSGRGGMVSVAAPEAQVREILPEG--VSLAAVN
ORF_21_AT01	DAAKVVALLAKAI-LALSGAGGMVAVALGRDDVLPRLTEWGDRIAAVN
AAF71775_ATMM01 NYST	DGARVVALLSQAIGRALAGRGGMMSVALSVDVLEPRLVEFEGRVSVAVN
	*. : * . : * * : : : : : : : : *
	M4

ORF_19_AT01	GPESVVVSGDEEAVAAVVS HF--EGRKSKRLTVSHAFSPLMEPMLDDFR
ORF_22_AT01	GPESVVLSGDEDAAVAVVS RF--EGRKHKRLAVSHAFSPLMEPMLDDFR
ORF_19_AT02	GPESVVVSGEEDAAVAVVS QF--EGRKSKRLTVSHAFSPLMEPMLDEFR
ORF_22_AT02	GPESVVVSGDEDAAVAVV----EGRKHKRLTVSHAFSPLMEPMLDEFR
ORF_21_AT02	GPEAVVLSGDEDAVTAVVDRF--ADRKSKRLVVSHAFSPLMEPMLADFR
AAF71776_ATMA03 NYST	GPTSVVVSGAESARTVADRLAENGRKTTLRVSHAFSPLMDPMLAEFR
ORF_22_AT03	GPVSVVVSGEEAAVTALAAGFAERGRKTKRLTVSHAFSPLMDGMLGEFR
ORF_18_AT01	GPRSVVVSGDEAAVEEVA AAF--ARRKTKRLKVSHAFSSHMDGMLDEFR
ORF_20_AT01	GPSAVVVSGDVAGLEALLKRCELLDVRAKRI PVDYASSAHVDAIEQEVL
ORF_23_AT01	GPSAVVVSGDVAGLEALLKRCELLDVRAKRI PVDYASSAHVDAIEQEVL
ORF_18_AT02	GPASVVVSGDVAGLEALLKRCELLDVRAKRV PVDYASSAHVDAIEQQVV
ORF_19_AT03	GPASVVVSGDVAGLDALMTACEASGLRAKRI PVDYASSAHVDAIEQDVL
ORF_21_AT01	GPASVVVSGDPEALDGLVSACEADGVRARRI PVDYASSPQVDVLR EELL
AAF71775_ATMM01 NYST	GPRSVVVAGEPEALDALHARLTADDIRARRI AVDYASSHQVEDLHEELL
	** : * : * : : : : : : : : : *
ORF_19_AT01	AVVEGLTFAEPRIPIVS-----GGLAEVSTSDYWVRHVRDAVRFHDSVE
ORF_22_AT01	AVADSLSYAAPRIPIVS-----GGLADVSTSDYWVRHVRDAVRFHDSVK
ORF_19_AT02	VVADSLSYAAPRIPIVS-----GGLAEVSTSDYWVRHVRDAVRFHDSVK
ORF_22_AT02	TVVEGLTFAAPRIPIVS-----GGLAEVSTSDYWVRHVRDAVRFHDSVK
ORF_21_AT02	RVVSGLSFSEPRIPIVSTVT--GRSDPEIASPGYWVRHVREAVRFHDAIR
AAF71776_AT03 NYST	AVAEGLSYATPTLPVVSNTLGRLATADDLCSAEYWARHVREAVRFADGVS
ORF_22_AT03	AVLDGIAAADPRIPLVSTLTGDP--LTDGQARSSEYWVRHVRDAVRFCD AIR
ORF_18_AT01	RF AEILTFRKPIPLVSTVSG--ELLTEATAPEYWVEHVRPVRFADGVR
ORF_20_AT01	SALAGIS PQAPVIFPYSTVTD-EPL E--LD AAYWFRNLRGTVRFAATVD
ORF_23_AT01	SALAGIS PQAPVIFPYSTVTD-EPL E--LD AGYWFRNLRGTVRFAATVD
ORF_18_AT02	TALSGIMPREAELPMYSTVTG-EPIDTTTLDAAYWFRNL RATVRFDQAVR
ORF_19_AT03	AALDGI EPRAP EIPFYSTVAG-EPLDP-VVDAAYWFRNLRGTVHFGQAVR
ORF_21_AT01	GLLDGVEHHA STVPFYSAVTG-EPLDTAGLTPEYWFRNL RATVRFDRSVR
AAF71775_AT01 NYST	EVLAELAPRTSEVPFFSTVTG-DWLDTARMDAGYWFRNLGRVRFADAVA
	: : : * : : : : : : : : *
ORF_19_AT01	F--LKAEGVTRFLEIGPDAVLTAM-----AKESAE----DAVVL PASRRD
ORF_22_AT01	F--LETEGVTRFLEIGPDAVLTAM-----AQESTE----GAVVVAASRRN
ORF_19_AT02	F--LEAEGVTRFLEIGPDGVL TAM-----AKETAE----DAVVVPALRRD
ORF_22_AT02	F--LEAEGVTRFLEIGPDGVL TAM-----AQDSLE----DAVVVPALRRD
ORF_21_AT02	FAEAEAEGVRAFVELGPEGVLSAM-----AKDFLE----DTVLIPTLRGE
AAF71776_AT03 NYST	T--LENEGVTTFLELGPDGVL SAM-----AQQLTG--DAATVPALRKD
ORF_22_AT03	T--LEAQGVRRYLELGPDAPLTALGEHCVTNESTVD--AQLFVPSLRAG
ORF_18_AT01	R--LDELGV DVLLELGPDAVLT PM-----AAEVL DGE--GAALVPSLRGS
ORF_20_AT01	R--LLEDGFRFFVEASPHVLPVPG-----ISE-----EAIALGSLRRG
ORF_23_AT01	R--LLEDGFRFFVETSPHPVLVPG-----ISE-----DAVALGSLRRG
ORF_18_AT02	R--LIADGFRFFVETSPHPVLVAG-----LTELV EEA VPAVALASLR RD
ORF_19_AT03	R--LLDDGFRFFVEASPHVLTG-----IADTAEDAGERAVAVGSLRRD
ORF_21_AT01	R--LLDDGHRFFVEASHPVLTGS-----VTETIEERGAHAVALGSLRRD
AAF71775_AT01 NYST	D--LLAAEYRAFVEVSSHVLTMA-----VLDLIEEAGVTAVATGTLRRD
	: * . . . * : : : : *

Figure 13c

ORF_19_AT01	RPEVTLLLTAVAGLHVHGAEVDWAPLFDG--ARRVDLPTYPFQYEHFWL-
ORF_22_AT01	RAEDVTLLAAVSTLHVHGASVDWTPLLAG--ARRVDLPTYAFQHRRFWL-
ORF_19_AT02	RPEVETLLTAVAGLHVHGVGVDLTALLGG--GSPVDLPTYAFQHRRFWL-
ORF_22_AT02	KPEVTLLLTAVAGLHVHGAGVDWSPLSAG--ARRVDLPTYAFQORTEFWL-
ORF_21_AT02	RPEVAALATTLGRLHVHGVGIDWAGVFDGVQASRVTLPTYPFQYEHFWL-
AAF71776_AT03 NYST	RDEETSALTALAHLHTAGLRVDWAAFFAGSGATRVDLPTYAFQHATYWP-
ORF_22_AT03	RSDVESFVTALARLHVDGVRVDWAKALPG--RKIDLPTYAFQHERFWL-
ORF_18_AT01	RPEAEALAASLAEWVRGAEWGWPQVFGA--HPRADLPTYAFQYRYWL-
ORF_20_AT01	EGGAERFVASLAEAHQGLSPSWSAVLPP--AERVDLPTYAFQHKRFWLE
ORF_23_AT01	EGGAERFVASLAEAHVHGLSPAWSSILPT--ADWVDLPTYPFQKRFWLE
ORF_18_AT02	EGGPTRFVTSLAEAHVHGLSPDWAALLPE--AGWVDLPPYAFQHQEFWLT
ORF_19_AT03	EGGPLRFLTSLAEAHVHGLSPDWAALAP--GTRVDLPTYAFQHEHYWLR
ORF_21_AT01	EGGPTRFLTSLAEAHVRGLRPDWAALWPT--ATRVDLPTYAFQRPYWLD
AAF71775_AT01 NYST	QGGAGRFLLSAAEVFVRGVDVDWAGAFEGTGAARVDLPTYAFQERYWNT
	. : . . * . **.*.*: :*

Figure 14

ORF 22_DH02	AGLSDAGHPLLGGAVTLPDSGGTVFTGRLSLAAQPWLADHAVGFTVLLPG
ORF 22_DH03	LGQSPAGHPLLGAAVEAPDSGAVLFTGRLSVQEQPWLADHVVACTTLLPG
ORF 20_DH01	FGQTVVDHPLLGAALPLADGDGLVLTGRISPDTQPWLVDHTVLETVLLPG
ORF 23_DH01	FGQTVVDHPLLGAVVAVPGTGGLLYTGRISLETHPWLADHAVSGTVLVPG
ORF 18_DH02	FGLGATGHPLLTAATALPGSGGLLLTGRISTAAQPWLADHAVQGVVLLPG
ORF 19_DH03	AGLDDGGHPLLGAVVPLAGSDGLVATGRISARNQTWLPDHAVGGALLPG
ORF 21_DH02	FGLGEAGHALLGAAPVPPGGSGISFTGRLSLRAQPWLAEHVVLGTALLPG
ORF 19_DH02	AGLGTTDHPLLGAAAALPGDGGFLLTGRLSGHAQPWLAEHVRVGGVVLLPG
ORF 22_DH01	LGLGATDHPLLGAVVTMADAHGVLLTGRLSLAAQPWLAGEHVVAGHVLLPG
ORF 19_DH01	AGLDASPHALLAAAVRPAGEDEILLTGRISLSTLPWLADHVVGGNVLLPG
ORF 18_DH01	YGLGDTGHPLLRAVTTAEDGALLLSGRLSPLTQPWLADHVVGCDVVLLPG
	* .** . :**:* .** * * ::**
ORF 22_DH02	TAFVDLALAAGRRHGRVVLDLTLTLESPLVLPFHGGVDLRVWVREPDDTGA
ORF 22_DH03	TAFVELALRAGELTGCAAVDELTLTLEAPLVLPDHGGTALRIVAAAPDETGR
ORF 20_DH01	TAFVELVLRAGREAGCDGVDELTLTLEAPLVLDG--PVALQVVLGEPDERGR
ORF 23_DH01	TAFVELALAAGTQVDCALLDELTLTLEAPLVLEEGTDVRLSVELGDADVDR
ORF 18_DH02	TAFVELALQAGTHAGCGRIDELTLTLEAPLPLPEQGGVRVQVVLG-SEVNGR
ORF 19_DH03	AALVDLALTVGERTGCGRIAEILTLEAPLVLGESGSARLQVTVGASADDGT
ORF 21_DH02	TAFVDLALHAGDRAGCGTVAELTLTLEAPLALPESGDVRLHVTVGEPGEDGG
ORF 19_DH02	TAFVEIALRAGDEAGCGHLEDLTLEAPLVLPERGATQLSVLVGAADDTGR
ORF 22_DH01	TAFVDLVVLHAGDKVDCGIVEELTLTLEAPLVLPEHDALSLQLVVGAPDETGR
ORF 19_DH01	TAFVELALAAAEAGCEAVEELNLEAPLVLPEKGGVQLQVAVGAADDQGR
ORF 18_DH01	TALLELALRAAELAGAGGVEELTLTLEVPMVLSEA-GVQVQVSVRDSG----
	:* : :.* . : :*.* * : * : :
ORF 22_DH02	CAVSVHS
ORF 22_DH03	RALDVYS
ORF 20_DH01	RAVSVHS
ORF 23_DH01	REVGVS
ORF 18_DH02	REVTVHS
ORF 19_DH03	REVAVYS
ORF 21_DH02	RTIEIHS
ORF 19_DH02	RTIEIHS
ORF 22_DH01	RTVGVHS
ORF 19_DH01	RSVTVHA
ORF 18_DH01	--LLIFF
	: :.

Figure 15

ORF 18_ER02	QLAWRDGELLVPRLAKVSTDGTLTPPEGP--WVLDAAPRRGTLEELALVPA
ORF 19_ER03	QLALRAGTVLGARLVKASADTALVPPPGSRAWTVDTLGGGTLENLVLRDR
ORF 19_ER02	QIALRDGRALAPRLATTASSTELTPPEGA--WRLDTTGRGTLENLTLVPS
AAF71767_ER01 NYST	QAVVREGTVRVGRLARLDSGRGLVPPPGT-PWRLGSRAGSLDGLALLPH
AAF71776_ER03 NYST	QLALRDGGVLAARLARFDTAALTPPADR-AWRLDSTAKGSLNGLALTPY
	* . * * * . : * . * . * : : * : * : * . *
ORF 18_ER02	PTAARPLADGEVRIQVRAAGINFRDVLITLDMYPE-DKAVMGSEGAGIVT
ORF 19_ER03	PDLLAPLADGQVRIAVRSAGLNFRDVVVALGLVP--GQEGIGGEGAGVVT
ORF 19_ER02	PEAVAPLAEGEVRIAVRAAGLNFRDVLIALGMYP--GAATLGSEGAGVVT
AAF71767_ER01 NYST	PEARPLTGHEVRVGIRAAAGLNFRDVLNALGMYPG-DAGLFGSEAAGVVV
AAF71776_ER03 NYST	PAALAPLTGHEVRVEVRAAGLNFRDVLNALGMYPGDDVGSFGSEAAGVVV
	* * : : * : : * : * : * : * : * : * : * : * : * .
ORF 18_ER02	EIGSGVTGLKPGDRVFLGFDGAFGPVAIADRRTVTEMPVDWTFEAAAALP
ORF 19_ER03	ETGPGVTDLAPGDRVLGMFDASFGPIAVADRKLIAPVPDDWSFTEASAP
ORF 19_ER02	EIGPGVTGLDVGDRVFLGMSNGFGPQVVDHRTLAKMPEDWSFATAASVP
AAF71767_ER01 NYST	EVGPEVTGLAPGDRVMGMLFGGFGPLGIADARLLTPVPADWSWETGASVP
AAF71776_ER03 NYST	EVGPEVTGLAPGDQVMGMITGSFGSLAVDDARRLARLPEDWSWETGASVP
	* * . * . * * * : * : * : . * . : * : : * * : : . * : *
ORF 18_ER02	VVFLTAYYGLVDLGGLRPGEKVIIGATGGVGMAAVQLARHLGAEVFATA
ORF 19_ER03	VAFLTAYVGLADLGLRPGQTVIHAAGGGVGMAAVQLARHFGAEIYVTA
ORF 19_ER02	IVFLTAYYGLFDLARLEAGESIIVHAAGGGVGMAATQLARHAGAIEVFGTA
AAF71767_ER01 NYST	LVFLTAYYALKELGGLRAGEKVIIVHAGAGGGVGMAAIQIARHVGAEVFATA
AAF71776_ER03 NYST	LVFLTAYYALKELGGLRAGEKVIIVHAGAGGGVGMAAIQIARHVGAEVFATA
	: . * * * * . * : * . * . * : : * : : * * * * * * : * : * * * : * *
ORF 18_ER02	SPGKWEVLRGLGFDDDEHIASSRTLDFEDRF-----GR-MDVVLDSLAKEF
ORF 19_ER03	SPAKWDTLRAMGFDDDHIASSRTLDFEDKIREATGGRGVLDVLDSLAREF
ORF 19_ER02	GPGKWDTLRANGFDDTHLSSSRDLGFEEKFRDATGGRGVLDVLNLSAGDY
AAF71767_ER01 NYST	SEGKWDVLRSLGVADDHIASSRTLDFEAAFAEVAGDRGLDVLNLSAGEF
AAF71776_ER03 NYST	SEGKWDVLRSLGVADDHIASSRTLDFEAAFAEVAGDRGLDVLNLSAGDF
	. . * : . * . * . * * : : * * * . * * : . * : * : * : * : : :
ORF 18_ER02	VDASLRLLGEGGRFVEMGKTDIRDADEVAAHPGVTYRAFDLLDAGRPRI
ORF 19_ER03	VDASLRLVREGGRFVEMGKTDIRDADEVAAHPGVTYRAFDLIDSGHDRI
ORF 19_ER02	VDASLRLLAGGRFAEMGKTDIRPGE-----TGVEYHPFDVIDAGPERI
AAF71767_ER01 NYST	VDASMRLLDGGRFLEMGKTDIRAADSVP---DGLSYHSFDLGMVDPEHI
AAF71776_ER03 NYST	VDASMRLLDGGRFLEMGKTDIRAADSVP---DGLSYQSFDLAWVVPETI
	* * * : * : : * * * * * * * * . . . * : * : * : * : *
ORF 18_ER02	GEILAEELDLFGAGSLTVPRPTVWDARRAPEVFRFMSQAKHIGKNVLTIP
ORF 19_ER03	QEILGELLALADKDVVRPLPTTAWDVRRAPEAFRFLSQAKHTGKIVLEPP
ORF 19_ER02	HEMLAALLELFAAGALTPLPVTGWDVRRGPDAFRFLSQAKHVGKNVLTMP
AAF71767_ER01 NYST	QRMLLDLVELFDRGALAALPVRSDVRRAGEAFRFLSLAQHIGKIVLTVP
AAF71776_ER03 NYST	GTMLAEELMDLFRGTALRPLPVRTWDVRHAKDAFRFMSMAKHIGKIVLTLP
	: * * : * . : * * . * : . * * : * * * * * * * *

20/27

Figure 18

ORF 23_TE01 AAF71768_TE01 NYST	KGPSGPELVCVPSLLAGSGAHEYARFAASFRDVQDVSVVPVPGFGHGQPL -GPGRPRLIFVSAPGATGGVHQYARIAAHFRGSRHVSALPLMGFAPGELL ** . *.*: *.: * .*.*:***:** ** . :.***.:*: ** . *: *
ORF 23_TE01 AAF71768_TE01 NYST	PDSIEAVLHAQADAILREG-GDPVVLVAHSSGGPLAHALARHLEEAG-SA PATSEAAAARIVAESVLMASEGEPFVMVGHSTGSLAYLAAGVLEDTW DVR * : **. : *:::* . *:.*:*.*:*.***: * **::
ORF 23_TE01 AAF71768_TE01 NYST	PRALVLIDVY-----PQDEHALDGIRDRLSGGLG-----DDTRLTAMGA PEAVVLLDTASIRYNPGE GNDLDR TTRFY LADIDSPSVTLNSARMSAMAH *.:***:*. * : : ** :.:*::**.
ORF 23_TE01 AAF71768_TE01 NYST	YLRLFADYVPAPTGVPTLLVRASEPLEAWRDRTEWRSGWALPHDTVDVEG WFMAMTDIQAPAPTAPTLLVRAARALDGFR LDTSSVP----ADEVRDIDA :: ::* *****:..*:::* * *:::.
ORF 23_TE01 AAF71768_TE01 NYST	DFTMLERHAGTTAEAVREWLGR LG DLSLAKEHSALTAQAIEGWLAEL- *::: :.*:. **:*:. **..*

Figure 19




Figure 20




Figure 21






Figure 22




Figure 23




Figure 24

